STUDY,STUDY TITLE ,STUDY DESCRIPTION,DATASET,DATASET TITLE,DATASET DESCRIPTION,SAMPLE TECHNOLOGY
EGAS00000000001,WTCCC case-control study for Bipolar Disorder,WTCCC genome-wide case-control association study for Bipolar disorder (BD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000001,WTCCC case-control study for Bipolar Disorder,WTCCC genome-wide case-control association study for Bipolar disorder (BD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000003,Title not provided,WTCCC1 project Bipolar Disorder (BD) samples, Affymetrix 500K
EGAS00000000001,WTCCC case-control study for Bipolar Disorder,WTCCC genome-wide case-control association study for Bipolar disorder (BD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000002,WTCCC case-control study for Bipolar Disorder - Combined Controls,WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000004,Title not provided,WTCCC1 project Coronary Artery Disease (CAD) samples, Affymetrix 500K
EGAS00000000002,WTCCC case-control study for Bipolar Disorder - Combined Controls,WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000009,Title not provided,WTCCC1 project Type 2 Diabetes (T2D) samples, Affymetrix 500K
EGAS00000000002,WTCCC case-control study for Bipolar Disorder - Combined Controls,WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000005,Title not provided,WTCCC1 project Inflammatory Bowel Disease (IBD) samples, Affymetrix 500K
EGAS00000000002,WTCCC case-control study for Bipolar Disorder - Combined Controls,WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000007,Title not provided,WTCCC1 project Rheumatooid arthritis (RA) samples, Affymetrix 500K
EGAS00000000002,WTCCC case-control study for Bipolar Disorder - Combined Controls,WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000002,WTCCC case-control study for Bipolar Disorder - Combined Controls,WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000006,Title not provided,WTCCC1 project Hypertension (HT) samples, Affymetrix 500K
EGAS00000000002,WTCCC case-control study for Bipolar Disorder - Combined Controls,WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000003,Title not provided,WTCCC1 project Bipolar Disorder (BD) samples, Affymetrix 500K
EGAS00000000002,WTCCC case-control study for Bipolar Disorder - Combined Controls,WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000008,Title not provided,WTCCC1 project Type 1 Diabetes (T1D) samples, Affymetrix 500K
EGAS00000000002,WTCCC case-control study for Bipolar Disorder - Combined Controls,WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000003,WTCCC case-control study for Coronary Artery Disease,WTCCC genome-wide case-control association study for Bipolar disorder (CAD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000004,Title not provided,WTCCC1 project Coronary Artery Disease (CAD) samples, Affymetrix 500K
EGAS00000000003,WTCCC case-control study for Coronary Artery Disease,WTCCC genome-wide case-control association study for Bipolar disorder (CAD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000003,WTCCC case-control study for Coronary Artery Disease,WTCCC genome-wide case-control association study for Bipolar disorder (CAD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000004,WTCCC case-control study for Coronary Artery Disease - Combined Controls,WTCCC genome-wide case-control association study for Coronary Artery Disease (CAD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000004,Title not provided,WTCCC1 project Coronary Artery Disease (CAD) samples, Affymetrix 500K
EGAS00000000004,WTCCC case-control study for Coronary Artery Disease - Combined Controls,WTCCC genome-wide case-control association study for Coronary Artery Disease (CAD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000009,Title not provided,WTCCC1 project Type 2 Diabetes (T2D) samples, Affymetrix 500K
EGAS00000000004,WTCCC case-control study for Coronary Artery Disease - Combined Controls,WTCCC genome-wide case-control association study for Coronary Artery Disease (CAD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000005,Title not provided,WTCCC1 project Inflammatory Bowel Disease (IBD) samples, Affymetrix 500K
EGAS00000000004,WTCCC case-control study for Coronary Artery Disease - Combined Controls,WTCCC genome-wide case-control association study for Coronary Artery Disease (CAD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000007,Title not provided,WTCCC1 project Rheumatooid arthritis (RA) samples, Affymetrix 500K
EGAS00000000004,WTCCC case-control study for Coronary Artery Disease - Combined Controls,WTCCC genome-wide case-control association study for Coronary Artery Disease (CAD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000004,WTCCC case-control study for Coronary Artery Disease - Combined Controls,WTCCC genome-wide case-control association study for Coronary Artery Disease (CAD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000006,Title not provided,WTCCC1 project Hypertension (HT) samples, Affymetrix 500K
EGAS00000000004,WTCCC case-control study for Coronary Artery Disease - Combined Controls,WTCCC genome-wide case-control association study for Coronary Artery Disease (CAD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000003,Title not provided,WTCCC1 project Bipolar Disorder (BD) samples, Affymetrix 500K
EGAS00000000004,WTCCC case-control study for Coronary Artery Disease - Combined Controls,WTCCC genome-wide case-control association study for Coronary Artery Disease (CAD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000008,Title not provided,WTCCC1 project Type 1 Diabetes (T1D) samples, Affymetrix 500K
EGAS00000000004,WTCCC case-control study for Coronary Artery Disease - Combined Controls,WTCCC genome-wide case-control association study for Coronary Artery Disease (CAD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000005,"WTCCC case-control study for Coronary Artery Disease, Hypertension, T2D - combined cases","WTCCC genome-wide case-control association study using the cardiovascular disease CAD, HT and T2D as combined case collection and the 1958 British Birth Cohort and the UK National Blood Service collections as controls.",EGAD00000000004,Title not provided,WTCCC1 project Coronary Artery Disease (CAD) samples, Affymetrix 500K
EGAS00000000005,"WTCCC case-control study for Coronary Artery Disease, Hypertension, T2D - combined cases","WTCCC genome-wide case-control association study using the cardiovascular disease CAD, HT and T2D as combined case collection and the 1958 British Birth Cohort and the UK National Blood Service collections as controls.",EGAD00000000009,Title not provided,WTCCC1 project Type 2 Diabetes (T2D) samples, Affymetrix 500K
EGAS00000000005,"WTCCC case-control study for Coronary Artery Disease, Hypertension, T2D - combined cases","WTCCC genome-wide case-control association study using the cardiovascular disease CAD, HT and T2D as combined case collection and the 1958 British Birth Cohort and the UK National Blood Service collections as controls.",EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000005,"WTCCC case-control study for Coronary Artery Disease, Hypertension, T2D - combined cases","WTCCC genome-wide case-control association study using the cardiovascular disease CAD, HT and T2D as combined case collection and the 1958 British Birth Cohort and the UK National Blood Service collections as controls.",EGAD00000000006,Title not provided,WTCCC1 project Hypertension (HT) samples, Affymetrix 500K
EGAS00000000005,"WTCCC case-control study for Coronary Artery Disease, Hypertension, T2D - combined cases","WTCCC genome-wide case-control association study using the cardiovascular disease CAD, HT and T2D as combined case collection and the 1958 British Birth Cohort and the UK National Blood Service collections as controls.",EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000006,Genomewide Association Study of Inflammatory Bowel Disease,WTCCC genome-wide case-control association study for Inflammatory Bowel Disease (IBD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000005,Title not provided,WTCCC1 project Inflammatory Bowel Disease (IBD) samples, Affymetrix 500K
EGAS00000000006,Genomewide Association Study of Inflammatory Bowel Disease,WTCCC genome-wide case-control association study for Inflammatory Bowel Disease (IBD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000006,Genomewide Association Study of Inflammatory Bowel Disease,WTCCC genome-wide case-control association study for Inflammatory Bowel Disease (IBD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000007,Genomewide Association Study of Inflammatory Bowel Disease - Combined Controls,WTCCC genome-wide case-control association study for Inflammatory Bowel Disease (IBD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000004,Title not provided,WTCCC1 project Coronary Artery Disease (CAD) samples, Affymetrix 500K
EGAS00000000007,Genomewide Association Study of Inflammatory Bowel Disease - Combined Controls,WTCCC genome-wide case-control association study for Inflammatory Bowel Disease (IBD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000009,Title not provided,WTCCC1 project Type 2 Diabetes (T2D) samples, Affymetrix 500K
EGAS00000000007,Genomewide Association Study of Inflammatory Bowel Disease - Combined Controls,WTCCC genome-wide case-control association study for Inflammatory Bowel Disease (IBD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000005,Title not provided,WTCCC1 project Inflammatory Bowel Disease (IBD) samples, Affymetrix 500K
EGAS00000000007,Genomewide Association Study of Inflammatory Bowel Disease - Combined Controls,WTCCC genome-wide case-control association study for Inflammatory Bowel Disease (IBD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000007,Title not provided,WTCCC1 project Rheumatooid arthritis (RA) samples, Affymetrix 500K
EGAS00000000007,Genomewide Association Study of Inflammatory Bowel Disease - Combined Controls,WTCCC genome-wide case-control association study for Inflammatory Bowel Disease (IBD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000007,Genomewide Association Study of Inflammatory Bowel Disease - Combined Controls,WTCCC genome-wide case-control association study for Inflammatory Bowel Disease (IBD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000006,Title not provided,WTCCC1 project Hypertension (HT) samples, Affymetrix 500K
EGAS00000000007,Genomewide Association Study of Inflammatory Bowel Disease - Combined Controls,WTCCC genome-wide case-control association study for Inflammatory Bowel Disease (IBD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000003,Title not provided,WTCCC1 project Bipolar Disorder (BD) samples, Affymetrix 500K
EGAS00000000007,Genomewide Association Study of Inflammatory Bowel Disease - Combined Controls,WTCCC genome-wide case-control association study for Inflammatory Bowel Disease (IBD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000008,Title not provided,WTCCC1 project Type 1 Diabetes (T1D) samples, Affymetrix 500K
EGAS00000000007,Genomewide Association Study of Inflammatory Bowel Disease - Combined Controls,WTCCC genome-wide case-control association study for Inflammatory Bowel Disease (IBD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000008,"WTCCC case-control study for Inflammatory Bowel Disease, T1D and RA - combined cases",WTCCC genome-wide case-control association study using three disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000005,Title not provided,WTCCC1 project Inflammatory Bowel Disease (IBD) samples, Affymetrix 500K
EGAS00000000008,"WTCCC case-control study for Inflammatory Bowel Disease, T1D and RA - combined cases",WTCCC genome-wide case-control association study using three disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000007,Title not provided,WTCCC1 project Rheumatooid arthritis (RA) samples, Affymetrix 500K
EGAS00000000008,"WTCCC case-control study for Inflammatory Bowel Disease, T1D and RA - combined cases",WTCCC genome-wide case-control association study using three disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000008,"WTCCC case-control study for Inflammatory Bowel Disease, T1D and RA - combined cases",WTCCC genome-wide case-control association study using three disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000008,Title not provided,WTCCC1 project Type 1 Diabetes (T1D) samples, Affymetrix 500K
EGAS00000000008,"WTCCC case-control study for Inflammatory Bowel Disease, T1D and RA - combined cases",WTCCC genome-wide case-control association study using three disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000009,WTCCC case-control study for Hypertension,WTCCC genome-wide case-control association study for Hypertension (HT) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000009,WTCCC case-control study for Hypertension,WTCCC genome-wide case-control association study for Hypertension (HT) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000006,Title not provided,WTCCC1 project Hypertension (HT) samples, Affymetrix 500K
EGAS00000000009,WTCCC case-control study for Hypertension,WTCCC genome-wide case-control association study for Hypertension (HT) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000010,WTCCC case-control study for Hypertension - Combined Controls,WTCCC genome-wide case-control association study for Hypertension (HT) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000004,Title not provided,WTCCC1 project Coronary Artery Disease (CAD) samples, Affymetrix 500K
EGAS00000000010,WTCCC case-control study for Hypertension - Combined Controls,WTCCC genome-wide case-control association study for Hypertension (HT) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000009,Title not provided,WTCCC1 project Type 2 Diabetes (T2D) samples, Affymetrix 500K
EGAS00000000010,WTCCC case-control study for Hypertension - Combined Controls,WTCCC genome-wide case-control association study for Hypertension (HT) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000005,Title not provided,WTCCC1 project Inflammatory Bowel Disease (IBD) samples, Affymetrix 500K
EGAS00000000010,WTCCC case-control study for Hypertension - Combined Controls,WTCCC genome-wide case-control association study for Hypertension (HT) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000007,Title not provided,WTCCC1 project Rheumatooid arthritis (RA) samples, Affymetrix 500K
EGAS00000000010,WTCCC case-control study for Hypertension - Combined Controls,WTCCC genome-wide case-control association study for Hypertension (HT) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000010,WTCCC case-control study for Hypertension - Combined Controls,WTCCC genome-wide case-control association study for Hypertension (HT) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000006,Title not provided,WTCCC1 project Hypertension (HT) samples, Affymetrix 500K
EGAS00000000010,WTCCC case-control study for Hypertension - Combined Controls,WTCCC genome-wide case-control association study for Hypertension (HT) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000003,Title not provided,WTCCC1 project Bipolar Disorder (BD) samples, Affymetrix 500K
EGAS00000000010,WTCCC case-control study for Hypertension - Combined Controls,WTCCC genome-wide case-control association study for Hypertension (HT) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000008,Title not provided,WTCCC1 project Type 1 Diabetes (T1D) samples, Affymetrix 500K
EGAS00000000010,WTCCC case-control study for Hypertension - Combined Controls,WTCCC genome-wide case-control association study for Hypertension (HT) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000011,WTCCC case-control study for Rheumatoid Arthritis,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000007,Title not provided,WTCCC1 project Rheumatooid arthritis (RA) samples, Affymetrix 500K
EGAS00000000011,WTCCC case-control study for Rheumatoid Arthritis,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000011,WTCCC case-control study for Rheumatoid Arthritis,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000008,Title not provided,WTCCC1 project Type 1 Diabetes (T1D) samples, Affymetrix 500K
EGAS00000000011,WTCCC case-control study for Rheumatoid Arthritis,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000012,WTCCC case-control study for Rheumatoid Arthritis - Combined Controls,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000004,Title not provided,WTCCC1 project Coronary Artery Disease (CAD) samples, Affymetrix 500K
EGAS00000000012,WTCCC case-control study for Rheumatoid Arthritis - Combined Controls,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000009,Title not provided,WTCCC1 project Type 2 Diabetes (T2D) samples, Affymetrix 500K
EGAS00000000012,WTCCC case-control study for Rheumatoid Arthritis - Combined Controls,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000005,Title not provided,WTCCC1 project Inflammatory Bowel Disease (IBD) samples, Affymetrix 500K
EGAS00000000012,WTCCC case-control study for Rheumatoid Arthritis - Combined Controls,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000007,Title not provided,WTCCC1 project Rheumatooid arthritis (RA) samples, Affymetrix 500K
EGAS00000000012,WTCCC case-control study for Rheumatoid Arthritis - Combined Controls,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000012,WTCCC case-control study for Rheumatoid Arthritis - Combined Controls,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000006,Title not provided,WTCCC1 project Hypertension (HT) samples, Affymetrix 500K
EGAS00000000012,WTCCC case-control study for Rheumatoid Arthritis - Combined Controls,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000003,Title not provided,WTCCC1 project Bipolar Disorder (BD) samples, Affymetrix 500K
EGAS00000000012,WTCCC case-control study for Rheumatoid Arthritis - Combined Controls,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000008,Title not provided,WTCCC1 project Type 1 Diabetes (T1D) samples, Affymetrix 500K
EGAS00000000012,WTCCC case-control study for Rheumatoid Arthritis - Combined Controls,WTCCC genome-wide case-control association study for Rheumatoid Arthritis (RA) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000013,WTCCC case-control study for T1D and RA - combined cases,WTCCC genome-wide case-control association study using two disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000007,Title not provided,WTCCC1 project Rheumatooid arthritis (RA) samples, Affymetrix 500K
EGAS00000000013,WTCCC case-control study for T1D and RA - combined cases,WTCCC genome-wide case-control association study using two disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000013,WTCCC case-control study for T1D and RA - combined cases,WTCCC genome-wide case-control association study using two disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000008,Title not provided,WTCCC1 project Type 1 Diabetes (T1D) samples, Affymetrix 500K
EGAS00000000013,WTCCC case-control study for T1D and RA - combined cases,WTCCC genome-wide case-control association study using two disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000014,WTCCC case-control study for Type 1 Diabetes,WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000014,WTCCC case-control study for Type 1 Diabetes,WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000008,Title not provided,WTCCC1 project Type 1 Diabetes (T1D) samples, Affymetrix 500K
EGAS00000000014,WTCCC case-control study for Type 1 Diabetes,WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000015,WTCCC case-control study for Type 1 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000004,Title not provided,WTCCC1 project Coronary Artery Disease (CAD) samples, Affymetrix 500K
EGAS00000000015,WTCCC case-control study for Type 1 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000009,Title not provided,WTCCC1 project Type 2 Diabetes (T2D) samples, Affymetrix 500K
EGAS00000000015,WTCCC case-control study for Type 1 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000005,Title not provided,WTCCC1 project Inflammatory Bowel Disease (IBD) samples, Affymetrix 500K
EGAS00000000015,WTCCC case-control study for Type 1 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000007,Title not provided,WTCCC1 project Rheumatooid arthritis (RA) samples, Affymetrix 500K
EGAS00000000015,WTCCC case-control study for Type 1 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000015,WTCCC case-control study for Type 1 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000006,Title not provided,WTCCC1 project Hypertension (HT) samples, Affymetrix 500K
EGAS00000000015,WTCCC case-control study for Type 1 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000003,Title not provided,WTCCC1 project Bipolar Disorder (BD) samples, Affymetrix 500K
EGAS00000000015,WTCCC case-control study for Type 1 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000008,Title not provided,WTCCC1 project Type 1 Diabetes (T1D) samples, Affymetrix 500K
EGAS00000000015,WTCCC case-control study for Type 1 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000016,WTCCC case-control study for Type 2 Diabetes,WTCCC genome-wide case-control association study for Type 2 Diabetes (T2D) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000009,Title not provided,WTCCC1 project Type 2 Diabetes (T2D) samples, Affymetrix 500K
EGAS00000000016,WTCCC case-control study for Type 2 Diabetes,WTCCC genome-wide case-control association study for Type 2 Diabetes (T2D) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000016,WTCCC case-control study for Type 2 Diabetes,WTCCC genome-wide case-control association study for Type 2 Diabetes (T2D) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000017,WTCCC case-control study for Type 2 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 2 Diabetes (T2D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000004,Title not provided,WTCCC1 project Coronary Artery Disease (CAD) samples, Affymetrix 500K
EGAS00000000017,WTCCC case-control study for Type 2 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 2 Diabetes (T2D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000009,Title not provided,WTCCC1 project Type 2 Diabetes (T2D) samples, Affymetrix 500K
EGAS00000000017,WTCCC case-control study for Type 2 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 2 Diabetes (T2D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000005,Title not provided,WTCCC1 project Inflammatory Bowel Disease (IBD) samples, Affymetrix 500K
EGAS00000000017,WTCCC case-control study for Type 2 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 2 Diabetes (T2D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000007,Title not provided,WTCCC1 project Rheumatooid arthritis (RA) samples, Affymetrix 500K
EGAS00000000017,WTCCC case-control study for Type 2 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 2 Diabetes (T2D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000001,WTCCC 1958BC Control dataset test,WTCCC1 project samples from 1958 British Birth Cohort, Affymetrix 500K
EGAS00000000017,WTCCC case-control study for Type 2 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 2 Diabetes (T2D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000006,Title not provided,WTCCC1 project Hypertension (HT) samples, Affymetrix 500K
EGAS00000000017,WTCCC case-control study for Type 2 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 2 Diabetes (T2D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000003,Title not provided,WTCCC1 project Bipolar Disorder (BD) samples, Affymetrix 500K
EGAS00000000017,WTCCC case-control study for Type 2 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 2 Diabetes (T2D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000008,Title not provided,WTCCC1 project Type 1 Diabetes (T1D) samples, Affymetrix 500K
EGAS00000000017,WTCCC case-control study for Type 2 Diabetes - Combined Controls,WTCCC genome-wide case-control association study for Type 2 Diabetes (T2D) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.,EGAD00000000002,Title not provided,WTCCC1 project samples from UK National Blood Service, Affymetrix 500K
EGAS00000000018,WTCCC case-control study for Ankylosing Spondylitis,WTCCC genome-wide case-control association study for Ankylosing Spondylitis (AS) using the 1958 British Birth Cohort collection as controls.,EGAD00000000014,Title not provided,WTCCC1 project samples from 1958 British Birth Cohort, Illumina 15K
EGAS00000000018,WTCCC case-control study for Ankylosing Spondylitis,WTCCC genome-wide case-control association study for Ankylosing Spondylitis (AS) using the 1958 British Birth Cohort collection as controls.,EGAD00000000010,Title not provided,WTCCC1 project Ankylosing Spondylitis (AS) samples, Illumina 15K
EGAS00000000019,WTCCC case-control study for Ankylosing Spondylitis - Combined Controls,WTCCC genome-wide case-control association study for Ankylosing Spondylitis (AS) - Combined Controls.,EGAD00000000011,Title not provided,WTCCC1 project Autoimmune Thyroid Disease (ATD) samples, Illumina 15K
EGAS00000000019,WTCCC case-control study for Ankylosing Spondylitis - Combined Controls,WTCCC genome-wide case-control association study for Ankylosing Spondylitis (AS) - Combined Controls.,EGAD00000000014,Title not provided,WTCCC1 project samples from 1958 British Birth Cohort, Illumina 15K
EGAS00000000019,WTCCC case-control study for Ankylosing Spondylitis - Combined Controls,WTCCC genome-wide case-control association study for Ankylosing Spondylitis (AS) - Combined Controls.,EGAD00000000010,Title not provided,WTCCC1 project Ankylosing Spondylitis (AS) samples, Illumina 15K
EGAS00000000019,WTCCC case-control study for Ankylosing Spondylitis - Combined Controls,WTCCC genome-wide case-control association study for Ankylosing Spondylitis (AS) - Combined Controls.,EGAD00000000012,Title not provided,WTCCC1 project Multiple Sclerosis (MS) samples, Illumina 15K
EGAS00000000019,WTCCC case-control study for Ankylosing Spondylitis - Combined Controls,WTCCC genome-wide case-control association study for Ankylosing Spondylitis (AS) - Combined Controls.,EGAD00000000013,Title not provided,WTCCC1 project Breast cancer (BC) samples, Illumina 15K
EGAS00000000020,WTCCC case-control study for Autoimmune Thyroid Disease,WTCCC genome-wide case-control association study for Autoimmune Thyroid Disease (ATD) using the 1958 British Birth Cohort collection as controls.,EGAD00000000011,Title not provided,WTCCC1 project Autoimmune Thyroid Disease (ATD) samples, Illumina 15K
EGAS00000000020,WTCCC case-control study for Autoimmune Thyroid Disease,WTCCC genome-wide case-control association study for Autoimmune Thyroid Disease (ATD) using the 1958 British Birth Cohort collection as controls.,EGAD00000000014,Title not provided,WTCCC1 project samples from 1958 British Birth Cohort, Illumina 15K
EGAS00000000021,WTCCC case-control study for Autoimmune Thyroid Disease - Combined Controls,WTCCC genome-wide case-control association study for Autoimmune Thyroid Disease (ATD) - Combined Controls.,EGAD00000000011,Title not provided,WTCCC1 project Autoimmune Thyroid Disease (ATD) samples, Illumina 15K
EGAS00000000021,WTCCC case-control study for Autoimmune Thyroid Disease - Combined Controls,WTCCC genome-wide case-control association study for Autoimmune Thyroid Disease (ATD) - Combined Controls.,EGAD00000000014,Title not provided,WTCCC1 project samples from 1958 British Birth Cohort, Illumina 15K
EGAS00000000021,WTCCC case-control study for Autoimmune Thyroid Disease - Combined Controls,WTCCC genome-wide case-control association study for Autoimmune Thyroid Disease (ATD) - Combined Controls.,EGAD00000000010,Title not provided,WTCCC1 project Ankylosing Spondylitis (AS) samples, Illumina 15K
EGAS00000000021,WTCCC case-control study for Autoimmune Thyroid Disease - Combined Controls,WTCCC genome-wide case-control association study for Autoimmune Thyroid Disease (ATD) - Combined Controls.,EGAD00000000012,Title not provided,WTCCC1 project Multiple Sclerosis (MS) samples, Illumina 15K
EGAS00000000021,WTCCC case-control study for Autoimmune Thyroid Disease - Combined Controls,WTCCC genome-wide case-control association study for Autoimmune Thyroid Disease (ATD) - Combined Controls.,EGAD00000000013,Title not provided,WTCCC1 project Breast cancer (BC) samples, Illumina 15K
EGAS00000000022,WTCCC case-control study for Multiple Sclerosis,WTCCC genome-wide case-control association study for Multiple Sclerosis (MS) using the 1958 British Birth Cohort collection as controls.,EGAD00000000014,Title not provided,WTCCC1 project samples from 1958 British Birth Cohort, Illumina 15K
EGAS00000000022,WTCCC case-control study for Multiple Sclerosis,WTCCC genome-wide case-control association study for Multiple Sclerosis (MS) using the 1958 British Birth Cohort collection as controls.,EGAD00000000012,Title not provided,WTCCC1 project Multiple Sclerosis (MS) samples, Illumina 15K
EGAS00000000023,WTCCC case-control study for Multiple Sclerosis - Combined controls,WTCCC genome-wide accosication study for Multiple Sclerosis (MS) - Combined controls,EGAD00000000011,Title not provided,WTCCC1 project Autoimmune Thyroid Disease (ATD) samples, Illumina 15K
EGAS00000000023,WTCCC case-control study for Multiple Sclerosis - Combined controls,WTCCC genome-wide accosication study for Multiple Sclerosis (MS) - Combined controls,EGAD00000000014,Title not provided,WTCCC1 project samples from 1958 British Birth Cohort, Illumina 15K
EGAS00000000023,WTCCC case-control study for Multiple Sclerosis - Combined controls,WTCCC genome-wide accosication study for Multiple Sclerosis (MS) - Combined controls,EGAD00000000010,Title not provided,WTCCC1 project Ankylosing Spondylitis (AS) samples, Illumina 15K
EGAS00000000023,WTCCC case-control study for Multiple Sclerosis - Combined controls,WTCCC genome-wide accosication study for Multiple Sclerosis (MS) - Combined controls,EGAD00000000012,Title not provided,WTCCC1 project Multiple Sclerosis (MS) samples, Illumina 15K
EGAS00000000023,WTCCC case-control study for Multiple Sclerosis - Combined controls,WTCCC genome-wide accosication study for Multiple Sclerosis (MS) - Combined controls,EGAD00000000013,Title not provided,WTCCC1 project Breast cancer (BC) samples, Illumina 15K
EGAS00000000024,WTCCC case-control study for Breast cancer,WTCCC genome-wide case-control association study for Breast cancer (BC) using the 1958 British Birth Cohort collection as controls.,EGAD00000000014,Title not provided,WTCCC1 project samples from 1958 British Birth Cohort, Illumina 15K
EGAS00000000024,WTCCC case-control study for Breast cancer,WTCCC genome-wide case-control association study for Breast cancer (BC) using the 1958 British Birth Cohort collection as controls.,EGAD00000000013,Title not provided,WTCCC1 project Breast cancer (BC) samples, Illumina 15K
EGAS00000000025,WTCCC case-control study for Breast cancer - Combined Controls,WTCCC genome-wide case-control association study for Breast cancer (BC) - Combined Controls.,EGAD00000000011,Title not provided,WTCCC1 project Autoimmune Thyroid Disease (ATD) samples, Illumina 15K
EGAS00000000025,WTCCC case-control study for Breast cancer - Combined Controls,WTCCC genome-wide case-control association study for Breast cancer (BC) - Combined Controls.,EGAD00000000014,Title not provided,WTCCC1 project samples from 1958 British Birth Cohort, Illumina 15K
EGAS00000000025,WTCCC case-control study for Breast cancer - Combined Controls,WTCCC genome-wide case-control association study for Breast cancer (BC) - Combined Controls.,EGAD00000000010,Title not provided,WTCCC1 project Ankylosing Spondylitis (AS) samples, Illumina 15K
EGAS00000000025,WTCCC case-control study for Breast cancer - Combined Controls,WTCCC genome-wide case-control association study for Breast cancer (BC) - Combined Controls.,EGAD00000000012,Title not provided,WTCCC1 project Multiple Sclerosis (MS) samples, Illumina 15K
EGAS00000000025,WTCCC case-control study for Breast cancer - Combined Controls,WTCCC genome-wide case-control association study for Breast cancer (BC) - Combined Controls.,EGAD00000000013,Title not provided,WTCCC1 project Breast cancer (BC) samples, Illumina 15K
EGAS00000000026,MalariaGEN case-control study in the Gambia,MalariaGEN case-control study in the Gambia.,EGAD00000000017,Title not provided,Cord blood control samples from Gambia, Affymetrix 500K
EGAS00000000026,MalariaGEN case-control study in the Gambia,MalariaGEN case-control study in the Gambia.,EGAD00000000018,Title not provided,Severe malaria cases from Gambia, Affymetrix 500K
EGAS00000000027,WTCCC case-control study for Tuberculosis,WTCCC genome-wide case-control association study for Tuberculosis (TB) using the African samples as controls.,EGAD00000000016,Title not provided,WTCCC project Tuberculosis (TB) samples, Affymetrix 500K
EGAS00000000027,WTCCC case-control study for Tuberculosis,WTCCC genome-wide case-control association study for Tuberculosis (TB) using the African samples as controls.,EGAD00000000015,Title not provided,WTCCC project African control samples, Affymetrix 500K
EGAS00000000028,WTCCC2 project controls - 1958 British Birth Cohort and National Blood Service,WTCCC2 project controls - 1958 British Birth Cohort and National Blood Service,EGAD00000000023,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Affymetrix 6.0
EGAS00000000028,WTCCC2 project controls - 1958 British Birth Cohort and National Blood Service,WTCCC2 project controls - 1958 British Birth Cohort and National Blood Service,EGAD00000000021,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Affymetrix 6.0
EGAS00000000028,WTCCC2 project controls - 1958 British Birth Cohort and National Blood Service,WTCCC2 project controls - 1958 British Birth Cohort and National Blood Service,EGAD00000000024,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Illumina 1.2M
EGAS00000000028,WTCCC2 project controls - 1958 British Birth Cohort and National Blood Service,WTCCC2 project controls - 1958 British Birth Cohort and National Blood Service,EGAD00000000022,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Illumina 1.2M
EGAS00000000029,Massive Genomic Rearrangment Acquired in a Single Catastrophic Event During Cancer Development,"Cancer is driven by mutation. Using Agilent exome hybridisation capture and Illumina GA massively parallel sequencing technology, we aim to sequence ~1600 microRNAs plus the protein coding genome of 25 matched human renal cancer samples. Bespoke algorithms are being developed to identify the somatically acquired point mutations, insertions and deletions in these samples. This project will give unprecedented insights into mutational processes, cellular repair pathways and gene networks associated with renal cancer development.Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 25 renal cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 50 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.
                   ",EGAD00001000002,Massive genomic rearrangement acquired in a single catastrophic event during cancer development,Massive genomic rearrangement acquired in a single catastrophic event during cancer development, 
EGAS00000000030,Nordic Samples on build 36,"Nordic control dataset
                   ",EGAD00000000036,Title not provided,NcOEDG Stockholm 1 samples, Affymetrix 500K
EGAS00000000030,Nordic Samples on build 36,"Nordic control dataset
                   ",EGAD00000000037,Title not provided,NcOEDG Stockholm 2 samples, Affymetrix 5.0
EGAS00000000030,Nordic Samples on build 36,"Nordic control dataset
                   ",EGAD00000000039,Title not provided,NcOEDG Malmo - Lund samples, Affymetrix 500K
EGAS00000000030,Nordic Samples on build 36,"Nordic control dataset
                   ",EGAD00000000042,Title not provided,GenomEUtwin Finnish (FIN) samples, Illumina HumanHap 300
EGAS00000000030,Nordic Samples on build 36,"Nordic control dataset
                   ",EGAD00000000032,Title not provided,NcOEDG Helsinki 1 samples, Illumina HumanHap 300
EGAS00000000030,Nordic Samples on build 36,"Nordic control dataset
                   ",EGAD00000000035,Title not provided,NcOEDG Helsinki 4 samples, Illumina CNV370
EGAS00000000030,Nordic Samples on build 36,"Nordic control dataset
                   ",EGAD00000000041,Title not provided,GenomEUtwin Swedish (SWE) samples, Illumina HumanHap 300
EGAS00000000030,Nordic Samples on build 36,"Nordic control dataset
                   ",EGAD00000000034,Title not provided,NcOEDG Helsinki 3 samples, Illumina HumanHap 300
EGAS00000000030,Nordic Samples on build 36,"Nordic control dataset
                   ",EGAD00000000033,Title not provided,NcOEDG Helsinki 2 samples, Illumina HumanHap 300
EGAS00000000030,Nordic Samples on build 36,"Nordic control dataset
                   ",EGAD00000000040,Title not provided,GenomEUtwin Danish (DK) samples, Illumina HumanHap 300
EGAS00000000030,Nordic Samples on build 36,"Nordic control dataset
                   ",EGAD00000000038,Title not provided,NcOEDG Stockholm 3 samples, Illumina HumanHap 550
EGAS00000000031,HLA has strongest association with IgA nephropathy in genome-wide analysis,"GWAS study of families with probands with IgA nephropathy from the UK Glomerulonephritis DNA bank
                   ",EGAD00000000024,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Illumina 1.2M
EGAS00000000031,HLA has strongest association with IgA nephropathy in genome-wide analysis,"GWAS study of families with probands with IgA nephropathy from the UK Glomerulonephritis DNA bank
                   ",EGAD00000000060,Title not provided,Samples from the UK Glomerulonephritis DNA bank," Illumina 610K Quad, Illumina Hap300"
EGAS00000000031,HLA has strongest association with IgA nephropathy in genome-wide analysis,"GWAS study of families with probands with IgA nephropathy from the UK Glomerulonephritis DNA bank
                   ",EGAD00000000022,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Illumina 1.2M
EGAS00000000032,Control sets genotyped with Dynal RELI SSO and Roche Molecular Systems platfroms,"HLA typing on subjects in WTCCC and T1DGC GWA studies using Dynal RELI SSO assays (Invitrogen, Paisley, UK), sequence-specific oligonucleotide probe-based method and  
                        line strips from Roche Molecular Systems (Alameda, CA, USA)
                   ",EGAD00000000031,Title not provided,HLA genotyping of 1958 British Birth Cohort samples, Dynal RELI SSO assay
EGAS00000000033,Geographical structure and differential natural selection among North European populations,"European populations and epidemiological cohorts are of special significance in the current era of genomic research aiming to characterize the background of common human diseases. The genome sequence, detailed information of genetic variations between individuals, high-throughput molecular technologies and novel statistical strategies create new possibilities to define genetic and life-style risk factors behind common health problems. Studies of large population cohorts are needed to transform the genetic information to detailed understanding of the predisposing factors in diseases affecting most human populations. European twin cohorts provide a unique competitive advantage for investigations of the role of genetics and environment or life style in the etiology of common diseases. This project will apply and develop new molecular and statistical strategies to analyze unique European twin and other population cohorts to define and characterise the genetic, environmental and life-style components in the background of health problems like obesity, migraine, coronary heart disease and stroke, representing major health care problems worldwide.
                   ",EGAD00000000043,Title not provided,GenomeEUtwin control samples," Illumina HumanHap300-Duo, Illumina HumanHap 550K"
EGAS00000000034,"
Genome wide association scan in Parkinson's disease
                    ","Genome-wide association scan was performed in 1,705 cases of parkinson's genotyped on the Illumina Human 660W SNP array, and 5,175 controls genotyped on the Illumina1.2M-Duo. Analysis was carried out on the overlaps set of SNPs.
                   ",EGAD00000000023,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Affymetrix 6.0
EGAS00000000034,"
Genome wide association scan in Parkinson's disease
                    ","Genome-wide association scan was performed in 1,705 cases of parkinson's genotyped on the Illumina Human 660W SNP array, and 5,175 controls genotyped on the Illumina1.2M-Duo. Analysis was carried out on the overlaps set of SNPs.
                   ",EGAD00000000021,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Affymetrix 6.0
EGAS00000000034,"
Genome wide association scan in Parkinson's disease
                    ","Genome-wide association scan was performed in 1,705 cases of parkinson's genotyped on the Illumina Human 660W SNP array, and 5,175 controls genotyped on the Illumina1.2M-Duo. Analysis was carried out on the overlaps set of SNPs.
                   ",EGAD00000000024,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Illumina 1.2M
EGAS00000000034,"
Genome wide association scan in Parkinson's disease
                    ","Genome-wide association scan was performed in 1,705 cases of parkinson's genotyped on the Illumina Human 660W SNP array, and 5,175 controls genotyped on the Illumina1.2M-Duo. Analysis was carried out on the overlaps set of SNPs.
                   ",EGAD00000000022,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Illumina 1.2M
EGAS00000000034,"
Genome wide association scan in Parkinson's disease
                    ","Genome-wide association scan was performed in 1,705 cases of parkinson's genotyped on the Illumina Human 660W SNP array, and 5,175 controls genotyped on the Illumina1.2M-Duo. Analysis was carried out on the overlaps set of SNPs.
                   ",EGAD00000000057,Title not provided,WTCCC project samples from the Parkinson's disase cohort, Illumina 610K Quad
EGAS00000000036,HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans,"Based on the prior knowledge of involvement of the human leukocyte antigen locus in Han Chinese patients with carbamazepine-induced Stevens-Johnson syndrome, we imputed the HLA types for each case and control subject from the array of SNPs in the Human610-Quad GWAS platform (NCBI Build 36.1). We then performed a genome-wide association test which included the imputed HLA alleles as markers.
                   ",EGAD00000000059,Title not provided,Aggregate results from 43 Carbamazepine-induced hypersensitivity syndrome patients and 1296 1958 British Birth Cohort control samples," Affymetrix 500K, Illumina 610K Quad"
EGAS00000000037,Carbamazepine-induced hypersensitivity reactions in Europeans,"An antiepileptic drug carbamazepine is well tolerated by the majority of patients, but can cause severe and potentialy fatal hypersensitivity reactions in a small number of individuals. The aim of this study was to identify genetic predictors of hypersensitivity reactions to carbamazepine. We undertook a genome-wide association study (GWAS) in 22 patients of European ancestry with carbamazepine-induced hypersensitivity syndrome (HSS) and compared our data with genotypes from a healthy population within the WTCCC. We performed imputation of classical HLA alleles according to  a recently described method (Science. 2010 Dec 10;330(6010):1551-7. Epub 2010 Nov 4). GWAS statistical analysis was performed using logistic regression with an additive model of inheritance. 
                   ",EGAD00000000058,Title not provided,Aggregate results from 22 Carbamazepine-induced hypersensitivity syndrome patients and 2691 UK National Blood Service (NBS) control samples, Illumina Infinium 1.2M
EGAS00000000038,T1DGC GWAS 1958 British Birth Cohort controls,"T1DGC genome-wide case-control association study for Type 1 Diabetes (T1D) using the 1958 British Birth Cohort as controls. The cases for this study are made available from the NCBI dbGAP.
                   ",EGAD00000000030,Title not provided,T1DGC project 1958 British Birth Cohort samples, Illumina HumanHap 550
EGAS00000000039,WTCCC3 case-control study for Primary Biliary Cirrhosis,"Genome-wide association scan was performed in 1,840 cases of primary biliary cirrhosis and 5,163 controls. Replication of new associations was tested in an independent set of 620 cases and 2,514 controls.
                   ",EGAD00000000024,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Illumina 1.2M
EGAS00000000039,WTCCC3 case-control study for Primary Biliary Cirrhosis,"Genome-wide association scan was performed in 1,840 cases of primary biliary cirrhosis and 5,163 controls. Replication of new associations was tested in an independent set of 620 cases and 2,514 controls.
                   ",EGAD00000000022,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Illumina 1.2M
EGAS00000000039,WTCCC3 case-control study for Primary Biliary Cirrhosis,"Genome-wide association scan was performed in 1,840 cases of primary biliary cirrhosis and 5,163 controls. Replication of new associations was tested in an independent set of 620 cases and 2,514 controls.
                   ",EGAD00000000056,Title not provided,WTCCC project samples from the primary biliary cirrhosis cohort, Illumina 610K Quad
EGAS00000000040,Mutation of FOXL2 in granulosa cell tumors of the ovary,"We generated paired-end RNA-Seq data using the Illumina Genome Analyzer II platform for four adult granulosa cell tumours (GCTs) of the ovary (1 primary, 3 recurrent). We screened this data for the presence of GCT specific sequence variants and detected a non-synonymous mutation in the FOXL2 gene that was found to be recurrent in 97% of 89 additional GCTs.  To measure genomic stability of the four index cases, we generated Affmetrix SNP 6.0 data and analysed these data for copy number changes.  Raw sequence reads as well as Affymetrix CEL files are available to applicants.
                   ",EGAD00000000047,Title not provided,Signal data for from 3 recurrent and 1 ovarian primary Granulosa Cell Tumour samples, Affymetrix 6.0
EGAS00000000040,Mutation of FOXL2 in granulosa cell tumors of the ovary,"We generated paired-end RNA-Seq data using the Illumina Genome Analyzer II platform for four adult granulosa cell tumours (GCTs) of the ovary (1 primary, 3 recurrent). We screened this data for the presence of GCT specific sequence variants and detected a non-synonymous mutation in the FOXL2 gene that was found to be recurrent in 97% of 89 additional GCTs.  To measure genomic stability of the four index cases, we generated Affmetrix SNP 6.0 data and analysed these data for copy number changes.  Raw sequence reads as well as Affymetrix CEL files are available to applicants.
                   ",EGAD00000000046,Title not provided,RNA-SEQ data from 3 recurrent and 1 ovarian primary Granulosa Cell Tumour samples, Illumina Genome Analyzer II
EGAS00000000043,WNT-signaling and Dupuytren's Disease,"The EGA hosts the summary genotype results of the GWAS in 856 patients with Dupuytren's disease and 2,836 population based controls from 'LifeLines' cohort study",EGAD00000000115,Summary data from case control analysis,Summary data from GWAS analysis on 856 cases and 2836 control, Illumina CytoSNP-12
EGAS00000000048,A MITF germline mutation predisposes to melanoma and renal cell carcinoma,,EGAD00000000122,Title not provided,Genotypes at MITF E318K variant," Illumina HumanHap 300 v2 Duo, Illumina HumanCNV370, Illumina Human660W-Quad"
EGAS00000000048,A MITF germline mutation predisposes to melanoma and renal cell carcinoma,,EGAD00000000121,Title not provided,Genotypes at MITF E318K variant, Taqman and sequencing
EGAS00000000051,A small cell lung cancer genome reports complex tobacco exposure signatures,"Cancer is driven by mutation. Worldwide, tobacco smoking is the major lifestyle exposure that causes cancer, exerting carcinogenicity through 60 chemicals that bind and mutate DNA. Using massively parallel sequencing technology, we sequenced a small cell lung cancer cell line, NCI-H209, to explore the mutational burden associated with tobacco smoking. 22,910 somatic substitutions were identified, including 132 in coding exons. Multiple mutation signatures testify to the cocktail of carcinogens in tobacco smoke and their proclivities for particular bases and surrounding sequence context. Effects of transcription-coupled repair and a second, more general expression-linked repair pathway were evident. We identified a tandem duplication that duplicates exons 3-8 of CHD7 in-frame, and another two lines carrying PVT1-CHD7 fusion genes, suggesting that CHD7 may be recurrently rearranged in this disease. These findings illustrate the potential for next-generation sequencing to provide unprecedented insights into mutational processes, cellular repair pathways and gene networks associated with cancer.
                   ",EGAD00000000054,Title not provided,"NCI-H209 is an immortal cell line derived from a bone marrow metastasis of a patient with small cell lung cancer, taken before chemotherapy. The specimen showed histologically typical small cells with classic neuroendocrine features. NCI-BL209 is an EBV-transformed B-cell line derived from the same patient as the small cell lung cancer cell line, NCI-H209", Life Tech - Solid
EGAS00000000052,A Comprehensive Catalogue of Somatic Mutations from a Human Cancer Genome,"We have carried out complete sequencing of the genome of the human male maligant melanoma cell line COLO-829 using the Illumina Genome Analyzer II. We generated a sequencing library with a median insert size of ~200 bp following random fragmentation and gel fractionation of the genomic DNA. We sequenced 75 bases from both ends of these templates to cover the COLO-829 genome to an average depth of more than 40x. We have carried out purity-filtering (PF) to remove mixed reads, where two or more different template molecules are close enough on the surface of the flow-cell to form a mixed or overlapping cluster. No other filtering of the data has been carried out prior to submission. We have also submitted sequence data for a lymphoblastoid control cell line COLO-829BL from the same individual.
                   ",EGAD00000000055,COLO-829/COLO-829BL,COLO-829 is a publicly available immortal cancer cell line and COLO-829BL is a lymphoblastoid cell line derived from the same patient, Illumina Genome Analyzer II
EGAS00000000053,Coeliac Disease Immunochip dataset,"Illumina Immunochip genotype data for coeliac disease and control samples. Data is in PLINK binary format. Calling algorithm for genotypes is based on GenomeStudio (GenTrain), with manual clustering of selected variants (please see published manuscript). Genotypes called in this way may not be exactly  identical to those generated by other algorithms - this is particularly relevant for groups wishing to utilise the control data (e.g. 1958 Birth Cohort). Please contact the investigators if you wish to discuss access to other data formats (e.g. .idat).
                   ",EGAD00010000250,Title not provided,NBS control samples," Illumina ImmunoBeadChip - Illuminus, GenoSNP"
EGAS00000000053,Coeliac Disease Immunochip dataset,"Illumina Immunochip genotype data for coeliac disease and control samples. Data is in PLINK binary format. Calling algorithm for genotypes is based on GenomeStudio (GenTrain), with manual clustering of selected variants (please see published manuscript). Genotypes called in this way may not be exactly  identical to those generated by other algorithms - this is particularly relevant for groups wishing to utilise the control data (e.g. 1958 Birth Cohort). Please contact the investigators if you wish to discuss access to other data formats (e.g. .idat).
                   ",EGAD00010000246,Title not provided,Coeliac disease cases and control samples. (1958BC samples excluded)," Illumina ImmunoBeadChip - Illuminus, GenoSNP"
EGAS00000000053,Coeliac Disease Immunochip dataset,"Illumina Immunochip genotype data for coeliac disease and control samples. Data is in PLINK binary format. Calling algorithm for genotypes is based on GenomeStudio (GenTrain), with manual clustering of selected variants (please see published manuscript). Genotypes called in this way may not be exactly  identical to those generated by other algorithms - this is particularly relevant for groups wishing to utilise the control data (e.g. 1958 Birth Cohort). Please contact the investigators if you wish to discuss access to other data formats (e.g. .idat).
                   ",EGAD00010000248,Title not provided,1958BC control samples ," Illumina ImmunoBeadChip - Illuminus, GenoSNP"
EGAS00000000054,Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution,"We have used next generation sequencing to sequence genomes (>43-fold coverage) and transcriptomes of an oestrogen-receptor-alpha-positive metastatic lobular breast cancer at depth. We found 32 somatic non-synonymous coding mutations present in the metastasis, and measured the frequency of these somatic mutations in DNA from the primary tumour of the same patient.
                   ",EGAD00000000048,Title not provided,Sequencing data from oestrogen-receptor-alpha-positive metastatic lobular breast cancer sample, Illumina Genome Analyzer II
EGAS00000000054,Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution,"We have used next generation sequencing to sequence genomes (>43-fold coverage) and transcriptomes of an oestrogen-receptor-alpha-positive metastatic lobular breast cancer at depth. We found 32 somatic non-synonymous coding mutations present in the metastasis, and measured the frequency of these somatic mutations in DNA from the primary tumour of the same patient.
                   ",EGAD00000000049,Title not provided,RNA-SEQ data from oestrogen-receptor-alpha-positive metastatic lobular breast cancer sample, Illumina Genome Analyzer II
EGAS00000000055,Procardis study on novel susceptibility genes for coronary artery disease (CAD),"An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary artery disease that is highly heritable. The genetic determinants of the Lp(a) lipoprotein level and their relevance for the risk of coronary disease are incompletely understood. METHODS: We used a novel gene chip containing 48,742 single-nucleotide polymorphisms (SNPs) in 2100 candidate genes to test for associations in 3145 case subjects with coronary disease and 3352 control subjects. Replication was tested in three independent populations involving 4846 additional case subjects with coronary disease and 4594 control subjects. RESULTS: Three chromosomal regions (6q26-27, 9p21, and 1p13) were strongly associated with the risk of coronary disease. The LPA locus on 6q26-27 encoding Lp(a) lipoprotein had the strongest association. We identified a common variant (rs10455872) at the LPA locus with an odds ratio for coronary disease of 1.70 (95% confidence interval [CI], 1.49 to 1.95) and another independent variant (rs3798220) with an odds ratio of 1.92 (95% CI, 1.48 to 2.49). Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines the number of kringle IV-type 2 repeats), and a small Lp(a) lipoprotein size. Replication studies confirmed the effects of both variants on the Lp(a) lipoprotein level and the risk of coronary disease. A meta-analysis showed that with a genotype score involving both LPA SNPs, the odds ratios for coronary disease were 1.51 (95% CI, 1.38 to 1.66) for one variant and 2.57 (95% CI, 1.80 to 3.67) for two or more variants. After adjustment for the Lp(a) lipoprotein level, the association between the LPA genotype score and the risk of coronary disease was abolished. CONCLUSIONS: We identified two LPA variants that were strongly associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease. Our findings provide support for a causal role of Lp(a) lipoprotein in coronary disease.
                   ",EGAD00000000028,Title not provided,Aggregate results from a GWAS study on 3352 cases abd 3145 controls, iSelect Beadchip
EGAS00000000056,Identification of cis- and trans-regulatory variation modulating microRNA expression levels in human fibroblasts,"MicroRNAs (miRNAs) are regulatory noncoding RNAs that affect the production of a significant fraction of human mRNAs via post-transcriptional regulation. Interindividual variation of the miRNA expression levels is likely to influence the expression of miRNA target genes and may therefore contribute to phenotypic differences in humans, including susceptibility to common disorders. The extent to which miRNA levels are genetically controlled is largely unknown. In this report, we assayed the expression levels of miRNAs in primary fibroblasts from 180 European newborns of the GenCord project and performed association analysis to identify eQTLs (expression quantitative traits loci). We detected robust expression for 121 miRNAs out of 365 interrogated. We have identified significant cis- (10%) and trans- (11%) eQTLs. Furthermore, we detected one genomic locus (rs1522653) that influences the expression levels of five miRNAs, thus unraveling a novel mechanism for coregulation of miRNA expression",EGAD00000000027,Title not provided,eQTL data for European newborns, Illumina HumanHap550
EGAS00000000059,Assessment of genomic copy number alterations in breast cancer,"The aim of this study was to assess genomic copy number alterations in a panel of breast cancer cell lines.  These data were used to identify common aberrations associated with breast cancer, and also to identify aberrations associated with response to therapeutic compounds.
                   ",EGAD00000000119,Title not provided,Genotypes from cell lines derived from breast carcinoma tissue, Affymetrix 6.0
EGAS00000000060,A genome-wide meta analysis on stroke and ischemic stroke within four populations,"In this analysis a genome-wide meta-analysis was performed on all stroke and ischemic stroke.
                   ",EGAD00000000029,Title not provided,Aggregate results from a case-control study on stroke and ischemic stroke., 
EGAS00000000062,Complex Landscapes of Somatic Rearrangements in Human Breast Cancer Genomes,"We have used massively parallel paired end sequencing strategies to reconstruct the genomic landscape of 24 breast cancer genomes, through the identification and characterization of 2166 somatically acquired genomic rearrangements. These studies have revealed considerable complexity in the patterns of structural variation, identified novel fusion genes and unveiled new insights into the complex structure of amplicons.
                   ",EGAD00000000053,Title not provided,Sequencing data from Breast Cancer samples, Illumina Genome Analyzer II
EGAS00000000064,The patterns and dynamics of genomic instability in metastatic pancreatic cancer,"Pancreatic cancer is an aggressive malignancy with a five-year mortality of 9798%, usually due to widespread metastatic disease. Previous studies indicate that this disease has a complex genomic landscape, with frequent copy number changes and point mutations, but genomic rearrangements have not been characterized in detail. Despite the clinical importance of metastasis, there remain fundamental questions about the clonal structures of metastatic tumours, including phylogenetic relationships among metastases, the scale of ongoing parallel evolution in metastatic and primary sites, and how the tumour disseminates. Here we harness advances in DNA sequencing to annotate genomic rearrangements in 13 patients with pancreatic cancer and explore clonal relationships among metastases. We find that pancreatic cancer acquires rearrangements indicative of telomere dysfunction and abnormal cell-cycle control, namely dysregulated G1-to-S-phase transition with intact G2M checkpoint. These initiate amplification of cancer genes and occur predominantly in early cancer development rather than the later stages of the disease. Genomic instability frequently persists after cancer dissemination, resulting in ongoing, parallel and even convergent evolution among different metastases. We find evidence that there is genetic heterogeneity among metastasis-initiating cells, that seeding metastasis may require driver mutations beyond those required for primary tumours, and that phylogenetic trees across metastases show organ-specific branches. These data attest to the richness of genetic variation in cancer, brought about by the tandem forces of genomic instability and evolutionary selection.",EGAD00000000052,Title not provided,Sequencing data from natching Pancreatic Carcinoma samples, Illumina Genome Analyzer II
EGAS00000000074,Evolution of an adenomacarcinoma in response to selection by targeted kinase inhibitors,"Background - Adenocarcinomas of the tongue are rare and represent the minority (20-25%) of salivary gland tumors affecting the tongue.  We investigated the utility of massively parallel sequencing to characterize an adenocarcinoma of the tongue, before and after treatment. 
                        Results - In the pre-treatment tumor we identified 7,629 genes within regions of copy number gain. 1,078 genes exhibited increased expression relative to the blood and unrelated tumors and four genes contained somatic protein-coding mutations. Our analysis suggested the tumor cells were driven by the RET oncogene. Genes whose protein products are targeted by the RET inhibitors sunitinib and sorafenib correlated with being amplified and or highly expressed. Consistent with our observations administration of sunitinib was associated with stable disease lasting 4 months, after which the lung lesions began to grow.  Administration of sorafenib and sulindac provided disease stabilization for an additional 3 months after which the cancer progressed and new lesions appeared. A recurring metastasis possessed 7,288 genes within copy number amplicons, 385 genes exhibiting increased expression relative to other tumours and 9 new somatic protein coding mutations. The observed mutations and amplif
                        ications were  consistent with therapeutic resistance arising through activation of the MAPK and AKT pathways. Conclusions - We conclude that complete genomic characterization of a rare tumour has the potential to aid in clinical decision making and identifying therapeutic approaches where no established treatment protocols exist.  These results also provide direct in-vivo genomic evidence for mutational evolution within a tumor under drug selection and potential mechanisms of drug resistance accrual.
                   ",EGAD00000000045,Title not provided,Genomic sequencing and transcriptome shotgun sequencing of a metastatic tumour and its recurrence after drug therapy in a single patient, Illumina Genome Analyzer II
EGAS00000000075,ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas,"We have sequenced the whole transcriptomes of 18 ovarian clear-cell carcinomas and 1 ovarian clear-cell carcinoma cell line and found somatic mutations in ARID1A (the AT-rich interactive domain 1A [SWI-like] gene) in 6 of the samples. ARID1A encodes BAF250a, a key component of the SWISNF chromatin remodeling complex. We sequenced ARID1A in an additional 210 ovarian carcinomas and a second ovarian clear-cell carcinoma cell line and measured BAF250a expression by means of immunohistochemical analysis in an additional 455 ovarian carcinomas",EGAD00000000114,Title not provided,Whole transcriptome sequence data from 18 ovarian clear-cell carcinoma samples and one TOV21G ovarian clear-cell carcinoma cell line, Illumina Genome Analyzer II
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000104,Title not provided,Gabriel samples from the Russian UFA cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000098,Title not provided,Gabriel samples from the Swiss SALPADIA cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000090,Title not provided,Gabriel samples from the Russian KMSU cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000105,Title not provided,Gabriel samples from the multicenter occupational cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000087,Title not provided,Gabriel samples from the multicenter GAIN cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000092,Title not provided,Gabriel samples from the German MAGIS cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000083,Title not provided,Gabriel samples from the French EGEA Cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000088,Title not provided,Gabriel samples from the Karelia Allergy Study, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000076,Title not provided,Gabriel samples from the Australian Bussleton Cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000095,Title not provided,Gabriel samples from the Dutch PIAMA cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000093,Title not provided,Gabriel samples from the German MAGIS cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000081,Title not provided,Gabriel samples from multicenter ECRHS Cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000082,Title not provided,Gabriel samples from the French EGEA Cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000102,Title not provided,Gabriel samples from the Russian TOMSK cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000106,Title not provided,Gabriel samples from the multicenter occupational cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000085,Title not provided,Gabriel samples from the German Gabriel Advanced Survey, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000108,Title not provided,Gabriel samples from the UK AUGOSA cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000075,Title not provided,Gabriel samples from the Swedish BAMSE Cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000080,Title not provided,Gabriel samples from multicenter ECRHS Cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000107,Title not provided,Gabriel samples from the multicenter occupational cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000091,Title not provided,Gabriel samples from the Russian KMSU cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000101,Title not provided,Gabriel samples from the Russian TOMSK cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000074,Title not provided,Gabriel samples from the Swedish BAMSE Cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000103,Title not provided,Gabriel samples from the Russian UFA cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000086,Title not provided,Gabriel samples from the multicenter GAIN cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000077,Title not provided,Gabriel samples from the Australian Bussleton Cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000097,Title not provided,Gabriel samples from the Swiss SALPADIA cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000110,Title not provided,Gabriel aggregate data from the asthma study samples, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000084,Title not provided,Gabriel samples from the German Gabriel Advanced Survey, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000089,Title not provided,Gabriel samples from the Karelia Allergy Study, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000094,Title not provided,Gabriel samples from the UK MRCA cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000109,Title not provided,Gabriel samples from the UK SEVERE cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000073,Title not provided,Gabriel samples from the 1958 British Birth Cohort, Illumina 610-Quad
EGAS00000000077,"A Large-Scale, Consortium-Based Genomewide Association Study of Asthma","We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma.",EGAD00000000096,Title not provided,Gabriel samples from the Dutch PIAMA cohort, Illumina 610-Quad
EGAS00000000082,ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.,"The telomeric amplicon at 8p12 is common in oestrogen receptor-positive (ER+) breast cancers. Array-CGH and expression analyses of 1172 primary breast tumours revealed that ZNF703 was the single gene within the minimal amplicon and was amplified predominantly in the Luminal B subtype. Amplification was shown to correlate with increased gene and protein expression and was associated with a distinct expression signature and poor clinical outcome. ZNF703 transformed NIH 3T3 fibroblasts, behaving as a classical oncogene, and regulated proliferation in human luminal breast cancer cell lines and immortalized human mammary epithelial cells. Manipulation of ZNF703 expression in the luminal MCF7 cell line modified the effects of TGF on proliferation. Overexpression of ZNF703 in normal human breast epithelial cells enhanced the frequency of in vitro colony-forming cells from luminal progenitors. Taken together, these data strongly point to ZNF703 as a novel oncogene in Luminal B breast cancer.",EGAD00010000158,Title not provided,Affymetrix 6.0 cel files, Affymetrix SNP 6.0
EGAS00000000082,ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.,"The telomeric amplicon at 8p12 is common in oestrogen receptor-positive (ER+) breast cancers. Array-CGH and expression analyses of 1172 primary breast tumours revealed that ZNF703 was the single gene within the minimal amplicon and was amplified predominantly in the Luminal B subtype. Amplification was shown to correlate with increased gene and protein expression and was associated with a distinct expression signature and poor clinical outcome. ZNF703 transformed NIH 3T3 fibroblasts, behaving as a classical oncogene, and regulated proliferation in human luminal breast cancer cell lines and immortalized human mammary epithelial cells. Manipulation of ZNF703 expression in the luminal MCF7 cell line modified the effects of TGF on proliferation. Overexpression of ZNF703 in normal human breast epithelial cells enhanced the frequency of in vitro colony-forming cells from luminal progenitors. Taken together, these data strongly point to ZNF703 as a novel oncogene in Luminal B breast cancer.",EGAD00010000160,Title not provided,Illumina HT 12 IDATS, Illumina HT 12
EGAS00000000083,METABRIC,"The elucidation of breast cancer subgroups and their molecular drivers
requires integrated views of the genome and transcriptome from
representative numbers of patients. We present an integrated analysis of
copy number and gene expression in a discovery and validation
set of 997 and 995 primary breast tumours, respectively, with long-term
clinical follow-up. Inherited variants (CNVs, SNPs) and acquired somatic
copy number aberrations (CNAs) were associated with expression in  40% of
genes, although the landscape was dominated by cis and trans-acting CNAs. By
delineating expression outlier genes driven in cis by CNAs, we identified
putative cancer genes, including deletions in PPP2R2A, MTAP, and MAP2K4.
Unsupervised analysis of paired DNA/RNA profiles revealed novel subgroups
with distinct clinical outcomes, which reproduced in the validation cohort.
These include a high-risk, ER-positive 11q13/14 cis-acting subgroup and a
favourable prognosis subgroup devoid of CNAs. Trans-acting aberration
0152hotspots were found to modulate subgroup-specific gene networks, including
a TCR deletion-mediated adaptive immune response in the 0152CNA-devoid
sub-group and a Basal-specific chromosome 5 deletion-driven mitotic network.
Our results provide a novel molecular stratification of the breast cancer
population, derived from the impact of somatic copy number aberrations on
the transcriptome.",EGAD00010000215,Title not provided,Segmented (CBS) copy number aberrations (CNA); validation set, Affymetrix SNP 6.0
EGAS00000000083,METABRIC,"The elucidation of breast cancer subgroups and their molecular drivers
requires integrated views of the genome and transcriptome from
representative numbers of patients. We present an integrated analysis of
copy number and gene expression in a discovery and validation
set of 997 and 995 primary breast tumours, respectively, with long-term
clinical follow-up. Inherited variants (CNVs, SNPs) and acquired somatic
copy number aberrations (CNAs) were associated with expression in  40% of
genes, although the landscape was dominated by cis and trans-acting CNAs. By
delineating expression outlier genes driven in cis by CNAs, we identified
putative cancer genes, including deletions in PPP2R2A, MTAP, and MAP2K4.
Unsupervised analysis of paired DNA/RNA profiles revealed novel subgroups
with distinct clinical outcomes, which reproduced in the validation cohort.
These include a high-risk, ER-positive 11q13/14 cis-acting subgroup and a
favourable prognosis subgroup devoid of CNAs. Trans-acting aberration
0152hotspots were found to modulate subgroup-specific gene networks, including
a TCR deletion-mediated adaptive immune response in the 0152CNA-devoid
sub-group and a Basal-specific chromosome 5 deletion-driven mitotic network.
Our results provide a novel molecular stratification of the breast cancer
population, derived from the impact of somatic copy number aberrations on
the transcriptome.",EGAD00010000217,Title not provided,Segmented (HMM) copy number aberrations (CNA); discovery set , Affymetrix SNP 6.0
EGAS00000000083,METABRIC,"The elucidation of breast cancer subgroups and their molecular drivers
requires integrated views of the genome and transcriptome from
representative numbers of patients. We present an integrated analysis of
copy number and gene expression in a discovery and validation
set of 997 and 995 primary breast tumours, respectively, with long-term
clinical follow-up. Inherited variants (CNVs, SNPs) and acquired somatic
copy number aberrations (CNAs) were associated with expression in  40% of
genes, although the landscape was dominated by cis and trans-acting CNAs. By
delineating expression outlier genes driven in cis by CNAs, we identified
putative cancer genes, including deletions in PPP2R2A, MTAP, and MAP2K4.
Unsupervised analysis of paired DNA/RNA profiles revealed novel subgroups
with distinct clinical outcomes, which reproduced in the validation cohort.
These include a high-risk, ER-positive 11q13/14 cis-acting subgroup and a
favourable prognosis subgroup devoid of CNAs. Trans-acting aberration
0152hotspots were found to modulate subgroup-specific gene networks, including
a TCR deletion-mediated adaptive immune response in the 0152CNA-devoid
sub-group and a Basal-specific chromosome 5 deletion-driven mitotic network.
Our results provide a novel molecular stratification of the breast cancer
population, derived from the impact of somatic copy number aberrations on
the transcriptome.",EGAD00010000213,Title not provided,Segmented (CBS) copy number aberrations (CNA); discovery set , Affymetrix SNP 6.0
EGAS00000000083,METABRIC,"The elucidation of breast cancer subgroups and their molecular drivers
requires integrated views of the genome and transcriptome from
representative numbers of patients. We present an integrated analysis of
copy number and gene expression in a discovery and validation
set of 997 and 995 primary breast tumours, respectively, with long-term
clinical follow-up. Inherited variants (CNVs, SNPs) and acquired somatic
copy number aberrations (CNAs) were associated with expression in  40% of
genes, although the landscape was dominated by cis and trans-acting CNAs. By
delineating expression outlier genes driven in cis by CNAs, we identified
putative cancer genes, including deletions in PPP2R2A, MTAP, and MAP2K4.
Unsupervised analysis of paired DNA/RNA profiles revealed novel subgroups
with distinct clinical outcomes, which reproduced in the validation cohort.
These include a high-risk, ER-positive 11q13/14 cis-acting subgroup and a
favourable prognosis subgroup devoid of CNAs. Trans-acting aberration
0152hotspots were found to modulate subgroup-specific gene networks, including
a TCR deletion-mediated adaptive immune response in the 0152CNA-devoid
sub-group and a Basal-specific chromosome 5 deletion-driven mitotic network.
Our results provide a novel molecular stratification of the breast cancer
population, derived from the impact of somatic copy number aberrations on
the transcriptome.",EGAD00010000216,Title not provided,Segmented (CBS) copy number variants (CNV); validation set, Affymetrix SNP 6.0
EGAS00000000083,METABRIC,"The elucidation of breast cancer subgroups and their molecular drivers
requires integrated views of the genome and transcriptome from
representative numbers of patients. We present an integrated analysis of
copy number and gene expression in a discovery and validation
set of 997 and 995 primary breast tumours, respectively, with long-term
clinical follow-up. Inherited variants (CNVs, SNPs) and acquired somatic
copy number aberrations (CNAs) were associated with expression in  40% of
genes, although the landscape was dominated by cis and trans-acting CNAs. By
delineating expression outlier genes driven in cis by CNAs, we identified
putative cancer genes, including deletions in PPP2R2A, MTAP, and MAP2K4.
Unsupervised analysis of paired DNA/RNA profiles revealed novel subgroups
with distinct clinical outcomes, which reproduced in the validation cohort.
These include a high-risk, ER-positive 11q13/14 cis-acting subgroup and a
favourable prognosis subgroup devoid of CNAs. Trans-acting aberration
0152hotspots were found to modulate subgroup-specific gene networks, including
a TCR deletion-mediated adaptive immune response in the 0152CNA-devoid
sub-group and a Basal-specific chromosome 5 deletion-driven mitotic network.
Our results provide a novel molecular stratification of the breast cancer
population, derived from the impact of somatic copy number aberrations on
the transcriptome.",EGAD00010000164,Title not provided,Affymetrix 6.0 CEL files, Affymetrix SNP 6.0
EGAS00000000083,METABRIC,"The elucidation of breast cancer subgroups and their molecular drivers
requires integrated views of the genome and transcriptome from
representative numbers of patients. We present an integrated analysis of
copy number and gene expression in a discovery and validation
set of 997 and 995 primary breast tumours, respectively, with long-term
clinical follow-up. Inherited variants (CNVs, SNPs) and acquired somatic
copy number aberrations (CNAs) were associated with expression in  40% of
genes, although the landscape was dominated by cis and trans-acting CNAs. By
delineating expression outlier genes driven in cis by CNAs, we identified
putative cancer genes, including deletions in PPP2R2A, MTAP, and MAP2K4.
Unsupervised analysis of paired DNA/RNA profiles revealed novel subgroups
with distinct clinical outcomes, which reproduced in the validation cohort.
These include a high-risk, ER-positive 11q13/14 cis-acting subgroup and a
favourable prognosis subgroup devoid of CNAs. Trans-acting aberration
0152hotspots were found to modulate subgroup-specific gene networks, including
a TCR deletion-mediated adaptive immune response in the 0152CNA-devoid
sub-group and a Basal-specific chromosome 5 deletion-driven mitotic network.
Our results provide a novel molecular stratification of the breast cancer
population, derived from the impact of somatic copy number aberrations on
the transcriptome.",EGAD00010000214,Title not provided,Segmented (CBS) copy number variants (CNV); discovery set , Affymetrix SNP 6.0
EGAS00000000083,METABRIC,"The elucidation of breast cancer subgroups and their molecular drivers
requires integrated views of the genome and transcriptome from
representative numbers of patients. We present an integrated analysis of
copy number and gene expression in a discovery and validation
set of 997 and 995 primary breast tumours, respectively, with long-term
clinical follow-up. Inherited variants (CNVs, SNPs) and acquired somatic
copy number aberrations (CNAs) were associated with expression in  40% of
genes, although the landscape was dominated by cis and trans-acting CNAs. By
delineating expression outlier genes driven in cis by CNAs, we identified
putative cancer genes, including deletions in PPP2R2A, MTAP, and MAP2K4.
Unsupervised analysis of paired DNA/RNA profiles revealed novel subgroups
with distinct clinical outcomes, which reproduced in the validation cohort.
These include a high-risk, ER-positive 11q13/14 cis-acting subgroup and a
favourable prognosis subgroup devoid of CNAs. Trans-acting aberration
0152hotspots were found to modulate subgroup-specific gene networks, including
a TCR deletion-mediated adaptive immune response in the 0152CNA-devoid
sub-group and a Basal-specific chromosome 5 deletion-driven mitotic network.
Our results provide a novel molecular stratification of the breast cancer
population, derived from the impact of somatic copy number aberrations on
the transcriptome.",EGAD00010000212,Title not provided,Normalized expression data; normals, Illumina HT 12
EGAS00000000083,METABRIC,"The elucidation of breast cancer subgroups and their molecular drivers
requires integrated views of the genome and transcriptome from
representative numbers of patients. We present an integrated analysis of
copy number and gene expression in a discovery and validation
set of 997 and 995 primary breast tumours, respectively, with long-term
clinical follow-up. Inherited variants (CNVs, SNPs) and acquired somatic
copy number aberrations (CNAs) were associated with expression in  40% of
genes, although the landscape was dominated by cis and trans-acting CNAs. By
delineating expression outlier genes driven in cis by CNAs, we identified
putative cancer genes, including deletions in PPP2R2A, MTAP, and MAP2K4.
Unsupervised analysis of paired DNA/RNA profiles revealed novel subgroups
with distinct clinical outcomes, which reproduced in the validation cohort.
These include a high-risk, ER-positive 11q13/14 cis-acting subgroup and a
favourable prognosis subgroup devoid of CNAs. Trans-acting aberration
0152hotspots were found to modulate subgroup-specific gene networks, including
a TCR deletion-mediated adaptive immune response in the 0152CNA-devoid
sub-group and a Basal-specific chromosome 5 deletion-driven mitotic network.
Our results provide a novel molecular stratification of the breast cancer
population, derived from the impact of somatic copy number aberrations on
the transcriptome.",EGAD00010000211,Title not provided,Normalized expression data; validation set, Illumina HT 12
EGAS00000000083,METABRIC,"The elucidation of breast cancer subgroups and their molecular drivers
requires integrated views of the genome and transcriptome from
representative numbers of patients. We present an integrated analysis of
copy number and gene expression in a discovery and validation
set of 997 and 995 primary breast tumours, respectively, with long-term
clinical follow-up. Inherited variants (CNVs, SNPs) and acquired somatic
copy number aberrations (CNAs) were associated with expression in  40% of
genes, although the landscape was dominated by cis and trans-acting CNAs. By
delineating expression outlier genes driven in cis by CNAs, we identified
putative cancer genes, including deletions in PPP2R2A, MTAP, and MAP2K4.
Unsupervised analysis of paired DNA/RNA profiles revealed novel subgroups
with distinct clinical outcomes, which reproduced in the validation cohort.
These include a high-risk, ER-positive 11q13/14 cis-acting subgroup and a
favourable prognosis subgroup devoid of CNAs. Trans-acting aberration
0152hotspots were found to modulate subgroup-specific gene networks, including
a TCR deletion-mediated adaptive immune response in the 0152CNA-devoid
sub-group and a Basal-specific chromosome 5 deletion-driven mitotic network.
Our results provide a novel molecular stratification of the breast cancer
population, derived from the impact of somatic copy number aberrations on
the transcriptome.",EGAD00010000162,Title not provided,Illumina HT 12 IDATS, Illumina HT 12
EGAS00000000083,METABRIC,"The elucidation of breast cancer subgroups and their molecular drivers
requires integrated views of the genome and transcriptome from
representative numbers of patients. We present an integrated analysis of
copy number and gene expression in a discovery and validation
set of 997 and 995 primary breast tumours, respectively, with long-term
clinical follow-up. Inherited variants (CNVs, SNPs) and acquired somatic
copy number aberrations (CNAs) were associated with expression in  40% of
genes, although the landscape was dominated by cis and trans-acting CNAs. By
delineating expression outlier genes driven in cis by CNAs, we identified
putative cancer genes, including deletions in PPP2R2A, MTAP, and MAP2K4.
Unsupervised analysis of paired DNA/RNA profiles revealed novel subgroups
with distinct clinical outcomes, which reproduced in the validation cohort.
These include a high-risk, ER-positive 11q13/14 cis-acting subgroup and a
favourable prognosis subgroup devoid of CNAs. Trans-acting aberration
0152hotspots were found to modulate subgroup-specific gene networks, including
a TCR deletion-mediated adaptive immune response in the 0152CNA-devoid
sub-group and a Basal-specific chromosome 5 deletion-driven mitotic network.
Our results provide a novel molecular stratification of the breast cancer
population, derived from the impact of somatic copy number aberrations on
the transcriptome.",EGAD00010000210,Title not provided,Normalized expression data; discovery set, Illumina HT 12
EGAS00000000084,WTCCC2 case-control study for Ulcerative Colitis,WTCCC2 project genome-wide case-control association study for Ulcerative Colitis (UC) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000023,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Affymetrix 6.0
EGAS00000000084,WTCCC2 case-control study for Ulcerative Colitis,WTCCC2 project genome-wide case-control association study for Ulcerative Colitis (UC) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000021,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Affymetrix 6.0
EGAS00000000084,WTCCC2 case-control study for Ulcerative Colitis,WTCCC2 project genome-wide case-control association study for Ulcerative Colitis (UC) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.     ,EGAD00000000025,Title not provided,WTCCC2 project Ulcerative Colitis (UC) samples, Affymetrix 6.0
EGAS00000000086,An immune response network associated with blood lipid levels,Genome-wide genotyping was performed on a population-based cohort from the capital region of Finland using the Illumina 610-Quad SNP microarray,EGAD00000000026,Title not provided,"Randomly-selected, unrelated individuals", Illumina 610-Quad
EGAS00000000087,Genome wide association study of severe malaria in Gambian mother-father-child trios,Genome-wide association study of severe malaria in Gambian mother-father-child trios,EGAD00000000019,Title not provided,840 families where both parents have been genotyped together with the child with severe malaria, Illumina 650Y
EGAS00000000088,Genome wide association study of severe malaria in Ghanain mother-farther-child trios,Genome-wide association study of severe malaria in Ghanain mother-farther-child trios,EGAD00000000020,Title not provided,685 families where both parents have been genotyped together with the child with severe malaria, Illumina 650Y
EGAS00000000092,CLL Genome,"The Chronic Lymphocytic Leukemia (CLL) Genome Project aims to identify genetic alterations involved in the development and progression of the CLL, which are still unknown, with the objective of generating a comprehensive catalogue of genetic alterations in 500 independent tumours. The CLL Genome Project, as a contributing member of the International Cancer Genome Consortium (ICGC), has the purposes of creating diagnostic tools, discovering therapeutic targets and developing new strategies that will allow a customized therapy for CLL in order to make it more precise and effective. This study consists of two datasets. EGAD00001000023 described in the Nature paper (2011), Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, and the dataset EGA00001000044 & & EGAD00001000083 described in the Nature (2011) paper, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.",EGAD00010000280,Title not provided,CLL Expression array, Affymetrix snp 6.0
EGAS00000000092,CLL Genome,"The Chronic Lymphocytic Leukemia (CLL) Genome Project aims to identify genetic alterations involved in the development and progression of the CLL, which are still unknown, with the objective of generating a comprehensive catalogue of genetic alterations in 500 independent tumours. The CLL Genome Project, as a contributing member of the International Cancer Genome Consortium (ICGC), has the purposes of creating diagnostic tools, discovering therapeutic targets and developing new strategies that will allow a customized therapy for CLL in order to make it more precise and effective. This study consists of two datasets. EGAD00001000023 described in the Nature paper (2011), Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, and the dataset EGA00001000044 & & EGAD00001000083 described in the Nature (2011) paper, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.",EGAD00010000238,Title not provided,CLL Expression array, Affymetrix GeneChip Human Genome U133 plus 2.0
EGAS00000000092,CLL Genome,"The Chronic Lymphocytic Leukemia (CLL) Genome Project aims to identify genetic alterations involved in the development and progression of the CLL, which are still unknown, with the objective of generating a comprehensive catalogue of genetic alterations in 500 independent tumours. The CLL Genome Project, as a contributing member of the International Cancer Genome Consortium (ICGC), has the purposes of creating diagnostic tools, discovering therapeutic targets and developing new strategies that will allow a customized therapy for CLL in order to make it more precise and effective. This study consists of two datasets. EGAD00001000023 described in the Nature paper (2011), Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, and the dataset EGA00001000044 & & EGAD00001000083 described in the Nature (2011) paper, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.",EGAD00010000470,Title not provided,CLL Expression Array, GPL570
EGAS00000000092,CLL Genome,"The Chronic Lymphocytic Leukemia (CLL) Genome Project aims to identify genetic alterations involved in the development and progression of the CLL, which are still unknown, with the objective of generating a comprehensive catalogue of genetic alterations in 500 independent tumours. The CLL Genome Project, as a contributing member of the International Cancer Genome Consortium (ICGC), has the purposes of creating diagnostic tools, discovering therapeutic targets and developing new strategies that will allow a customized therapy for CLL in order to make it more precise and effective. This study consists of two datasets. EGAD00001000023 described in the Nature paper (2011), Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, and the dataset EGA00001000044 & & EGAD00001000083 described in the Nature (2011) paper, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.",EGAD00001000023,Recurrent Somatic Mutations in CLL,Recurrent Somatic Mutations in CLL, Illumina Genome Analyzer IIx
EGAS00000000092,CLL Genome,"The Chronic Lymphocytic Leukemia (CLL) Genome Project aims to identify genetic alterations involved in the development and progression of the CLL, which are still unknown, with the objective of generating a comprehensive catalogue of genetic alterations in 500 independent tumours. The CLL Genome Project, as a contributing member of the International Cancer Genome Consortium (ICGC), has the purposes of creating diagnostic tools, discovering therapeutic targets and developing new strategies that will allow a customized therapy for CLL in order to make it more precise and effective. This study consists of two datasets. EGAD00001000023 described in the Nature paper (2011), Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, and the dataset EGA00001000044 & & EGAD00001000083 described in the Nature (2011) paper, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.",EGAD00001000044,Recurrent Somatic Mutations in CLL,Recurrent Somatic Mutations in CLL, Illumina Genome Analyzer IIx
EGAS00000000092,CLL Genome,"The Chronic Lymphocytic Leukemia (CLL) Genome Project aims to identify genetic alterations involved in the development and progression of the CLL, which are still unknown, with the objective of generating a comprehensive catalogue of genetic alterations in 500 independent tumours. The CLL Genome Project, as a contributing member of the International Cancer Genome Consortium (ICGC), has the purposes of creating diagnostic tools, discovering therapeutic targets and developing new strategies that will allow a customized therapy for CLL in order to make it more precise and effective. This study consists of two datasets. EGAD00001000023 described in the Nature paper (2011), Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, and the dataset EGA00001000044 & & EGAD00001000083 described in the Nature (2011) paper, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.",EGAD00001000083,Recurrent Somatic Mutations in CLL,Recurrent Somatic Mutations in CLL," Illumina Genome Analyzer II;, Illumina Genome Analyzer IIx"
EGAS00000000097,"Genome wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP 
 ","We conducted GWAS of sporadic CJD, variant CJD, iatrogenic CJD, inherited prion disease, kuru and resistance to kuru despite attendance at mortuary feasts. After quality control we analysed 2000 samples and 6015 control individuals (provided by the Wellcome Trust Case Control Consortium and KORA-gen), for 491032-511862 SNPs in the European study. Association studies were done in each geographical and aetiological group followed by several combined analyses.",EGAD00010000202,Title not provided,Case samples (Illumina_660K & Illumina_670K), Illumina_660K/Illumina_670K
EGAS00000000098,METABRIC,"Solid tumors are complex tissues composed of a mixture of cancer and normal cells, which complicates the interpretation of their molecular profiles. Normal cell contamination can dilute cancer cell information and tissue architecture is generally not reflected in molecular assays. To address these challenges, we developed a computational approach based on standard Haematoxylin and Eosin-stained sections and demonstrated its power in a discovery cohort of  323 breast tumors and an independent validation cohort of 241 tumors. First, to deconvolute cellular heterogeneity and detect subtle genomic aberrations, we introduced an algorithm  based on tumor cellularity to increase the comparability of copy-number profiles between samples. Second, we demonstrated that a predictor for survival integrating image-based and molecular features significantly outperforms classifiers based on single data types. Third, we described and validated a novel, independent prognostic factor based on quantitative analysis of spatial patterns between stromal cells, which are not detectable by molecular assays. Our quantitative methods refine and complement molecular assays of tumor samples and could benefit all large-scale cancer studies.First, to deconvolute cellular heterogeneity and detect subtle genomic aberrations, we introduced an algorithm  based on tumor cellularity to increase the comparability of copy-number profiles between samples. Second, we demonstrated that a predictor for survival integrating image-based and molecular features significantly outperforms classifiers based on single data types. Third, we described and validated a novel, independent prognostic factor based on quantitative analysis of spatial patterns between stromal cells, which are not detectable by molecular assays. Our quantitative methods refine and complement molecular assays of tumor samples and could benefit all large-scale cancer studies.",EGAD00010000266,Title not provided,Metabric breast cancer samples (Genotype raw data), Affymetrix SNP 6.0
EGAS00000000098,METABRIC,"Solid tumors are complex tissues composed of a mixture of cancer and normal cells, which complicates the interpretation of their molecular profiles. Normal cell contamination can dilute cancer cell information and tissue architecture is generally not reflected in molecular assays. To address these challenges, we developed a computational approach based on standard Haematoxylin and Eosin-stained sections and demonstrated its power in a discovery cohort of  323 breast tumors and an independent validation cohort of 241 tumors. First, to deconvolute cellular heterogeneity and detect subtle genomic aberrations, we introduced an algorithm  based on tumor cellularity to increase the comparability of copy-number profiles between samples. Second, we demonstrated that a predictor for survival integrating image-based and molecular features significantly outperforms classifiers based on single data types. Third, we described and validated a novel, independent prognostic factor based on quantitative analysis of spatial patterns between stromal cells, which are not detectable by molecular assays. Our quantitative methods refine and complement molecular assays of tumor samples and could benefit all large-scale cancer studies.First, to deconvolute cellular heterogeneity and detect subtle genomic aberrations, we introduced an algorithm  based on tumor cellularity to increase the comparability of copy-number profiles between samples. Second, we demonstrated that a predictor for survival integrating image-based and molecular features significantly outperforms classifiers based on single data types. Third, we described and validated a novel, independent prognostic factor based on quantitative analysis of spatial patterns between stromal cells, which are not detectable by molecular assays. Our quantitative methods refine and complement molecular assays of tumor samples and could benefit all large-scale cancer studies.",EGAD00010000270,Title not provided,Metabric breast cancer samples (Images), Aperio image - H&E stained tissue_section
EGAS00000000098,METABRIC,"Solid tumors are complex tissues composed of a mixture of cancer and normal cells, which complicates the interpretation of their molecular profiles. Normal cell contamination can dilute cancer cell information and tissue architecture is generally not reflected in molecular assays. To address these challenges, we developed a computational approach based on standard Haematoxylin and Eosin-stained sections and demonstrated its power in a discovery cohort of  323 breast tumors and an independent validation cohort of 241 tumors. First, to deconvolute cellular heterogeneity and detect subtle genomic aberrations, we introduced an algorithm  based on tumor cellularity to increase the comparability of copy-number profiles between samples. Second, we demonstrated that a predictor for survival integrating image-based and molecular features significantly outperforms classifiers based on single data types. Third, we described and validated a novel, independent prognostic factor based on quantitative analysis of spatial patterns between stromal cells, which are not detectable by molecular assays. Our quantitative methods refine and complement molecular assays of tumor samples and could benefit all large-scale cancer studies.First, to deconvolute cellular heterogeneity and detect subtle genomic aberrations, we introduced an algorithm  based on tumor cellularity to increase the comparability of copy-number profiles between samples. Second, we demonstrated that a predictor for survival integrating image-based and molecular features significantly outperforms classifiers based on single data types. Third, we described and validated a novel, independent prognostic factor based on quantitative analysis of spatial patterns between stromal cells, which are not detectable by molecular assays. Our quantitative methods refine and complement molecular assays of tumor samples and could benefit all large-scale cancer studies.",EGAD00010000268,Title not provided,Metabric breast cancer samples (Expression raw data), Illumina HT 12
EGAS00000000099,Identification of genetic etiology of CAMRQ2,"We aimed to identify genetic etiology of cerebellar ataxia, mental retardation, and disequilibrium syndrome (CAMRQ). Targeted sequencing of the entire CAMRQ2 locus, 7.1 Mb interval on chromosome 17p13, in three affected individuals and two obligate carriers uncovered the mutation associated with CAMRQ2.",EGAD00010000130,Title not provided,"Cerebellar ataxia, mental retardation, and disequilibrium syndrome (CAMRQ) samples"," Illumina 300 Duo V2 - Bead Studio, Illumina"
EGAS00000000101,The Genetic Analysis of multiple sclerosis,"We created these data in order to identify genetic variants associated with increased susceptibility to multiple sclerosis. Cases from many parts of the world were genotyped with the Illumina 660 chip along with Swedish controls. In our analysis we also used control data from the WTCCC2 common UK controls and from other published studies.
                   ",EGAD00000000023,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Affymetrix 6.0
EGAS00000000101,The Genetic Analysis of multiple sclerosis,"We created these data in order to identify genetic variants associated with increased susceptibility to multiple sclerosis. Cases from many parts of the world were genotyped with the Illumina 660 chip along with Swedish controls. In our analysis we also used control data from the WTCCC2 common UK controls and from other published studies.
                   ",EGAD00000000021,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Affymetrix 6.0
EGAS00000000101,The Genetic Analysis of multiple sclerosis,"We created these data in order to identify genetic variants associated with increased susceptibility to multiple sclerosis. Cases from many parts of the world were genotyped with the Illumina 660 chip along with Swedish controls. In our analysis we also used control data from the WTCCC2 common UK controls and from other published studies.
                   ",EGAD00000000120,Title not provided,WTCCC2 project Multiple Sclerosis (MS) samples, Human670-QuadCustom v1
EGAS00000000101,The Genetic Analysis of multiple sclerosis,"We created these data in order to identify genetic variants associated with increased susceptibility to multiple sclerosis. Cases from many parts of the world were genotyped with the Illumina 660 chip along with Swedish controls. In our analysis we also used control data from the WTCCC2 common UK controls and from other published studies.
                   ",EGAD00000000024,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Illumina 1.2M
EGAS00000000101,The Genetic Analysis of multiple sclerosis,"We created these data in order to identify genetic variants associated with increased susceptibility to multiple sclerosis. Cases from many parts of the world were genotyped with the Illumina 660 chip along with Swedish controls. In our analysis we also used control data from the WTCCC2 common UK controls and from other published studies.
                   ",EGAD00000000022,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Illumina 1.2M
EGAS00000000103,WTCCC2 Ischaemic Stroke study,"Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke
                   ",EGAD00000000023,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Affymetrix 6.0
EGAS00000000103,WTCCC2 Ischaemic Stroke study,"Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke
                   ",EGAD00000000021,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Affymetrix 6.0
EGAS00000000103,WTCCC2 Ischaemic Stroke study,"Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke
                   ",EGAD00000000024,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Illumina 1.2M
EGAS00000000103,WTCCC2 Ischaemic Stroke study,"Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke
                   ",EGAD00000000022,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Illumina 1.2M
EGAS00000000103,WTCCC2 Ischaemic Stroke study,"Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke
                   ",EGAD00010000264,Title not provided,WTCCC2 project samples from Ischaemic Stroke Cohort, Illumina_670k - Illuminus
EGAS00000000104,Genomewide association studies in ankylosing spondylitis,The aim of this study was to identify genes associated with ankylosing spondylitis susceptibility in British and Australian individuals of European descent.,EGAD00000000023,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Affymetrix 6.0
EGAS00000000104,Genomewide association studies in ankylosing spondylitis,The aim of this study was to identify genes associated with ankylosing spondylitis susceptibility in British and Australian individuals of European descent.,EGAD00000000021,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Affymetrix 6.0
EGAS00000000104,Genomewide association studies in ankylosing spondylitis,The aim of this study was to identify genes associated with ankylosing spondylitis susceptibility in British and Australian individuals of European descent.,EGAD00000000024,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Illumina 1.2M
EGAS00000000104,Genomewide association studies in ankylosing spondylitis,The aim of this study was to identify genes associated with ankylosing spondylitis susceptibility in British and Australian individuals of European descent.,EGAD00000000022,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Illumina 1.2M
EGAS00000000104,Genomewide association studies in ankylosing spondylitis,The aim of this study was to identify genes associated with ankylosing spondylitis susceptibility in British and Australian individuals of European descent.,EGAD00010000150,Title not provided,WTCCC2 project samples from Ankylosing spondylitis Cohort,  Illumina_670k - Illuminus
EGAS00000000105,Copy number analysis of Diamond-Blackfan Anemia (DBA) using SNP array,"DiamondBlackfan anemia (DBA), is a rare congenital anemia that usually presents in infancy. About fifty percent of DBA patients possess mutations in ribosomal protains (RPs). In this study, we performed genomic copy number analysis using SNP arrays for 27 Japanese DBA patients to detect genomic copy number lesions of the RP genes' loci.",EGAD00010000096,Title not provided,DBA case samples using 250K Nsp, Affymetrix_250K(Nsp) - gtype
EGAS00000000108,Genome wide association scan in psoriasis,"To identify novel susceptibility loci for psoriasis, we undertook a genome-wide association scan of of 594,224 SNPs in 2,622 individuals with psoriasis and 5,667 controls.",EGAD00000000023,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Affymetrix 6.0
EGAS00000000108,Genome wide association scan in psoriasis,"To identify novel susceptibility loci for psoriasis, we undertook a genome-wide association scan of of 594,224 SNPs in 2,622 individuals with psoriasis and 5,667 controls.",EGAD00000000021,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Affymetrix 6.0
EGAS00000000108,Genome wide association scan in psoriasis,"To identify novel susceptibility loci for psoriasis, we undertook a genome-wide association scan of of 594,224 SNPs in 2,622 individuals with psoriasis and 5,667 controls.",EGAD00000000024,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Illumina 1.2M
EGAS00000000108,Genome wide association scan in psoriasis,"To identify novel susceptibility loci for psoriasis, we undertook a genome-wide association scan of of 594,224 SNPs in 2,622 individuals with psoriasis and 5,667 controls.",EGAD00000000022,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Illumina 1.2M
EGAS00000000108,Genome wide association scan in psoriasis,"To identify novel susceptibility loci for psoriasis, we undertook a genome-wide association scan of of 594,224 SNPs in 2,622 individuals with psoriasis and 5,667 controls.",EGAD00010000124,Title not provided,Psoriasis cases as part of WTCCC2 phase 2, Illumina_670k - Illuminus
EGAS00000000109,"Genetics of gene expression in primary human immune cells 
 ",The purpose of this study was to identify cell specific expression quantitative trait loci in freshly isolated highly purified primary B-cells and monocytes from healthy subjects of European ancestry. Cells were purified from Ficoll gradient prepared peripheral blood mononuclear cell fractions using positive selection via magnetic bead labelling of the B-cell marker CD19 and monocyte marker CD14. RNA was extracted from 287 B-cell samples and 288 monocyte samples. RNA was then hybridised to HumanHT-12 v4 BeadChips whole genome expression arrays (Illumina). Individuals were genotyped on HumanOmniExpress-12v1.0 BeadChips (Illumina) at 733202 genetic markers. Data presented include the raw expression values and Robust Spline Normalised values (RSN) for expression for each cell type per individual. Additional genotype data per individual is available on request.,EGAD00010000144,Title not provided,Healthy volunteer collection of European Ancestry, Illumin OmniExpress v1.0 - Illumina GenomeStudio
EGAS00000000114,Krakow experiment - Northern Finland Birth Cohort 1966,,EGAD00000000044,Title not provided,Northern Finland Birth Cohort 1966 samples, Illumina HumanHap370
EGAS00000000115,"Association studies using the Metabochip array - Samples analysed by the WTCCC (1958 British Birth Cohort (58BC), Hypertension cohort (HT), Type 2 Diabetes Cohort (T2D) and Coronary Artery Disease (CAD) cohort)","Genomewide association studies (GWAS) have proven a powerful hypothesis-free method to identify common disease-associated variants. Even quite large GWAS, however, have only at best identified moderate proportions of the genetic variants contributing to disease heritability. To provide cost-effective genotyping of common and rare variants to map the remaining heritability and to fine-map established loci, the Metabochip Consortium has developed a 200,000 SNP chip that has been produced in very large numbers for a fraction of the cost of GWAS chips. This chip provides a powerful tool for genetic studies of metabolic, cardiovascular and anthropometric traits (Voight et al., in press PLoS Genetics).",EGAD00010000230,Title not provided,WTCCC2 samples from Hypertension Cohort ,  - Illuminus
EGAS00000000115,"Association studies using the Metabochip array - Samples analysed by the WTCCC (1958 British Birth Cohort (58BC), Hypertension cohort (HT), Type 2 Diabetes Cohort (T2D) and Coronary Artery Disease (CAD) cohort)","Genomewide association studies (GWAS) have proven a powerful hypothesis-free method to identify common disease-associated variants. Even quite large GWAS, however, have only at best identified moderate proportions of the genetic variants contributing to disease heritability. To provide cost-effective genotyping of common and rare variants to map the remaining heritability and to fine-map established loci, the Metabochip Consortium has developed a 200,000 SNP chip that has been produced in very large numbers for a fraction of the cost of GWAS chips. This chip provides a powerful tool for genetic studies of metabolic, cardiovascular and anthropometric traits (Voight et al., in press PLoS Genetics).",EGAD00010000234,Title not provided,WTCCC2 samples from 1958 British Birth Cohort ,"  - Illuminus, GenoSNP, GenCall"
EGAS00000000115,"Association studies using the Metabochip array - Samples analysed by the WTCCC (1958 British Birth Cohort (58BC), Hypertension cohort (HT), Type 2 Diabetes Cohort (T2D) and Coronary Artery Disease (CAD) cohort)","Genomewide association studies (GWAS) have proven a powerful hypothesis-free method to identify common disease-associated variants. Even quite large GWAS, however, have only at best identified moderate proportions of the genetic variants contributing to disease heritability. To provide cost-effective genotyping of common and rare variants to map the remaining heritability and to fine-map established loci, the Metabochip Consortium has developed a 200,000 SNP chip that has been produced in very large numbers for a fraction of the cost of GWAS chips. This chip provides a powerful tool for genetic studies of metabolic, cardiovascular and anthropometric traits (Voight et al., in press PLoS Genetics).",EGAD00010000236,Title not provided,WTCCC2 samples from Coronary Artery Disease Cohort ,"  - Illuminus, GenoSNP"
EGAS00000000115,"Association studies using the Metabochip array - Samples analysed by the WTCCC (1958 British Birth Cohort (58BC), Hypertension cohort (HT), Type 2 Diabetes Cohort (T2D) and Coronary Artery Disease (CAD) cohort)","Genomewide association studies (GWAS) have proven a powerful hypothesis-free method to identify common disease-associated variants. Even quite large GWAS, however, have only at best identified moderate proportions of the genetic variants contributing to disease heritability. To provide cost-effective genotyping of common and rare variants to map the remaining heritability and to fine-map established loci, the Metabochip Consortium has developed a 200,000 SNP chip that has been produced in very large numbers for a fraction of the cost of GWAS chips. This chip provides a powerful tool for genetic studies of metabolic, cardiovascular and anthropometric traits (Voight et al., in press PLoS Genetics).",EGAD00010000232,Title not provided,WTCCC2 samples from Type 2 Diabetes Cohort ,  - Illuminus
EGAS00000000116,Molecular Sub-grouping of CNS-PNET,"In our study we aimed to define CNS-PNET subgroups.  We performed Expression, Genotyping and/or Immunohistochemistry on 142 samples from 20 worldwide centers.  Using these techniques, we have identified three molecular subgroups with distinct expression and copy number patterns, as well as, unique clinical characteristics.  Specifically, these molecular subgroups were distinguished by primitive neural (group 1), oligoneural (group 2), and mesenchymal lineage (group 3) gene-expression signatures with differential expression of cell-lineage markers LIN28 and OLIG2.  Our report underscores the importance of concerted, collaborative efforts to study large retrospective cohorts of tumours and patients to accelerate biological and ultimately therapeutic studies of rare tumours. The outcome of such a collaboration allowed us to identify LIN28 and OLIG2  as promising diagnostic and prognostic molecular markers for CNS PNET that warrant further assessment in prospective clinical trials.",EGAD00010000256,Title not provided,PNET expression_2, Illumina HumanHT12-v4
EGAS00000000116,Molecular Sub-grouping of CNS-PNET,"In our study we aimed to define CNS-PNET subgroups.  We performed Expression, Genotyping and/or Immunohistochemistry on 142 samples from 20 worldwide centers.  Using these techniques, we have identified three molecular subgroups with distinct expression and copy number patterns, as well as, unique clinical characteristics.  Specifically, these molecular subgroups were distinguished by primitive neural (group 1), oligoneural (group 2), and mesenchymal lineage (group 3) gene-expression signatures with differential expression of cell-lineage markers LIN28 and OLIG2.  Our report underscores the importance of concerted, collaborative efforts to study large retrospective cohorts of tumours and patients to accelerate biological and ultimately therapeutic studies of rare tumours. The outcome of such a collaboration allowed us to identify LIN28 and OLIG2  as promising diagnostic and prognostic molecular markers for CNS PNET that warrant further assessment in prospective clinical trials.",EGAD00010000258,Title not provided,PNET expression_1, Illumina HumanHT6-v3
EGAS00000000116,Molecular Sub-grouping of CNS-PNET,"In our study we aimed to define CNS-PNET subgroups.  We performed Expression, Genotyping and/or Immunohistochemistry on 142 samples from 20 worldwide centers.  Using these techniques, we have identified three molecular subgroups with distinct expression and copy number patterns, as well as, unique clinical characteristics.  Specifically, these molecular subgroups were distinguished by primitive neural (group 1), oligoneural (group 2), and mesenchymal lineage (group 3) gene-expression signatures with differential expression of cell-lineage markers LIN28 and OLIG2.  Our report underscores the importance of concerted, collaborative efforts to study large retrospective cohorts of tumours and patients to accelerate biological and ultimately therapeutic studies of rare tumours. The outcome of such a collaboration allowed us to identify LIN28 and OLIG2  as promising diagnostic and prognostic molecular markers for CNS PNET that warrant further assessment in prospective clinical trials.",EGAD00010000260,Title not provided,PNET genotyping, Illumina OmniQuad 2.5 - CNVpartition
EGAS00000000118,WTCCC2 Schizophrenia study,A WTCCC2 project genome-wide case-control association study for schizophrenia (SP) in individuals from Ireland.,EGAD00010000262,Title not provided,WTCCC2 project Schizophrenia (SP) samples, Affyemtrix 6.0 - CHIAMO
EGAS00000000118,WTCCC2 Schizophrenia study,A WTCCC2 project genome-wide case-control association study for schizophrenia (SP) in individuals from Ireland.,EGAD00000000023,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Affymetrix 6.0
EGAS00000000118,WTCCC2 Schizophrenia study,A WTCCC2 project genome-wide case-control association study for schizophrenia (SP) in individuals from Ireland.,EGAD00000000021,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Affymetrix 6.0
EGAS00000000118,WTCCC2 Schizophrenia study,A WTCCC2 project genome-wide case-control association study for schizophrenia (SP) in individuals from Ireland.,EGAD00000000024,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Illumina 1.2M
EGAS00000000118,WTCCC2 Schizophrenia study,A WTCCC2 project genome-wide case-control association study for schizophrenia (SP) in individuals from Ireland.,EGAD00000000022,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Illumina 1.2M
EGAS00000000121,WTCCC2 Pharmacogenomic Response to Statins study,A WTCCC2 project genome-wide study for pharmacogenomic response to statins (PR) in individuals from Scotland.,EGAD00000000023,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Affymetrix 6.0
EGAS00000000121,WTCCC2 Pharmacogenomic Response to Statins study,A WTCCC2 project genome-wide study for pharmacogenomic response to statins (PR) in individuals from Scotland.,EGAD00000000021,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Affymetrix 6.0
EGAS00000000121,WTCCC2 Pharmacogenomic Response to Statins study,A WTCCC2 project genome-wide study for pharmacogenomic response to statins (PR) in individuals from Scotland.,EGAD00010000282,Title not provided,Pharmacogenomic response to Statins samples (Genotypes/Phenotypes), Affymetrix 6.0 - CHIAMO
EGAS00000000121,WTCCC2 Pharmacogenomic Response to Statins study,A WTCCC2 project genome-wide study for pharmacogenomic response to statins (PR) in individuals from Scotland.,EGAD00000000024,Title not provided,WTCCC2 project samples from National Blood Donors (NBS) Cohort, Illumina 1.2M
EGAS00000000121,WTCCC2 Pharmacogenomic Response to Statins study,A WTCCC2 project genome-wide study for pharmacogenomic response to statins (PR) in individuals from Scotland.,EGAD00000000022,Title not provided,WTCCC2 project samples from 1958 British Birth Cohort, Illumina 1.2M
EGAS00000000122,METABRIC miRNA landscape,"MicroRNAs (miRNAs) are key players in cancer pathogenesis1. They display differential expression across breast cancer subtypes, and play oncogenic and tumor-suppressive roles2-6. A systematic study of the global miRNA landscape in breast cancer and the factors shaping it has not been undertaken. Here we report the results of profiling miRNA expression in 1,302 breast tumors with detailed clinical annotation and long-term follow-up, and for which matching genomic and mRNA expression data were available7. This provides a comprehensive view of the quantity, distribution and variation of the miRNA population and dissects how much genomic, transcriptional and post-transcriptional events contribute to miRNA expression architecture. The key clinical parameters and cellular pathways related to the miRNA landscape are identified, exemplified by context-dependent interaction with cell adhesion and Wnt signaling. Strikingly, in breast cancer miRNAs appear to act as modulators of mRNA-mRNA interactions rather than molecular switches. We demonstrate an important modulatory role for miRNAs in the biology of breast tumors devoid of somatic copy number aberrations, a common subtype where immune response is prominent. Remarkably, prognostic miRNA signatures derived in this subtype are consistently prognostic across several other subtypes and validate in external cohorts. These findings represent a new framework to study the biology of miRNA in human cancer.",EGAD00010000442,Title not provided,Affymetrix SNP 6.0 CEL files, Affymetrix_SNP6_raw
EGAS00000000122,METABRIC miRNA landscape,"MicroRNAs (miRNAs) are key players in cancer pathogenesis1. They display differential expression across breast cancer subtypes, and play oncogenic and tumor-suppressive roles2-6. A systematic study of the global miRNA landscape in breast cancer and the factors shaping it has not been undertaken. Here we report the results of profiling miRNA expression in 1,302 breast tumors with detailed clinical annotation and long-term follow-up, and for which matching genomic and mRNA expression data were available7. This provides a comprehensive view of the quantity, distribution and variation of the miRNA population and dissects how much genomic, transcriptional and post-transcriptional events contribute to miRNA expression architecture. The key clinical parameters and cellular pathways related to the miRNA landscape are identified, exemplified by context-dependent interaction with cell adhesion and Wnt signaling. Strikingly, in breast cancer miRNAs appear to act as modulators of mRNA-mRNA interactions rather than molecular switches. We demonstrate an important modulatory role for miRNAs in the biology of breast tumors devoid of somatic copy number aberrations, a common subtype where immune response is prominent. Remarkably, prognostic miRNA signatures derived in this subtype are consistently prognostic across several other subtypes and validate in external cohorts. These findings represent a new framework to study the biology of miRNA in human cancer.",EGAD00010000440,Title not provided,Segmented copy number data, Affymetrix_SNP6_raw
EGAS00000000122,METABRIC miRNA landscape,"MicroRNAs (miRNAs) are key players in cancer pathogenesis1. They display differential expression across breast cancer subtypes, and play oncogenic and tumor-suppressive roles2-6. A systematic study of the global miRNA landscape in breast cancer and the factors shaping it has not been undertaken. Here we report the results of profiling miRNA expression in 1,302 breast tumors with detailed clinical annotation and long-term follow-up, and for which matching genomic and mRNA expression data were available7. This provides a comprehensive view of the quantity, distribution and variation of the miRNA population and dissects how much genomic, transcriptional and post-transcriptional events contribute to miRNA expression architecture. The key clinical parameters and cellular pathways related to the miRNA landscape are identified, exemplified by context-dependent interaction with cell adhesion and Wnt signaling. Strikingly, in breast cancer miRNAs appear to act as modulators of mRNA-mRNA interactions rather than molecular switches. We demonstrate an important modulatory role for miRNAs in the biology of breast tumors devoid of somatic copy number aberrations, a common subtype where immune response is prominent. Remarkably, prognostic miRNA signatures derived in this subtype are consistently prognostic across several other subtypes and validate in external cohorts. These findings represent a new framework to study the biology of miRNA in human cancer.",EGAD00010000438,Title not provided,Normalized miRNA expression data, Agilent ncRNA 60k
EGAS00000000122,METABRIC miRNA landscape,"MicroRNAs (miRNAs) are key players in cancer pathogenesis1. They display differential expression across breast cancer subtypes, and play oncogenic and tumor-suppressive roles2-6. A systematic study of the global miRNA landscape in breast cancer and the factors shaping it has not been undertaken. Here we report the results of profiling miRNA expression in 1,302 breast tumors with detailed clinical annotation and long-term follow-up, and for which matching genomic and mRNA expression data were available7. This provides a comprehensive view of the quantity, distribution and variation of the miRNA population and dissects how much genomic, transcriptional and post-transcriptional events contribute to miRNA expression architecture. The key clinical parameters and cellular pathways related to the miRNA landscape are identified, exemplified by context-dependent interaction with cell adhesion and Wnt signaling. Strikingly, in breast cancer miRNAs appear to act as modulators of mRNA-mRNA interactions rather than molecular switches. We demonstrate an important modulatory role for miRNAs in the biology of breast tumors devoid of somatic copy number aberrations, a common subtype where immune response is prominent. Remarkably, prognostic miRNA signatures derived in this subtype are consistently prognostic across several other subtypes and validate in external cohorts. These findings represent a new framework to study the biology of miRNA in human cancer.",EGAD00010000444,Title not provided,Agilent ncRNA 60k txt files, Agilent ncRNA 60k
EGAS00000000122,METABRIC miRNA landscape,"MicroRNAs (miRNAs) are key players in cancer pathogenesis1. They display differential expression across breast cancer subtypes, and play oncogenic and tumor-suppressive roles2-6. A systematic study of the global miRNA landscape in breast cancer and the factors shaping it has not been undertaken. Here we report the results of profiling miRNA expression in 1,302 breast tumors with detailed clinical annotation and long-term follow-up, and for which matching genomic and mRNA expression data were available7. This provides a comprehensive view of the quantity, distribution and variation of the miRNA population and dissects how much genomic, transcriptional and post-transcriptional events contribute to miRNA expression architecture. The key clinical parameters and cellular pathways related to the miRNA landscape are identified, exemplified by context-dependent interaction with cell adhesion and Wnt signaling. Strikingly, in breast cancer miRNAs appear to act as modulators of mRNA-mRNA interactions rather than molecular switches. We demonstrate an important modulatory role for miRNAs in the biology of breast tumors devoid of somatic copy number aberrations, a common subtype where immune response is prominent. Remarkably, prognostic miRNA signatures derived in this subtype are consistently prognostic across several other subtypes and validate in external cohorts. These findings represent a new framework to study the biology of miRNA in human cancer.",EGAD00010000434,Title not provided,Normalised mRNA expression, Illumina HT 12
EGAS00000000122,METABRIC miRNA landscape,"MicroRNAs (miRNAs) are key players in cancer pathogenesis1. They display differential expression across breast cancer subtypes, and play oncogenic and tumor-suppressive roles2-6. A systematic study of the global miRNA landscape in breast cancer and the factors shaping it has not been undertaken. Here we report the results of profiling miRNA expression in 1,302 breast tumors with detailed clinical annotation and long-term follow-up, and for which matching genomic and mRNA expression data were available7. This provides a comprehensive view of the quantity, distribution and variation of the miRNA population and dissects how much genomic, transcriptional and post-transcriptional events contribute to miRNA expression architecture. The key clinical parameters and cellular pathways related to the miRNA landscape are identified, exemplified by context-dependent interaction with cell adhesion and Wnt signaling. Strikingly, in breast cancer miRNAs appear to act as modulators of mRNA-mRNA interactions rather than molecular switches. We demonstrate an important modulatory role for miRNAs in the biology of breast tumors devoid of somatic copy number aberrations, a common subtype where immune response is prominent. Remarkably, prognostic miRNA signatures derived in this subtype are consistently prognostic across several other subtypes and validate in external cohorts. These findings represent a new framework to study the biology of miRNA in human cancer.",EGAD00010000436,Title not provided,Illumina HT 12 IDAT files, Illumina HT 12
EGAS00000000129,The complex SNP and CNV genetic architecture of the increased risk of  congenital heart defects in Down syndrome ,"Here we aimed to contribute to the description of the genetic architecture of Congenital heart defect (CHD) in Down syndrome (DS), and report the results of a genome-wide association study using samples from DS individuals with and without CHD. CHD is a common developmental defect of DS occurring in 40% of cases. This case-control GWAS includes 187 DS with CHD as cases, and 151 DS without CHD as controls.",EGAD00010000464,Title not provided,Down syndrome SNP genotyping data, Illumina 550K - Illumina Genome Studio
EGAS00000000129,The complex SNP and CNV genetic architecture of the increased risk of  congenital heart defects in Down syndrome ,"Here we aimed to contribute to the description of the genetic architecture of Congenital heart defect (CHD) in Down syndrome (DS), and report the results of a genome-wide association study using samples from DS individuals with and without CHD. CHD is a common developmental defect of DS occurring in 40% of cases. This case-control GWAS includes 187 DS with CHD as cases, and 151 DS without CHD as controls.",EGAD00010000466,Title not provided,Down syndrome CNV genotyping data, NimbleGen 135K aCGH - NimbleScan 
EGAS00000000132,The Haemgen RBC study,"Anaemia is a major determinant of global ill-health. To refine our understanding of the genetic factors influencing red blood cell formation and function, we carried out a meta-analysis of genome-wide association studies (GWAS) for six red blood cell traits: haemoglobin (HB), mean cell haemoglobin (MCH), mean cell haemoglobin concentration (MCHC), mean cell volume (MCV), packed cell volume (PCV) and red blood cell count (RBC). We provide genome-wide association results for 62,553 people of European ancestry using up to 2,644,161 autosomal SNPs. Participants with extreme measurements (>+/-3SD from mean) were excluded on a per phenotype basis. Imputation was done using haplotypes from HapMap Phase 2. SNP associations with each phenotype were tested by linear regression using an additive genetic model. Associations were tested separately in each cohort, with principal components and other study specific factors as covariates to account of population substructure. We then carried out meta-analysis of results from the individual cohorts using z-scores weighted by square root of sample size. SNPs with MAF<1% (weighted average across cohorts) were removed, as were SNPs with weight <50% of phenotype sample size.  
  
  
  
  
  
  
  
  
  
  
  
  
  Anaemia is a major determinant of global ill-health. To refine our understanding of the genetic factors influencing red blood cell formation and function, we carried out a meta-analysis of genome-wide association studies (GWAS) for six red blood cell traits: haemoglobin (HB), mean cell haemoglobin (MCH), mean cell haemoglobin concentration (MCHC), mean cell volume (MCV), packed cell volume (PCV) and red blood cell count (RBC). We provide genome-wide association results for 62,553 people of European ancestry using up to 2,644,161 autosomal SNPs. Participants with extreme measurements (>+/-3SD from mean) were excluded on a per phenotype basis. Imputation was done using haplotypes from HapMap Phase 2. SNP associations with each phenotype were tested by linear regression using an additive genetic model. Associations were tested separately in each cohort, with principal components and other study specific factors as covariates to account of population substructure. We then carried out meta-analysis of results from the individual cohorts using z-scores weighted by square root of sample size. SNPs with MAF<1% (weighted average across cohorts) were removed, as were SNPs with weight <50% of phenotype sample size.  
  
  
  
  
  
  
  
  
  
  
  
  
 ",EGAD00010000300,Title not provided,Summary statistics from Haemgen RBC GWAS," Illumina, Affymetrix, Perlegen"
EGAS00000000134,NOWAC blood-based breast cancer case-control study,"Tumor-host interactions extend beyond the local microenvironment and cancer development largely depends on the ability of malignant cells to hijack and exploit the normal physiological processes of the host. Although abnormalities in a hosts systemic immunity are associated with increased cancer susceptibility, the functional interplay between tumor cells and circulating immune cells in regulating tumorigenic responses is unclear. We employed the Norwegian Women and Cancer study, a large prospective population-based cohort study, to identify gene expression changes in blood cells that provide a robust and reproducible diagnostic signal specific to breast cancer patients. We further show that circulating blood cells in breast cancer patients are enriched in genes involved in systemic immunosuppression and the motility, metabolism, growth, and proliferation of immune cells. By mining of the cancer-associated blood transcriptome, we identified immune mediators or biomarkers that could permit early detection of breast cancer and open avenues to novel targeted immunotherapies.",EGAD00010000476,Title not provided,blood-based gene expression from breast cancer cases and age-matched controls in case-control serie 1 (CC1), Illumina
EGAS00000000134,NOWAC blood-based breast cancer case-control study,"Tumor-host interactions extend beyond the local microenvironment and cancer development largely depends on the ability of malignant cells to hijack and exploit the normal physiological processes of the host. Although abnormalities in a hosts systemic immunity are associated with increased cancer susceptibility, the functional interplay between tumor cells and circulating immune cells in regulating tumorigenic responses is unclear. We employed the Norwegian Women and Cancer study, a large prospective population-based cohort study, to identify gene expression changes in blood cells that provide a robust and reproducible diagnostic signal specific to breast cancer patients. We further show that circulating blood cells in breast cancer patients are enriched in genes involved in systemic immunosuppression and the motility, metabolism, growth, and proliferation of immune cells. By mining of the cancer-associated blood transcriptome, we identified immune mediators or biomarkers that could permit early detection of breast cancer and open avenues to novel targeted immunotherapies.",EGAD00010000474,Title not provided,blood-based gene expression from breast cancer cases and age-matched controls in case-control serie 2 (CC2), Illumina
EGAS00000000134,NOWAC blood-based breast cancer case-control study,"Tumor-host interactions extend beyond the local microenvironment and cancer development largely depends on the ability of malignant cells to hijack and exploit the normal physiological processes of the host. Although abnormalities in a hosts systemic immunity are associated with increased cancer susceptibility, the functional interplay between tumor cells and circulating immune cells in regulating tumorigenic responses is unclear. We employed the Norwegian Women and Cancer study, a large prospective population-based cohort study, to identify gene expression changes in blood cells that provide a robust and reproducible diagnostic signal specific to breast cancer patients. We further show that circulating blood cells in breast cancer patients are enriched in genes involved in systemic immunosuppression and the motility, metabolism, growth, and proliferation of immune cells. By mining of the cancer-associated blood transcriptome, we identified immune mediators or biomarkers that could permit early detection of breast cancer and open avenues to novel targeted immunotherapies.",EGAD00010000478,Title not provided,blood-based gene expression from breast cancer cases and age-matched controls in case-control serie 3 (CC3), Illumina
EGAS00000000135,"Genome wide differential DNA methylation signatures in pediatric acute
lymphoblastic leukemia","The aim of our study is to provide a comprehensive analysis of DNA methylation in a large collection of primary pediatric acute lymphoblastic leukemia (ALL) samples taken at diagnosis and relapse of the disease as well as non-leukemic control blood cells from healthy individuals. Complementary gene expression data available at the Gene Expression Omnibus under series GSE26878.  
  
  
  
 ",EGAD00010000458,Title not provided,Controls using 450K DNA methylation, 
EGAS00000000135,"Genome wide differential DNA methylation signatures in pediatric acute
lymphoblastic leukemia","The aim of our study is to provide a comprehensive analysis of DNA methylation in a large collection of primary pediatric acute lymphoblastic leukemia (ALL) samples taken at diagnosis and relapse of the disease as well as non-leukemic control blood cells from healthy individuals. Complementary gene expression data available at the Gene Expression Omnibus under series GSE26878.  
  
  
  
 ",EGAD00010000456,Title not provided,Leukemia samples using 450K DNA methylation, 
EGAS00000000137,MRCA and MRCE SNP genotypes,"Gene expression levels can be an important link DNA between variation and phenotypic manifestations. Our previous map of global gene expression based on approximately 400K SNPs and 50K transcripts in 400 sib pairs from the MRCA family panel has been widely used to interpret the results of GWAS. Here, we more than double the size of our initial dataset with expression data on 550 additional individuals from the MRCE family panel using the Illumina whole genome expression array. We have used new statistical methods for dimension reduction to account for non-genetic effects in estimates of expression levels and we have also included SNPs imputed from the 1000 Genomes Project. Our methods reduced false discovery rates and increased the number of eQTLs mapped either locally or at a distance (i.e. in cis or trans) from 1,534 in the MRCA dataset to 4,452 (with <5% FDR). Imputation of 1000 Genomes SNPs further increased the number of eQTLs to 7,302. Using the same methods and imputed SNPs in the newly acquired MRCE dataset we identified eQTLs for 9000 genes. The combined results identify strong local and distant effects for transcripts from 14,177 genes. Our eQTL database (http://www.hsph.harvard.edu/faculty/liming-liang/software/eqtl/) based on these results is freely available to help define the function of disease-associated variants.",EGAD00010000383,Title not provided,MRCA sample using 100K, Illumina 100K - GenomeStudio
EGAS00000000137,MRCA and MRCE SNP genotypes,"Gene expression levels can be an important link DNA between variation and phenotypic manifestations. Our previous map of global gene expression based on approximately 400K SNPs and 50K transcripts in 400 sib pairs from the MRCA family panel has been widely used to interpret the results of GWAS. Here, we more than double the size of our initial dataset with expression data on 550 additional individuals from the MRCE family panel using the Illumina whole genome expression array. We have used new statistical methods for dimension reduction to account for non-genetic effects in estimates of expression levels and we have also included SNPs imputed from the 1000 Genomes Project. Our methods reduced false discovery rates and increased the number of eQTLs mapped either locally or at a distance (i.e. in cis or trans) from 1,534 in the MRCA dataset to 4,452 (with <5% FDR). Imputation of 1000 Genomes SNPs further increased the number of eQTLs to 7,302. Using the same methods and imputed SNPs in the newly acquired MRCE dataset we identified eQTLs for 9000 genes. The combined results identify strong local and distant effects for transcripts from 14,177 genes. Our eQTL database (http://www.hsph.harvard.edu/faculty/liming-liang/software/eqtl/) based on these results is freely available to help define the function of disease-associated variants.",EGAD00010000385,Title not provided,MRCA sample using 300K,  Illumina 300K - GenomeStudio
EGAS00000000137,MRCA and MRCE SNP genotypes,"Gene expression levels can be an important link DNA between variation and phenotypic manifestations. Our previous map of global gene expression based on approximately 400K SNPs and 50K transcripts in 400 sib pairs from the MRCA family panel has been widely used to interpret the results of GWAS. Here, we more than double the size of our initial dataset with expression data on 550 additional individuals from the MRCE family panel using the Illumina whole genome expression array. We have used new statistical methods for dimension reduction to account for non-genetic effects in estimates of expression levels and we have also included SNPs imputed from the 1000 Genomes Project. Our methods reduced false discovery rates and increased the number of eQTLs mapped either locally or at a distance (i.e. in cis or trans) from 1,534 in the MRCA dataset to 4,452 (with <5% FDR). Imputation of 1000 Genomes SNPs further increased the number of eQTLs to 7,302. Using the same methods and imputed SNPs in the newly acquired MRCE dataset we identified eQTLs for 9000 genes. The combined results identify strong local and distant effects for transcripts from 14,177 genes. Our eQTL database (http://www.hsph.harvard.edu/faculty/liming-liang/software/eqtl/) based on these results is freely available to help define the function of disease-associated variants.",EGAD00010000381,Title not provided,MRCE sample using 300K, Illumina 300K - GenomeStudio
EGAS00001000001,Exome Resequencing of Progressive Hearing Loss,Exome resequencing of progressive hearing loss.,EGAD00001000197,Progressive Hearing Loss,Progressive Hearing Loss, Illumina Genome Analyzer II;
EGAS00001000002,Breast Cancer Follow Up Series,"This study's purpose is to use data generated in whole genome and exome Breast Cancer sequencing to target specific areas in multiple other Breast Cancer samples. These areas will then be subjected to PCR in multiple cases, tagged and then pool the resultant amplicons. These amplicons will then be sequenced on the Illumina GAII. This is hoped to show the prevalence of previous findings in multiple individuals in a high throughput method.",EGAD00001000066,Breast Cancer Follow Up Series,Breast Cancer Follow Up Series, Illumina Genome Analyzer II
EGAS00001000003,Cancer Single Cell Sequencing,"This study is to ascertain whether it is feasible to extract a single cell form a Cancer cell line, amplify it and sequence it.",EGAD00001000067,Cancer Single Cell Sequencing,Cancer Single Cell Sequencing," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000003,Cancer Single Cell Sequencing,"This study is to ascertain whether it is feasible to extract a single cell form a Cancer cell line, amplify it and sequence it.",EGAD00001000154,Single-cell genome sequencing reveals DNA-mutation per cell cycle,Single-cell genome sequencing reveals DNA-mutation per cell cycle," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000004,Multifocal Breast Project,"Comparison of genomic rearrangements and DNA methylation
patterns between different foci of multiple synchronous
(multifocal and multicentric) invasive breast cancers",EGAD00001000068,Multifocal Breast Project,Multifocal Breast Project, Illumina Genome Analyzer II
EGAS00001000005,Lung Rearrangement Study,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from cancer samples and subjected to 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000069,Lung Rearrangement Study,Lung Rearrangement Study, Illumina HiSeq 2000
EGAS00001000005,Lung Rearrangement Study,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from cancer samples and subjected to 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000638,Somatic pseudogenes acquired during cancer development  Whole Genome sequencing,Insertion of processed pseudogenes is known to occur in the germline but has not previously been observed in somatic cells. Formation of pseudogenes could represent a new class of mutation in cancers and a new source of potential driver events., Illumina HiSeq 2000;
EGAS00001000006,Renal Cancer Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 25 renal cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 50 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00000000051,Title not provided,Sequencing data from matching Renal Carcinoma samples, Illumina Genome Analyzer II
EGAS00001000006,Renal Cancer Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 25 renal cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 50 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000287,Renal Cancer Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 25 renal cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 50 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes., Illumina Genome Analyzer II;
EGAS00001000006,Renal Cancer Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 25 renal cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 50 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000014,Renal Cancer Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 25 renal cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 50 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.," Illumina Genome Analyzer II;, Illumina Genome Analyzer II"
EGAS00001000006,Renal Cancer Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 25 renal cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 50 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000001,Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma,Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma, 
EGAS00001000008,Whole Genome Sequencing of hiPS cells,Human induced pluripotent stem (hiPS) cells hold great promise for regenerative medicine. Safety issues of use of hiPS cells however remain to be addressed. One of such issues is mutations derived from somatic donor cells and introduced during genome manipulation. We sequence whole genomes of hiPS cells and analyzed mutations. Our study brings hiPS cell technology one step closer to application to regenerative medicine.,EGAD00001000362,Whole Genome Sequencing of hiPS cells,Human induced pluripotent stem (hiPS) cells hold great promise for regenerative medicine. Safety issues of use of hiPS cells however remain to be addressed. One of such issues is mutations derived from somatic donor cells and introduced during genome manipulation. We sequence whole genomes of hiPS cells and analyzed mutations. Our study brings hiPS cell technology one step closer to application to regenerative medicine., Illumina HiSeq 2000;
EGAS00001000009,SCLC,"The aim of this study is to use sequence data generated from 500 bp paired end reads using the Illumina platform to characterise the breakpoints of chromosomal translocations, amplifications and deletions at high resolution (to the bp).",EGAD00001000002,Massive genomic rearrangement acquired in a single catastrophic event during cancer development,Massive genomic rearrangement acquired in a single catastrophic event during cancer development, 
EGAS00001000011,CLL cancer Sample Sequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from CLL cancer samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000004,CLL cancer Sample Sequencing,CLL cancer Sample Sequencing," Illumina Genome Analyzer II, Illumina Genome Analyzer"
EGAS00001000011,CLL cancer Sample Sequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from CLL cancer samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000002,Massive genomic rearrangement acquired in a single catastrophic event during cancer development,Massive genomic rearrangement acquired in a single catastrophic event during cancer development, 
EGAS00001000012,Various Cancer Fusion Gene Sequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from 50 commomon epithelial cancer samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000005,Various Cancer Fusion Gene Sequencing,Various Cancer Fusion Gene Sequencing," Illumina Genome Analyzer II;, Illumina Genome Analyzer II"
EGAS00001000012,Various Cancer Fusion Gene Sequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from 50 commomon epithelial cancer samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000002,Massive genomic rearrangement acquired in a single catastrophic event during cancer development,Massive genomic rearrangement acquired in a single catastrophic event during cancer development, 
EGAS00001000013,Osteosarcoma Sequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from 25 osetocarcinoma samples and subjected to total of three lanes of 37 bp paired end sequencing on the llumina GA per sample. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000007,Osteosarcoma Sequencing,Osteosarcoma Sequencing," Illumina Genome Analyzer II;, Illumina Genome Analyzer II"
EGAS00001000013,Osteosarcoma Sequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from 25 osetocarcinoma samples and subjected to total of three lanes of 37 bp paired end sequencing on the llumina GA per sample. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000002,Massive genomic rearrangement acquired in a single catastrophic event during cancer development,Massive genomic rearrangement acquired in a single catastrophic event during cancer development, 
EGAS00001000014,CLL Cancer Whole Genome Sequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from a range of cancer samples and subjected paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000013,CLL Cancer Whole Genome Sequencing,CLL Cancer Whole Genome Sequencing, Illumina Genome Analyzer II
EGAS00001000014,CLL Cancer Whole Genome Sequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from a range of cancer samples and subjected paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000002,Massive genomic rearrangement acquired in a single catastrophic event during cancer development,Massive genomic rearrangement acquired in a single catastrophic event during cancer development, 
EGAS00001000016,The GENCODE exome   sequencing the complete human exome,The aim of this study was to construct and assess a hybrid capture product which targeted the complete human GENCODE exome.,EGAD00001000003,Gencode Exome Pilot,Gencode Exome Pilot, Illumina Genome Analyzer II
EGAS00001000017,Familial Melanoma Sequencing,The sequence of familial melanoma cases to identify candidate susceptibility alleles,EGAD00001000016,Familial Melanoma Sequencing,Familial Melanoma Sequencing," Illumina HiSeq 2000, Illumina Genome Analyzer II, Illumina HiSeq 2000;"
EGAS00001000020,Genetic variation in Kuusamo,"The aim of this study is to characterize as completely as possible the genetic variation and structure of Kuusamo and surrounding regions. We will perform low coverage, whole genome sequencing in a relatively limited number (approximately 200) of individuals from the FINRISK study both of whose parents are born in Kuusamo, Posio or Taivalkoski. Sequencing will be performed at the Wellcome Trust Sanger Institute (WTSI). We have previously shown using simulations and genome wide SNP data that the genetic characteristics agree with known genealogical data, and that approximately 200 individuals suffice to capture the majority of the genetic variation in this population.

We have also developed methods for long-range haplotyping and long-range imputation, which are more accurate than traditional methods. This will allow us to identify a majority of the founder haplotypes in this population. The information from the haplotypes identified in this study can be used in other studies to impute from genome-wide SNP data the full genome sequence of samples ascertained for specific phenotypes.",EGAD00001000055,Genetic variation in Kuusamo,Genetic variation in Kuusamo," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000020,Genetic variation in Kuusamo,"The aim of this study is to characterize as completely as possible the genetic variation and structure of Kuusamo and surrounding regions. We will perform low coverage, whole genome sequencing in a relatively limited number (approximately 200) of individuals from the FINRISK study both of whose parents are born in Kuusamo, Posio or Taivalkoski. Sequencing will be performed at the Wellcome Trust Sanger Institute (WTSI). We have previously shown using simulations and genome wide SNP data that the genetic characteristics agree with known genealogical data, and that approximately 200 individuals suffice to capture the majority of the genetic variation in this population.

We have also developed methods for long-range haplotyping and long-range imputation, which are more accurate than traditional methods. This will allow us to identify a majority of the founder haplotypes in this population. The information from the haplotypes identified in this study can be used in other studies to impute from genome-wide SNP data the full genome sequence of samples ascertained for specific phenotypes.",EGAD00001000299,Kuusamo whole exome sequencing,"Whole exome sequencing of samples selected from the Finrisk sample collection. The samples sequenced in this study have all been collected in Kuusamo, Finland.", Illumina HiSeq 2000;
EGAS00001000023,Identifying autosomal recessive mutations causing neurological disorders,"The objective of this study is to resequence of targeted intervals containing autosomal recessive variants causing neurological disorders in consanguineous pedigrees. Using homozygosity mapping, three intervals of very different sizes have previously been unambiguously mapped for three different neurological diseases: 2.4Mb, 8Mb and 14.3Mb in size, for Microlissencephaly, Severe Mental Retardation and Complicated hereditary spastic paraplegia respectively. This study is a pilot to assess how well custom targeted resequencing performs across a broad size range of intervals. The study design is to use a different custom capture probe set for each interval, pulldown from a single patient from each family, and sequence 1 lane using Illumina paired-reads for each sample. Candidate variants will be followed up in the families themselves, and in patients with similar phenotypes from outbred populations.",EGAD00001000340,Identifying autosomal recessive mutations causing neurological disorders,"The objective of this study is to resequence of targeted intervals containing autosomal recessive variants causing neurological disorders in consanguineous pedigrees. Using homozygosity mapping, three intervals of very different sizes have previously been unambiguously mapped for three different neurological diseases: 2.4Mb, 8Mb and 14.3Mb in size, for Microlissencephaly, Severe Mental Retardation and Complicated hereditary spastic paraplegia respectively. This study is a pilot to assess how well custom targeted resequencing performs across a broad size range of intervals. The study design is to use a different custom capture probe set for each interval, pulldown from a single patient from each family, and sequence 1 lane using Illumina paired-reads for each sample. Candidate variants will be followed up in the families themselves, and in patients with similar phenotypes from outbred populations", Illumina Genome Analyzer II;
EGAS00001000024,Piloting exome resequencing in consanguineous families with homozygosity mapping intervals,This pilot study aims to generate pilot data to inform future study designs in consanguineous families or inbred populations by resequencing the exome of six individuals from five families with neurodevelopmental diseases. For all of these families a single mapping interval containing the causal variant has previously been identified.,EGAD00001000341,Piloting exome resequencing in consanguineous families with homozygosity mapping intervals,This pilot study aims to generate pilot data to inform future study designs in consanguineous families or inbred populations by resequencing the exome of six individuals from five families with neurodevelopmental diseases. For all of these families a single mapping interval containing the causal variant has previously been identified., Illumina HiSeq 2000;
EGAS00001000025,Whole exome sequencing of Severe Insulin Resistant patients ,Illumina paired-end sequencing of whole- exome pulldown DNA from Severe Insulin Resistant patients.,EGAD00001000380,Whole exome sequencing of Severe Insulin Resistant patients.,Illumina paired-end sequencing of whole- exome pulldown DNA from Severe Insulin Resistant patients.," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000026,Whole Exome Sequencing for Characterization of Disease Causing Mutations in two Pakistani Families Suffering from Autosomal Recessive Ocular Disorders ,"We propose to use whole exome Agilent solution
probes and paired end Illumina sequencing to sequence 4 individuals
from two families suffering from novel autosomal recessive disease
[microphthalmia, MOP (OMIM %251600) and non-syndromic persistent
hyperplastic primary vitreous, PHPV (OMIM %611311)]. Selected
candidate variants will subsequently be genotyped in the remaining
family members in Pakistan with the aim of identifying the rare
homozygous recessive mutations responsible for the disease phenotype.  This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/",EGAD00001000024,Whole Exome Sequencing for Characterization of Disease Causing Mutations in two Pakistani Families Suffering from Autosomal Recessive Ocular Disorders.,Whole Exome Sequencing for Characterization of Disease Causing Mutations in two Pakistani Families Suffering from Autosomal Recessive Ocular Disorders., Illumina Genome Analyzer II
EGAS00001000027,TMD AMLK Exome Study,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 20 Primary Acute Megakaryocytic Leukemia samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes,EGAD00001000070,TMD_AMLK Exome Study,TMD_AMLK Exome Study," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000028,PV Exome Study,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 Polycythemia Vera Myeloproliferative Disease  samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000123,Polycythemia Vera Myeloproliferative Disease exome sequencing,Polycythemia Vera Myeloproliferative Disease exome sequencing," Illumina HiSeq 2000, Illumina Genome Analyzer II, Illumina HiSeq 2000;"
EGAS00001000030,ADCC Rearrangement Screen,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from 25 adenoid cystic carcinoma samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000062,ADCC Rearrangement Screen,ADCC Rearrangement Screen," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000031,Matched breast cancer fusion gene study,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from 40 breast cancer samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000138,Mutational processes moulding the genomes of 21 breast cancers,"The expression data for this study can be found here: 

http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1088/

and its SNP6 data can be found here:
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1087/"," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000031,Matched breast cancer fusion gene study,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from 40 breast cancer samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000097,Matched breast cancer fusion gene study,Matched breast cancer fusion gene study, Illumina Genome Analyzer II
EGAS00001000032,Kaposi sarcoma exome,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Kaposi sarcoma cancer and matched normal DNA from the same patients. Next Generation sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes,EGAD00001000071,Kaposi sarcoma exome,Kaposi sarcoma exome, Illumina HiSeq 2000
EGAS00001000033,1  Fanconi Anemia transformation to AML,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from 7 Fanconi anemia (FA) derived Acute myeloid leukemia samples and subjected to total of two lanes of 50 bp, paired end sequencing on the llumina HiSeq. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000072,Fanconi Anemia transformation to AML,Fanconi Anemia transformation to AML, Illumina HiSeq 2000
EGAS00001000034,MDSMPN Rearrangement Screen,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from 11 Myelodysplastic Myeloproliferative neoplasms (MDSMPN) and subjected to total of two lanes of 50 bp, paired end sequencing on the llumina HiSeq. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000073,MDSMPN Rearrangement Screen,MDSMPN Rearrangement Screen," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000035,Sequencing Acute Myeloid Leukaemia ,"This project will aim at sequencing and analysing three samples from a patient with acute myeloid leukaemia (AML) with t(15;17) translocation (acute promyelocytic leukaemia). The patient was treated with standard chemotherapy and samples (blood and bone marrow) taken for minimal residual disease measured during and after chemotherapy.  2-3years later the patient presented a second AML containing inv (16).
In this project we will sequence both AML and normal genomes to find associated mutations This will allow unprecedented insights into the dynamics of appearance of secondary AML, since we will be able to use the MRD samples to track the emergence of the inv(16) leukaemia. We will also be able to distinguish whether the 2 leukaemias are clonally related or not. 
This project will entail sequencing and analysis of three samples (whole genome 30x coverage) using Hi-Seq. The funds from this grant will cover the cost of sequencing 9 lanes from the AML t(15;17) sample, 9 lanes from AML inv(16) sample and 8 lanes from the normal genome.",EGAD00001000124,Sequencing Acute Myeloid Leukaemia,Sequencing Acute Myeloid Leukaemia, Illumina HiSeq 2000
EGAS00001000036,Integrative Oncogenomics of Multiple Myeloma,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Multiple Myeloma patient DNA and matched normal DNA from the same patients. Two lanes of Illumina GA sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00010000395,Title not provided,Myeloma case sample genotype using Affymetrix SNP6.0, Affymetrix_SNP6
EGAS00001000036,Integrative Oncogenomics of Multiple Myeloma,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Multiple Myeloma patient DNA and matched normal DNA from the same patients. Two lanes of Illumina GA sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000339,"Somatic mutations, clonal architecture and genomic evolution in multiple myeloma","Multiple myeloma is an incurable plasma cell malignancy whose molecular pathogenesis is incompletely understood. We used whole exome sequencing, copy number profiling and cytogenetic to analyses 84 samples from 67 patients with myeloma. In addition to known myeloma genes, we identify new candidate genes, including truncations of SP140, ROBO1 and FAT3 and clustered missense mutations in EGR1. We find oncogenic mutations in cancer genes not previously implicated in myeloma, including SF3B1, PI3KCA and PTEN. We define diverse processes contributing to the mutational repertoire, including kataegis and somatic hypermutation. Most cases have at least one cluster of subclonal variants, including subclonal driver mutations, implying on-going tumor evolution. Serial samples revealed diverse patterns of clonal evolution, including linear evolution, differential clonal response and branching evolution. Our findings reveal the myeloma genome to be heterogeneous across patients and, within individual patients, to exhibit diversity in clonal admixture and dynamics in response to therapy."," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000036,Integrative Oncogenomics of Multiple Myeloma,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Multiple Myeloma patient DNA and matched normal DNA from the same patients. Two lanes of Illumina GA sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000074,Integrative Oncogenomics of Multiple Myeloma,Integrative Oncogenomics of Multiple Myeloma," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000037,Gastric and Esophageal tumour rearrangement screen,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from gastric and esophageal tumours and subjected to total of two lanes of 50 bp, paired end sequencing on the llumina HiSeq. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000075,Gastric and Esophageal tumour rearrangement screen,Gastric and Esophageal tumour rearrangement screen, Illumina HiSeq 2000
EGAS00001000037,Gastric and Esophageal tumour rearrangement screen,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from gastric and esophageal tumours and subjected to total of two lanes of 50 bp, paired end sequencing on the llumina HiSeq. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000638,Somatic pseudogenes acquired during cancer development  Whole Genome sequencing,Insertion of processed pseudogenes is known to occur in the germline but has not previously been observed in somatic cells. Formation of pseudogenes could represent a new class of mutation in cancers and a new source of potential driver events., Illumina HiSeq 2000;
EGAS00001000038,Chondrosarcoma Exome ,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Chondrosarcoma cancer and matched normal DNA from the same patients. Next Generation sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes,EGAD00010000452,Title not provided,Chondrosarcoma case sample genotype using Affymetrix SNP6.0, Affymetrix_SNP6
EGAS00001000038,Chondrosarcoma Exome ,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Chondrosarcoma cancer and matched normal DNA from the same patients. Next Generation sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes,EGAD00001000125,Chondrosarcoma Exome,Chondrosarcoma Exome," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000038,Chondrosarcoma Exome ,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Chondrosarcoma cancer and matched normal DNA from the same patients. Next Generation sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes,EGAD00001000358,"Frequent mutation of the major cartilage collagen gene, COL2A1, in chondrosarcoma","Chondrosarcoma (CHS) is a heterogeneous collection of malignant bone tumours and is the second most common primary malignancy of bone after osteosarcoma. Recent work has identified frequent, recurrent mutations in IDH1/2 in nearly half of central CHS. However, there has been little systematic genomic analysis of this tumour type and thus the contribution of other genes is unclear. Here we report comprehensive genomic analyses of 49 cases of CHS. We identified hypermutability of the major cartilage collagen COL2A1 with insertions, deletions and rearrangements identified in 37% of cases. The patterns of mutation were consistent with selection for variants likely to impair normal collagen biosynthesis. In addition we identified mutations in IDH1/2 (59%), TP53 (20%), the RB1 pathway (27%) and hedgehog signaling (22%).", Illumina HiSeq 2000;
EGAS00001000038,Chondrosarcoma Exome ,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Chondrosarcoma cancer and matched normal DNA from the same patients. Next Generation sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes,EGAD00010000432,Title not provided,Chondrosarcoma case sample genotype using Affymetrix SNP6.0, 
EGAS00001000040,Exome sequencing of hyperplastic polyposis patients,"In this project we are sequencing the exomes of patients with hyperplastic polyposis, and tumours from these patients.",EGAD00001000015,Exome sequencing of hyperplastic polyposis patients.,Exome sequencing of hyperplastic polyposis patients.," Illumina HiSeq 2000, Illumina Genome Analyzer II, Illumina HiSeq 2000;"
EGAS00001000041,Disorders of growth and insulin action ,Illumina paired-end sequencing of whole- exome pulldown DNA from Severe Insulin Resistant patients.,EGAD00001000381,Disorders of growth and insulin action,Illumina paired-end sequencing of whole- exome pulldown DNA from Severe Insulin Resistant patients., Illumina HiSeq 2000;
EGAS00001000042,HER2 positive Breast Cancer ,We propose to definitively characterise the somatic genetics of HER2+ve breast cancer through generation of comprehensive catalogues of somatic mutations in a number of cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.,EGAD00001000126,HER2 positive Breast Cancer,HER2 positive Breast Cancer, Illumina HiSeq 2000
EGAS00001000046,Mutational Screening of Human Acute Myleloid Leukaemia Samples,Characterization of somatic mutations in Acute Myeloid Leukaemia samples to identify whether they can be classified into three mutually exclusive groups.,EGAD00001000054,Mutational Screening of Human Acute Myleloid Leukaemia Samples,Mutational Screening of Human Acute Myleloid Leukaemia Samples, Illumina HiSeq 2000
EGAS00001000047,Whole Exome Sequencing of Permanent Neonatal Diabetes Patients,Whole Exome Sequencing of Permanent Neonatal Diabetes Patients,EGAD00001000382,Whole Exome Sequencing of Permanent Neonatal Diabetes Patients,Whole Exome Sequencing of Permanent Neonatal Diabetes Patients, Illumina HiSeq 2000;
EGAS00001000048,Paroxysmal neurological disorders,We are sequencing the exomes of patients with paroxysmal neurological disorders mainly focusing on migraine and epilepsy. Cases are collected from performance sites of members of the International Headache Genetics consortium and EuroEPINOMICS. Most cases have a strong family history. The study sample will include both cases and controls.,EGAD00001000021,Paroxysmal neurological disorders,Paroxysmal neurological disorders," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000048,Paroxysmal neurological disorders,We are sequencing the exomes of patients with paroxysmal neurological disorders mainly focusing on migraine and epilepsy. Cases are collected from performance sites of members of the International Headache Genetics consortium and EuroEPINOMICS. Most cases have a strong family history. The study sample will include both cases and controls.,EGAD00001000108,Paroxysmal neurological disorders,Paroxysmal neurological disorders," Illumina HiSeq 2000, Illumina Genome Analyzer II, Illumina HiSeq 2000;"
EGAS00001000049,Exome sequencing in patients with Calcific Aortic Valve Stenosis,"The objective is to identify new genes involved in calcific aortic valve stenosis (CAVS) by screening the exome of at least 20 patients with familial CAVS. The recruitment of patients with CAVS has been achieved by linstitut du thorax (Nantes, France). DNA from the selected patients has been analysed by exome capture (Agilent SureSelect) and massively parallel sequencing (Illumina). The data generated by this project will lead to the identification of candidate genes involved in CAVS, which can be further screened for mutation in additional patients with CAVS.",EGAD00001000053,Exome sequencing in patients with Calcific Aortic Valve Stenosis,Exome sequencing in patients with Calcific Aortic Valve Stenosis, Illumina HiSeq 2000
EGAS00001000052,PAS Pedigrees: Identification of novel genetic variants contributing to cardiovascular disease in pedigrees with premature atherosclerosis.,"The heritability of CVD has been estimated to be between 40 and 55%. Due to the low MAF, PAS-causing mutations cannot be identified by indirect genotyping because their presence cannot be inferred from common haplotypes, as has been done successfully to uncover common risk variants by GWAS. It has been shown by Ng et al that the causative gene for rare syndromes can be unequivocally identified by sequencing the exomes of only four cases and eight controls. We expect exome sequencing to result in a high number of mutations and non-causitive coding variants.",EGAD00001000017,PAS Pedigrees: Identification of novel genetic variants contributing to cardiovascular disease in pedigrees with premature atherosclerosis.,PAS Pedigrees: Identification of novel genetic variants contributing to cardiovascular disease in pedigrees with premature atherosclerosis.," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000053,Investigation of the genetic basis of the rare syndrome Post-Transfusion Purpura (PTP),The Post-Transfusion Pupura (PTP) syndrome although rare has severe side effects for 5-10 cases per annum in the UK as a result of transfusion. High quality DNA has been isolated from either whole blood or from cryopreserved mononuclear cells of 4 patients in order to study our postulation that the condition is caused by a loss-of-function mutation in a specific gene.,EGAD00001000026,Investigation of the genetic basis of the rare syndrome Post-Transfusion Purpura (PTP),Investigation of the genetic basis of the rare syndrome Post-Transfusion Purpura (PTP), Illumina Genome Analyzer II
EGAS00001000054,Identifying causative mutations for Thrombocytopenia with Absent Radii,"Thrombocytopenia with Absent Radii is an inherited disorder that manifests itself with major limb skeletal abnormalities and low platelet count (and therefore a bleeding diathesis). The syndrome is well-characterised and defined phenotypically and there is a well-established database of UK-based families affected with ths disorder. The causative mutation for the disorder is yet to be identified. If known, it would allow for pre-natal screening and counselling avoiding life-long care for patients who are affected and are therefore severely disabled. We postulate that exon sequencing of 4 unrelated affected individuals would give enough power to narrow down potential candidate mutations which would thereafter be confirmed using DNA from other affected families.",EGAD00001000018,Identifying causative mutations for Thrombocytopenia with Absent Radii,Identifying causative mutations for Thrombocytopenia with Absent Radii, Illumina Genome Analyzer II
EGAS00001000055,Analysis of genomic integrity of disease corrected human induced pluripotent stem cells by exome sequencing,"Four human cell lines, one fibroblast cell line, two induced pluripotent stem cell lines (one by lentiviral and the other by sendai viral reprogramming) and one muttion-corrected line, will be analyzed by exome sequencing to find changes during reprogramming and genomic modification.",EGAD00001000030,Analysis of genomic integrity of disease-corrected human induced pluripotent stem cells by exome sequencing,Analysis of genomic integrity of disease-corrected human induced pluripotent stem cells by exome sequencing, Illumina HiSeq 2000
EGAS00001000055,Analysis of genomic integrity of disease corrected human induced pluripotent stem cells by exome sequencing,"Four human cell lines, one fibroblast cell line, two induced pluripotent stem cell lines (one by lentiviral and the other by sendai viral reprogramming) and one muttion-corrected line, will be analyzed by exome sequencing to find changes during reprogramming and genomic modification.",EGAD00001000086,Analysis of genomic integrity of disease-corrected human induced pluripotent stem cells by exome sequencing,Analysis of genomic integrity of disease-corrected human induced pluripotent stem cells by exome sequencing, Illumina HiSeq 2000
EGAS00001000057,An exome sequencing pilot study of HIV elite long term non progressors and rapid progressors,A pilot study examining genetic determinants associated with elite long term non progression and rapid progression using exome sequencing of individuals at the extremes of the distribution of HIV control and progression.,EGAD00001000087,An exome sequencing pilot study of HIV elite-long term non progressors and rapid progressors,An exome sequencing pilot study of HIV elite-long term non progressors and rapid progressors, Illumina HiSeq 2000
EGAS00001000057,An exome sequencing pilot study of HIV elite long term non progressors and rapid progressors,A pilot study examining genetic determinants associated with elite long term non progression and rapid progression using exome sequencing of individuals at the extremes of the distribution of HIV control and progression.,EGAD00001000047,"An exome sequencing pilot study of HIV elite-long term non progressors and rapid progressors.

**ACCESS TO THIS DATASET IS ONLY PROVIDED FOR HIV RELATED RESEARCH**","An exome sequencing pilot study of HIV elite-long term non progressors and rapid progressors.

**ACCESS TO THIS DATASET IS ONLY PROVIDED FOR HIV RELATED RESEARCH**"," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000058,Acute Lymphoblastic Leukemia Sequencing,"Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 Acute Lymphoblastic Leukemia samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped build 37 of the human reference genome to facilitate the identification of novel cancer genes. In addition, 500bp, NO_PCR total genomic libraries will be prepared from the same samples and five lanes of Illumina GA sequencing will be analysed to characterise genome wide, somatically acquired structural variation.",EGAD00001000116,Acute Lymphoblastic Leukemia Sequencing,Acute Lymphoblastic Leukemia Sequencing," Illumina HiSeq 2000, Illumina Genome Analyzer II, Illumina HiSeq 2000;"
EGAS00001000058,Acute Lymphoblastic Leukemia Sequencing,"Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 Acute Lymphoblastic Leukemia samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped build 37 of the human reference genome to facilitate the identification of novel cancer genes. In addition, 500bp, NO_PCR total genomic libraries will be prepared from the same samples and five lanes of Illumina GA sequencing will be analysed to characterise genome wide, somatically acquired structural variation.",EGAD00001000634,RAG mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 Acute Lymphoblastic Leukemia (Whole_Genome_sequencing_data),"The ETV6-RUNX1 fusion gene, found in 25% of childhood acute lymphoblastic leukemia (ALL), is acquired in utero but requires additional somatic mutations for overt leukemia. We used exome and low-coverage whole-genome sequencing to characterize the critical secondary events associated with leukemic transformation. RAG-mediated deletions emerge as the dominant mutational process, accounting for at least 43% of genomic rearrangements and characterized by the presence of recombination signal sequence motifs near the breakpoints; incorporation of non-templated sequence at the junction and a ten-fold enrichment at promoters and enhancers of genes actively transcribed in early B-lineage development. Single-cell tracking shows that this mechanism is not restricted to one founder cell but is rather active throughout leukemic evolution. Integration of point mutation and rearrangement data identifies recurrent inactivation of ATF7IP and MGA as two new tumor suppressor genes.Thus, a remarkably parsimonious mutational process transforms ETV6-RUNX1 lymphoblasts, striking promoters and enhancers of the genes that normally control B-cell differentiation.", Illumina HiSeq 2000;
EGAS00001000058,Acute Lymphoblastic Leukemia Sequencing,"Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 Acute Lymphoblastic Leukemia samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped build 37 of the human reference genome to facilitate the identification of novel cancer genes. In addition, 500bp, NO_PCR total genomic libraries will be prepared from the same samples and five lanes of Illumina GA sequencing will be analysed to characterise genome wide, somatically acquired structural variation.",EGAD00001000635,RAG mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 Acute Lymphoblastic Leukemia (Rearrangement_sequencing_data),"The ETV6-RUNX1 fusion gene, found in 25% of childhood acute lymphoblastic leukemia (ALL), is acquired in utero but requires additional somatic mutations for overt leukemia. We used exome and low-coverage whole-genome sequencing to characterize the critical secondary events associated with leukemic transformation. RAG-mediated deletions emerge as the dominant mutational process, accounting for at least 43% of genomic rearrangements and characterized by the presence of recombination signal sequence motifs near the breakpoints; incorporation of non-templated sequence at the junction and a ten-fold enrichment at promoters and enhancers of genes actively transcribed in early B-lineage development. Single-cell tracking shows that this mechanism is not restricted to one founder cell but is rather active throughout leukemic evolution. Integration of point mutation and rearrangement data identifies recurrent inactivation of ATF7IP and MGA as two new tumor suppressor genes.Thus, a remarkably parsimonious mutational process transforms ETV6-RUNX1 lymphoblasts, striking promoters and enhancers of the genes that normally control B-cell differentiation."," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000058,Acute Lymphoblastic Leukemia Sequencing,"Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 Acute Lymphoblastic Leukemia samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped build 37 of the human reference genome to facilitate the identification of novel cancer genes. In addition, 500bp, NO_PCR total genomic libraries will be prepared from the same samples and five lanes of Illumina GA sequencing will be analysed to characterise genome wide, somatically acquired structural variation.",EGAD00001000658,Constitutional and somatic genomic rearrangements coherently restructure chromosome 21 in acute lymphoblastic leukaemia,"Changes in gene dosage are a major driver of cancer1, engineered from a finite, but increasingly well annotated, repertoire of mutational mechanisms2-6. These processes operate over levels ranging from individual exons to whole chromosomes, often generating correlated copy number alterations across hundreds of linked genes. An example of the latter is the 2% of childhood acute lymphoblastic leukemia (ALL) characterized by recurrent intrachromosomal amplification of megabase regions of chromosome 21 (iAMP21)7,8  To dissect the interplay between mutational processes and selection on this scale, we used genomic, cytogenetic and transcriptional analysis, coupled with novel bioinformatic approaches, to reconstruct the evolution of iAMP21 ALL. We find that individuals born with the rare constitutional Robertsonian translocation between chromosomes 15 and 21, rob(15;21)(q10;q10)c, have ~2700-fold increased risk of developing iAMP21 ALL compared to the general population. In such cases, amplification is initiated by chromothripsis involving both sister chromatids of the dicentric Robertsonian chromosome. In contrast, sporadic iAMP21 is typically initiated by breakage-fusion-bridge (BFB) events, often followed by chromothripsis or other rearrangements. In both sporadic and iAMP21 in rob(15;21)c individuals, the final stages of amplification frequently involve large-scale duplications of the abnormal chromosome. The end-product is a derivative chromosome 21 or a derivative originating from the rob(15;21)c chromosome, der(15;21), respectively, with gene dosage optimised for leukemic potential, showing constrained copy number levels over multiple linked genes. In summary, the constitutional translocation, rob(15;21)c, predisposes to leukemia through a novel mechanism, namely a propensity to undergo chromothripsis, likely related to its dicentric nature. More generally, our data illustrate that several cancer-specific mutational processes, applied sequentially, can co-ordinate to fashion copy number profiles over large genomic scales, incrementally refining the fitness benefits of aggregated gene dosage changes.", Illumina HiSeq 2000;
EGAS00001000059,De novo mutations in schizophrenia ,Project contains full exome data from 100-150 trios (up to 450 samples),EGAD00001000251,De novo mutations in schizophrenia,De novo mutations in schizophrenia, Illumina HiSeq 2000;
EGAS00001000061,Lethal malformation syndrome,"Identification of the genetic basis of rare monogenic diseases can provide insights into disease mechanisms, biological pathways and potential therapeutic targets. Exome sequencing has proven to be a powerful, efficient strategy for the identification of the genes underlying rare Mendelian disorders. The genetic defect behind the lethal malformation syndrome under study is known in some cases and has proven useful in revealing the primary underlying defect. We have six typical unrelated families with no known mutation.  The aim of this study is to identify the locus associated with this lethal malformation syndrome in these families using exome sequencing.",EGAD00001000019,Lethal malformation syndrome,Lethal malformation syndrome, Illumina Genome Analyzer II
EGAS00001000063,Exome sequencing in patients with cardiac arrhythmias,"The institut du thorax in Nantes (FR), the Academic Medical Center in Amsterdam (NL) and the University Hospital of Muenster (DE) have recruited 20 large families comprising at least 3 patients with cardiac arrhythmias and showing history of sudden cardiac death. For each family, the exome of one affected individual has been sequenced at the Wellcome Trust Sanger Institute (UK), in order to identify new genes associated with high risk of sudden cardiac death.",EGAD00001000022,Exome sequencing in patients with cardiac arrhythmias,Exome sequencing in patients with cardiac arrhythmias, Illumina Genome Analyzer II
EGAS00001000064,Genetics of Microcephalic Osteodysplatics Primordial Dwarfism,"This project aims to find causal variants in 50 patients diagnosed with Microcephalic Osteodysplastic Primordial Dwarfism (MOPD), of presumed recessive inheritance performing whole exome sequencing to ~50x mean depth. This is a collaboration with Prof A. Jackson, MRC Human Genetics Unit, Edinburgh",EGAD00001000342,Genetics of Microcephalic Osteodysplatics Primordial Dwarfism,"This project aims to find causal variants in 50 patients diagnosed with Microcephalic Osteodysplastic Primordial Dwarfism (MOPD), of presumed recessive inheritance performing whole exome sequencing to ~50x mean depth.
This is a collaboration with Prof A. Jackson, MRC Human Genetics Unit, Edinburgh"," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000066,Congenital Heart Disease in UK Families,"This project aims to identify highly penetrant coding variants increasing the risk of Congenital Heart Disease (CHD) performing whole exome sequencing on DNA samples from 23 affected individuals, selected from 10 families with presumed Autosomal Recessive Inheritance. This is a collaboration with Prof. Eamonn Maher and Dr. Chirag Patel from the Department of Medical and Molecular Genetics, University of Birmingham plans to sequence 23 indexed Agilent whole exome pulldown libraries on 75Bp PE HiSeq (Illumina).",EGAD00001000343,Congenital Heart Disease in UK Families,"This project aims to identify highly penetrant coding variants increasing the risk of Congenital Heart Disease (CHD) performing whole exome sequencing on DNA samples from 23 affected individuals, selected from 10 families with presumed Autosomal Recessive Inheritance. 
This is a collaboration with Prof. Eamonn Maher and Dr. Chirag Patel from the Department of Medical and Molecular Genetics, University of Birmingham plans to sequence 23 indexed Agilent whole exome pulldown libraries on 75Bp PE HiSeq (Illumina)", Illumina HiSeq 2000;
EGAS00001000068,ORCADES WGA,"The ORCADES Whole Genome Sequence Study plans to sequence the genomes of 400 subjects from the Orkney Complex Disease Study (ORCADES) at low coverage, each with data on up to 300 quantitative traits and other risk factors associated with cardiovascular, metabolic and other complex diseases",EGAD00001000199,ORCADES_WGA,ORCADES_WGA, Illumina HiSeq 2000;
EGAS00001000069,Determination of the molecular nature of the Vel blood group by exome sequencing,"The genetic basis of the Vel group is yet to be determined. We have collected DNA samples from about 90 Vel negative blood donors by phenotyping 270,000 donors. Understanding the genetic basis of the Vel group could have clinical significance as transfusion of Vel positive blood to Vel negative recipients with anti-Vel can cause severe and acute haemolytic transfusion reactions.",EGAD00001000025,Determination of the molecular nature of the Vel blood group by exome sequencing,Determination of the molecular nature of the Vel blood group by exome sequencing, Illumina Genome Analyzer II
EGAS00001000071,Tetralogy of Fallot Exome Trios,"Exome sequencing of 30 parent-offspring trios to >50X mean depth, where the offspring has sporadic TOF, to identify potential causal de novo mutations. We will use the exome plus design for pulldown that incorporates ~6.8Mb of additional regulatory sequences in addition to the ~50Mb GENCODE exome.",EGAD00001000344,Tetralogy of Fallot Exome Trios,"Exome sequencing of 30 parent-offspring trios to >50X mean depth, where the offspring has sporadic TOF, to identify potential causal de novo mutations. We will use the exome plus design for pulldown that incorporates  ~6.8Mb of additional regulatory sequences in addition to the ~50Mb GENCODE exome.", Illumina HiSeq 2000;
EGAS00001000074,Screening for human epigenetic variation at CpG islands,"Many human characteristics, including susceptibility to disease, are determined genetically. An unexplored alternative to such genetic determination concerns epigenetic mechanisms such as DNA methylation. CpG islands (CGIs) are generally constitutively hypomethylated, however there are circumstances in which they become heavily methylated and, when coincident with a gene promoter, this invariably causes transcriptional silencing. CGI methylation occurs in normal tissues during processes such as X-inactivation, but abnormal patterns of methylation have also been implicated in disease. The vast majority of evidence relates to cancer, where silencing of multiple genes in this way appears to be a causal contributor to the cancer state. To address the role and extent of CGI methylation in normal and diseased cells we applied MBD-affinity purification in conjunction with next generation sequencing in a panel of human brain autopsy samples. These samples represent a panel of individuals as well as specific brain regions and neurological pathologies.",EGAD00001000059,Screening for human epigenetic variation at CpG islands,Screening for human epigenetic variation at CpG islands, Illumina Genome Analyzer II
EGAS00001000075,Functional characterisation of CpG islands in human and mouse tissues,"Tissue-specific methylation patterns suggest a role for CpG island (CGI) methylation in differentiation and cell-type-specific gene regulation. We have applied CXXC affinity purification (CAP), MBD affinity purification (MAP) and chromatin immunoprecipitation (ChIP) in combination with solexa sequencing to investigate the extent and functional significance of CGI methylation in sperm, blood, cerebellum and ES cells for both human and mouse.",EGAD00001000212,Functional characterisation of CpG islands in human tissues,Functional characterisation of CpG islands in human tissues, Illumina Genome Analyzer II;
EGAS00001000076,Screening for abnormal CGI methylation in primary colorectal tumours,"A common hallmark of neoplastic cells is abnormal acquisition of CpG island (CGI) methylation and the silencing of associated gene promoters. To determine the extent and distribution of CGI methylation in colorectal cancer, we solexa sequenced MBD affinity purified DNA prepared from five colorectal tumours and matched colon mucosa from the same individuals.",EGAD00001000213,Screening for abnormal CGI methylation in primary colorectal tumours,Screening for abnormal CGI methylation in primary colorectal tumours, Illumina Genome Analyzer II;
EGAS00001000077,Human Colorectal Cancer Exome Sequencing,"In this experiment we sequenced a collection of genes identified as being mutated in a Sleeping Beauty Screen in a mouse colorectal Cancer Model in human tumours collected from patients with germline mutations in APC and also other familial CRC predisposition syndromes. We also sequenced the germline of these patients allowing us to identify somatically mutated genes. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/",EGAD00001000031,Human Colorectal Cancer Exome Sequencing,Human Colorectal Cancer Exome Sequencing, Illumina Genome Analyzer II
EGAS00001000080,CRLF2 sequencing project ,"I hope to gain insight into novel genetic aberrations present in these patients that will highlight
important pathways that are involved in this subtype of leukaemia. It would be interesting to see if
the mutations and pathways that are activated are consistent between the patients, or differences
are observed dependent upon whether the patient has the translocation or the PAR1 deletion. Of
note is the high association with either numerical gains of chromosome X or numerical/structural
abnormalities of chromosome 21 (Down syndrome, iAMP21) in patients with CRLF2 deregulation. I
hope to find abnormalities linking chromosomes X and 21 to CRLF2 deregulation in BCPALL. By
including the three patients that are normal for CRLF2, but have consistent genetic abnormalities
found in the experimental cohort, I expect to find genetic differences between these two groups
that will help us to identify novel molecular targets specific to CRLF2 deregulation.",EGAD00001000076,CRLF2 sequencing project,CRLF2 sequencing project, Illumina HiSeq 2000
EGAS00001000081,CRLF2 sequencing project Exomes,"I hope to gain insight into novel genetic aberrations present in these patients that will highlight important pathways that are involved in this subtype of leukaemia. It would be interesting to see if the mutations and pathways that are activated are consistent between the patients, or differences are observed dependent upon whether the patient has the translocation or the PAR1 deletion. Of note is the high association with either numerical gains of chromosome X or numerical/structural abnormalities of chromosome 21 (Down syndrome, iAMP21) in patients with CRLF2 deregulation. I hope to find abnormalities linking chromosomes X and 21 to CRLF2 deregulation in BCPALL. By including the three patients that are normal for CRLF2, but have consistent genetic abnormalities found in the experimental cohort, I expect to find genetic differences between these two groups that will help us to identify novel molecular targets specific to CRLF2 deregulation.",EGAD00001000077,CRLF2 sequencing project Exomes,CRLF2 sequencing project Exomes, Illumina HiSeq 2000
EGAS00001000082,ALK inhibitors in the context of ALK dependent cancer cell lines,"Anaplastic lymphoma kinase (ALK) has recently been found to be a critical cancer gene in cases of lung cancer, neuroblastomas and lymphomas. ALK inhibitors  have  recently shown significant activity in lung cancer patients with tumours that harbour the EML4-ALK gene rearrangement, but already drug-resistance is emerging. We have taken a lung cancer cell line H3122 (with the EML4-ALK rearrangement) and generated clones resistant to a small molecule inhibitor of ALK by serial exposure to the drug over 8 weeks. We now wish to characterise at the exome level whether the acquisiton of resistance has been accompanied by the development of new mutations that we can take forward for further study as the potential mechansims underlying the resistance. We therefore propose to exome sequence the parental NCI-H3122 cell line as well as drug-resistant clones.",EGAD00001000078,ALK inhibitors in the context of ALK-dependent cancer cell lines,ALK inhibitors in the context of ALK-dependent cancer cell lines," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000085,"Linking genes, genomic instability and molecular subgroups in medulloblastoma","Brain tumors are the second most common pediatric cancer and carry the highest mortality rates in this age group. 
	Medulloblastoma is the most frequent malignant brain tumor of childhood. 
	Recent studies indicate that medulloblastoma comprises at least four sub-entities (SHH-signaling, WNT-signaling, Group-C, Group-D) that differ in molecular alterations, cell of origin, clinicopathological features and outcome. 
	Further characterization of the entire spectrum of genomic alterations underlying the formation of these distinct groups is urgently needed to identify diagnostic and prognostic biomarkers for clinical management and uncover novel therapeutic targets.",EGAD00001000027,ICGC Germany PedBrain Medulloblastoma Pilot_2_LM,ICGC Germany PedBrain Medulloblastoma Pilot_2_LM," Illumina HiSeq 2000, Illumina Genome Analyzer IIx"
EGAS00001000086,Dilgom Exome,"The Finrisk sample sets are part of the National FINRISK Study. It is a large population survey on risk factors of chronic, noncommunicable diseases. The survey is carried out since 1972 every five years using independent, random and representative population samples from different parts of Finland. The main results from the previous FINRISK 2007 survey are published.
The National FINRISK Study Survey was carried out in 5 areas in Finland and 2000 inhabitants aged 25-75 years were invited to participate in each year. Among findings were that Finns continue to gain weight.
Data from FINRISK surveys are used for many different research projects and for national health monitoring needs. The recent research activities deal, in addition to cardiovascular diseases and the classical risk factors, also with e.g. asthma and allergy, alcohol, socioeconomic factors and genetic epidemiology.
The FINRISK study is part of the MORGAM Project (MONICA Risk, Genetics, Archiving and Monigraph), sponsored by the EU and MDECODE (Molecular Diversity and Epidemiology of Common Disease) program coordinated by the University of Michigan.
The exome sequencing study will be part of the Dilgom study, which is a part of the larger Finrisk population based health study performed in Finland. It consists of 5000 individuals with a prospective aspect of metabolic traits. The cohort has been extensively phenotyped for their cardiovascular and metabolic status. So far, we have performed a 660K Illumina GWAS and a full genome wide expression study from peripheral blood cells of 500 individuals. The cohort has also been in total genotyped by the cardiometabochip",EGAD00001000200,Dilgom Exome,Dilgom Exome, Illumina HiSeq 2000;
EGAS00001000087,Burden of Disease in Sarcoma,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from cancer samples and subjected to 50 bp, paired end sequencing on the llumina HiSeq 2000. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000127,Burden of Disease in Sarcoma,Burden of Disease in Sarcoma, Illumina HiSeq 2000
EGAS00001000088,Familial Thrombocytosis germline exome sequencing,"Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 3 relatives from a family with multiple affected familial thrombocytosis (FT) patients.  Germline DNA from 2-4 patients affected with FT will be used to prepare libraries and sequenced in one lane of HiSeq sequencing, mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.",EGAD00001000128,Familial Thrombocytosis germline exome sequencing,Familial Thrombocytosis germline exome sequencing," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000089,Myelodysplastic Syndrome Exome Sequnecing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Myelodysplastic Syndrome samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting exome libraries and mapped build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000045,Somatic mutation of SF3B1 in myelodysplasia with ring sideroblasts and other cancers,Somatic mutation of SF3B1 in myelodysplasia with ring sideroblasts and other cancers, Illumina Genome Analyzer II
EGAS00001000089,Myelodysplastic Syndrome Exome Sequnecing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Myelodysplastic Syndrome samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting exome libraries and mapped build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000117,Myelodysplastic Syndrome Exome Sequencing,Myelodysplastic Syndrome Exome Sequencing," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000090,UK10K COHORT ALSPAC,"The UK10K project proposes a series of complementary genetic approaches to find new low-frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome-wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein-coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will directly analyse quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The Avon Longitudinal Study of Parents and Children (ALSPAC) is a two-generation prospective study. Pregnant women living in one of three health districts in the former county of Avon with an expected delivery date between April 1991 and December 1992 were eligible to be enrolled in the study, and this formed the initial point of contact for the development of a large, family based resource.

Information has been collected on the children and the mothers through retrieval of biological materials (e.g. antenatal blood samples, placentas), biological sampling (e.g. collection of cord blood, umbilical cord, milk teeth, hair, toenails, blood and urine), self-administered questionnaires, data extraction from medical notes, linkage to routine information systems and at repeat research clinics.",EGAD00001000195,UK10K_COHORT_ALSPAC REL-2011-12-01,"For information about this sample set, please contact the sample custodian Nic Timpson: N.J.Timpson@bristol.ac.uk", Illumina HiSeq 2000;
EGAS00001000091,Grey Platelet Syndrome  GPS ,"As part of the Bloodomics collaboration we have several categories of pedigrees with diseases/syndromes relevant to cardiovascular diseases (CVD). One such pedigree, Grey Platelet Syndrome (GPS) is a rare congenital bleeding disorder caused by a reduction or absence of alpha granules in platelets. Exome sequencing has been performed as part of a discovery program to ascertain potential causative variants of the clinical phenotype.",EGAD00001000029,Grey Platelet Syndrome (GPS),Grey Platelet Syndrome (GPS), Illumina Genome Analyzer II
EGAS00001000092,Triple Negative Breast Cancer Whole Genomes,We propose to definitively characterise the somatic genetics of Triple negative breast cancer through generation of comprehensive catalogues of somatic mutations in 500 cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.,EGAD00001000141,Triple Negative Breast Cancer Whole Genomes,Triple Negative Breast Cancer Whole Genomes," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000093,Unraveling the genetic basis of a collagen migration defect in patients with a combined  platelet dysfunction and reduced bone density,"In this project we study cases from unrelated pedigrees that present at a young age with a phenotype which inludes hypotonia and hypodensity of bones, a chronic elevation of some liver and muscle enzymes as well as abnormal platelet number and volume. We aim to use exome sequencing to discover the causative variants reponsible for these defects.",EGAD00001000109,Unraveling the genetic basis of a collagen migration defect in patients with a combined  platelet dysfunction and reduced bone density,Unraveling the genetic basis of a collagen migration defect in patients with a combined  platelet dysfunction and reduced bone density, Illumina HiSeq 2000
EGAS00001000094,PREDICT,PREDICT/Predicting individual response and resistance to VEGFR/mTOR pathway therapeutic intervention using biomarkers discovered through tumour functional genomics.,EGAD00001000079,PREDICT,PREDICT," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000095,Renal Follow Up Series,"This study's purpose is to use data generated in Renal whole genome and exome Cancer sequencing to target specific areas in multiple other Renal Cancer samples. These areas will then be subjected to bespoke pull downs, tagged and then pool the resultant amplicons. These amplicons will then be sequenced. This is hoped to show the prevalence of previous findings in multiple individuals in a high throughput method.",EGAD00001000142,Renal Follow Up Series,Renal Follow Up Series," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000096,Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort,"The hepatitis C virus infects nearly 3% of the Worlds population, causing severe liver
disease in many. Standard of care therapy is currently pegylated interferon alpha and ribavirin
(PegIFN/R), which is effective in less than half of those infected with the most common viral genotype. Two IL28B SNPs, rs8099917 and rs12979860, predict response to (PegIFN/R) therapy in treatment of hepatitis C virus infection. These SNPs were identified in genome wide analyses using Illumina genotyping chips. In people of European ancestry, there are 6 common (>1%) haplotypes for IL28B, one tagged by rs8099917 minor allele, four tagged by rs12979860.
We used massive parallel sequencing of the IL28B and IL28A gene regions generated by PCR 
from pooled DNA samples from 100 responders and 99 non-responders to therapy, to identify
common variants. Variants that had high odds ratios and were validated were then genotyped
in a cohort of 905 responders and non-responders. Their predictive power was assessed, alone
and in combination with HLA-C. Only SNPs in the IL28B linkage disequilibrium block predicted drug response. Eighteen
SNPs were identified with evidence for association with drug response, and with a high degree of confidence in the sequence call.
We found that two SNPs, rs4803221 (homozygote minor allele positive predictive value (PPV) of 77%) and rs7248668 (PPV 78%), predicted 
failure to respond better than the current best, rs8099917 (PPV 73%) and rs12979860 (PPV
68%) in this cross-sectional cohort. The best SNPs tagged a single common haplotype, haplotype 2. Genotypes predicted lack of response better than alleles.
However, combination of IL28B haplotype 2 carrier status with the HLA-C C2C2 genotype, which has previousl y
been reported to improve prediction in combination with IL28B, provides the highest PPV
(80%). The haplotypes present alternative putative transcription factor binding and
methylation sites. Massive parallel sequencing allowed identification and comparison of the best common SNPs 
for identifying treatment failure in therapy for HCV SNPs tagging a single haplotype have
the highest PPV, especially in combination with HLA-C. The functional basis for the association may be due to altered regulation of the gene.
These approaches have utility in improving diagnostic testing and identifying causal haplotypes or SNPs.",EGAD00001000032,Hepatitis C IL28B pooled resequencing study with 100 responders and 100 non-responders,Hepatitis C IL28B pooled resequencing study with 100 responders and 100 non-responders, Illumina Genome Analyzer IIx
EGAS00001000101,UK10K RARE NEUROMUSCULAR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

The neuromuscular disorder samples are part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Francesco Muntoni (f.muntoni@ucl.ac.uk).",EGAD00001000298,UK10K_RARE_NEUROMUSCULAR REL-2012-11-27,UK10K_RARE_NEUROMUSCULAR REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000101,UK10K RARE NEUROMUSCULAR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

The neuromuscular disorder samples are part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Francesco Muntoni (f.muntoni@ucl.ac.uk).",EGAD00001000180,UK10K_RARE_NEUROMUSCULAR REL-2012-01-13,UK10K_RARE_NEUROMUSCULAR REL-2012-01-13, Illumina HiSeq 2000;
EGAS00001000101,UK10K RARE NEUROMUSCULAR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

The neuromuscular disorder samples are part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Francesco Muntoni (f.muntoni@ucl.ac.uk).",EGAD00001000189,UK10K_RARE_NEUROMUSCULAR REL-2012-02-22,UK10K_RARE_NEUROMUSCULAR REL-2012-02-22, Illumina HiSeq 2000;
EGAS00001000101,UK10K RARE NEUROMUSCULAR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

The neuromuscular disorder samples are part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Francesco Muntoni (f.muntoni@ucl.ac.uk).",EGAD00001000219,UK10K_RARE_NEUROMUSCULAR REL-2012-07-05,UK10K_RARE_NEUROMUSCULAR REL-2012-07-05, Illumina HiSeq 2000;
EGAS00001000101,UK10K RARE NEUROMUSCULAR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

The neuromuscular disorder samples are part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Francesco Muntoni (f.muntoni@ucl.ac.uk).",EGAD00001000418,UK10K_RARE_NEUROMUSCULAR REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000102,ET Exome,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 Essential Thrombocythemia Myeloproliferative Disease  samples and matched normal DNA from the same patients. Samples will be multiplexed in one  lane of Illumina HiSeq. Sequencing to a coverage of at least 30x will be performed and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000129,Essential Thrombocythemia Myeloproliferative Disease exome sequencing,Essential Thrombocythemia Myeloproliferative Disease exome sequencing," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000103,Genomics of Colorectal Cancer Metastases   Massively Parallel Sequencing of Matched Primary and Metastatic tumours to Identify a Metastatic Signature of Somatic Mutations  MOSAIC ,Exome pulldown and SNP6 Affymetrix array of matched primary and metastatic colorectal cancer samples from 20 patients,EGAD00001000080,Genomics of Colorectal Cancer Metastases - Massively Parallel Sequencing of Matched Primary and Metastatic tumours to Identify a Metastatic Signature of Somatic Mutations (MOSAIC),Genomics of Colorectal Cancer Metastases - Massively Parallel Sequencing of Matched Primary and Metastatic tumours to Identify a Metastatic Signature of Somatic Mutations (MOSAIC)," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000103,Genomics of Colorectal Cancer Metastases   Massively Parallel Sequencing of Matched Primary and Metastatic tumours to Identify a Metastatic Signature of Somatic Mutations  MOSAIC ,Exome pulldown and SNP6 Affymetrix array of matched primary and metastatic colorectal cancer samples from 20 patients,EGAD00001000637,Somatic pseudogenes acquired during cancer development  Whole Exome sequencing,Insertion of processed pseudogenes is known to occur in the germline but has not previously been observed in somatic cells. Formation of pseudogenes could represent a new class of mutation in cancers and a new source of potential driver events.," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000104,Hyperfibrinolysis,"As part of the Bloodomics collaboration we have several categories of pedigrees with diseases/syndromes relevant to cardiovascular diseases (CVD). One such pedigree, hyperfibrinolysis is associated with increased fibrinolytic activity, resulting in increased bleeding.  Exome sequencing has been performed as part of a discovery program to ascertain potential causative variants of the clinical phenotype.",EGAD00001000038,Hyperfibrinolysis,Hyperfibrinolysis, Illumina Genome Analyzer II
EGAS00001000105,Platelet collagen defect,"As part of the Bloodomics collaboration we have several categories of pedigrees with diseases/syndromes relevant to cardiovascular diseases (CVD). One such pedigree, is from families who have a platelet collagen defect.  Exome sequencing has been performed as part of a discovery program to ascertain potential causative variants of the clinical phenotype.",EGAD00001000039,Platelet collagen defect,Platelet collagen defect," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000106,Bleeding,"As part of the Bloodomics collaboration we have several categories of pedigrees with diseases/syndromes relevant to cardiovascular diseases (CVD). One such group, is from individuals who exhibit severe bleeding with an unknown cause.  Exome sequencing has been performed as part of a discovery program to ascertain potential causative variants of the clinical phenotype.",EGAD00001000040,Bleeding,Bleeding, Illumina Genome Analyzer II
EGAS00001000107,Various Platelet Disorders,"As part of the Bloodomics collaboration we have several categories of pedigrees with diseases/syndromes relevant to cardiovascular diseases (CVD). One such group, is from individuals who have a platelet disorder with an unknown cause.  Exome sequencing has been performed as part of a discovery program to ascertain potential causative variants of the clinical phenotype.",EGAD00001000041,Various Platelet Disorders,Various Platelet Disorders, Illumina Genome Analyzer II
EGAS00001000108,UK10K COHORTS TWINSUK,"The UK10K project proposes a series of complementary genetic approaches to find new low-frequency/rare variants contributing to disease phenotypes.  These will be based on obtaining the genome-wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein-coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes.  Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will directly analyse quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.  

The TwinsUK samples will be part of the cohort study and will undergo whole genome sequencing. For further information with regard to this cohort please contact Brent Richards (brent.richards@kcl.ac.uk) or Nicole Soranzo (ns6@sanger.ac.uk).",EGAD00001000151,UK10K OBESITY REL-2011-07-14,UK10K OBESITY REL-2011-07-14, Illumina HiSeq 2000;
EGAS00001000108,UK10K COHORTS TWINSUK,"The UK10K project proposes a series of complementary genetic approaches to find new low-frequency/rare variants contributing to disease phenotypes.  These will be based on obtaining the genome-wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein-coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes.  Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will directly analyse quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.  

The TwinsUK samples will be part of the cohort study and will undergo whole genome sequencing. For further information with regard to this cohort please contact Brent Richards (brent.richards@kcl.ac.uk) or Nicole Soranzo (ns6@sanger.ac.uk).",EGAD00001000194,UK10K_COHORT_TWINS REL-2011-12-01,UK10K_COHORT_TWINS REL-2011-12-01," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000109,UK10K NEURO ABERDEEN,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This sample set comprises cases of schizophrenia with additional cognitive measurements, collected in Aberdeen, Scotland.For further information on the Aberdeen cohort please contact David St Clair (d.stclair@abdn.ac.uk).",EGAD00001000227,UK10K_NEURO_ABERDEEN REL-2012-07-05,EGAD00001000227_UK10K_NEURO_ABERDEEN_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000109,UK10K NEURO ABERDEEN,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This sample set comprises cases of schizophrenia with additional cognitive measurements, collected in Aberdeen, Scotland.For further information on the Aberdeen cohort please contact David St Clair (d.stclair@abdn.ac.uk).",EGAD00001000315,UK10K_NEURO_ABERDEEN REL-2012-11-27,UK10K_NEURO_ABERDEEN REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000109,UK10K NEURO ABERDEEN,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This sample set comprises cases of schizophrenia with additional cognitive measurements, collected in Aberdeen, Scotland.For further information on the Aberdeen cohort please contact David St Clair (d.stclair@abdn.ac.uk).",EGAD00001000433,UK10K_NEURO_ABERDEEN REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000110,UK10K NEURO ASD FI,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

These samples are a subset of a nationwide collection of Finnish autism spectrum disorder (ASD) samples.  The samples have been collected from Central Hospitals across Finland in collaboration with the University of Helsinki. The samples consist of 93 individuals with a diagnosis of autistic disorder or Asperger syndrome from 36 families with at least two affected individuals.  Of these individuals, 16 can be genealogically connected to form two large pedigrees originating from Central Finland, suggesting possible genetic risk factors shared identical by descent within the pedigrees. All diagnoses are based on ICD-10 and DSM-IV diagnostic criteria for ASDs. Additional phenotypic data is available for a subset of the individuals.For further information with regard to this cohort please contact Aarno Palotie (Aarno.palotie@helsinki.fi).",EGAD00001000229,UK10K_NEURO_ASD_FI REL-2012-07-05,EGAD00001000229_UK10K_NEURO_ASD_FI_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000110,UK10K NEURO ASD FI,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

These samples are a subset of a nationwide collection of Finnish autism spectrum disorder (ASD) samples.  The samples have been collected from Central Hospitals across Finland in collaboration with the University of Helsinki. The samples consist of 93 individuals with a diagnosis of autistic disorder or Asperger syndrome from 36 families with at least two affected individuals.  Of these individuals, 16 can be genealogically connected to form two large pedigrees originating from Central Finland, suggesting possible genetic risk factors shared identical by descent within the pedigrees. All diagnoses are based on ICD-10 and DSM-IV diagnostic criteria for ASDs. Additional phenotypic data is available for a subset of the individuals.For further information with regard to this cohort please contact Aarno Palotie (Aarno.palotie@helsinki.fi).",EGAD00001000173,UK10K_NEURO_ASD_FI REL-2012-01-13,UK10K_NEURO_ASD_FI REL-2012-01-13, Illumina HiSeq 2000;
EGAS00001000110,UK10K NEURO ASD FI,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

These samples are a subset of a nationwide collection of Finnish autism spectrum disorder (ASD) samples.  The samples have been collected from Central Hospitals across Finland in collaboration with the University of Helsinki. The samples consist of 93 individuals with a diagnosis of autistic disorder or Asperger syndrome from 36 families with at least two affected individuals.  Of these individuals, 16 can be genealogically connected to form two large pedigrees originating from Central Finland, suggesting possible genetic risk factors shared identical by descent within the pedigrees. All diagnoses are based on ICD-10 and DSM-IV diagnostic criteria for ASDs. Additional phenotypic data is available for a subset of the individuals.For further information with regard to this cohort please contact Aarno Palotie (Aarno.palotie@helsinki.fi).",EGAD00001000311,UK10K_NEURO_ASD_FI REL-2012-11-27,UK10K_NEURO_ASD_FI REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000110,UK10K NEURO ASD FI,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

These samples are a subset of a nationwide collection of Finnish autism spectrum disorder (ASD) samples.  The samples have been collected from Central Hospitals across Finland in collaboration with the University of Helsinki. The samples consist of 93 individuals with a diagnosis of autistic disorder or Asperger syndrome from 36 families with at least two affected individuals.  Of these individuals, 16 can be genealogically connected to form two large pedigrees originating from Central Finland, suggesting possible genetic risk factors shared identical by descent within the pedigrees. All diagnoses are based on ICD-10 and DSM-IV diagnostic criteria for ASDs. Additional phenotypic data is available for a subset of the individuals.For further information with regard to this cohort please contact Aarno Palotie (Aarno.palotie@helsinki.fi).",EGAD00001000435,UK10K_NEURO_ASD_FI REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000111,UK10K NEURO ASD BIONED,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

The BioNED (Biomarkers for Childhood onset neuropsychiatric disorders) study has been carrying out detailed phenotypic assessments evaluating children with an autism spectrum disorder. These assessments included ADI-R, ADOS, neuropsychology, EEG etc. There are 56 DNA samples from this study (25 extracted from blood). For further information with regard to this cohort please contact Patrick Bolton (patrick.bolton@kcl.ac.uk).",EGAD00001000310,UK10K_NEURO_ASD_BIONED REL-2012-11-27,UK10K_NEURO_ASD_BIONED REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000111,UK10K NEURO ASD BIONED,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

The BioNED (Biomarkers for Childhood onset neuropsychiatric disorders) study has been carrying out detailed phenotypic assessments evaluating children with an autism spectrum disorder. These assessments included ADI-R, ADOS, neuropsychology, EEG etc. There are 56 DNA samples from this study (25 extracted from blood). For further information with regard to this cohort please contact Patrick Bolton (patrick.bolton@kcl.ac.uk).",EGAD00001000228,UK10K_NEURO_ASD_BIONED REL-2012-07-05,EGAD00001000228_UK10K_NEURO_ASD_BIONED_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000111,UK10K NEURO ASD BIONED,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

The BioNED (Biomarkers for Childhood onset neuropsychiatric disorders) study has been carrying out detailed phenotypic assessments evaluating children with an autism spectrum disorder. These assessments included ADI-R, ADOS, neuropsychology, EEG etc. There are 56 DNA samples from this study (25 extracted from blood). For further information with regard to this cohort please contact Patrick Bolton (patrick.bolton@kcl.ac.uk).",EGAD00001000434,UK10K_NEURO_ASD_BIONED REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000112,UK10K NEURO ASD GALLAGHER,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This is an Irish sample set of individuals with ASD (approximately 50% with comorbid intellectual disability). Individuals have been diagnosed with ADI/ ADOS, measures of cognition/ adaptive function. They represent a more severe, narrowly defined cohort of ASD subjects. Family histories are available for some with measures of broader phenotype. For further information on this cohort please contact Nadia Bolshakova (bolshakn@tcd.ie).",EGAD00001000230,UK10K_NEURO_ASD_GALLAGHER REL-2012-07-05,EGAD00001000230_UK10K_NEURO_ASD_GALLAGHER_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000112,UK10K NEURO ASD GALLAGHER,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This is an Irish sample set of individuals with ASD (approximately 50% with comorbid intellectual disability). Individuals have been diagnosed with ADI/ ADOS, measures of cognition/ adaptive function. They represent a more severe, narrowly defined cohort of ASD subjects. Family histories are available for some with measures of broader phenotype. For further information on this cohort please contact Nadia Bolshakova (bolshakn@tcd.ie).",EGAD00001000316,UK10K_NEURO_ASD_GALLAGHER REL-2012-11-27,UK10K_NEURO_ASD_GALLAGHER REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000112,UK10K NEURO ASD GALLAGHER,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This is an Irish sample set of individuals with ASD (approximately 50% with comorbid intellectual disability). Individuals have been diagnosed with ADI/ ADOS, measures of cognition/ adaptive function. They represent a more severe, narrowly defined cohort of ASD subjects. Family histories are available for some with measures of broader phenotype. For further information on this cohort please contact Nadia Bolshakova (bolshakn@tcd.ie).",EGAD00001000436,UK10K_NEURO_ASD_GALLAGHER REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000113,UK10K NEURO ASD MGAS,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.  

The MGAS (Molecular Genetics of Autism Study) samples are from a clinical sample seen by specialists at the Maudsley hospital and who have had detailed phenotypic assessments with ADI-R and ADOS.For further information on this cohort please contact Patrick Bolton (patrick.bolton@kcl.ac.uk).",EGAD00001000242,UK10K_NEURO_ASD_MGAS REL-2012-07-05,EGAD00001000242_UK10K_NEURO_ASD_MGAS_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000113,UK10K NEURO ASD MGAS,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.  

The MGAS (Molecular Genetics of Autism Study) samples are from a clinical sample seen by specialists at the Maudsley hospital and who have had detailed phenotypic assessments with ADI-R and ADOS.For further information on this cohort please contact Patrick Bolton (patrick.bolton@kcl.ac.uk).",EGAD00001000312,UK10K_NEURO_ASD_MGAS REL-2012-11-27,UK10K_NEURO_ASD_MGAS REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000113,UK10K NEURO ASD MGAS,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.  

The MGAS (Molecular Genetics of Autism Study) samples are from a clinical sample seen by specialists at the Maudsley hospital and who have had detailed phenotypic assessments with ADI-R and ADOS.For further information on this cohort please contact Patrick Bolton (patrick.bolton@kcl.ac.uk).",EGAD00001000613,UK10K_NEURO_ASD_MGAS REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000114,UK10K NEURO ASD SKUSE,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This sample set of UK origin consists of clinically identified subjects with Autism Spectrum Disorders, mostly without intellectual disability (ie. Verbal IQs >70). The subjects represent children and adults with Autism, Asperger syndrome or Atypical Autism, identified according to standardized research criteria (ADI-algorithm, ADOS). A minority has identified comorbid neurodevelopmental disorders (e.g. ADHD). Family histories are available, with measures of broader phenotype in first-degree relatives.For further information on this cohort please contact David Skuse (d.skuse@ucl.ac.uk).",EGAD00001000231,UK10K_NEURO_ASD_SKUSE REL-2012-07-05,EGAD00001000231_UK10K_NEURO_ASD_SKUSE_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000114,UK10K NEURO ASD SKUSE,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This sample set of UK origin consists of clinically identified subjects with Autism Spectrum Disorders, mostly without intellectual disability (ie. Verbal IQs >70). The subjects represent children and adults with Autism, Asperger syndrome or Atypical Autism, identified according to standardized research criteria (ADI-algorithm, ADOS). A minority has identified comorbid neurodevelopmental disorders (e.g. ADHD). Family histories are available, with measures of broader phenotype in first-degree relatives.For further information on this cohort please contact David Skuse (d.skuse@ucl.ac.uk).",EGAD00001000313,UK10K_NEURO_ASD_SKUSE REL-2012-11-27,UK10K_NEURO_ASD_SKUSE REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000114,UK10K NEURO ASD SKUSE,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This sample set of UK origin consists of clinically identified subjects with Autism Spectrum Disorders, mostly without intellectual disability (ie. Verbal IQs >70). The subjects represent children and adults with Autism, Asperger syndrome or Atypical Autism, identified according to standardized research criteria (ADI-algorithm, ADOS). A minority has identified comorbid neurodevelopmental disorders (e.g. ADHD). Family histories are available, with measures of broader phenotype in first-degree relatives.For further information on this cohort please contact David Skuse (d.skuse@ucl.ac.uk).",EGAD00001000614,UK10K_NEURO_ASD_SKUSE REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000115,UK10K NEURO ASD TAMPERE,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. The Tampere Autism sample set consists of samples from Finnish subjects with ASD (autism spectrum disorders) with IQs over 70 recruited from a clinical centre for the diagnosis and treatment of children with ASD. For further information on this cohort please contact either Terho Lehtimaki (terho.lehtimaki@uta.fi) or Kaija Puura (kaija.puura@pshp.fi).",EGAD00001000232,UK10K_NEURO_ASD_TAMPERE REL-2012-07-05,EGAD00001000232_UK10K_NEURO_ASD_TAMPERE_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000115,UK10K NEURO ASD TAMPERE,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. The Tampere Autism sample set consists of samples from Finnish subjects with ASD (autism spectrum disorders) with IQs over 70 recruited from a clinical centre for the diagnosis and treatment of children with ASD. For further information on this cohort please contact either Terho Lehtimaki (terho.lehtimaki@uta.fi) or Kaija Puura (kaija.puura@pshp.fi).",EGAD00001000314,UK10K_NEURO_ASD_TAMPERE REL-2012-11-27,UK10K_NEURO_ASD_TAMPERE REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000115,UK10K NEURO ASD TAMPERE,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. The Tampere Autism sample set consists of samples from Finnish subjects with ASD (autism spectrum disorders) with IQs over 70 recruited from a clinical centre for the diagnosis and treatment of children with ASD. For further information on this cohort please contact either Terho Lehtimaki (terho.lehtimaki@uta.fi) or Kaija Puura (kaija.puura@pshp.fi).",EGAD00001000437,UK10K_NEURO_ASD_TAMPERE REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000117,UK10K NEURO EDINBURGH,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This sample set consists of subjects with schizophrenia recruited from psychiatric in-patient and out-patient facilities in Scotland. All diagnoses are based on standard research procedures and family histories are available. Patients have IQ>70 and the cohort includes the following groups: 100 cases with detailed clinical, cognitive and structural and functional neuroimaging phenotypes; 138 familial cases who are the probands of families where DNA has been collected from other affected members; 162 unrelated individuals. In most cases patients and their families may be re contacted to take part in further studies.For further information on this cohort please contact Andrew McIntosh (andrew.mcintosh@ed.ac.uk).",EGAD00001000317,UK10K_NEURO_EDINBURGH REL-2012-11-27,UK10K_NEURO_EDINBURGH REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000117,UK10K NEURO EDINBURGH,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This sample set consists of subjects with schizophrenia recruited from psychiatric in-patient and out-patient facilities in Scotland. All diagnoses are based on standard research procedures and family histories are available. Patients have IQ>70 and the cohort includes the following groups: 100 cases with detailed clinical, cognitive and structural and functional neuroimaging phenotypes; 138 familial cases who are the probands of families where DNA has been collected from other affected members; 162 unrelated individuals. In most cases patients and their families may be re contacted to take part in further studies.For further information on this cohort please contact Andrew McIntosh (andrew.mcintosh@ed.ac.uk).",EGAD00001000233,UK10K_NEURO_EDINBURGH REL-2012-07-05,EGAD00001000233_UK10K_NEURO_EDINBURGH_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000117,UK10K NEURO EDINBURGH,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This sample set consists of subjects with schizophrenia recruited from psychiatric in-patient and out-patient facilities in Scotland. All diagnoses are based on standard research procedures and family histories are available. Patients have IQ>70 and the cohort includes the following groups: 100 cases with detailed clinical, cognitive and structural and functional neuroimaging phenotypes; 138 familial cases who are the probands of families where DNA has been collected from other affected members; 162 unrelated individuals. In most cases patients and their families may be re contacted to take part in further studies.For further information on this cohort please contact Andrew McIntosh (andrew.mcintosh@ed.ac.uk).",EGAD00001000438,UK10K_NEURO_EDINBURGH REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000118,UK10K NEURO FSZ,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.
 
These Finnish schizophrenia samples have been collected from a population cohort using national registers. The entire sample collection consists of 2756 individuals from 458 families of whom 931 are diagnosed with schizophrenia spectrum disorder, each family having at least two affected siblings. 170 families originate from an internal isolate (Kuusamo) with a three-fold lifetime risk for the trait. The genealogy of the internal isolate is well documented and the individuals form a megapedigree reaching to the 17th Century. All diagnoses are based on DSM-IV and for a large fraction of cases there is cognitive data. For further details/descriptions with regard to this data set please contact Tiina Paunio (tiina.paunio@thl.fi)",EGAD00001000318,UK10K_NEURO_FSZ REL-2012-11-27,UK10K_NEURO_FSZ REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000118,UK10K NEURO FSZ,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.
 
These Finnish schizophrenia samples have been collected from a population cohort using national registers. The entire sample collection consists of 2756 individuals from 458 families of whom 931 are diagnosed with schizophrenia spectrum disorder, each family having at least two affected siblings. 170 families originate from an internal isolate (Kuusamo) with a three-fold lifetime risk for the trait. The genealogy of the internal isolate is well documented and the individuals form a megapedigree reaching to the 17th Century. All diagnoses are based on DSM-IV and for a large fraction of cases there is cognitive data. For further details/descriptions with regard to this data set please contact Tiina Paunio (tiina.paunio@thl.fi)",EGAD00001000184,UK10K_NEURO_FSZ REL-2012-01-13,EGAD00001000184_UK10K_NEURO_FSZ_REL_2012_01_13, Illumina HiSeq 2000;
EGAS00001000118,UK10K NEURO FSZ,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.
 
These Finnish schizophrenia samples have been collected from a population cohort using national registers. The entire sample collection consists of 2756 individuals from 458 families of whom 931 are diagnosed with schizophrenia spectrum disorder, each family having at least two affected siblings. 170 families originate from an internal isolate (Kuusamo) with a three-fold lifetime risk for the trait. The genealogy of the internal isolate is well documented and the individuals form a megapedigree reaching to the 17th Century. All diagnoses are based on DSM-IV and for a large fraction of cases there is cognitive data. For further details/descriptions with regard to this data set please contact Tiina Paunio (tiina.paunio@thl.fi)",EGAD00001000240,UK10K_NEURO_FSZ REL-2012-07-05,EGAD00001000240_UK10K_NEURO_FSZ_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000118,UK10K NEURO FSZ,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.
 
These Finnish schizophrenia samples have been collected from a population cohort using national registers. The entire sample collection consists of 2756 individuals from 458 families of whom 931 are diagnosed with schizophrenia spectrum disorder, each family having at least two affected siblings. 170 families originate from an internal isolate (Kuusamo) with a three-fold lifetime risk for the trait. The genealogy of the internal isolate is well documented and the individuals form a megapedigree reaching to the 17th Century. All diagnoses are based on DSM-IV and for a large fraction of cases there is cognitive data. For further details/descriptions with regard to this data set please contact Tiina Paunio (tiina.paunio@thl.fi)",EGAD00001000615,UK10K_NEURO_FSZ REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000119,UK10K NEURO FSZNK,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This Finnish schizophrenia sample set has been collected from a population cohort using national registers. The entire sample collection consists of 2756 individuals from 458 families of whom 931 are diagnosed with schizophrenia spectrum disorder. Families outside Kuusamo (n=288) all had at least two affected siblings. All diagnoses are based on DSM-IV and for a large fraction of cases there is cognitive data.For further details/descriptions with regard to this data set please contact Tiina Paunio (tiina.paunio@thl.fi)",EGAD00001000184,UK10K_NEURO_FSZ REL-2012-01-13,EGAD00001000184_UK10K_NEURO_FSZ_REL_2012_01_13, Illumina HiSeq 2000;
EGAS00001000119,UK10K NEURO FSZNK,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This Finnish schizophrenia sample set has been collected from a population cohort using national registers. The entire sample collection consists of 2756 individuals from 458 families of whom 931 are diagnosed with schizophrenia spectrum disorder. Families outside Kuusamo (n=288) all had at least two affected siblings. All diagnoses are based on DSM-IV and for a large fraction of cases there is cognitive data.For further details/descriptions with regard to this data set please contact Tiina Paunio (tiina.paunio@thl.fi)",EGAD00001000183,UK10K_NEURO_FSZNK REL-2012-01-13,UK10K_NEURO_FSZNK REL-2012-01-13, Illumina HiSeq 2000;
EGAS00001000119,UK10K NEURO FSZNK,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This Finnish schizophrenia sample set has been collected from a population cohort using national registers. The entire sample collection consists of 2756 individuals from 458 families of whom 931 are diagnosed with schizophrenia spectrum disorder. Families outside Kuusamo (n=288) all had at least two affected siblings. All diagnoses are based on DSM-IV and for a large fraction of cases there is cognitive data.For further details/descriptions with regard to this data set please contact Tiina Paunio (tiina.paunio@thl.fi)",EGAD00001000234,UK10K_NEURO_FSZNK REL-2012-07-05,EGAD00001000234_UK10K_NEURO_FSZNK_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000119,UK10K NEURO FSZNK,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This Finnish schizophrenia sample set has been collected from a population cohort using national registers. The entire sample collection consists of 2756 individuals from 458 families of whom 931 are diagnosed with schizophrenia spectrum disorder. Families outside Kuusamo (n=288) all had at least two affected siblings. All diagnoses are based on DSM-IV and for a large fraction of cases there is cognitive data.For further details/descriptions with regard to this data set please contact Tiina Paunio (tiina.paunio@thl.fi)",EGAD00001000332,UK10K_NEURO_FSZNK REL-2012-11-27,UK10K_NEURO_FSZNK REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000119,UK10K NEURO FSZNK,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This Finnish schizophrenia sample set has been collected from a population cohort using national registers. The entire sample collection consists of 2756 individuals from 458 families of whom 931 are diagnosed with schizophrenia spectrum disorder. Families outside Kuusamo (n=288) all had at least two affected siblings. All diagnoses are based on DSM-IV and for a large fraction of cases there is cognitive data.For further details/descriptions with regard to this data set please contact Tiina Paunio (tiina.paunio@thl.fi)",EGAD00001000439,UK10K_NEURO_FSZNK REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000120,UK10K NEURO IMGSAC,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.
The IMGSAC cohort is an international collection of families containing children ascertained for ASDs (autism spectrum disorders). The affected individuals are have been phenotyped, including using the ADI-R and ADOS instruments. Individuals with a past or current medical disorder of probable etiological significance or TSC have been excluded. Where possible, karyotyping has been performed on one affected individual per family to exclude Fragile X syndrome. Many of the samples have been genotyped, using the Affymetrix 10k and Illumina 1M platforms. All samples to be included in the current study are of UK origin.For further information on this cohort please contact Jeremy Parr (jeremy.parr@newcastle.ac.uk).",EGAD00001000320,UK10K_NEURO_IMGSAC REL-2012-11-27,UK10K_NEURO_IMGSAC REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000120,UK10K NEURO IMGSAC,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.
The IMGSAC cohort is an international collection of families containing children ascertained for ASDs (autism spectrum disorders). The affected individuals are have been phenotyped, including using the ADI-R and ADOS instruments. Individuals with a past or current medical disorder of probable etiological significance or TSC have been excluded. Where possible, karyotyping has been performed on one affected individual per family to exclude Fragile X syndrome. Many of the samples have been genotyped, using the Affymetrix 10k and Illumina 1M platforms. All samples to be included in the current study are of UK origin.For further information on this cohort please contact Jeremy Parr (jeremy.parr@newcastle.ac.uk).",EGAD00001000239,UK10K_NEURO_IMGSAC REL-2012-07-05,EGAD00001000239_UK10K_NEURO_IMGSAC_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000120,UK10K NEURO IMGSAC,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.
The IMGSAC cohort is an international collection of families containing children ascertained for ASDs (autism spectrum disorders). The affected individuals are have been phenotyped, including using the ADI-R and ADOS instruments. Individuals with a past or current medical disorder of probable etiological significance or TSC have been excluded. Where possible, karyotyping has been performed on one affected individual per family to exclude Fragile X syndrome. Many of the samples have been genotyped, using the Affymetrix 10k and Illumina 1M platforms. All samples to be included in the current study are of UK origin.For further information on this cohort please contact Jeremy Parr (jeremy.parr@newcastle.ac.uk).",EGAD00001000441,UK10K_NEURO_IMGSAC REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000121,UK10K NEURO IOP COLLIER,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

The Genetics and Psychosis (GAP) set consists of samples from subjects with schizophrenia, ascertained as a new-onset sample. This set is of UK origin, with data on cognition, brain imaging and other endophenotypes. 

The Maudsley twin series consists of probands ascertained from the Maudsley Twin Register, defined as patients of multiple birth who had suffered psychotic symptoms. This set is of UK origin, with data on cognition, brain imaging and other endophenotypes, with DNA available from an MZ or DZ affected or unaffected co-twin. 

The Maudsley family study (MFS) consists of over 250 families who have a history of schizophrenia or bipolar disorder Within the Maudsley Family Study, biological markers of psychosis include neuropsychological tests, Evoked Response Potentials Tests (ERPs), MRI scans, dermatoglyphics and eye tracking. Early risk factors for psychosis and clinical symptoms are also investigated.  This set is of UK origin, with DNA available from both affected and unaffected relatives in many of the probands. For further information on this study please contact David Collier (david.collier@kcl.ac.uk).",EGAD00001000235,UK10K_NEURO_IOP_COLLIER REL-2012-07-05,EGAD00001000235_UK10K_NEURO_IOP_COLLIER_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000121,UK10K NEURO IOP COLLIER,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

The Genetics and Psychosis (GAP) set consists of samples from subjects with schizophrenia, ascertained as a new-onset sample. This set is of UK origin, with data on cognition, brain imaging and other endophenotypes. 

The Maudsley twin series consists of probands ascertained from the Maudsley Twin Register, defined as patients of multiple birth who had suffered psychotic symptoms. This set is of UK origin, with data on cognition, brain imaging and other endophenotypes, with DNA available from an MZ or DZ affected or unaffected co-twin. 

The Maudsley family study (MFS) consists of over 250 families who have a history of schizophrenia or bipolar disorder Within the Maudsley Family Study, biological markers of psychosis include neuropsychological tests, Evoked Response Potentials Tests (ERPs), MRI scans, dermatoglyphics and eye tracking. Early risk factors for psychosis and clinical symptoms are also investigated.  This set is of UK origin, with DNA available from both affected and unaffected relatives in many of the probands. For further information on this study please contact David Collier (david.collier@kcl.ac.uk).",EGAD00001000321,UK10K_NEURO_IOP_COLLIER REL-2012-11-27,UK10K_NEURO_IOP_COLLIER REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000121,UK10K NEURO IOP COLLIER,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

The Genetics and Psychosis (GAP) set consists of samples from subjects with schizophrenia, ascertained as a new-onset sample. This set is of UK origin, with data on cognition, brain imaging and other endophenotypes. 

The Maudsley twin series consists of probands ascertained from the Maudsley Twin Register, defined as patients of multiple birth who had suffered psychotic symptoms. This set is of UK origin, with data on cognition, brain imaging and other endophenotypes, with DNA available from an MZ or DZ affected or unaffected co-twin. 

The Maudsley family study (MFS) consists of over 250 families who have a history of schizophrenia or bipolar disorder Within the Maudsley Family Study, biological markers of psychosis include neuropsychological tests, Evoked Response Potentials Tests (ERPs), MRI scans, dermatoglyphics and eye tracking. Early risk factors for psychosis and clinical symptoms are also investigated.  This set is of UK origin, with DNA available from both affected and unaffected relatives in many of the probands. For further information on this study please contact David Collier (david.collier@kcl.ac.uk).",EGAD00001000442,UK10K_NEURO_IOP_COLLIER REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000122,UK10K NEURO MUIR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The sample selection consists of subjects with schizophrenia (SZ), autism, or other psychoses all with mental retardation (learning disability). The samples were initially collected under the leadership of Walter J Muir (deceased), now with Prof. Blackwood, Dr McKechanie and Prof McIntosh as custodians. These subjects represent the intersection of severe forms of neurodevelopmental disorders, appear to have a higher rate of familiality of SZ than typical, and are likely to have more serious and penetrant forms of mutations.For further information on this cohort please contact Andrew McIntosh (andrew.mcintosh@ed.ac.uk).",EGAD00001000052,UK10K Exomes REL-2011-01-28,UK10K Exomes REL-2011-01-28, Illumina Genome Analyzer II;
EGAS00001000122,UK10K NEURO MUIR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The sample selection consists of subjects with schizophrenia (SZ), autism, or other psychoses all with mental retardation (learning disability). The samples were initially collected under the leadership of Walter J Muir (deceased), now with Prof. Blackwood, Dr McKechanie and Prof McIntosh as custodians. These subjects represent the intersection of severe forms of neurodevelopmental disorders, appear to have a higher rate of familiality of SZ than typical, and are likely to have more serious and penetrant forms of mutations.For further information on this cohort please contact Andrew McIntosh (andrew.mcintosh@ed.ac.uk).",EGAD00001000322,UK10K_NEURO_MUIR REL-2012-11-27,UK10K_NEURO_MUIR REL-2012-11-27," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000122,UK10K NEURO MUIR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The sample selection consists of subjects with schizophrenia (SZ), autism, or other psychoses all with mental retardation (learning disability). The samples were initially collected under the leadership of Walter J Muir (deceased), now with Prof. Blackwood, Dr McKechanie and Prof McIntosh as custodians. These subjects represent the intersection of severe forms of neurodevelopmental disorders, appear to have a higher rate of familiality of SZ than typical, and are likely to have more serious and penetrant forms of mutations.For further information on this cohort please contact Andrew McIntosh (andrew.mcintosh@ed.ac.uk).",EGAD00001000170,UK10K_NEURO_MUIR REL-2012-01-13,UK10K_NEURO_MUIR REL-2012-01-13," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000122,UK10K NEURO MUIR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The sample selection consists of subjects with schizophrenia (SZ), autism, or other psychoses all with mental retardation (learning disability). The samples were initially collected under the leadership of Walter J Muir (deceased), now with Prof. Blackwood, Dr McKechanie and Prof McIntosh as custodians. These subjects represent the intersection of severe forms of neurodevelopmental disorders, appear to have a higher rate of familiality of SZ than typical, and are likely to have more serious and penetrant forms of mutations.For further information on this cohort please contact Andrew McIntosh (andrew.mcintosh@ed.ac.uk).",EGAD00001000236,UK10K_NEURO_MUIR REL-2012-07-05,EGAD00001000236_UK10K_NEURO_MUIR_REL_2012_07_05," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000122,UK10K NEURO MUIR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The sample selection consists of subjects with schizophrenia (SZ), autism, or other psychoses all with mental retardation (learning disability). The samples were initially collected under the leadership of Walter J Muir (deceased), now with Prof. Blackwood, Dr McKechanie and Prof McIntosh as custodians. These subjects represent the intersection of severe forms of neurodevelopmental disorders, appear to have a higher rate of familiality of SZ than typical, and are likely to have more serious and penetrant forms of mutations.For further information on this cohort please contact Andrew McIntosh (andrew.mcintosh@ed.ac.uk).",EGAD00001000443,UK10K_NEURO_MUIR REL-2013-04-20,," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000123,UK10K NEURO UKSCZ,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
These samples have been collected from throughout the UK and Ireland. The samples fall into two main categories, approximately 500 have a full diagnostic work up. A proportion of these are cases with a positive family history of schizophrenia, either collected as sib-pairs or from multiplex kindred's. The second group consist mainly of  >300 samples that have been systematically collected within South Wales and in addition to full diagnostic work up have undergone detailed cognitive testing. All samples have obtained a DSM IV diagnosis of schizophrenia or schizoaffective disorder.For further information on this cohort please contact Michael Owen (OwenMJ@cardiff.ac.uk).",EGAD00001000256,UK10K_NEURO_UKSCZ REL-2012-07-05,UK10K_NEURO_UKSCZ REL-2012-07-05, Illumina HiSeq 2000;
EGAS00001000123,UK10K NEURO UKSCZ,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
These samples have been collected from throughout the UK and Ireland. The samples fall into two main categories, approximately 500 have a full diagnostic work up. A proportion of these are cases with a positive family history of schizophrenia, either collected as sib-pairs or from multiplex kindred's. The second group consist mainly of  >300 samples that have been systematically collected within South Wales and in addition to full diagnostic work up have undergone detailed cognitive testing. All samples have obtained a DSM IV diagnosis of schizophrenia or schizoaffective disorder.For further information on this cohort please contact Michael Owen (OwenMJ@cardiff.ac.uk).",EGAD00001000335,UK10K_NEURO_UKSCZ REL-2012-11-27,UK10K_NEURO_UKSCZ REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000123,UK10K NEURO UKSCZ,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
These samples have been collected from throughout the UK and Ireland. The samples fall into two main categories, approximately 500 have a full diagnostic work up. A proportion of these are cases with a positive family history of schizophrenia, either collected as sib-pairs or from multiplex kindred's. The second group consist mainly of  >300 samples that have been systematically collected within South Wales and in addition to full diagnostic work up have undergone detailed cognitive testing. All samples have obtained a DSM IV diagnosis of schizophrenia or schizoaffective disorder.For further information on this cohort please contact Michael Owen (OwenMJ@cardiff.ac.uk).",EGAD00001000182,UK10K_NEURO_UKSCZ REL-2012-01-13,UK10K_NEURO_UKSCZ REL-2012-01-13, Illumina HiSeq 2000;
EGAS00001000123,UK10K NEURO UKSCZ,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
These samples have been collected from throughout the UK and Ireland. The samples fall into two main categories, approximately 500 have a full diagnostic work up. A proportion of these are cases with a positive family history of schizophrenia, either collected as sib-pairs or from multiplex kindred's. The second group consist mainly of  >300 samples that have been systematically collected within South Wales and in addition to full diagnostic work up have undergone detailed cognitive testing. All samples have obtained a DSM IV diagnosis of schizophrenia or schizoaffective disorder.For further information on this cohort please contact Michael Owen (OwenMJ@cardiff.ac.uk).",EGAD00001000430,UK10K_NEURO_UKSCZ REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000124,UK10K OBESITY SCOOP,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The SCOOP samples are part of the Obesity group and will undergo exome sequencing. Severe Childhood Onset Obesity Project (SCOOP) is a sub-cohort of the Genetics Of Obesity Study (GOOS) cohort established by Sadaf Farooqi and Steve ORahilly at the University of Cambridge over the last 12 years. The GOOS cohort contains >4,000 patients of diverse geographic origin, many of whom have monogenic and syndromic forms of obesity, and includes patients that are offspring of consanguineous union. SCOOP is a subset of >1500 UK Caucasian patients with severe, early onset obesity (all patients have a BMI Standard Deviation Score (SDS) > 3 and obesity onset before the age of 10 years), in whom all known monogenic causes of obesity have been excluded.  GWAS data on the SCOOP cohort will be available (WTCCC2 independent study) at the time of the start of this study. Data from this cohort has demonstrated that the prevalence of the common obesity risk alleles in FTO, MC4R and NEGR1 are amongst the highest within SCOOP, demonstrating its value also in the study of genetic variants with an impact on more common obesity. For further information with regard to this cohort please contact Sadaf Farooqi (isf20@medschl.cam.ac.uk).",EGAD00001000336,UK10K_OBESITY_SCOOP REL-2012-11-27,UK10K_OBESITY_SCOOP REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000124,UK10K OBESITY SCOOP,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The SCOOP samples are part of the Obesity group and will undergo exome sequencing. Severe Childhood Onset Obesity Project (SCOOP) is a sub-cohort of the Genetics Of Obesity Study (GOOS) cohort established by Sadaf Farooqi and Steve ORahilly at the University of Cambridge over the last 12 years. The GOOS cohort contains >4,000 patients of diverse geographic origin, many of whom have monogenic and syndromic forms of obesity, and includes patients that are offspring of consanguineous union. SCOOP is a subset of >1500 UK Caucasian patients with severe, early onset obesity (all patients have a BMI Standard Deviation Score (SDS) > 3 and obesity onset before the age of 10 years), in whom all known monogenic causes of obesity have been excluded.  GWAS data on the SCOOP cohort will be available (WTCCC2 independent study) at the time of the start of this study. Data from this cohort has demonstrated that the prevalence of the common obesity risk alleles in FTO, MC4R and NEGR1 are amongst the highest within SCOOP, demonstrating its value also in the study of genetic variants with an impact on more common obesity. For further information with regard to this cohort please contact Sadaf Farooqi (isf20@medschl.cam.ac.uk).",EGAD00001000241,UK10K_OBESITY_SCOOP REL-2012-07-05,EGAD00001000241_UK10K_OBESITY_SCOOP_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000124,UK10K OBESITY SCOOP,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The SCOOP samples are part of the Obesity group and will undergo exome sequencing. Severe Childhood Onset Obesity Project (SCOOP) is a sub-cohort of the Genetics Of Obesity Study (GOOS) cohort established by Sadaf Farooqi and Steve ORahilly at the University of Cambridge over the last 12 years. The GOOS cohort contains >4,000 patients of diverse geographic origin, many of whom have monogenic and syndromic forms of obesity, and includes patients that are offspring of consanguineous union. SCOOP is a subset of >1500 UK Caucasian patients with severe, early onset obesity (all patients have a BMI Standard Deviation Score (SDS) > 3 and obesity onset before the age of 10 years), in whom all known monogenic causes of obesity have been excluded.  GWAS data on the SCOOP cohort will be available (WTCCC2 independent study) at the time of the start of this study. Data from this cohort has demonstrated that the prevalence of the common obesity risk alleles in FTO, MC4R and NEGR1 are amongst the highest within SCOOP, demonstrating its value also in the study of genetic variants with an impact on more common obesity. For further information with regard to this cohort please contact Sadaf Farooqi (isf20@medschl.cam.ac.uk).",EGAD00001000151,UK10K OBESITY REL-2011-07-14,UK10K OBESITY REL-2011-07-14, Illumina HiSeq 2000;
EGAS00001000124,UK10K OBESITY SCOOP,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The SCOOP samples are part of the Obesity group and will undergo exome sequencing. Severe Childhood Onset Obesity Project (SCOOP) is a sub-cohort of the Genetics Of Obesity Study (GOOS) cohort established by Sadaf Farooqi and Steve ORahilly at the University of Cambridge over the last 12 years. The GOOS cohort contains >4,000 patients of diverse geographic origin, many of whom have monogenic and syndromic forms of obesity, and includes patients that are offspring of consanguineous union. SCOOP is a subset of >1500 UK Caucasian patients with severe, early onset obesity (all patients have a BMI Standard Deviation Score (SDS) > 3 and obesity onset before the age of 10 years), in whom all known monogenic causes of obesity have been excluded.  GWAS data on the SCOOP cohort will be available (WTCCC2 independent study) at the time of the start of this study. Data from this cohort has demonstrated that the prevalence of the common obesity risk alleles in FTO, MC4R and NEGR1 are amongst the highest within SCOOP, demonstrating its value also in the study of genetic variants with an impact on more common obesity. For further information with regard to this cohort please contact Sadaf Farooqi (isf20@medschl.cam.ac.uk).",EGAD00001000181,UK10K_OBESITY_SCOOP REL-2012-01-13,UK10K_OBESITY_SCOOP REL-2012-01-13, Illumina HiSeq 2000;
EGAS00001000124,UK10K OBESITY SCOOP,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The SCOOP samples are part of the Obesity group and will undergo exome sequencing. Severe Childhood Onset Obesity Project (SCOOP) is a sub-cohort of the Genetics Of Obesity Study (GOOS) cohort established by Sadaf Farooqi and Steve ORahilly at the University of Cambridge over the last 12 years. The GOOS cohort contains >4,000 patients of diverse geographic origin, many of whom have monogenic and syndromic forms of obesity, and includes patients that are offspring of consanguineous union. SCOOP is a subset of >1500 UK Caucasian patients with severe, early onset obesity (all patients have a BMI Standard Deviation Score (SDS) > 3 and obesity onset before the age of 10 years), in whom all known monogenic causes of obesity have been excluded.  GWAS data on the SCOOP cohort will be available (WTCCC2 independent study) at the time of the start of this study. Data from this cohort has demonstrated that the prevalence of the common obesity risk alleles in FTO, MC4R and NEGR1 are amongst the highest within SCOOP, demonstrating its value also in the study of genetic variants with an impact on more common obesity. For further information with regard to this cohort please contact Sadaf Farooqi (isf20@medschl.cam.ac.uk).",EGAD00001000193,UK10K_OBESITY_SCOOP REL-2012-02-22,UK10K_OBESITY_SCOOP REL-2012-02-22, Illumina HiSeq 2000;
EGAS00001000124,UK10K OBESITY SCOOP,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The SCOOP samples are part of the Obesity group and will undergo exome sequencing. Severe Childhood Onset Obesity Project (SCOOP) is a sub-cohort of the Genetics Of Obesity Study (GOOS) cohort established by Sadaf Farooqi and Steve ORahilly at the University of Cambridge over the last 12 years. The GOOS cohort contains >4,000 patients of diverse geographic origin, many of whom have monogenic and syndromic forms of obesity, and includes patients that are offspring of consanguineous union. SCOOP is a subset of >1500 UK Caucasian patients with severe, early onset obesity (all patients have a BMI Standard Deviation Score (SDS) > 3 and obesity onset before the age of 10 years), in whom all known monogenic causes of obesity have been excluded.  GWAS data on the SCOOP cohort will be available (WTCCC2 independent study) at the time of the start of this study. Data from this cohort has demonstrated that the prevalence of the common obesity risk alleles in FTO, MC4R and NEGR1 are amongst the highest within SCOOP, demonstrating its value also in the study of genetic variants with an impact on more common obesity. For further information with regard to this cohort please contact Sadaf Farooqi (isf20@medschl.cam.ac.uk).",EGAD00001000432,UK10K_OBESITY_SCOOP REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000125,UK10K RARE CHD,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. The CHD (congenital heart disease) samples will be part of the rare disease group, and will undergo exome sequencing.For further information with regard to this cohort please contact Shoumo Bhattacharya (shoumo@me.com).",EGAD00001000178,UK10K_RARE_CHD REL-2012-01-13,UK10K_RARE_CHD REL-2012-01-13," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000125,UK10K RARE CHD,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. The CHD (congenital heart disease) samples will be part of the rare disease group, and will undergo exome sequencing.For further information with regard to this cohort please contact Shoumo Bhattacharya (shoumo@me.com).",EGAD00001000294,UK10K_RARE_CHD REL-2012-11-27,UK10K_RARE_CHD REL-2012-11-27," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000125,UK10K RARE CHD,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. The CHD (congenital heart disease) samples will be part of the rare disease group, and will undergo exome sequencing.For further information with regard to this cohort please contact Shoumo Bhattacharya (shoumo@me.com).",EGAD00001000210,UK10K_RARE_CHD REL-2012-07-05,UK10K_RARE_CHD REL-2012-07-05," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000125,UK10K RARE CHD,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. The CHD (congenital heart disease) samples will be part of the rare disease group, and will undergo exome sequencing.For further information with regard to this cohort please contact Shoumo Bhattacharya (shoumo@me.com).",EGAD00001000192,UK10K_RARE_CHD REL-2012-02-22,UK10K_RARE_CHD REL-2012-02-22," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000125,UK10K RARE CHD,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. The CHD (congenital heart disease) samples will be part of the rare disease group, and will undergo exome sequencing.For further information with regard to this cohort please contact Shoumo Bhattacharya (shoumo@me.com).",EGAD00001000413,UK10K_RARE_CHD REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000126,UK10K RARE CILIOPATHIES,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
The Ciliopathies samples will be part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Phil Beales (p.beales@ich.ucl.ac.uk).",EGAD00001000191,UK10K_RARE_CILIOPATHIES REL-2012-02-22,UK10K_RARE_CILIOPATHIES REL-2012-02-22," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000126,UK10K RARE CILIOPATHIES,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
The Ciliopathies samples will be part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Phil Beales (p.beales@ich.ucl.ac.uk).",EGAD00001000296,UK10K_RARE_CILIOPATHIES REL-2012-11-27,UK10K_RARE_CILIOPATHIES REL-2012-11-27," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000126,UK10K RARE CILIOPATHIES,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
The Ciliopathies samples will be part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Phil Beales (p.beales@ich.ucl.ac.uk).",EGAD00001000168,UK10K_RARE_CILIOPATHIES REL-2012-01-13,UK10K_RARE_CILIOPATHIES REL-2012-01-13," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000126,UK10K RARE CILIOPATHIES,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
The Ciliopathies samples will be part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Phil Beales (p.beales@ich.ucl.ac.uk).",EGAD00001000217,UK10K_RARE_CILIOPATHIES REL-2012-07-05,UK10K_RARE_CILIOPATHIES REL-2012-07-05," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000126,UK10K RARE CILIOPATHIES,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
The Ciliopathies samples will be part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Phil Beales (p.beales@ich.ucl.ac.uk).",EGAD00001000414,UK10K_RARE_CILIOPATHIES REL-2013-04-20,," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000127,UK10K RARE COLOBOMA,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

Ocular coloboma is the most common significant developmental eye defect with an incidence of ~1 in 5,000 live births. It results from failure of optic fissure closure during embryogenesis. The position and extent of the fusion failure dictates the clinical appearance and functional effect. ~30% of coloboma cases are associated with other systemic malformations. These UK10K samples will mostly comprise isolated coloboma cases without systemic involvement (aka non-syndromal coloboma). There is strong evidence from family studies that coloboma has a major genetic component with autosomal dominance being the most common pattern of inheritance. However, many cases are isolated or show complex patterns of familial clustering. The genes responsible for isolated coloboma are largely unknown, but in a small number of families mutations in SHH, CHX10, and PAX6 have been identified indicating marked genetic heterogeneity. Thus in addition to the clinical benefits of achieving a molecular diagnosis there are also major scientific advantages to identifying coloboma genes, as these are likely to provide insights into the complex process of optic fissure closure, that is critical to normal eye development. In the longer term, understanding the molecular basis of the disease may provide clues to therapeutic strategies.For further information with regard to this cohort please contact David Fitzpatrick (david.fitzpatrick@ed.ac.uk).",EGAD00001000307,UK10K_RARE_COLOBOMA REL-2012-11-27,UK10K_RARE_COLOBOMA REL-2012-11-27," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000127,UK10K RARE COLOBOMA,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

Ocular coloboma is the most common significant developmental eye defect with an incidence of ~1 in 5,000 live births. It results from failure of optic fissure closure during embryogenesis. The position and extent of the fusion failure dictates the clinical appearance and functional effect. ~30% of coloboma cases are associated with other systemic malformations. These UK10K samples will mostly comprise isolated coloboma cases without systemic involvement (aka non-syndromal coloboma). There is strong evidence from family studies that coloboma has a major genetic component with autosomal dominance being the most common pattern of inheritance. However, many cases are isolated or show complex patterns of familial clustering. The genes responsible for isolated coloboma are largely unknown, but in a small number of families mutations in SHH, CHX10, and PAX6 have been identified indicating marked genetic heterogeneity. Thus in addition to the clinical benefits of achieving a molecular diagnosis there are also major scientific advantages to identifying coloboma genes, as these are likely to provide insights into the complex process of optic fissure closure, that is critical to normal eye development. In the longer term, understanding the molecular basis of the disease may provide clues to therapeutic strategies.For further information with regard to this cohort please contact David Fitzpatrick (david.fitzpatrick@ed.ac.uk).",EGAD00001000206,UK10K_RARE_COLOBOMA REL-2012-07-05,UK10K_RARE_COLOBOMA REL-2012-07-05," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000127,UK10K RARE COLOBOMA,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

Ocular coloboma is the most common significant developmental eye defect with an incidence of ~1 in 5,000 live births. It results from failure of optic fissure closure during embryogenesis. The position and extent of the fusion failure dictates the clinical appearance and functional effect. ~30% of coloboma cases are associated with other systemic malformations. These UK10K samples will mostly comprise isolated coloboma cases without systemic involvement (aka non-syndromal coloboma). There is strong evidence from family studies that coloboma has a major genetic component with autosomal dominance being the most common pattern of inheritance. However, many cases are isolated or show complex patterns of familial clustering. The genes responsible for isolated coloboma are largely unknown, but in a small number of families mutations in SHH, CHX10, and PAX6 have been identified indicating marked genetic heterogeneity. Thus in addition to the clinical benefits of achieving a molecular diagnosis there are also major scientific advantages to identifying coloboma genes, as these are likely to provide insights into the complex process of optic fissure closure, that is critical to normal eye development. In the longer term, understanding the molecular basis of the disease may provide clues to therapeutic strategies.For further information with regard to this cohort please contact David Fitzpatrick (david.fitzpatrick@ed.ac.uk).",EGAD00001000179,UK10K_RARE_COLOBOMA REL-2012-01-13,UK10K_RARE_COLOBOMA REL-2012-01-13," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000127,UK10K RARE COLOBOMA,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

Ocular coloboma is the most common significant developmental eye defect with an incidence of ~1 in 5,000 live births. It results from failure of optic fissure closure during embryogenesis. The position and extent of the fusion failure dictates the clinical appearance and functional effect. ~30% of coloboma cases are associated with other systemic malformations. These UK10K samples will mostly comprise isolated coloboma cases without systemic involvement (aka non-syndromal coloboma). There is strong evidence from family studies that coloboma has a major genetic component with autosomal dominance being the most common pattern of inheritance. However, many cases are isolated or show complex patterns of familial clustering. The genes responsible for isolated coloboma are largely unknown, but in a small number of families mutations in SHH, CHX10, and PAX6 have been identified indicating marked genetic heterogeneity. Thus in addition to the clinical benefits of achieving a molecular diagnosis there are also major scientific advantages to identifying coloboma genes, as these are likely to provide insights into the complex process of optic fissure closure, that is critical to normal eye development. In the longer term, understanding the molecular basis of the disease may provide clues to therapeutic strategies.For further information with regard to this cohort please contact David Fitzpatrick (david.fitzpatrick@ed.ac.uk).",EGAD00001000185,UK10K_RARE_COLOBOMA REL-2012-02-22,UK10K_RARE_COLOBOMA REL-2012-02-22," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000127,UK10K RARE COLOBOMA,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing.  We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

Ocular coloboma is the most common significant developmental eye defect with an incidence of ~1 in 5,000 live births. It results from failure of optic fissure closure during embryogenesis. The position and extent of the fusion failure dictates the clinical appearance and functional effect. ~30% of coloboma cases are associated with other systemic malformations. These UK10K samples will mostly comprise isolated coloboma cases without systemic involvement (aka non-syndromal coloboma). There is strong evidence from family studies that coloboma has a major genetic component with autosomal dominance being the most common pattern of inheritance. However, many cases are isolated or show complex patterns of familial clustering. The genes responsible for isolated coloboma are largely unknown, but in a small number of families mutations in SHH, CHX10, and PAX6 have been identified indicating marked genetic heterogeneity. Thus in addition to the clinical benefits of achieving a molecular diagnosis there are also major scientific advantages to identifying coloboma genes, as these are likely to provide insights into the complex process of optic fissure closure, that is critical to normal eye development. In the longer term, understanding the molecular basis of the disease may provide clues to therapeutic strategies.For further information with regard to this cohort please contact David Fitzpatrick (david.fitzpatrick@ed.ac.uk).",EGAD00001000415,UK10K_RARE_COLOBOMA REL-2013-04-20,," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000128,UK10K RARE FIND,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
The Raymond samples will be part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Lucy Raymond (flr24@cam.ac.uk).",EGAD00001000297,UK10K_RARE_FIND REL-2012-11-27,UK10K_RARE_FIND REL-2012-11-27," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000128,UK10K RARE FIND,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
The Raymond samples will be part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Lucy Raymond (flr24@cam.ac.uk).",EGAD00001000171,UK10K_RARE_FIND REL-2012-01-13,UK10K_RARE_FIND REL-2012-01-13," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000128,UK10K RARE FIND,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
The Raymond samples will be part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Lucy Raymond (flr24@cam.ac.uk).",EGAD00001000209,UK10K_RARE_FIND REL-2012-07-05,UK10K_RARE_FIND REL-2012-07-05," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000128,UK10K RARE FIND,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
The Raymond samples will be part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Lucy Raymond (flr24@cam.ac.uk).",EGAD00001000190,UK10K_RARE_FIND REL-2012-02-22,UK10K_RARE_FIND REL-2012-02-22," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000128,UK10K RARE FIND,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 
The Raymond samples will be part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Lucy Raymond (flr24@cam.ac.uk).",EGAD00001000416,UK10K_RARE_FIND REL-2013-04-20,," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000129,UK10K RARE HYPERCHOL,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

Familial Hypercholesterolemia is a condition where the affected person has a consistently high level of LDL which can lead to early clogging of the coronary arteries. All patients selected for this study will have been found not to carry the common APOB and PCSK9 mutations, and to have no detectable LDLR mutations by testing for 18 common mutations. For further information with regard to this cohort please contact Steve Humphries(steve.humphries@ucl.ac.uk).",EGAD00001000295,UK10K_RARE_HYPERCHOL REL-2012-11-27,UK10K_RARE_HYPERCHOL REL-2012-11-27," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000129,UK10K RARE HYPERCHOL,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

Familial Hypercholesterolemia is a condition where the affected person has a consistently high level of LDL which can lead to early clogging of the coronary arteries. All patients selected for this study will have been found not to carry the common APOB and PCSK9 mutations, and to have no detectable LDLR mutations by testing for 18 common mutations. For further information with regard to this cohort please contact Steve Humphries(steve.humphries@ucl.ac.uk).",EGAD00001000186,UK10K_RARE_HYPERCHOL REL-2012-02-22,UK10K_RARE_HYPERCHOL REL-2012-02-22," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000129,UK10K RARE HYPERCHOL,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

Familial Hypercholesterolemia is a condition where the affected person has a consistently high level of LDL which can lead to early clogging of the coronary arteries. All patients selected for this study will have been found not to carry the common APOB and PCSK9 mutations, and to have no detectable LDLR mutations by testing for 18 common mutations. For further information with regard to this cohort please contact Steve Humphries(steve.humphries@ucl.ac.uk).",EGAD00001000167,UK10K_RARE_HYPERCHOL REL-2012-01-13,UK10K_RARE_HYPERCHOL REL-2012-01-13," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000129,UK10K RARE HYPERCHOL,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

Familial Hypercholesterolemia is a condition where the affected person has a consistently high level of LDL which can lead to early clogging of the coronary arteries. All patients selected for this study will have been found not to carry the common APOB and PCSK9 mutations, and to have no detectable LDLR mutations by testing for 18 common mutations. For further information with regard to this cohort please contact Steve Humphries(steve.humphries@ucl.ac.uk).",EGAD00001000207,UK10K_RARE_HYPERCHOL REL-2012-07-05,UK10K_RARE_HYPERCHOL REL-2012-07-05," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000129,UK10K RARE HYPERCHOL,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

Familial Hypercholesterolemia is a condition where the affected person has a consistently high level of LDL which can lead to early clogging of the coronary arteries. All patients selected for this study will have been found not to carry the common APOB and PCSK9 mutations, and to have no detectable LDLR mutations by testing for 18 common mutations. For further information with regard to this cohort please contact Steve Humphries(steve.humphries@ucl.ac.uk).",EGAD00001000417,UK10K_RARE_HYPERCHOL REL-2013-04-20,," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000130,UK10K RARE SIR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes.

Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. 

We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The SIR (Severe Insulin Resistance) samples are part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Robert Semple (rks16@cam.ac.uk).",EGAD00001000188,UK10K_RARE_SIR REL-2012-02-22,UK10K_RARE_SIR REL-2012-02-22," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000130,UK10K RARE SIR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes.

Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. 

We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The SIR (Severe Insulin Resistance) samples are part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Robert Semple (rks16@cam.ac.uk).",EGAD00001000334,UK10K_RARE_SIR REL-2012-11-27,UK10K_RARE_SIR REL-2012-11-27," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000130,UK10K RARE SIR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes.

Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. 

We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The SIR (Severe Insulin Resistance) samples are part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Robert Semple (rks16@cam.ac.uk).",EGAD00001000218,UK10K_RARE_SIR REL-2012-07-05,UK10K_RARE_SIR REL-2012-07-05," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000130,UK10K RARE SIR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes.

Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. 

We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The SIR (Severe Insulin Resistance) samples are part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Robert Semple (rks16@cam.ac.uk).",EGAD00001000153,UK10K_RARE_SIR REL-2012-01-13,UK10K_RARE_SIR REL-2012-01-13," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000130,UK10K RARE SIR,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes.

Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. 

We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

The SIR (Severe Insulin Resistance) samples are part of the rare disease group, and will undergo exome sequencing. For further information with regard to this cohort please contact Robert Semple (rks16@cam.ac.uk).",EGAD00001000419,UK10K_RARE_SIR REL-2013-04-20,," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000131,UK10K RARE THYROID,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

Two cohorts of subjects are being analysed: Individuals with Congenital Hypothyroidism (CH) due either to dysgenesis or dyshormonogenesis; Patients with Resistance to Thyroid hormone (RTH), a disorder characterized by elevated thyroid hormones and variable tissue refractoriness to hormone action. The CH cohort has been enriched for genetic aetiologies by recruiting cases that are familial, on a consanguineous background or syndromic. The RTH cohort consists of cases in which candidate gene analyses have been negative.For further information with regard to this cohort please contact Krishna Chatterjee (kkc1@medschl.cam.ac.uk).",EGAD00001000152,UK10K_RARE_THYROID REL-2012-01-13,UK10K_RARE_THYROID REL-2012-01-13," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000131,UK10K RARE THYROID,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

Two cohorts of subjects are being analysed: Individuals with Congenital Hypothyroidism (CH) due either to dysgenesis or dyshormonogenesis; Patients with Resistance to Thyroid hormone (RTH), a disorder characterized by elevated thyroid hormones and variable tissue refractoriness to hormone action. The CH cohort has been enriched for genetic aetiologies by recruiting cases that are familial, on a consanguineous background or syndromic. The RTH cohort consists of cases in which candidate gene analyses have been negative.For further information with regard to this cohort please contact Krishna Chatterjee (kkc1@medschl.cam.ac.uk).",EGAD00001000208,UK10K_RARE_THYROID REL-2012-07-05,UK10K_RARE_THYROID REL-2012-07-05," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000131,UK10K RARE THYROID,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

Two cohorts of subjects are being analysed: Individuals with Congenital Hypothyroidism (CH) due either to dysgenesis or dyshormonogenesis; Patients with Resistance to Thyroid hormone (RTH), a disorder characterized by elevated thyroid hormones and variable tissue refractoriness to hormone action. The CH cohort has been enriched for genetic aetiologies by recruiting cases that are familial, on a consanguineous background or syndromic. The RTH cohort consists of cases in which candidate gene analyses have been negative.For further information with regard to this cohort please contact Krishna Chatterjee (kkc1@medschl.cam.ac.uk).",EGAD00001000187,UK10K_RARE_THYROID REL-2012-02-22,UK10K_RARE_THYROID REL-2012-02-22," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000131,UK10K RARE THYROID,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

Two cohorts of subjects are being analysed: Individuals with Congenital Hypothyroidism (CH) due either to dysgenesis or dyshormonogenesis; Patients with Resistance to Thyroid hormone (RTH), a disorder characterized by elevated thyroid hormones and variable tissue refractoriness to hormone action. The CH cohort has been enriched for genetic aetiologies by recruiting cases that are familial, on a consanguineous background or syndromic. The RTH cohort consists of cases in which candidate gene analyses have been negative.For further information with regard to this cohort please contact Krishna Chatterjee (kkc1@medschl.cam.ac.uk).",EGAD00001000329,UK10K_RARE_THYROID REL-2012-11-27,UK10K_RARE_THYROID REL-2012-11-27," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000131,UK10K RARE THYROID,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.

Two cohorts of subjects are being analysed: Individuals with Congenital Hypothyroidism (CH) due either to dysgenesis or dyshormonogenesis; Patients with Resistance to Thyroid hormone (RTH), a disorder characterized by elevated thyroid hormones and variable tissue refractoriness to hormone action. The CH cohort has been enriched for genetic aetiologies by recruiting cases that are familial, on a consanguineous background or syndromic. The RTH cohort consists of cases in which candidate gene analyses have been negative.For further information with regard to this cohort please contact Krishna Chatterjee (kkc1@medschl.cam.ac.uk).",EGAD00001000420,UK10K_RARE_THYROID REL-2013-04-20,," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000132,The clonal and mutational evolution spectrum of primary triple negative breast cancers,"Primary triple negative breast cancers (TNBC) represent approximately 16% of all breast cancers and are a tumour type defined by exclusion,for which comprehensive landscapes of somatic mutation have not been determined. Here we show in 104 early TNBC cases, that at the time of diagnosis these cancers exhibit a wide and continuous spectrum of genomic evolution, with some exhibiting only a handful of somatic aberrations in a few pathways, whereas others contain hundreds of somatic events and multiple pathways implicated. Integration with matched whole transcriptome sequence data revealed that only 36% of mutations are expressed.  By examining single nucleotide variant (SNV) allelic abundance derived from deep re-sequencing (median > 20,000 fold) measurements in 2414 somatic mutations, we determine for the first time in an epithelial tumour, the relative abundance of clonal genotypes among cases in the population. We show that TNBC vary widely and continuously in their clonal frequencies at the time of diagnosis, with basal subtype TNBC exhibiting more variation than non-basal TNBC. Although p53 and  somatic mutations appear clonally dominant compared with other pathways, in some tumours their clonal frequencies are incompatible with founder status. Mutations in cytoskeletal and cell shape/motility proteins occurred at lower clonal frequencies, suggesting they occurred later during tumour progression.  Taken together our results show that future attempts to dissect the biology and therapeutic responses of TNBC will require the determination of individual tumour clonal genotypes.",EGAD00001000115,Mutational landscapes of primary triple negative breast cancers - WGS,Mutational landscapes of primary triple negative breast cancers - WGS, ABI_SOLID
EGAS00001000132,The clonal and mutational evolution spectrum of primary triple negative breast cancers,"Primary triple negative breast cancers (TNBC) represent approximately 16% of all breast cancers and are a tumour type defined by exclusion,for which comprehensive landscapes of somatic mutation have not been determined. Here we show in 104 early TNBC cases, that at the time of diagnosis these cancers exhibit a wide and continuous spectrum of genomic evolution, with some exhibiting only a handful of somatic aberrations in a few pathways, whereas others contain hundreds of somatic events and multiple pathways implicated. Integration with matched whole transcriptome sequence data revealed that only 36% of mutations are expressed.  By examining single nucleotide variant (SNV) allelic abundance derived from deep re-sequencing (median > 20,000 fold) measurements in 2414 somatic mutations, we determine for the first time in an epithelial tumour, the relative abundance of clonal genotypes among cases in the population. We show that TNBC vary widely and continuously in their clonal frequencies at the time of diagnosis, with basal subtype TNBC exhibiting more variation than non-basal TNBC. Although p53 and  somatic mutations appear clonally dominant compared with other pathways, in some tumours their clonal frequencies are incompatible with founder status. Mutations in cytoskeletal and cell shape/motility proteins occurred at lower clonal frequencies, suggesting they occurred later during tumour progression.  Taken together our results show that future attempts to dissect the biology and therapeutic responses of TNBC will require the determination of individual tumour clonal genotypes.",EGAD00010000148,Title not provided,tumour samples using Affymetrix Genome-Wide SNP6.0 arrays, Affymetrix_GenomeWide_SNP6.34
EGAS00001000132,The clonal and mutational evolution spectrum of primary triple negative breast cancers,"Primary triple negative breast cancers (TNBC) represent approximately 16% of all breast cancers and are a tumour type defined by exclusion,for which comprehensive landscapes of somatic mutation have not been determined. Here we show in 104 early TNBC cases, that at the time of diagnosis these cancers exhibit a wide and continuous spectrum of genomic evolution, with some exhibiting only a handful of somatic aberrations in a few pathways, whereas others contain hundreds of somatic events and multiple pathways implicated. Integration with matched whole transcriptome sequence data revealed that only 36% of mutations are expressed.  By examining single nucleotide variant (SNV) allelic abundance derived from deep re-sequencing (median > 20,000 fold) measurements in 2414 somatic mutations, we determine for the first time in an epithelial tumour, the relative abundance of clonal genotypes among cases in the population. We show that TNBC vary widely and continuously in their clonal frequencies at the time of diagnosis, with basal subtype TNBC exhibiting more variation than non-basal TNBC. Although p53 and  somatic mutations appear clonally dominant compared with other pathways, in some tumours their clonal frequencies are incompatible with founder status. Mutations in cytoskeletal and cell shape/motility proteins occurred at lower clonal frequencies, suggesting they occurred later during tumour progression.  Taken together our results show that future attempts to dissect the biology and therapeutic responses of TNBC will require the determination of individual tumour clonal genotypes.",EGAD00001000132,Mutational landscapes of primary triple negative breast cancers - RNA seq,Mutational landscapes of primary triple negative breast cancers - RNA seq," Illumina Genome Analyzer IIx, Illumina Genome Analyzer IIx;"
EGAS00001000132,The clonal and mutational evolution spectrum of primary triple negative breast cancers,"Primary triple negative breast cancers (TNBC) represent approximately 16% of all breast cancers and are a tumour type defined by exclusion,for which comprehensive landscapes of somatic mutation have not been determined. Here we show in 104 early TNBC cases, that at the time of diagnosis these cancers exhibit a wide and continuous spectrum of genomic evolution, with some exhibiting only a handful of somatic aberrations in a few pathways, whereas others contain hundreds of somatic events and multiple pathways implicated. Integration with matched whole transcriptome sequence data revealed that only 36% of mutations are expressed.  By examining single nucleotide variant (SNV) allelic abundance derived from deep re-sequencing (median > 20,000 fold) measurements in 2414 somatic mutations, we determine for the first time in an epithelial tumour, the relative abundance of clonal genotypes among cases in the population. We show that TNBC vary widely and continuously in their clonal frequencies at the time of diagnosis, with basal subtype TNBC exhibiting more variation than non-basal TNBC. Although p53 and  somatic mutations appear clonally dominant compared with other pathways, in some tumours their clonal frequencies are incompatible with founder status. Mutations in cytoskeletal and cell shape/motility proteins occurred at lower clonal frequencies, suggesting they occurred later during tumour progression.  Taken together our results show that future attempts to dissect the biology and therapeutic responses of TNBC will require the determination of individual tumour clonal genotypes.",EGAD00001000113,Mutational landscapes of primary triple negative breast cancers - Exomes,Mutational landscapes of primary triple negative breast cancers - Exomes," Illumina Genome Analyzer IIx, Illumina Genome Analyzer IIx;"
EGAS00001000132,The clonal and mutational evolution spectrum of primary triple negative breast cancers,"Primary triple negative breast cancers (TNBC) represent approximately 16% of all breast cancers and are a tumour type defined by exclusion,for which comprehensive landscapes of somatic mutation have not been determined. Here we show in 104 early TNBC cases, that at the time of diagnosis these cancers exhibit a wide and continuous spectrum of genomic evolution, with some exhibiting only a handful of somatic aberrations in a few pathways, whereas others contain hundreds of somatic events and multiple pathways implicated. Integration with matched whole transcriptome sequence data revealed that only 36% of mutations are expressed.  By examining single nucleotide variant (SNV) allelic abundance derived from deep re-sequencing (median > 20,000 fold) measurements in 2414 somatic mutations, we determine for the first time in an epithelial tumour, the relative abundance of clonal genotypes among cases in the population. We show that TNBC vary widely and continuously in their clonal frequencies at the time of diagnosis, with basal subtype TNBC exhibiting more variation than non-basal TNBC. Although p53 and  somatic mutations appear clonally dominant compared with other pathways, in some tumours their clonal frequencies are incompatible with founder status. Mutations in cytoskeletal and cell shape/motility proteins occurred at lower clonal frequencies, suggesting they occurred later during tumour progression.  Taken together our results show that future attempts to dissect the biology and therapeutic responses of TNBC will require the determination of individual tumour clonal genotypes.",EGAD00001000114,Title not provided,Mutational landscapes of primary triple negative breast cancers - RNA-seq, Illumina Genome Analyzer IIx;
EGAS00001000134,An evaluation of different strategies for large scale pooled sequencing study design ,"Second generation sequencing technology has enabled the design of large-scale sequencing experiments in targeted disease-related regions in thousands of cases and controls. Cost implications dictate a pooled DNA sequencing design, evaluation of allele frequency differences based on the resequenced samples and large-scale targeted follow-up in further samples. To evaluate the feasibility of this approach and to assess different study design strategies, we have carried out a pilot study which tests the feasibility of PCR-based and pull-down DNA pooling for (a) SNP discovery and (b) allele frequency comparison purposes. All samples are from the HapMap or 1958 BC. The sample composition of the pool is listed below: Pool 5: 31 HapMap Individuals (NA12249, NA12156, NA12004, NA11831, NA12716, NA11832, NA11993, NA12057, NA11995, NA12006, NA12144, NA12802, NA12146, NA12005, NA12003, NA07000, NA12043, NA12044, NA11992, NA11881, NA11994, NA07345, NA12154, NA06994, NA06985, NA12239, NA07022, NA07034, NA12155, NA07056, NA06993); 19 1958 BC Individuals (WTCCC88214, WTCCC88215, WTCCC88216, WTCCC88217, WTCCC88222, WTCCC88233, WTCCC88240, WTCCC88241, WTCCC88242, WTCCC88247, WTCCC88249, WTCCC88262, WTCCC88264, WTCCC88278, WTCCC88294, WTCCC88298, WTCCC88302, WTCCC88305, WTCCC88321) Some pools were carried out in duplicate to assess reproducibility. We focused on 10 (PD), 7(PCR) chromosomal regions, ~2(PD), ~1.6 (PCR) Mb in total.",EGAD00001000037,An evaluation of different strategies for large-scale pooled sequencing study design.,An evaluation of different strategies for large-scale pooled sequencing study design., Illumina Genome Analyzer II
EGAS00001000135,Recurrent somatic DICER1 mutations in non-epithelial ovarian tumors,"Background: Germline truncating mutations in DICER1, an RNase III-type endoribonuclease essential for processing of microRNAs, are seen in families with the pleuropulmonary blastoma-family tumor and dysplasia syndrome; these individuals have a propensity to develop non-epithelial ovarian tumors (i.e. sex-cord stromal and germ cell tumors). Methods:  We sequenced the whole transcriptomes or exomes of 14 non-epithelial ovarian tumors and noted closely clustered mutations in the RNase IIIb domain of DICER1 in four cases.  Using Sanger sequencing, we then analyzed additional ovarian tumors for mutations in this region.  The impact of the mutations on the enzymatic activity of Dicer1 was determined using in vitro RNA cleavage assays. Results:  RNase IIIb domain DICER1 mutations were found in 30/102 non-epithelial ovarian tumors (29%), predominantly Sertoli-Leydig cell tumors (26/43, 60%), including 4/4 from individuals with germline DICER1 mutations.  The mutations were restricted to metal binding sites within the RNase IIIb catalytic centres critical for miRNA interaction and cleavage, and were somatic in all 14 cases where germline DNA was available for testing. Of 266 epithelial ovarian and endometrial cancers tested, one case, an ovarian carcinosarcoma, had a hotspot mutation.  In vitro, the mutant DICER proteins showed reduced RNase IIIb activity but retained RNase IIIa activity. Conclusions:  Somatic missense mutations of the RNase IIIb domain of DICER1 are common in non-epithelial ovarian tumors.  Genetic, pathologic, and functional evidence suggest that these mutations do not obliterate DICER1 function, rather, they alter it in specific cell types, a novel mechanism through which perturbed microRNA expression is oncogenic.",EGAD00001000058,Exome Sequencing analysis,Exome Sequencing analysis, Illumina Genome Analyzer II
EGAS00001000135,Recurrent somatic DICER1 mutations in non-epithelial ovarian tumors,"Background: Germline truncating mutations in DICER1, an RNase III-type endoribonuclease essential for processing of microRNAs, are seen in families with the pleuropulmonary blastoma-family tumor and dysplasia syndrome; these individuals have a propensity to develop non-epithelial ovarian tumors (i.e. sex-cord stromal and germ cell tumors). Methods:  We sequenced the whole transcriptomes or exomes of 14 non-epithelial ovarian tumors and noted closely clustered mutations in the RNase IIIb domain of DICER1 in four cases.  Using Sanger sequencing, we then analyzed additional ovarian tumors for mutations in this region.  The impact of the mutations on the enzymatic activity of Dicer1 was determined using in vitro RNA cleavage assays. Results:  RNase IIIb domain DICER1 mutations were found in 30/102 non-epithelial ovarian tumors (29%), predominantly Sertoli-Leydig cell tumors (26/43, 60%), including 4/4 from individuals with germline DICER1 mutations.  The mutations were restricted to metal binding sites within the RNase IIIb catalytic centres critical for miRNA interaction and cleavage, and were somatic in all 14 cases where germline DNA was available for testing. Of 266 epithelial ovarian and endometrial cancers tested, one case, an ovarian carcinosarcoma, had a hotspot mutation.  In vitro, the mutant DICER proteins showed reduced RNase IIIb activity but retained RNase IIIa activity. Conclusions:  Somatic missense mutations of the RNase IIIb domain of DICER1 are common in non-epithelial ovarian tumors.  Genetic, pathologic, and functional evidence suggest that these mutations do not obliterate DICER1 function, rather, they alter it in specific cell types, a novel mechanism through which perturbed microRNA expression is oncogenic.",EGAD00001000057,RNA-Seq analysis,RNA-Seq analysis, Illumina Genome Analyzer II
EGAS00001000136,"""Targeted High Throughput Sequencing in Clinical Cancer Settings: Formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity""","""Background: Massively parallel sequencing technologies have brought an enormous increase in sequencing throughput. However, these technologies need to be further improved with regard to reproducibility and applicability to clinical samples and settings. 
Methods: Using identification of genetic variations in prostate cancer as an example we address three crucial challenges in the field of targeted re-sequencing: Small nucleotide variation (SNV) detection in samples of formalin-fixed paraffin embedded (FFPE) tissue material, minimal amount of input sample and sampling in view of tissue heterogeneity.
Results: We show that FFPE tissue material can supplement for fresh frozen tissues for the detection of SNVs and that solution-based enrichment experiments can be accomplished with small amounts of DNA with only minimal effects on enrichment uniformity and data variance. 
Finally, we address the question whether the heterogeneity of a tumor is reflected by different genetic alterations, e.g. different foci of a tumor display different genomic patterns. We show that the tumor heterogeneity plays an important role for the detection of copy number variations, but is of minor importance for the detection of somatic variations.
Conclusions: The application of high throughput sequencing technologies in cancer genomics opens up a new dimension for the identification of disease mechanisms. In particular the ability to use small amounts of FFPE samples available from surgical tumor resections and histopathological examinations facilitates the collection of precious tissue materials. However, care needs to be taken in regard to the locations of the biopsies taken, which can have an influence on the prediction of copy number variations. Bearing these technological challenges in mind will significantly improve many large-scale sequencing studies and will - on a long-range - result in a more reliable prediction of individual cancer therapies.""",EGAD00001000034,"""Usage of small amounts of DNA for Illumina sequencing""","""Usage of small amounts of DNA for Illumina sequencing""", Illumina Genome Analyzer II
EGAS00001000136,"""Targeted High Throughput Sequencing in Clinical Cancer Settings: Formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity""","""Background: Massively parallel sequencing technologies have brought an enormous increase in sequencing throughput. However, these technologies need to be further improved with regard to reproducibility and applicability to clinical samples and settings. 
Methods: Using identification of genetic variations in prostate cancer as an example we address three crucial challenges in the field of targeted re-sequencing: Small nucleotide variation (SNV) detection in samples of formalin-fixed paraffin embedded (FFPE) tissue material, minimal amount of input sample and sampling in view of tissue heterogeneity.
Results: We show that FFPE tissue material can supplement for fresh frozen tissues for the detection of SNVs and that solution-based enrichment experiments can be accomplished with small amounts of DNA with only minimal effects on enrichment uniformity and data variance. 
Finally, we address the question whether the heterogeneity of a tumor is reflected by different genetic alterations, e.g. different foci of a tumor display different genomic patterns. We show that the tumor heterogeneity plays an important role for the detection of copy number variations, but is of minor importance for the detection of somatic variations.
Conclusions: The application of high throughput sequencing technologies in cancer genomics opens up a new dimension for the identification of disease mechanisms. In particular the ability to use small amounts of FFPE samples available from surgical tumor resections and histopathological examinations facilitates the collection of precious tissue materials. However, care needs to be taken in regard to the locations of the biopsies taken, which can have an influence on the prediction of copy number variations. Bearing these technological challenges in mind will significantly improve many large-scale sequencing studies and will - on a long-range - result in a more reliable prediction of individual cancer therapies.""",EGAD00001000035,"""Single nucleotide variant detection in multiple foci of three prostate cancer tumors""","""Single nucleotide variant detection in multiple foci of three prostate cancer tumors""", Illumina Genome Analyzer II
EGAS00001000136,"""Targeted High Throughput Sequencing in Clinical Cancer Settings: Formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity""","""Background: Massively parallel sequencing technologies have brought an enormous increase in sequencing throughput. However, these technologies need to be further improved with regard to reproducibility and applicability to clinical samples and settings. 
Methods: Using identification of genetic variations in prostate cancer as an example we address three crucial challenges in the field of targeted re-sequencing: Small nucleotide variation (SNV) detection in samples of formalin-fixed paraffin embedded (FFPE) tissue material, minimal amount of input sample and sampling in view of tissue heterogeneity.
Results: We show that FFPE tissue material can supplement for fresh frozen tissues for the detection of SNVs and that solution-based enrichment experiments can be accomplished with small amounts of DNA with only minimal effects on enrichment uniformity and data variance. 
Finally, we address the question whether the heterogeneity of a tumor is reflected by different genetic alterations, e.g. different foci of a tumor display different genomic patterns. We show that the tumor heterogeneity plays an important role for the detection of copy number variations, but is of minor importance for the detection of somatic variations.
Conclusions: The application of high throughput sequencing technologies in cancer genomics opens up a new dimension for the identification of disease mechanisms. In particular the ability to use small amounts of FFPE samples available from surgical tumor resections and histopathological examinations facilitates the collection of precious tissue materials. However, care needs to be taken in regard to the locations of the biopsies taken, which can have an influence on the prediction of copy number variations. Bearing these technological challenges in mind will significantly improve many large-scale sequencing studies and will - on a long-range - result in a more reliable prediction of individual cancer therapies.""",EGAD00001000033,"""SNV detection from formalin fixed paraffin embedded (FFPE) samples""","""SNV detection from formalin fixed paraffin embedded (FFPE) samples""", Illumina Genome Analyzer II
EGAS00001000136,"""Targeted High Throughput Sequencing in Clinical Cancer Settings: Formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity""","""Background: Massively parallel sequencing technologies have brought an enormous increase in sequencing throughput. However, these technologies need to be further improved with regard to reproducibility and applicability to clinical samples and settings. 
Methods: Using identification of genetic variations in prostate cancer as an example we address three crucial challenges in the field of targeted re-sequencing: Small nucleotide variation (SNV) detection in samples of formalin-fixed paraffin embedded (FFPE) tissue material, minimal amount of input sample and sampling in view of tissue heterogeneity.
Results: We show that FFPE tissue material can supplement for fresh frozen tissues for the detection of SNVs and that solution-based enrichment experiments can be accomplished with small amounts of DNA with only minimal effects on enrichment uniformity and data variance. 
Finally, we address the question whether the heterogeneity of a tumor is reflected by different genetic alterations, e.g. different foci of a tumor display different genomic patterns. We show that the tumor heterogeneity plays an important role for the detection of copy number variations, but is of minor importance for the detection of somatic variations.
Conclusions: The application of high throughput sequencing technologies in cancer genomics opens up a new dimension for the identification of disease mechanisms. In particular the ability to use small amounts of FFPE samples available from surgical tumor resections and histopathological examinations facilitates the collection of precious tissue materials. However, care needs to be taken in regard to the locations of the biopsies taken, which can have an influence on the prediction of copy number variations. Bearing these technological challenges in mind will significantly improve many large-scale sequencing studies and will - on a long-range - result in a more reliable prediction of individual cancer therapies.""",EGAD00001000036,"""Copy number variant detection in multiple foci of three prostate cancer tumors""","""Copy number variant detection in multiple foci of three prostate cancer tumors""", Illumina Genome Analyzer II
EGAS00001000137,ENGAGE   Amendment  500 genes exon sequencing ,The ENGAGE project is a FP7 funded EU project aiming to combine genetic and phenotype information from European population based cohorts. In this sub-project we aim to do whole exome sequencing of individuals selected from Health 2000 and FINRISK cohorts. Individuals have been selected based on their metabolic trait phenotypes,EGAD00001000403,"ENGAGE - Amendment ""500 genes exon sequencing""",The ENGAGE project is a FP7 funded EU project aiming to combine genetic and phenotype information from European population based cohorts. In this sub-project we aim to do whole exome sequencing of individuals selected from Health 2000 and FINRISK cohorts. Individuals have been selected based on their metabolic trait phenotypes, Illumina HiSeq 2000;
EGAS00001000139,Splenic Marginal Zone Lymphoma with villous lymphocytes exome sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from ~3 Splenic Marginal Zone Lymphoma with villous lymphocytes samples and matched normal DNA from the same patients. Samples will be multiplexed in one lane of Illumina HiSeq. Sequencing to a coverage of at least 30x will be performed and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000081,Splenic Marginal Zone Lymphoma with villous lymphocytes exome sequencing,Splenic Marginal Zone Lymphoma with villous lymphocytes exome sequencing, Illumina HiSeq 2000
EGAS00001000140,Xenograft Sequencing,Sequencing of mouse/human carcinoma xenograft samples.,EGAD00001000143,Xenograft Seqeuncing,Xenograft Seqeuncing," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000142,Exome sequencing of patients with structural brain malformations,Exome sequencing of 12 DNA samples obtained from patients with structural brain malformations.,EGAD00001000345,Exome sequencing of patients with structural brain malformations,Exome sequencing of  12 DNA samples obtained from patients with structural brain malformations., Illumina HiSeq 2000;
EGAS00001000143,Kuusamo low coverage WGS,The Low coverage Kuusamo whole genome sequencing study will produce whole genome sequencing with 1x coverage on a subset of the Finrisk 2012 sample collection. The sampels in this study have all been collected in Kuusamo.,EGAD00001000055,Genetic variation in Kuusamo,Genetic variation in Kuusamo," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000147,Osteosarcoma Whole Genome,We propose to definitively characterise the somatic genetics of Osteosarcoma cancer through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing.,EGAD00001000147,Osteosarcoma Whole Genome,Osteosarcoma Whole Genome," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000148,Lung Cancer Whole Genomes,We propose to definitively characterise the somatic genetics of Lung cancer through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing.,EGAD00001000144,Lung Cancer Whole Genomes,Lung Cancer Whole Genomes," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000148,Lung Cancer Whole Genomes,We propose to definitively characterise the somatic genetics of Lung cancer through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing.,EGAD00001000638,Somatic pseudogenes acquired during cancer development  Whole Genome sequencing,Insertion of processed pseudogenes is known to occur in the germline but has not previously been observed in somatic cells. Formation of pseudogenes could represent a new class of mutation in cancers and a new source of potential driver events., Illumina HiSeq 2000;
EGAS00001000149,Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency,"Whole-exome sequencing (Exome-Seq) has been successfully applied in several recent studies. We here performed Exome-Seq of 15 pancreatic tumor-normal pairs. We captured 162,073 exons of 16,954 genes and sequenced the targeted regions to a mean coverage of 56 folds. This study identified a total of 1,517 somatic mutations and validated 934 of them by transcriptome sequencing. We detected recurrent mutations in 56 genes. Among them, 41 have not been described. The mutation rates varied widely among tumors. The diversity of mutation rates was significantly correlated with the distinct MLH1 copy-number status. Exome-Seq revealed intensive genomic instability in a tumor with MLH1 homozygous deletion, indicated by a dramatically elevated mutation rate of somatic substitutions, small insertions/deletions (indels), as well as indels presented at microsatellites. Notably, we detected MLH1 allelic loss in 4 tumors. MLH1 expression was decreased by nearly half in these cases. While they were negative in the conventional microsatellite instability assay, they showed a 10.5-fold increase in the mutation rate of somatic indels, e.g. truncating indels in TP53 and TGFBR2, indicating MLH1 haploinsufficiency in correction of DNA indel errors. We further analyzed the exomes of 15 renal cell carcinomas (RCCs) and confirmed MLH1 haploinsufficiency. We observed a significant increase in the mutation rate of somatic indels in affected cases and identified recurrent truncating indels in several cancer genes such as VHL, PBRM1 and JARID1C. Together, our data suggest that MLH1 hemizygous deletion, through increasing the mutation rate of somatic indels, could drive the development and progression of sporadic cancers.",EGAD00010000050,Title not provided,Matched tumor-negative pancreas tissues, Affymetrix SNP 6.0
EGAS00001000149,Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency,"Whole-exome sequencing (Exome-Seq) has been successfully applied in several recent studies. We here performed Exome-Seq of 15 pancreatic tumor-normal pairs. We captured 162,073 exons of 16,954 genes and sequenced the targeted regions to a mean coverage of 56 folds. This study identified a total of 1,517 somatic mutations and validated 934 of them by transcriptome sequencing. We detected recurrent mutations in 56 genes. Among them, 41 have not been described. The mutation rates varied widely among tumors. The diversity of mutation rates was significantly correlated with the distinct MLH1 copy-number status. Exome-Seq revealed intensive genomic instability in a tumor with MLH1 homozygous deletion, indicated by a dramatically elevated mutation rate of somatic substitutions, small insertions/deletions (indels), as well as indels presented at microsatellites. Notably, we detected MLH1 allelic loss in 4 tumors. MLH1 expression was decreased by nearly half in these cases. While they were negative in the conventional microsatellite instability assay, they showed a 10.5-fold increase in the mutation rate of somatic indels, e.g. truncating indels in TP53 and TGFBR2, indicating MLH1 haploinsufficiency in correction of DNA indel errors. We further analyzed the exomes of 15 renal cell carcinomas (RCCs) and confirmed MLH1 haploinsufficiency. We observed a significant increase in the mutation rate of somatic indels in affected cases and identified recurrent truncating indels in several cancer genes such as VHL, PBRM1 and JARID1C. Together, our data suggest that MLH1 hemizygous deletion, through increasing the mutation rate of somatic indels, could drive the development and progression of sporadic cancers.",EGAD00010000051,Title not provided,Cell line derived from microdissected primary pancreatic ductal adenocarcinoma tissues, Affymetrix SNP 6.0
EGAS00001000149,Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency,"Whole-exome sequencing (Exome-Seq) has been successfully applied in several recent studies. We here performed Exome-Seq of 15 pancreatic tumor-normal pairs. We captured 162,073 exons of 16,954 genes and sequenced the targeted regions to a mean coverage of 56 folds. This study identified a total of 1,517 somatic mutations and validated 934 of them by transcriptome sequencing. We detected recurrent mutations in 56 genes. Among them, 41 have not been described. The mutation rates varied widely among tumors. The diversity of mutation rates was significantly correlated with the distinct MLH1 copy-number status. Exome-Seq revealed intensive genomic instability in a tumor with MLH1 homozygous deletion, indicated by a dramatically elevated mutation rate of somatic substitutions, small insertions/deletions (indels), as well as indels presented at microsatellites. Notably, we detected MLH1 allelic loss in 4 tumors. MLH1 expression was decreased by nearly half in these cases. While they were negative in the conventional microsatellite instability assay, they showed a 10.5-fold increase in the mutation rate of somatic indels, e.g. truncating indels in TP53 and TGFBR2, indicating MLH1 haploinsufficiency in correction of DNA indel errors. We further analyzed the exomes of 15 renal cell carcinomas (RCCs) and confirmed MLH1 haploinsufficiency. We observed a significant increase in the mutation rate of somatic indels in affected cases and identified recurrent truncating indels in several cancer genes such as VHL, PBRM1 and JARID1C. Together, our data suggest that MLH1 hemizygous deletion, through increasing the mutation rate of somatic indels, could drive the development and progression of sporadic cancers.",EGAD00001000042,Whole-Exome-Seq-Dataset,Whole-Exome-Seq-Dataset, Illumina Genome Analyzer IIx
EGAS00001000149,Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency,"Whole-exome sequencing (Exome-Seq) has been successfully applied in several recent studies. We here performed Exome-Seq of 15 pancreatic tumor-normal pairs. We captured 162,073 exons of 16,954 genes and sequenced the targeted regions to a mean coverage of 56 folds. This study identified a total of 1,517 somatic mutations and validated 934 of them by transcriptome sequencing. We detected recurrent mutations in 56 genes. Among them, 41 have not been described. The mutation rates varied widely among tumors. The diversity of mutation rates was significantly correlated with the distinct MLH1 copy-number status. Exome-Seq revealed intensive genomic instability in a tumor with MLH1 homozygous deletion, indicated by a dramatically elevated mutation rate of somatic substitutions, small insertions/deletions (indels), as well as indels presented at microsatellites. Notably, we detected MLH1 allelic loss in 4 tumors. MLH1 expression was decreased by nearly half in these cases. While they were negative in the conventional microsatellite instability assay, they showed a 10.5-fold increase in the mutation rate of somatic indels, e.g. truncating indels in TP53 and TGFBR2, indicating MLH1 haploinsufficiency in correction of DNA indel errors. We further analyzed the exomes of 15 renal cell carcinomas (RCCs) and confirmed MLH1 haploinsufficiency. We observed a significant increase in the mutation rate of somatic indels in affected cases and identified recurrent truncating indels in several cancer genes such as VHL, PBRM1 and JARID1C. Together, our data suggest that MLH1 hemizygous deletion, through increasing the mutation rate of somatic indels, could drive the development and progression of sporadic cancers.",EGAD00001000043,RNA-Seq-Dataset,RNA-Seq-Dataset, Illumina Genome Analyzer IIx
EGAS00001000152,Full genome sequencing of a monozygotic twin discordant for schizophrenia,"We sequenced the genomes from a monozygotic twin discordant for schizophrenia and a tumor-normal pair of an ovarian cancer patient. Using whole-genome twin data to discriminate between correctly identified single nucleotide variants (SNVs) and errors a strategy for the accurate detection of SNVs was developed. By applying stringent sequencing quality measures, excluding error-prone regions and selecting SNVs identified by different mapping and variation calling algorithms, error rates were ~37-fold reduced. This enabled us to identify the first discordant SNVs in monozygotic twins using whole-genome sequencing. In addition, by showing that novel SNVs are highly enriched in errors, accurate estimates of the number of novel and rare SNVs occurring in unrelated Caucasian individuals were obtained. Finally, somatic mutations in coding and regulatory sequences were reliably identified in the highly rearranged ovarian tumor. Overall, our data demonstrate that strategies to reduce error rates in whole-genomes are required for disease gene discovery.",EGAD00010000052,Title not provided,Monozygotic twins that are discordant for schizophrenia (Genotyping), CompleteGenomics build 1.4.2.8 - CG Build 1.4.2.8
EGAS00001000152,Full genome sequencing of a monozygotic twin discordant for schizophrenia,"We sequenced the genomes from a monozygotic twin discordant for schizophrenia and a tumor-normal pair of an ovarian cancer patient. Using whole-genome twin data to discriminate between correctly identified single nucleotide variants (SNVs) and errors a strategy for the accurate detection of SNVs was developed. By applying stringent sequencing quality measures, excluding error-prone regions and selecting SNVs identified by different mapping and variation calling algorithms, error rates were ~37-fold reduced. This enabled us to identify the first discordant SNVs in monozygotic twins using whole-genome sequencing. In addition, by showing that novel SNVs are highly enriched in errors, accurate estimates of the number of novel and rare SNVs occurring in unrelated Caucasian individuals were obtained. Finally, somatic mutations in coding and regulatory sequences were reliably identified in the highly rearranged ovarian tumor. Overall, our data demonstrate that strategies to reduce error rates in whole-genomes are required for disease gene discovery.",EGAD00001000148,monozygotic twin discordant for schizophrenia (Sequencing),monozygotic twin discordant for schizophrenia (Sequencing), Complete Genomics
EGAS00001000152,Full genome sequencing of a monozygotic twin discordant for schizophrenia,"We sequenced the genomes from a monozygotic twin discordant for schizophrenia and a tumor-normal pair of an ovarian cancer patient. Using whole-genome twin data to discriminate between correctly identified single nucleotide variants (SNVs) and errors a strategy for the accurate detection of SNVs was developed. By applying stringent sequencing quality measures, excluding error-prone regions and selecting SNVs identified by different mapping and variation calling algorithms, error rates were ~37-fold reduced. This enabled us to identify the first discordant SNVs in monozygotic twins using whole-genome sequencing. In addition, by showing that novel SNVs are highly enriched in errors, accurate estimates of the number of novel and rare SNVs occurring in unrelated Caucasian individuals were obtained. Finally, somatic mutations in coding and regulatory sequences were reliably identified in the highly rearranged ovarian tumor. Overall, our data demonstrate that strategies to reduce error rates in whole-genomes are required for disease gene discovery.",EGAD00001000048,Title not provided,monozygotic twin discordant for schizophrenia, CompleteGenomics build 1.4.2.8 - CG Build 1.4.2.8 
EGAS00001000153,Exome Sequencing of Gastric Cancer,DNA was extracted from 22 gastric cancers and corresponding uninvolved gastric tissue and subjected to Agilent SureSelect Target Enrichment (Human All Exon 37 Mb kit) followed by paired-end sequencing with 75 bp reads on the Illumina Genome Analyzer.,EGAD00001000046,Gastric Cancer Exome Sequencing,Gastric Cancer Exome Sequencing," Illumina HiSeq 2000, Illumina Genome Analyzer IIx"
EGAS00001000154,Genome Landscape of Primary Pancreatic Ductal Adenocarcinoma,"The purpose of Australia's ICGC Pancreatic Cancer Genome Sequencing Initiative
study is to identify the common driving mutations underlying the initiation and
development of Pancreatic Adenocarcinoma in a large cohort of pancreatic cancer
patients (n=350). Matched genome sequences will be generated from normal tissue
(duodenum) and resected primary tumour tissue in each patient using exome and
whole genome sequencing. The complete repertoire of somatic mutations will be
determined (substitutions, indels, copy number changes and structural changes).
Where possible, matched transcriptome sequencing will also be carried out to
determine locus activity, which mutations are actively expressed and which
rearrangements give rise to gene-fusion transcripts.",EGAD00001000096,Pancreatic adenocarcinoma QCMG 20120201,Pancreatic adenocarcinoma QCMG 20120201, AB SOLiD 4 System
EGAS00001000154,Genome Landscape of Primary Pancreatic Ductal Adenocarcinoma,"The purpose of Australia's ICGC Pancreatic Cancer Genome Sequencing Initiative
study is to identify the common driving mutations underlying the initiation and
development of Pancreatic Adenocarcinoma in a large cohort of pancreatic cancer
patients (n=350). Matched genome sequences will be generated from normal tissue
(duodenum) and resected primary tumour tissue in each patient using exome and
whole genome sequencing. The complete repertoire of somatic mutations will be
determined (substitutions, indels, copy number changes and structural changes).
Where possible, matched transcriptome sequencing will also be carried out to
determine locus activity, which mutations are actively expressed and which
rearrangements give rise to gene-fusion transcripts.",EGAD00001000323,Sequencing data for Australian Pancreatic Cancer study submitted 20130102,Sequencing data for Australian Pancreatic Cancer study submitted 20130102," AB SOLiD 4 System;, Illumina HiSeq 2000;"
EGAS00001000154,Genome Landscape of Primary Pancreatic Ductal Adenocarcinoma,"The purpose of Australia's ICGC Pancreatic Cancer Genome Sequencing Initiative
study is to identify the common driving mutations underlying the initiation and
development of Pancreatic Adenocarcinoma in a large cohort of pancreatic cancer
patients (n=350). Matched genome sequences will be generated from normal tissue
(duodenum) and resected primary tumour tissue in each patient using exome and
whole genome sequencing. The complete repertoire of somatic mutations will be
determined (substitutions, indels, copy number changes and structural changes).
Where possible, matched transcriptome sequencing will also be carried out to
determine locus activity, which mutations are actively expressed and which
rearrangements give rise to gene-fusion transcripts.",EGAD00001000049,Pancreatic adenocarcinoma QCMG 20110901,Pancreatic adenocarcinoma QCMG 20110901," AB SOLiD System 3.0, AB SOLiD 4 System"
EGAS00001000154,Genome Landscape of Primary Pancreatic Ductal Adenocarcinoma,"The purpose of Australia's ICGC Pancreatic Cancer Genome Sequencing Initiative
study is to identify the common driving mutations underlying the initiation and
development of Pancreatic Adenocarcinoma in a large cohort of pancreatic cancer
patients (n=350). Matched genome sequences will be generated from normal tissue
(duodenum) and resected primary tumour tissue in each patient using exome and
whole genome sequencing. The complete repertoire of somatic mutations will be
determined (substitutions, indels, copy number changes and structural changes).
Where possible, matched transcriptome sequencing will also be carried out to
determine locus activity, which mutations are actively expressed and which
rearrangements give rise to gene-fusion transcripts.",EGAD00001000371,Sequencing data for PDAC cell lines generated by QCMG,Sequencing data for PDAC cell lines generated by QCMG," Illumina HiSeq 2000;, Illumina HiSeq 2500;"
EGAS00001000155,Matched Ovarian Cancer Sequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from 15 ovarian cancer samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000050,Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes,Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes, Illumina Genome Analyzer II
EGAS00001000155,Matched Ovarian Cancer Sequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from 15 ovarian cancer samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000084,Matched Ovarian Cancer Sequencing,Matched Ovarian Cancer Sequencing, Illumina Genome Analyzer II
EGAS00001000156,Otosclerosis gene discovery ,DNA from patients with otosclerosis will be subjected to exome sequencing,EGAD00001000203,Otosclerosis gene discovery,Otosclerosis gene discovery, Illumina HiSeq 2000;
EGAS00001000157,Hearing loss in adults from South Carolina ,DNA  from ten individuals from South Carolina with progressive hearing loss will be subjected to exome sequencing,EGAD00001000204,Hearing loss in adults from South Carolina,Hearing loss in adults from South Carolina, Illumina HiSeq 2000;
EGAS00001000158,Complete Genomics paired end sequencing; Ovarian cancer,"We sequenced the genomes from a monozygotic twin discordant for schizophrenia and a tumor-normal pair of an ovarian cancer patient. Using whole-genome twin data to discriminate between correctly identified single nucleotide variants (SNVs) and errors a strategy for the accurate detection of SNVs was developed. By applying stringent sequencing quality measures, excluding error-prone regions and selecting SNVs identified by different mapping and variation calling algorithms, error rates were ~37-fold reduced. This enabled us to identify the first discordant SNVs in monozygotic twins using whole-genome sequencing. In addition, by showing that novel SNVs are highly enriched in errors, accurate estimates of the number of novel and rare SNVs occurring in unrelated Caucasian individuals were obtained. Finally, somatic mutations in coding and regulatory sequences were reliably identified in the highly rearranged ovarian tumor. Overall, our data demonstrate that strategies to reduce error rates in whole-genomes are required for disease gene discovery.",EGAD00001000139,Tumor sample of a serious ovarian carcinoma,Tumor sample of a serious ovarian carcinoma, Complete Genomics
EGAS00001000158,Complete Genomics paired end sequencing; Ovarian cancer,"We sequenced the genomes from a monozygotic twin discordant for schizophrenia and a tumor-normal pair of an ovarian cancer patient. Using whole-genome twin data to discriminate between correctly identified single nucleotide variants (SNVs) and errors a strategy for the accurate detection of SNVs was developed. By applying stringent sequencing quality measures, excluding error-prone regions and selecting SNVs identified by different mapping and variation calling algorithms, error rates were ~37-fold reduced. This enabled us to identify the first discordant SNVs in monozygotic twins using whole-genome sequencing. In addition, by showing that novel SNVs are highly enriched in errors, accurate estimates of the number of novel and rare SNVs occurring in unrelated Caucasian individuals were obtained. Finally, somatic mutations in coding and regulatory sequences were reliably identified in the highly rearranged ovarian tumor. Overall, our data demonstrate that strategies to reduce error rates in whole-genomes are required for disease gene discovery.",EGAD00010000220,Title not provided,Ovarian & matched normal (Genotypes), Complete Genomics - CG Build 1.4.2.8
EGAS00001000158,Complete Genomics paired end sequencing; Ovarian cancer,"We sequenced the genomes from a monozygotic twin discordant for schizophrenia and a tumor-normal pair of an ovarian cancer patient. Using whole-genome twin data to discriminate between correctly identified single nucleotide variants (SNVs) and errors a strategy for the accurate detection of SNVs was developed. By applying stringent sequencing quality measures, excluding error-prone regions and selecting SNVs identified by different mapping and variation calling algorithms, error rates were ~37-fold reduced. This enabled us to identify the first discordant SNVs in monozygotic twins using whole-genome sequencing. In addition, by showing that novel SNVs are highly enriched in errors, accurate estimates of the number of novel and rare SNVs occurring in unrelated Caucasian individuals were obtained. Finally, somatic mutations in coding and regulatory sequences were reliably identified in the highly rearranged ovarian tumor. Overall, our data demonstrate that strategies to reduce error rates in whole-genomes are required for disease gene discovery.",EGAD00001000140,Blood sample of serious ovarian carcinoma patient,Blood sample of serious ovarian carcinoma patient, Complete Genomics
EGAS00001000159,Exome sequencing of patients with rare neurological disorders,"Exome sequencing of patients and their families with diverse rare neurological disorders. Some families have prior linkage data identifying a specific chromosomal interval or interest, other families do not have linkage data available. Many of these families come from special populations whose demography or preference for consanguineous marriages make them particularly tractable for genetic studies.",EGAD00001000346,Exome sequencing of patients with rare neurological disorders,"Exome sequencing of patients and their families with diverse rare neurological disorders. Some families have prior linkage data identifying a specific chromosomal interval or interest, other families do not have linkage data available. Many of these families come from special populations whose demography or preference for consanguineous marriages make them particularly tractable for genetic studies.", Illumina HiSeq 2000;
EGAS00001000160,Matched Pair Cancer Cell line Whole Genomes,We propose to definitively characterise the somatic genetics of 29 matched pair cell lines through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing.,EGAD00001000145,Matched Pair Cancer Cell line Whole Genomes,Matched Pair Cancer Cell line Whole Genomes," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000160,Matched Pair Cancer Cell line Whole Genomes,We propose to definitively characterise the somatic genetics of 29 matched pair cell lines through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing.,EGAD00001000638,Somatic pseudogenes acquired during cancer development  Whole Genome sequencing,Insertion of processed pseudogenes is known to occur in the germline but has not previously been observed in somatic cells. Formation of pseudogenes could represent a new class of mutation in cancers and a new source of potential driver events., Illumina HiSeq 2000;
EGAS00001000161,Triple Negative Breast Cancer sequencing,We propose to definitively characterise the somatic genetics of triple-ve breast cancer through generation of comprehensive catalogues of somatic mutations in a number of cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.,EGAD00001000138,Mutational processes moulding the genomes of 21 breast cancers,"The expression data for this study can be found here: 

http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1088/

and its SNP6 data can be found here:
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1087/"," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000161,Triple Negative Breast Cancer sequencing,We propose to definitively characterise the somatic genetics of triple-ve breast cancer through generation of comprehensive catalogues of somatic mutations in a number of cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.,EGAD00001000063,Triple Negative Breast Cancer sequencing,Triple Negative Breast Cancer sequencing, Illumina Genome Analyzer II
EGAS00001000163,Osteosarcoma Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 osteosarcoma cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000118,Osteosarcoma Exome Sequencing,Osteosarcoma Exome Sequencing," Illumina Genome Analyzer II, Illumina HiSeq 2000;"
EGAS00001000165,Monotherapy Breast Cancer,These samples are from locally advanced breast cancers that have been treated with epirubicin monotherapy before surgery. We will sequence some samples from patients with good response to the therapy and some with poor response to the therapy.,EGAD00001000349,Monotherapy Breast Cancer,These samples are from locally advanced breast cancers that have been treated with epirubicin monotherapy before surgery. We will sequence some samples from patients with good response to the therapy and some with poor response to the therapy., Illumina HiSeq 2000;
EGAS00001000166,Breast Cancer Matched Pair Cell Line Whole Genomes,We propose to definitively characterise the somatic genetics of matched pair breast cancer cell lines through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.,EGAD00001000130,Breast Cancer Matched Pair Cell Line Whole Genomes,Breast Cancer Matched Pair Cell Line Whole Genomes," Illumina HiSeq 2000, Illumina HiSeq 2000;"
EGAS00001000169,Whole genome sequencing of matched primary and metastatic acral melanomas,"Next generation sequencing has enabled systematic discovery of mutational spectra in cancer samples. Here we used whole genome sequencing to characterise somatic mutations and structural variation in a primary acral melanoma and its lymph node metastasis. Our data show that the somatic mutational rates in this acral melanoma sample pair was more comparable to the rate reported in cancer genomes not associated with mutagenic exposure than in the genome of a melanoma cell line or the transcriptome of melanoma short-term cultures. Despite the perception that acral skin is sun-protected, the dominant mutational signature in these samples is compatible with damage due to ultraviolet light exposure. A nonsense mutation in ERCC5 discovered in both the primary and metastatic tumours, could also have contributed to the mutational signature through accumulation of unrepaired dipyrimidine lesions. However, evidence of transcription-coupled repair was suggested by the lower mutational rate in the transcribed regions and expressed genes. The primary and the metastasis are highly similar at the level of global gene copy number alterations, loss of heterozygosity and single nucleotide variation (SNV). Furthermore, the majority of the SNVs in the primary tumour were propagated in the metastasis and one non-synonymous coding SNV and one splice site mutation appeared to arise de novo in the metastatic lesion.",EGAD00001000060,Acral melanoma study whole genomes,Acral melanoma study whole genomes, Complete Genomics
EGAS00001000169,Whole genome sequencing of matched primary and metastatic acral melanomas,"Next generation sequencing has enabled systematic discovery of mutational spectra in cancer samples. Here we used whole genome sequencing to characterise somatic mutations and structural variation in a primary acral melanoma and its lymph node metastasis. Our data show that the somatic mutational rates in this acral melanoma sample pair was more comparable to the rate reported in cancer genomes not associated with mutagenic exposure than in the genome of a melanoma cell line or the transcriptome of melanoma short-term cultures. Despite the perception that acral skin is sun-protected, the dominant mutational signature in these samples is compatible with damage due to ultraviolet light exposure. A nonsense mutation in ERCC5 discovered in both the primary and metastatic tumours, could also have contributed to the mutational signature through accumulation of unrepaired dipyrimidine lesions. However, evidence of transcription-coupled repair was suggested by the lower mutational rate in the transcribed regions and expressed genes. The primary and the metastasis are highly similar at the level of global gene copy number alterations, loss of heterozygosity and single nucleotide variation (SNV). Furthermore, the majority of the SNVs in the primary tumour were propagated in the metastasis and one non-synonymous coding SNV and one splice site mutation appeared to arise de novo in the metastatic lesion.",EGAD00001000061,Acral melanoma study whole exomes,Acral melanoma study whole exomes, Illumina Genome Analyzer IIx
EGAS00001000170,20 Matched Pair Breast Cancer Genomes,We propose to definitively characterise the somatic genetics of 20 breast cancers through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing coupled with integrated transcriptomic.,EGAD00001000138,Mutational processes moulding the genomes of 21 breast cancers,"The expression data for this study can be found here: 

http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1088/

and its SNP6 data can be found here:
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1087/"," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000170,20 Matched Pair Breast Cancer Genomes,We propose to definitively characterise the somatic genetics of 20 breast cancers through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing coupled with integrated transcriptomic.,EGAD00001000082,20 Matched Pair Breast Cancer Genomes,20 Matched Pair Breast Cancer Genomes," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000173,Testing the feasibility of genome scale sequencing in routinely collected FFPE cancer specimens versus matched fresh frozen samples,Testing the feasibility of genome-scale sequencing in routinely collected formalin-fixed paraffin-embedded (FFPE) cancer specimens versus matched fresh-frozen samples using whole exome and targeted exome capture prior to Illumina sequencing.,EGAD00001000255,Testing the feasibility of genome scale sequencing in routinely collected FFPE cancer specimens versus matched fresh frozen samples,Testing the feasibility of genome scale sequencing in routinely collected FFPE cancer specimens versus matched fresh frozen samples, Illumina HiSeq 2000;
EGAS00001000174,Balanced Ependymoma,"We propose to definitively characterise the somatic genetics of a number of pediatric malignant tumours including ependymoma, high grade glioma and central nervous system primitive neurectodermal tumours through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing.",EGAD00001000350,Balanced Ependymoma,"We propose to definitively characterise the somatic genetics of a number of pediatric malignant tumours including ependymoma, high grade glioma and central nervous system primitive neurectodermal tumours through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing.", Illumina HiSeq 2000;
EGAS00001000175,PMF Exome Study,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 Primary Myelofibrosis Myeloproliferative Disease  samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000106,Primary Myelofibrosis Myeloproliferative Disease exome sequencing,Primary Myelofibrosis Myeloproliferative Disease exome sequencing," Illumina Genome Analyzer II, Illumina HiSeq 2000;"
EGAS00001000176,FRCC Exome sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from FRCC patients. one lane of Illumina Hiseq sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000098,FRCC Exome sequencing,FRCC Exome sequencing, Illumina Genome Analyzer II
EGAS00001000177,Meningioma Exome,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Meningioma tumour samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting exome libraries and mapped build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000099,Meningioma Exome,Meningioma Exome, Illumina Genome Analyzer II
EGAS00001000178,Cell Line Sub Clone Rearrangement Screen,"Genomic libraries (500 bps) will be generated from total genomic DNA cancer samples and subjected to paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000154,Single-cell genome sequencing reveals DNA-mutation per cell cycle,Single-cell genome sequencing reveals DNA-mutation per cell cycle," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000178,Cell Line Sub Clone Rearrangement Screen,"Genomic libraries (500 bps) will be generated from total genomic DNA cancer samples and subjected to paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000064,Cell Line Sub Clone Rearrangement Screen,Cell Line Sub Clone Rearrangement Screen, Illumina Genome Analyzer II
EGAS00001000179,Renal Matched Pair Cell Line Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from renal cancer cell lines and matched normal DNA from the same patient. Illumina GA sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000100,Renal Matched Pair Cell Line Exome Sequencing,Renal Matched Pair Cell Line Exome Sequencing, Illumina Genome Analyzer II
EGAS00001000180,Mixed Leukemia Rearrangement Screen,"Genomic libraries will be generated from total genomic DNA derived from Mixed Leukemia and MPD samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the illumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000065,Mixed Leukemia Rearrangement Screen,Mixed Leukemia Rearrangement Screen, Illumina Genome Analyzer II
EGAS00001000181,Chondrosarcoma Validation Study,Agilent whole exome hybridisation capture was performed on genomic DNA derived from Chondrosarcoma cancer and matched normal DNA from the same patients. Next Generation sequencing performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Now we aim to re find and validate the findings of those exome libraries using bespoke pulldown methods and sequencing the products.,EGAD00001000392,Chondrosarcoma Validation Study,Agilent whole exome hybridisation capture was performed on genomic DNA derived from Chondrosarcoma cancer and matched normal DNA from the same patients. Next Generation sequencing performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Now we aim to re find and validate the findings of those exome libraries using bespoke pulldown methods and sequencing the products., Illumina MiSeq;
EGAS00001000188,Chordoma Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Chordoma cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000226,A common single nucleotide variant in T is strongly associated with chordoma,"Chordoma is a rare malignant bone tumor that expresses the transcription factor T. We conducted an association study of 40 patients with chordoma and 358 ancestry-matched, unaffected individuals with replication in an independent cohort.  Whole-exome and Sanger sequencing of T exons reveals a strong risk association ( allelic odds ratio (OR) = 4.9, P = 3.3x10-11, CI= 2.9-8.1) with the common (minor allelic frequency >5%) non-synonymous SNP rs2305089 in chordoma, which is exceptional in cancer genetics."," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000188,Chordoma Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Chordoma cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000119,Chordoma Exome Sequencing,Chordoma Exome Sequencing," Illumina HiSeq 2000, Illumina Genome Analyzer II, Illumina HiSeq 2000;"
EGAS00001000189,Dyslipidemia,These samples include exome sequences of family members with dyslipidemias from Finnish origin.,EGAD00001000347,Dyslipidemia,These samples include exome sequences of family members with dyslipidemias from Finnish origin., Illumina HiSeq 2000;
EGAS00001000191,CML blast phase rearrangement screen,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from 10 Chronic Myeloid Leukemia in blast phase samples and subjected to a total of two lanes of 50 bp, paired end sequencing on the llumina HiSeq. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions",EGAD00001000136,CML blast phase rearrangement screen,CML blast phase rearrangement screen, Illumina HiSeq 2000
EGAS00001000192,Somatic Histone H3 Mutations in Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Paediatric Glioblastomas,"To identify somatic mutations in paediatric diffuse intrinsic pontine gliomas (DIPGs), we performed whole genome sequencing of 7 DIPGs and matched germline DNA, and targeted sequencing of an additional 43 DIPGs and 36 non-brainstem paediatric glioblastomas (non-BS-PGs).  78% of DIPGs and 22% of non-BS-PGs contained K27M mutation in H3F3A, encoding histone H3.3, or the related HIST1H3B, encoding histone H3.1. An additional 14% of non-BS-PGs had somatic G34R H3F3A mutations.",EGAD00001000085,Somatic Histone H3 mutations,Somatic Histone H3 mutations, Illumina HiSeq 2000
EGAS00001000193,ADCC Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Adenoid cystic carcinomas and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000175,Identification of SPEN as a novel cancer gene and FGFR2 as a potential therapeutic target in adenoid cystic carcinoma,Identification of SPEN as a novel cancer gene and FGFR2 as a potential therapeutic target in adenoid cystic carcinoma, Illumina Genome Analyzer II;
EGAS00001000193,ADCC Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from Adenoid cystic carcinomas and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000101,ADCC Exome Sequencing,ADCC Exome Sequencing," Illumina Genome Analyzer II, Illumina HiSeq 2000;"
EGAS00001000195,Breast Cancer Somatic Genetics Study ,"We propose to definitively characterise the somatic genetics of ER+ve, HER2-ve breast cancer through generation of comprehensive catalogues of somatic mutations in 500 cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.",EGAD00001000120,Breast Cancer Somatic Genetics Study,Breast Cancer Somatic Genetics Study, Illumina HiSeq 2000
EGAS00001000195,Breast Cancer Somatic Genetics Study ,"We propose to definitively characterise the somatic genetics of ER+ve, HER2-ve breast cancer through generation of comprehensive catalogues of somatic mutations in 500 cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.",EGAD00001000138,Mutational processes moulding the genomes of 21 breast cancers,"The expression data for this study can be found here: 

http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1088/

and its SNP6 data can be found here:
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1087/"," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000196,SCAT osteosarcoma sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 osteosarcoma cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes,EGAD00001000107,SCAT osteosarcoma sequencing,SCAT osteosarcoma sequencing," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000196,SCAT osteosarcoma sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 osteosarcoma cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes,EGAD00001000280,SCAT_Osteosarcoma_Validation,"This experiment is to validate putative somatic substitutions and indels identified in an exome screen of ~50 osteosarcoma tumour/normal pairs. It is the first stage in our ICGC commitment to study osteosarcoma. The validation process is an important component of our analysis to clarify the data prior to looking for evidence of new cancer genes, or subverted pathways important in the development of cancer. 

This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/", Illumina HiSeq 2000;
EGAS00001000197,ER   HER2   PR  breast Cancer genome sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from X triple negative breast cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting X exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000133,The landscape of cancer genes and mutational processes in breast cancer,The landscape of cancer genes and mutational processes in breast cancer," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000197,ER   HER2   PR  breast Cancer genome sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from X triple negative breast cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting X exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000088,"ER-, HER2-, PR- breast Cancer genome sequencing","ER-, HER2-, PR- breast Cancer genome sequencing", Illumina Genome Analyzer II
EGAS00001000198,Myeloproliferative Disorder Sequencing,"Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 myeloproliferative disorder samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. In addition, 500bp, NO_PCR total genomic libraries will be prepared from the same samples and five lanes of Illumina GA sequencing will be analysed to characterise genome wide, somatically acquired structural variation.",EGAD00001000102,Myeloproliferative Disorder Sequencing,Myeloproliferative Disorder Sequencing, Illumina Genome Analyzer II
EGAS00001000199,Myeloproliferative Disorder Sequencing,"Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 myeloproliferative disorder samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. In addition, 500bp, NO_PCR total genomic libraries will be prepared from the same samples and five lanes of Illumina GA sequencing will be analysed to characterise genome wide, somatically acquired structural variation.",EGAD00001000103,Myeloproliferative Disorder Sequencing,Myeloproliferative Disorder Sequencing, Illumina Genome Analyzer II
EGAS00001000200,Acute Lymphoblastic Leukemia Exome sequencing 2 ,"Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 Acute Lymphoblastic Leukemia samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped build 37 of the human reference genome to facilitate the identification of novel cancer genes. In addition, 500bp, NO_PCR total genomic libraries will be prepared from the same samples and five lanes of Illumina GA sequencing will be analysed to characterise genome wide, somatically acquired structural variation.",EGAD00001000104,Acute Lymphoblastic Leukemia Exome sequencing 2,Acute Lymphoblastic Leukemia Exome sequencing 2, Illumina Genome Analyzer II
EGAS00001000200,Acute Lymphoblastic Leukemia Exome sequencing 2 ,"Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 Acute Lymphoblastic Leukemia samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped build 37 of the human reference genome to facilitate the identification of novel cancer genes. In addition, 500bp, NO_PCR total genomic libraries will be prepared from the same samples and five lanes of Illumina GA sequencing will be analysed to characterise genome wide, somatically acquired structural variation.",EGAD00001000636,RAG mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 Acute Lymphoblastic Leukemia (Whole_exome_sequencing_data),"The ETV6-RUNX1 fusion gene, found in 25% of childhood acute lymphoblastic leukemia (ALL), is acquired in utero but requires additional somatic mutations for overt leukemia. We used exome and low-coverage whole-genome sequencing to characterize the critical secondary events associated with leukemic transformation. RAG-mediated deletions emerge as the dominant mutational process, accounting for at least 43% of genomic rearrangements and characterized by the presence of recombination signal sequence motifs near the breakpoints; incorporation of non-templated sequence at the junction and a ten-fold enrichment at promoters and enhancers of genes actively transcribed in early B-lineage development. Single-cell tracking shows that this mechanism is not restricted to one founder cell but is rather active throughout leukemic evolution. Integration of point mutation and rearrangement data identifies recurrent inactivation of ATF7IP and MGA as two new tumor suppressor genes.Thus, a remarkably parsimonious mutational process transforms ETV6-RUNX1 lymphoblasts, striking promoters and enhancers of the genes that normally control B-cell differentiation.", Illumina Genome Analyzer II;
EGAS00001000201,Acute Lymphoblastic Leukemia Exome sequencing,"Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 Acute Lymphoblastic Leukemia samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped build 37 of the human reference genome to facilitate the identification of novel cancer genes. In addition, 500bp, NO_PCR total genomic libraries will be prepared from the same samples and five lanes of Illumina GA sequencing will be analysed to characterise genome wide, somatically acquired structural variation.",EGAD00001000089,Acute Lymphoblastic Leukemia Exome sequencing,Acute Lymphoblastic Leukemia Exome sequencing, Illumina Genome Analyzer II
EGAS00001000201,Acute Lymphoblastic Leukemia Exome sequencing,"Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 50 Acute Lymphoblastic Leukemia samples and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 100 exome libraries and mapped build 37 of the human reference genome to facilitate the identification of novel cancer genes. In addition, 500bp, NO_PCR total genomic libraries will be prepared from the same samples and five lanes of Illumina GA sequencing will be analysed to characterise genome wide, somatically acquired structural variation.",EGAD00001000636,RAG mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 Acute Lymphoblastic Leukemia (Whole_exome_sequencing_data),"The ETV6-RUNX1 fusion gene, found in 25% of childhood acute lymphoblastic leukemia (ALL), is acquired in utero but requires additional somatic mutations for overt leukemia. We used exome and low-coverage whole-genome sequencing to characterize the critical secondary events associated with leukemic transformation. RAG-mediated deletions emerge as the dominant mutational process, accounting for at least 43% of genomic rearrangements and characterized by the presence of recombination signal sequence motifs near the breakpoints; incorporation of non-templated sequence at the junction and a ten-fold enrichment at promoters and enhancers of genes actively transcribed in early B-lineage development. Single-cell tracking shows that this mechanism is not restricted to one founder cell but is rather active throughout leukemic evolution. Integration of point mutation and rearrangement data identifies recurrent inactivation of ATF7IP and MGA as two new tumor suppressor genes.Thus, a remarkably parsimonious mutational process transforms ETV6-RUNX1 lymphoblasts, striking promoters and enhancers of the genes that normally control B-cell differentiation.", Illumina Genome Analyzer II;
EGAS00001000202,Glioma cell lines rearrangement screen,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from commomon epithelial cancer samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000090,Glioma cell lines rearrangement screen,Glioma cell lines rearrangement screen, Illumina Genome Analyzer II
EGAS00001000205,Non Tumour Renal Cell Line Sequencing,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from commomon epithelial cancer samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000091,Non Tumour Renal Cell Line Sequencing,Non Tumour Renal Cell Line Sequencing, Illumina Genome Analyzer II
EGAS00001000206,Cancer Exome Resequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from a range of cancer samples and subjected paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000092,Cancer Exome Resequencing,Cancer Exome Resequencing, Illumina Genome Analyzer II
EGAS00001000206,Cancer Exome Resequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from a range of cancer samples and subjected paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000133,The landscape of cancer genes and mutational processes in breast cancer,The landscape of cancer genes and mutational processes in breast cancer," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000207,Breast Cancer Exome Resequencing,Agilent whole exome hybridisation capture was performed on genomic DNA derived from Chondrosarcoma cancer and matched normal DNA from the same patients. Next Generation sequencing performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Now we aim to re find and validate the findings of those exome libraries using bespoke pulldown methods and sequencing the products.,EGAD00001000093,Breast Cancer Exome Resequencing,Breast Cancer Exome Resequencing, Illumina Genome Analyzer II
EGAS00001000208,Cancer Genome Libraries Tests,"Testing library production.
Genomic libraries (500 bps) will be generated from  total genomic DNA derived from commomon epithelial cancer samples and subjected to paired end sequencing on the llumina plateforms. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000094,Cancer Genome Libraries Tests,Cancer Genome Libraries Tests, Illumina Genome Analyzer II
EGAS00001000209,Acute Myeloid Leukemia Sequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from 25 acute myeloid leukemia  samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000095,Acute Myeloid Leukemia Sequencing,Acute Myeloid Leukemia Sequencing, Illumina Genome Analyzer II
EGAS00001000209,Acute Myeloid Leukemia Sequencing,"Genomic libraries (500 bps) will be generated from  total genomic DNA derived from 25 acute myeloid leukemia  samples and subjected to total of eight lanes of 37 bp, paired end sequencing on the llumina GA. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000658,Constitutional and somatic genomic rearrangements coherently restructure chromosome 21 in acute lymphoblastic leukaemia,"Changes in gene dosage are a major driver of cancer1, engineered from a finite, but increasingly well annotated, repertoire of mutational mechanisms2-6. These processes operate over levels ranging from individual exons to whole chromosomes, often generating correlated copy number alterations across hundreds of linked genes. An example of the latter is the 2% of childhood acute lymphoblastic leukemia (ALL) characterized by recurrent intrachromosomal amplification of megabase regions of chromosome 21 (iAMP21)7,8  To dissect the interplay between mutational processes and selection on this scale, we used genomic, cytogenetic and transcriptional analysis, coupled with novel bioinformatic approaches, to reconstruct the evolution of iAMP21 ALL. We find that individuals born with the rare constitutional Robertsonian translocation between chromosomes 15 and 21, rob(15;21)(q10;q10)c, have ~2700-fold increased risk of developing iAMP21 ALL compared to the general population. In such cases, amplification is initiated by chromothripsis involving both sister chromatids of the dicentric Robertsonian chromosome. In contrast, sporadic iAMP21 is typically initiated by breakage-fusion-bridge (BFB) events, often followed by chromothripsis or other rearrangements. In both sporadic and iAMP21 in rob(15;21)c individuals, the final stages of amplification frequently involve large-scale duplications of the abnormal chromosome. The end-product is a derivative chromosome 21 or a derivative originating from the rob(15;21)c chromosome, der(15;21), respectively, with gene dosage optimised for leukemic potential, showing constrained copy number levels over multiple linked genes. In summary, the constitutional translocation, rob(15;21)c, predisposes to leukemia through a novel mechanism, namely a propensity to undergo chromothripsis, likely related to its dicentric nature. More generally, our data illustrate that several cancer-specific mutational processes, applied sequentially, can co-ordinate to fashion copy number profiles over large genomic scales, incrementally refining the fitness benefits of aggregated gene dosage changes.", Illumina HiSeq 2000;
EGAS00001000210,Breast Cancer Whole Genome Sequencing,"We propose to definitively characterise the somatic genetics of ER+ve, HER2-ve breast cancer through generation of comprehensive catalogues of somatic mutations in 500 cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.",EGAD00001000121,Breast Cancer Whole Genome Sequencing,Breast Cancer Whole Genome Sequencing, Illumina HiSeq 2000
EGAS00001000211,Breast Cancer Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 100 breast cancers of all subtypes and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 200 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000133,The landscape of cancer genes and mutational processes in breast cancer,The landscape of cancer genes and mutational processes in breast cancer," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000211,Breast Cancer Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 100 breast cancers of all subtypes and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 200 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000110,Breast Cancer Exome Sequencing,Breast Cancer Exome Sequencing," Illumina HiSeq 2000, Illumina Genome Analyzer II"
EGAS00001000211,Breast Cancer Exome Sequencing,Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 100 breast cancers of all subtypes and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 200 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.,EGAD00001000637,Somatic pseudogenes acquired during cancer development  Whole Exome sequencing,Insertion of processed pseudogenes is known to occur in the germline but has not previously been observed in somatic cells. Formation of pseudogenes could represent a new class of mutation in cancers and a new source of potential driver events.," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000212,MuTHER adipose tissue small RNA expression,"Human reference population small RNA expression variation profiling and assessment of its extent, causes, and consequences.",EGAD00001000105,MuTHER adipose tissue small RNA expression,MuTHER adipose tissue small RNA expression, Illumina Genome Analyzer II
EGAS00001000213,Association of Age at Diagnosis and Genetic Mutations in Patients with Neuroblastoma,"Neuroblastoma is diagnosed over a wide age range from birth through young adulthood, and older age at diagnosis is associated with a decline in survivability. We performed whole genome sequencing of DNA from diagnostic tumors and their matched germlines from 40 patients with metastatic neuroblastoma obtained between 1987 and 2009.  To identify genetic lesions that are associated with age at diagnosis in patients with metastatic neuroblastoma. Age groups at diagnosis included infants (0-18 months), children (18 months-12 years), and adolescents and young adults (>12 years). To confirm the findings from this discovery cohort, validation testing using tumors from an additional 64 patients obtained between 1985 and 2009 was also performed.  Formalin-fixed paraffin-embedded tumor tissue was used for immunohistochemistry and fluorescent in situ hybridization.  Telomere lengths were analyzed using the whole genome sequencing data, quantitative polymerase chain reaction and fluorescent in situ hybridization",EGAD00001000135,DATA FILES FOR NBL,DATA FILES FOR NBL, Illumina HiSeq 2000
EGAS00001000214,Test of PCR library method on whole genmoe samples,We will sequence 2 whole genome pairs which have had the libraries prepared with a PCR step. The resulting sequence will be compared to teh same samples which have had sequence obtain using a no_PCR library method. the sequence obtained in this experiment may or may not be used in conjunction with the other sequence obtain for these samples in the search for novel cancer mutations.,EGAD00001000252,Evaluation of PCR library method on whole genome samples,Evaluation of PCR library method on whole genome samples, Illumina HiSeq 2000;
EGAS00001000215,ICGC PedBrain: Deep-seuqencing of childhood brain tumors.,"Brain tumors constitute the childhood tumors with the highest mortality rates and survival is often associated with severe long-term sequelae due to intensive multimodal treatment regimens. Thus, the PedBrainTumor network aims at the identification of robust biomarkers for clinical management and novel molecular targets for therapeutic interventions. Using massively parallel whole-genome sequencing, and transcriptome and methylome sequencing for subsets of cases, we aim to decipher the molecular causes of medulloblastoma as well as low-grade astrocytoma, and to identify markers to stratify patients for specialized treatment. As the PedBrain network is affiliated with clinical trials in medulloblastoma and pilocytic astrocytoma, validation cohorts for the translation of key findings into clinical settings are readily available.",EGAD00001000328,ICGC PedBrain: RNA sequencing,ICGC PedBrain: RNA sequencing, Illumina HiSeq 2000;
EGAS00001000215,ICGC PedBrain: Deep-seuqencing of childhood brain tumors.,"Brain tumors constitute the childhood tumors with the highest mortality rates and survival is often associated with severe long-term sequelae due to intensive multimodal treatment regimens. Thus, the PedBrainTumor network aims at the identification of robust biomarkers for clinical management and novel molecular targets for therapeutic interventions. Using massively parallel whole-genome sequencing, and transcriptome and methylome sequencing for subsets of cases, we aim to decipher the molecular causes of medulloblastoma as well as low-grade astrocytoma, and to identify markers to stratify patients for specialized treatment. As the PedBrain network is affiliated with clinical trials in medulloblastoma and pilocytic astrocytoma, validation cohorts for the translation of key findings into clinical settings are readily available.",EGAD00001000122,DATA_SET_ICGC_PedBrainTumor_Medulloblastoma,DATA_SET_ICGC_PedBrainTumor_Medulloblastoma," Illumina HiSeq 2000, Illumina Genome Analyzer IIx"
EGAS00001000215,ICGC PedBrain: Deep-seuqencing of childhood brain tumors.,"Brain tumors constitute the childhood tumors with the highest mortality rates and survival is often associated with severe long-term sequelae due to intensive multimodal treatment regimens. Thus, the PedBrainTumor network aims at the identification of robust biomarkers for clinical management and novel molecular targets for therapeutic interventions. Using massively parallel whole-genome sequencing, and transcriptome and methylome sequencing for subsets of cases, we aim to decipher the molecular causes of medulloblastoma as well as low-grade astrocytoma, and to identify markers to stratify patients for specialized treatment. As the PedBrain network is affiliated with clinical trials in medulloblastoma and pilocytic astrocytoma, validation cohorts for the translation of key findings into clinical settings are readily available.",EGAD00001000327,ICGC PedBrain: whole genome mate-pair sequencing,ICGC PedBrain: whole genome mate-pair sequencing," Illumina HiSeq 2000;, Illumina Genome Analyzer IIx;"
EGAS00001000216,Melanoma TIL Study Exomes,"In this study, mutations present in a series of human melanomas (stage IV disease) will be determined, using autologous blood cells to obtain a reference genome. From each of teh samples that are analyzed, tumour-infiltrating T lymphocytes have also been isolated. This offers a unique opportunity to determine which (fraction of) mutations in human cancer leads to epitopes that are recognized by T cells. The resulting information is likely to be of value to understand how T cell activating drugs exert their action.",EGAD00001000243,Melanoma-TIL Study Exomes,Melanoma-TIL Study Exomes, Illumina HiSeq 2000;
EGAS00001000217,Exome-sequencing identifies new oncogenes and tumor suppressor genes recurrently altered in hepatocellular carcinoma,"""Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. High-resolution copy number analysis of 125 tumors of which 24 were subjected to whole-exome sequencing identified 135 homozygous deletions and 994 somatic gene mutations with predicted functional consequences. We identified new recurrent alterations in 4 genes (ARID1A, RPS6KA3, NFE2L2 and IRF2) not previously described in HCC. Functional analyses demonstrated tumor suppressor properties for IRF2 whose inactivation, exclusively found in hepatitis B virus related tumors, leads to impaired TP53 function. Alternatively, inactivation of proteins involved in chromatin remodeling was frequent and predominant in alcohol related tumors. Moreover, activation of the oxidative stress metabolism and inactivation of RPS6KA3 were new pathways associated with WNT/beta-catenin activation, thereby suggesting a cooperative effect in tumorigenesis. This study shows the dramatic somatic genetic diversity in HCC, it reveals interactions between oncogene and tumor suppressor gene mutations markedly related to specific risk factors. """,EGAD00001000131,Genetic landscape of hepatocellular carcinoma,Genetic landscape of hepatocellular carcinoma, Illumina HiSeq 2000
EGAS00001000218,CML Discovery Project,To identify mutations in CML,EGAD00001000111,CML Discovery Project,CML Discovery Project, Illumina Genome Analyzer II
EGAS00001000220,Identifying Novel Fusion Genes in Myeloma,To identify novel fusion genes in Myeloma samples,EGAD00001000112,Identifying Novel Fusion Genes in Myeloma,Identifying Novel Fusion Genes in Myeloma, Illumina Genome Analyzer II
EGAS00001000222,Whole Genome Sequencing of Neuroblastoma,"Neuroblastoma is a childhood tumour of the peripheral sympathetic nervous system. The pathogenesis has for a long time been quite enigmatic, as only very few gene defects were identified in this often lethal tumour1. Frequently detected gene alterations are limited to MYCN amplification (20%) and ALK activations (7%)2-5. Here we present a whole genome sequence analysis of 87 neuroblastoma of all stages. Only few recurrent amino-acid changing mutations were found. In contrast, analysis of structural defects identified in 18% of high stage neuroblastoma a local shredding of chromosomes, known as chromothripsis6. These tumours are associated with a poor outcome. Structural alterations recurrently affected ODZ3, PTPRD and CSMD1, which are involved in neuronal growth cone stabilization7-9. In addition, ATRX, TIAM1 and a series of regulators of the Rac Rho pathway were mutated, further implicating defects in neuritogenesis in neuroblastoma. Most tumors with defects in these genes were aggressive high stage neuroblastoma, but did not carry MYCN amplifications. The genomic landscape of neuroblastoma therefore reveals two novel molecular defects, chromotripsis and neuritogenesis gene alterations, which frequently occur in high risk tumors.",EGAD00001000196,Neuroblastoma samples,Neuroblastoma samples, Complete Genomics;
EGAS00001000222,Whole Genome Sequencing of Neuroblastoma,"Neuroblastoma is a childhood tumour of the peripheral sympathetic nervous system. The pathogenesis has for a long time been quite enigmatic, as only very few gene defects were identified in this often lethal tumour1. Frequently detected gene alterations are limited to MYCN amplification (20%) and ALK activations (7%)2-5. Here we present a whole genome sequence analysis of 87 neuroblastoma of all stages. Only few recurrent amino-acid changing mutations were found. In contrast, analysis of structural defects identified in 18% of high stage neuroblastoma a local shredding of chromosomes, known as chromothripsis6. These tumours are associated with a poor outcome. Structural alterations recurrently affected ODZ3, PTPRD and CSMD1, which are involved in neuronal growth cone stabilization7-9. In addition, ATRX, TIAM1 and a series of regulators of the Rac Rho pathway were mutated, further implicating defects in neuritogenesis in neuroblastoma. Most tumors with defects in these genes were aggressive high stage neuroblastoma, but did not carry MYCN amplifications. The genomic landscape of neuroblastoma therefore reveals two novel molecular defects, chromotripsis and neuritogenesis gene alterations, which frequently occur in high risk tumors.",EGAD00001000202,Neuroblastoma samples (Analyses_vcf files),Neuroblastoma samples (Analyses_vcf files), 
EGAS00001000224,Myelodysplastic Syndrome Follow Up Series,Agilent whole exome hybridisation capture was performed on genomic DNA derived from MDS and matched normal DNA from the same patients. Next Generation sequencing performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Now we aim to discover the prevalence of our findings using bespoke pulldown methods and sequencing the products from a larger set of patient DNA.,EGAD00001000283,Myelodysplastic Syndrome Follow Up Series,Agilent whole exome hybridisation capture was performed on genomic DNA derived from MDS and matched normal DNA from the same patients. Next Generation sequencing performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Now we aim to discover the prevalence of our findings using bespoke pulldown methods and sequencing the products from a larger set of patient DNA., Illumina HiSeq 2000;
EGAS00001000225,UK10K NEURO GURLING,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This sample set consists of DNA from multiply affected schizophrenia families. The families have been diagnosed using the SADS-L clinical instrument which gives diagnoses at the probable level of the research diagnostic criteria (RDC). In addition all diagnoses are available using DSMIIIR criteria. These criteria are widely accepted as being valid and reliable for the diagnosis of schizophrenia. All families have been collected to ensure that they are uni-lineal for transmission of schizophrenia, i.e. they have only one affected parent with schizophrenia, or a relative of only one transmitting or obligate carrier parent with schizophrenia. Families with bi-lineal transmission of schizophrenia (i.e. with both parents being affected) were not sampled for this study. All families have multiple cases of schizophrenia and related disorders. The families have been selected to ensure there are no cases of bipolar disorder within them and that they do not contain bipolar disorder in any relatives on either side of the family.For further information on this cohort please contact Hugh Gurling (h.gurling@ucl.ac.uk).",EGAD00001000319,UK10K_NEURO_GURLING REL-2012-11-27,UK10K_NEURO_GURLING REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000225,UK10K NEURO GURLING,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This sample set consists of DNA from multiply affected schizophrenia families. The families have been diagnosed using the SADS-L clinical instrument which gives diagnoses at the probable level of the research diagnostic criteria (RDC). In addition all diagnoses are available using DSMIIIR criteria. These criteria are widely accepted as being valid and reliable for the diagnosis of schizophrenia. All families have been collected to ensure that they are uni-lineal for transmission of schizophrenia, i.e. they have only one affected parent with schizophrenia, or a relative of only one transmitting or obligate carrier parent with schizophrenia. Families with bi-lineal transmission of schizophrenia (i.e. with both parents being affected) were not sampled for this study. All families have multiple cases of schizophrenia and related disorders. The families have been selected to ensure there are no cases of bipolar disorder within them and that they do not contain bipolar disorder in any relatives on either side of the family.For further information on this cohort please contact Hugh Gurling (h.gurling@ucl.ac.uk).",EGAD00001000237,UK10K_NEURO_GURLING REL-2012-07-05,EGAD00001000237_UK10K_NEURO_GURLING_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000225,UK10K NEURO GURLING,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

This sample set consists of DNA from multiply affected schizophrenia families. The families have been diagnosed using the SADS-L clinical instrument which gives diagnoses at the probable level of the research diagnostic criteria (RDC). In addition all diagnoses are available using DSMIIIR criteria. These criteria are widely accepted as being valid and reliable for the diagnosis of schizophrenia. All families have been collected to ensure that they are uni-lineal for transmission of schizophrenia, i.e. they have only one affected parent with schizophrenia, or a relative of only one transmitting or obligate carrier parent with schizophrenia. Families with bi-lineal transmission of schizophrenia (i.e. with both parents being affected) were not sampled for this study. All families have multiple cases of schizophrenia and related disorders. The families have been selected to ensure there are no cases of bipolar disorder within them and that they do not contain bipolar disorder in any relatives on either side of the family.For further information on this cohort please contact Hugh Gurling (h.gurling@ucl.ac.uk).",EGAD00001000440,UK10K_NEURO_GURLING REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000226,Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma,"Glioblastoma multiforme (GBM) is a lethal brain tumour in adults and children. However, DNA copy number and gene expression signatures indicate differences between adult and paediatric cases. To explore the genetic events underlying this distinction, we sequenced the exomes of 48 paediatric GBM samples. Somatic mutations in the H3.3-ATRX-DAXX chromatin remodelling pathway were identified in 44% of tumours (21/48). Recurrent mutations in H3F3A, which encodes the replication-independent histone 3 variant H3.3, were observed in 31% of tumours, and led to amino acid substitutions at two critical positions within the histone tail (K27M, G34R/G34V) involved in key regulatory post-translational modifications. Mutations in ATRX (alpha-thalassaemia/mental retardation syndrome X-linked) and DAXX (death-domain associated protein), encoding two subunits of a chromatin remodelling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres, were identified in 31% of samples overall, and in 100% of tumours harbouring a G34R or G34V H3.3 mutation. Somatic TP53 mutations were identified in 54% of all cases, and in 86% of samples with H3F3A and/or ATRX mutations. Screening of a large cohort of gliomas of various grades and histologies (n=784) showed H3F3A mutations to be specific to GBM and highly prevalent in children and young adults. Furthermore, the presence of H3F3A/ATRX-DAXX/TP53 mutations was strongly associated with alternative lengthening of telomeres and specific gene expression profiles. This is, to our knowledge, the first report to highlight recurrent mutations in a regulatory histone in humans, and our data suggest that defects of the chromatin architecture underlie paediatric and young adult GBM pathogenesis.",EGAD00001000134,"Sequence reads for pediatric GBM samples for manuscript: Driver mutations in histone H3.3 and chromatin
remodelling genes in paediatric glioblastoma","Sequence reads for pediatric GBM samples for manuscript: Driver mutations in histone H3.3 and chromatin
remodelling genes in paediatric glioblastoma", Illumina HiSeq 2000
EGAS00001000230,RNAseq Pulldown ,"We propose to definitively characterise the somatic genetics of ER+ve, HER2-ve breast cancer through generation of comprehensive catalogues of somatic mutations in breast cancer cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses. In this experiment cDNA derived form Breast Cancer Cell lines was used in an Agilent whole exome pulldown experiment.",EGAD00001000248,RNAseq Pulldown,RNAseq Pulldown, Illumina HiSeq 2000;
EGAS00001000233,Pulldown cytosine deaminases,We are looking at the causal factors behind hyper-mutator phenotypes found in previous Breast Cancer sequencing studies.,EGAD00001000245,Pulldown cytosine deaminases,Pulldown cytosine deaminases, Illumina HiSeq 2000;
EGAS00001000238,Ethiopia Genome Project  low coverage ,"The Ethiopian area stands among the most ancient ones ever occupied by human populations and their ancestors. Particularly, according to archaeological evidences, it is possible to trace back the presence of Hominids up to at least 3 million years ago. Furthermore, the present day human populations show a great cultural, linguistic and historic diversity which makes them essential candidate to investigate a considerable part of the African variability. Following the typing of 300 Ethiopian samples on Illumina Omni 1M (see Human Variability in Ethiopia project, previously approved by the Genotyping committee) we now have a clearer idea on which populations living in the area include the most of the diversity.
This project therefore aims to sequence the whole genome of 300 individuals at low (4-8x) depth belonging to the six most representative populations of the Ethiopian area to produce a unique catalogue of variants peculiar of the North East Africa. Furthermore 6 samples (one from each population) will also be sequenced at high  (30x) depth to ensure full coverage of the diversity spectrum.

The retrieved variants will be of great help in evaluating the demographic dynamics of those populations as well as shedding light on the migrations out of Africa.",EGAD00001000598,Ethiopia Genome Project (low coverage),"The Ethiopian area stands among the most ancient ones ever occupied by human populations and their ancestors. Particularly, according to archaeological evidences, it is possible to trace back the presence of Hominids up to at least 3 million years ago. Furthermore, the present day human populations show a great cultural, linguistic and historic diversity which makes them essential candidate to investigate a considerable part of the African variability. Following the typing of 300 Ethiopian samples on Illumina Omni 1M (see Human Variability in Ethiopia project, previously approved by the Genotyping committee) we now have a clearer idea on which populations living in the area include the most of the diversity.
This project therefore aims to sequence the whole genome of 300 individuals at low (4-8x) depth belonging to the six most representative populations of the Ethiopian area to produce a unique catalogue of variants peculiar of the North East Africa. Furthermore 6 samples (one from each population) will also be sequenced at high  (30x) depth to ensure full coverage of the diversity spectrum.

The retrieved variants will be of great help in evaluating the demographic dynamics of those populations as well as shedding light on the migrations out of Africa.", Illumina HiSeq 2000;
EGAS00001000242,UK10K OBESITY GS,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. The GS samples are part of the Obesity group and will undergo exome sequencing.",EGAD00001000309,UK10K_OBESITY_GS REL-2012-11-27,UK10K_OBESITY_GS REL-2012-11-27, Illumina HiSeq 2000;
EGAS00001000242,UK10K OBESITY GS,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. The GS samples are part of the Obesity group and will undergo exome sequencing.",EGAD00001000300,UK10K_OBESITY_GS_REL_2012_07_05,UK10K_OBESITY_GS_REL_2012_07_05, Illumina HiSeq 2000;
EGAS00001000242,UK10K OBESITY GS,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. The GS samples are part of the Obesity group and will undergo exome sequencing.",EGAD00001000431,UK10K_OBESITY_GS REL-2013-04-20,UK10K_OBESITY_GS REL-2013-04-20, Illumina HiSeq 2000;
EGAS00001000243,Integrative Oncogenomics of multiple myeloma,We used targeted capture and massively parallel sequencing of exomes of CD138 purified plasma cells and matched somatic DNA from 53 patients with Multiple Myeloma. 2281 variants were validated by 454 sequencing. The present study will validate an additional 5538 variants by targeted pull-down and sequencing. The normal and tumor samples will be indexed separately and pre-pooled in groups of 10 or 11. The sequence capture will use 5 reactions each for the normals and tumors. All normal samples will then be pooled and go thorugh one lane of HiSeq. Same for the tumors.,EGAD00001000246,Integrative Oncogenomics of multiple myeloma,Integrative Oncogenomics of multiple myeloma, Illumina HiSeq 2000;
EGAS00001000244,Integrative Oncogenomics of multiple myeloma,"We used targeted capture and massively parallel sequencing of exomes of CD138 purified plasma cells and matched somatic DNA from 17 patients with Multiple Myeloma. For each patient, an early tumor sample (at diagnosis) and a late one (at relapse) were available. For few of them, an additional late sample (2nd progression) was present. In total, the study has 52 samples. 1044 variants were validated by 454 sequencing. The present study will validate an additional 4630 variants by targeted pull-down and sequencing. All 52 samples will be indexed and then will be pre-pooled in groups of 5 or 6. The sequence capture will use 10 reactions. All samples will then be pooled and go thorugh one lane of HiSeq.",EGAD00001000247,Integrative Oncogenomics of multiple myeloma,Integrative Oncogenomics of multiple myeloma, Illumina HiSeq 2000;
EGAS00001000245,A Comprehensive Catalogue of Somatic Mutations from a Human Cancer Genome,"We previously reported the whole-genome sequencing of the well-studied human malignant melanoma cell line, COLO-829, and a lymphoblastoid cell line from the same individual, providing the first comprehensive catalogue of somatic mutations from an individual cancer (Pleasance et al. (2010) Nature 463, 191). This initial study was carried out using the Illumina Genome Analyzer II, largely using paired-end reads of 75 bases from standard Illumina paired-end libraries. Here we report the results of sequencing the genomes of COLO-829 and its matched lymphoblastoid sample using HiSeq2000 with v3 cluster-generation and sequencing chemistries. This has significantly improved the evenness and completeness of genomic coverage, particularly in areas of extreme sequence composition that were underrepresented in the initial study.",EGAD00001000149,A Comprehensive Catalogue of Somatic Mutations from a Human Cancer Genome,A Comprehensive Catalogue of Somatic Mutations from a Human Cancer Genome, Illumina HiSeq 2000
EGAS00001000246,Genetic landscape of pediatric Infant Acute Lymphoblastic leukemia,"We performed whole genome sequencing of tumor and normal DNA samples obtained from 22 infant ALL cases with MLL rearrangements. In addition, we sequenced 2 paired diagnostic-relapse samples. Using complementary pipelines, somatically acquired genetic changes were analyzed, including single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the cancer genomes. In addition, exome sequencing was performed on paired diagnostic and normal DNA samples obtained from 20 cases of non-infant MLL rearranged leukemias and somatic mutations in the coding regions were identified.",EGAD00001000165,DATA FILES FOR SJINF,DATA FILES FOR SJINF, Illumina HiSeq 2000
EGAS00001000250,Poikiloderma syndrome RNAseq,"We will sequence the RNA of lymphoblast samples, transformed with EBV, which have poikiloderma syndrome with mutations in c16orf57. The aim of the experiment is to characterise RNA structural effects in this disease.",EGAD00001000324,Poikiloderma syndrome RNAseq,"We will sequence the RNA of lymphoblast samples, transformed with EBV, which have poikiloderma syndrome with mutations in c16orf57. The aim of the experiment is to characterise RNA structural effects in this disease.", Illumina HiSeq 2000;
EGAS00001000253,Whole genome sequencing of pediatric BCR-ABL1 positive acute lymphoblastic leukemia,"We performed whole-genome sequencing of 18 paired tumor/normal BCR-ABL1+ leukemia genomes and analyzed single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the tumor and normal genomes",EGAD00001000163,DATA FILES FOR SJPHALL,DATA FILES FOR SJPHALL, Illumina HiSeq 2000
EGAS00001000254,Genetic landscape of pediatric ependymoma,"We performed whole-genome sequencing of 42 paired tumor/normal EPD genomes and analyzed somatically acquired single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the cancer genomes",EGAD00001000162,DATA FILES FOR SJEPD,DATA FILES FOR SJEPD, Illumina HiSeq 2000
EGAS00001000255,Genetic landscape of pediatric Low Grade Gliomas & Glioneuronal tumors,"We performed whole-genome sequencing of 42 paired tumor/normal LGG genomes and analyzed somatically acquired single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the cancer genomes",EGAD00010000462,Title not provided,SJLGG Case samples using Gene Expression Array, Affymetrix_U133v2
EGAS00001000255,Genetic landscape of pediatric Low Grade Gliomas & Glioneuronal tumors,"We performed whole-genome sequencing of 42 paired tumor/normal LGG genomes and analyzed somatically acquired single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the cancer genomes",EGAD00001000352,DATA FILES FOR SJLGG,DATA FILES FOR SJLGG, Illumina HiSeq 2000;
EGAS00001000255,Genetic landscape of pediatric Low Grade Gliomas & Glioneuronal tumors,"We performed whole-genome sequencing of 42 paired tumor/normal LGG genomes and analyzed somatically acquired single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the cancer genomes",EGAD00001000353,DATA FILES FOR SJLGG,DATA FILES FOR SJLGG, Illumina HiSeq 2000;
EGAS00001000255,Genetic landscape of pediatric Low Grade Gliomas & Glioneuronal tumors,"We performed whole-genome sequencing of 42 paired tumor/normal LGG genomes and analyzed somatically acquired single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the cancer genomes",EGAD00001000161,DATA FILES FOR SJLGG,DATA FILES FOR SJLGG, Illumina HiSeq 2000
EGAS00001000255,Genetic landscape of pediatric Low Grade Gliomas & Glioneuronal tumors,"We performed whole-genome sequencing of 42 paired tumor/normal LGG genomes and analyzed somatically acquired single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the cancer genomes",EGAD00001000655,DATA FILES FOR Histone-NSD2_RNASeq,, Illumina HiSeq 2000;
EGAS00001000256,Genetic landscape of pediatric Rhabdomyosarcoma,"We performed whole-genome sequencing of 13 paired tumor/normal RHG genomes and analyzed somatically acquired single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the cancer genomes",EGAD00001000164,DATA FILES FOR SJRHB,DATA FILES FOR SJRHB, Illumina HiSeq 2000
EGAS00001000257,Genetic landscape of pediatric Adrenocortical Tumor,"We performed whole-genome sequencing of 17 paired tumor/normal ACT genomes and analyzed somatically acquired single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the cancer genomes",EGAD00001000160,DATA FILES FOR SJACT,DATA FILES FOR SJACT, Illumina HiSeq 2000
EGAS00001000261,Transcriptome Sequencing of Cancer Cell Lines,In this study we will sequence the transcriptome of Verified Cancer Cell lines. This will be married up to whole exome and whole genome sequencing data to establish a full catalog of the variations and mutations found.,EGAD00001000359,Transcriptome Sequencing of Cancer Cell Lines,In this study we will sequence the transcriptome of Verified Cancer Cell lines. This will be married up to whole exome and whole genome sequencing data to establish a full catalog of the variations and mutations found., Illumina HiSeq 2000;
EGAS00001000262,ICGC Prostate Cancer Whole Genome Sequencing,We propose to definitively characterise the somatic genetics of Prostate cancer through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing. See ICGC website for more information: http://icgc.org/icgc/cgp/70/508/71331,EGAD00001000263,ICGC Prostate Cancer Whole Genome Sequencing,We propose to definitively characterise the somatic genetics of Prostate cancer through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing. See ICGC website for more information: http://icgc.org/icgc/cgp/70/508/71331, Illumina HiSeq 2000;
EGAS00001000263,Genetic landscape of pediatric Osteosarcoma,"We performed whole-genome sequencing of 37 paired tumor/normal OS genomes and analyzed somatically acquired single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the cancer genomes",EGAD00001000159,DATA FILES FOR SJOS,DATA FILES FOR SJOS, Illumina HiSeq 2000
EGAS00001000268,Accurate mutation detection in leukemia by re-sequencing a cancer gene set,"With the advent of whole-genome and whole-exome sequencing, high-quality catalogs of recurrently mutated cancer genes are becoming available for many cancer types. Increasing access to sequencing technology, including bench-top sequencers, provide the opportunity to re-sequence a limited set of cancer genes across a patient cohort with limited processing time. Here, we re-sequenced a set of cancer genes in T-cell acute lymphoblastic leukemia (T-ALL) using the Roche/454 technology coupled with Nimblegen sequence capture. First, we investigated how a maximal sensitivity and specificity of mutation detection can be achieved through a benchmark study. We tested nine combinations of different mapping and variant-calling methods, varied the variant calling parameters, and compared the predicted mutations with a large independent validation set obtained by capillary re-sequencing. We found that the combination of two mapping algorithms, namely BWA-SW and SSAHA2, coupled with the variant calling algorithm Atlas-SNP2 yields the highest sensitivity (95%) and the highest specificity (93%). Next, we applied this analysis pipeline to identify mutations in a set of 58 cancer genes, in a panel of 18 T-ALL cell lines and 15 T-ALL patient samples. We confirmed mutations in known T-ALL drivers, including PHF6, NF1, FBXW7, NOTCH1, KRAS, NRAS, PIK3CA, and PTEN. Interestingly, we also found mutations in several cancer genes that had not been linked to T-ALL before, including JAK3. Finally, we re-sequenced a small set of 39 candidate genes and identified recurrent mutations in TET1, SPRY3 and SPRY4. In conclusion, we established an optimized analysis pipeline for Roche/454 data that can be applied to accurately detect gene mutations in cancer, which led to the identification of several new candidate T-ALL driver mutations.",EGAD00001000150,Targeted re-sequencing of 97 genes in T-ALL,Targeted re-sequencing of 97 genes in T-ALL, 454 GS FLX Titanium
EGAS00001000269,Identification of the underlying causal variant in a multi generational family with autosomal dominant common variable immunodeficiency,"Common variable immunodeficiency (CVID) is the most common form of primary immunodeficiency with an estimated incidence of 1:10,000. It has been apparent for many years that CVID has a genetic component, occurs frequently in families and can have both a recessive or dominant mode of inheritance. In recent years, 4 genes underlying CVID have been identified; however, mutations within in them are estimated to account for no more than 10% of all cases of CVID.
We have identified a multi-generational family with autosomal dominant CVID. Genome-wide linkage analysis has mapped the locus underlying CVID in this family to an approximately 9.2 Mb interval on chromosome 3q27.3-q29, between the markers D3S3570 and D3S1265. This locus is distinct from any of the previously mapped susceptibility loci suggesting a novel genetic variant is responsible for disease in this family. The aim of this study is to use exome sequencing of affected (n = 4) and unaffected (n = 4) individuals, in tandem with the available genetic mapping data, to identify the causal variant underlying CVID in this family.",EGAD00001000363,Identification of the underlying causal variant in a multi-generational family with autosomal dominant common variable immunodeficiency,"Common variable immunodeficiency (CVID) is the most common form of primary immunodeficiency with an estimated incidence of 1:10,000. It has been apparent for many years that CVID has a genetic component, occurs frequently in families and can have both a recessive or dominant mode of inheritance. In recent years, 4 genes underlying CVID have been identified; however, mutations within in them are estimated to account for no more than 10% of all cases of CVID.
We have identified a multi-generational family with autosomal dominant CVID. Genome-wide linkage analysis has mapped the locus underlying CVID in this family to an approximately 9.2 Mb interval on chromosome 3q27.3-q29, between the markers D3S3570 and D3S1265. This locus is distinct from any of the previously mapped susceptibility loci suggesting a novel genetic variant is responsible for disease in this family. The aim of this study is to use exome sequencing of affected (n = 4) and unaffected (n = 4) individuals, in tandem with the available genetic mapping data, to identify the causal variant underlying CVID in this family.", Illumina HiSeq 2000;
EGAS00001000271,Comparing sequencing of four proto-typical Burkitt lymphomas (BL) with IG-MYC translocation.,"By whole-genome, exome, transcriptome and methylome sequencing of four proto-typical Burkitt lymphomas (BL) with IG-MYC translocation we identified seven recurrently mutated genes including ID3. In an extended cohort, 36/53 (68%) molecularly-defined BL carried potentially damaging mutations of ID3 which were enriched at somatic hypermutation motifs. Only 6/47 (13%) other IG-MYC-positive B-cell lymphomas carried ID3 mutations suggesting cooperation of ID3 inactivation and IG-MYC translocation to be a hallmark of Burkitt lymphomagenesis.",EGAD00010000427,Title not provided,DNA methylation analysis of 4 peripheral blood samples, HumanMethylation450k Bead Chip - Genome Studio
EGAS00001000271,Comparing sequencing of four proto-typical Burkitt lymphomas (BL) with IG-MYC translocation.,"By whole-genome, exome, transcriptome and methylome sequencing of four proto-typical Burkitt lymphomas (BL) with IG-MYC translocation we identified seven recurrently mutated genes including ID3. In an extended cohort, 36/53 (68%) molecularly-defined BL carried potentially damaging mutations of ID3 which were enriched at somatic hypermutation motifs. Only 6/47 (13%) other IG-MYC-positive B-cell lymphomas carried ID3 mutations suggesting cooperation of ID3 inactivation and IG-MYC translocation to be a hallmark of Burkitt lymphomagenesis.",EGAD00010000429,Title not provided,DNA methylation analysis of 4 primary lymphoma samples, HumanMethylation450k Bead Chip - Genome Studio
EGAS00001000271,Comparing sequencing of four proto-typical Burkitt lymphomas (BL) with IG-MYC translocation.,"By whole-genome, exome, transcriptome and methylome sequencing of four proto-typical Burkitt lymphomas (BL) with IG-MYC translocation we identified seven recurrently mutated genes including ID3. In an extended cohort, 36/53 (68%) molecularly-defined BL carried potentially damaging mutations of ID3 which were enriched at somatic hypermutation motifs. Only 6/47 (13%) other IG-MYC-positive B-cell lymphomas carried ID3 mutations suggesting cooperation of ID3 inactivation and IG-MYC translocation to be a hallmark of Burkitt lymphomagenesis.",EGAD00001000356,ICGC MMML-seq Data Freeze March 2013 transcriptome sequencing,ICGC MMML-seq Data Freeze March 2013 transcriptome sequencing, Illumina HiSeq 2000;
EGAS00001000271,Comparing sequencing of four proto-typical Burkitt lymphomas (BL) with IG-MYC translocation.,"By whole-genome, exome, transcriptome and methylome sequencing of four proto-typical Burkitt lymphomas (BL) with IG-MYC translocation we identified seven recurrently mutated genes including ID3. In an extended cohort, 36/53 (68%) molecularly-defined BL carried potentially damaging mutations of ID3 which were enriched at somatic hypermutation motifs. Only 6/47 (13%) other IG-MYC-positive B-cell lymphomas carried ID3 mutations suggesting cooperation of ID3 inactivation and IG-MYC translocation to be a hallmark of Burkitt lymphomagenesis.",EGAD00001000355,ICGC MMML-seq Data Freeze March 2013 whole genome sequencing,ICGC MMML-seq Data Freeze March 2013 whole genome sequencing, Illumina HiSeq 2000;
EGAS00001000271,Comparing sequencing of four proto-typical Burkitt lymphomas (BL) with IG-MYC translocation.,"By whole-genome, exome, transcriptome and methylome sequencing of four proto-typical Burkitt lymphomas (BL) with IG-MYC translocation we identified seven recurrently mutated genes including ID3. In an extended cohort, 36/53 (68%) molecularly-defined BL carried potentially damaging mutations of ID3 which were enriched at somatic hypermutation motifs. Only 6/47 (13%) other IG-MYC-positive B-cell lymphomas carried ID3 mutations suggesting cooperation of ID3 inactivation and IG-MYC translocation to be a hallmark of Burkitt lymphomagenesis.",EGAD00001000274,DATA_SET_TRANSCIPTOME_Comparing_sequencing_four_proto-typical_Burkitt_lymphomas_BL_IG-MYC_translocation,DATA_SET_TRANSCIPTOME_Comparing_sequencing_four_proto-typical_Burkitt_lymphomas_BL_IG-MYC_translocation, Illumina HiSeq 2000;
EGAS00001000271,Comparing sequencing of four proto-typical Burkitt lymphomas (BL) with IG-MYC translocation.,"By whole-genome, exome, transcriptome and methylome sequencing of four proto-typical Burkitt lymphomas (BL) with IG-MYC translocation we identified seven recurrently mutated genes including ID3. In an extended cohort, 36/53 (68%) molecularly-defined BL carried potentially damaging mutations of ID3 which were enriched at somatic hypermutation motifs. Only 6/47 (13%) other IG-MYC-positive B-cell lymphomas carried ID3 mutations suggesting cooperation of ID3 inactivation and IG-MYC translocation to be a hallmark of Burkitt lymphomagenesis.",EGAD00001000176,DATA_SET_Comparing_sequencing_four_proto-typical_Burkitt_lymphomas_BL_IG-MYC_translocation,DATA_SET_Comparing_sequencing_four_proto-typical_Burkitt_lymphomas_BL_IG-MYC_translocation," Illumina HiSeq 2000;, Illumina Genome Analyzer IIx;"
EGAS00001000272,Whole Genome Methylation in CLL,We have extensively characterized the DNA methylome of chronic lymphocytic leukemia (CLL) with mutated and unmutated IGHV as well as several mature B cell subpopulations using whole-genome bisulfite sequencing and high-density microarrays.,EGAD00010000252,Title not provided,CLL Expression Arrays, Affymetrix U219
EGAS00001000272,Whole Genome Methylation in CLL,We have extensively characterized the DNA methylome of chronic lymphocytic leukemia (CLL) with mutated and unmutated IGHV as well as several mature B cell subpopulations using whole-genome bisulfite sequencing and high-density microarrays.,EGAD00010000254,Title not provided,CLL Methylation Arrays, Illumina HumanMethylation450
EGAS00001000272,Whole Genome Methylation in CLL,We have extensively characterized the DNA methylome of chronic lymphocytic leukemia (CLL) with mutated and unmutated IGHV as well as several mature B cell subpopulations using whole-genome bisulfite sequencing and high-density microarrays.,EGAD00001000177,Whole Genome Methylation in CLL,Whole Genome Methylation in CLL, Illumina Genome Analyzer IIx;
EGAS00001000273,Stratifying and Targeting Pediatric Medulloblastoma through Genomics,,EGAD00001000158,BCGSC Pediatric medulloblastoma data set 2,BCGSC Pediatric medulloblastoma data set 2, 
EGAS00001000273,Stratifying and Targeting Pediatric Medulloblastoma through Genomics,,EGAD00001000157,BCGSC Pediatric medulloblastoma data set 1,BCGSC Pediatric medulloblastoma data set 1, 
EGAS00001000274,Coverage bias and sensitivity of variant calling for four whole-genome sequencing technologies,"Massively parallel sequencing has revolutionized research in cancer genetics and genomics and enhanced our understanding of natural human genetic variation. Recently, Lam et al. have performed a detailed comparison of two next-generation sequencing technologies with respect to their sensitivity to call single nucleotide variants (SNV) and indels. Here, we sequenced two tumor/normal pairs obtained from two paedriatic medulloblastoma patients with Life Technologies SOLiD 4 and 5500xl SOLiD, Illuminas HiSeq2000, and Complete Genomics technology.  We then compared their ability to call SNVs with high confidence. As gold standard for SNV calling, we used genotypes determined by an Affymetrix SNP array. Additionally, we performed a detailed analysis of how evenly each technology covers the genome and how the reads are distributed across functional genomic regions. Finally, we studied how a combination of data from different technologies might help to overcome the limitations in SNV calling by any of the four technologies alone.",EGAD00001000174,DATA_SET_Coverage_bias_sensitivity_of_variant_calling_for_4_WG_seq_tech,DATA_SET_Coverage_bias_sensitivity_of_variant_calling_for_4_WG_seq_tech," Complete Genomics;, unspecified;"
EGAS00001000275,AML targeted resequencing study,"Genomic libraries will be generated from whole genome amplified  genomic DNA derived from 3,000 myeloid neoplasms.  Targeted capture will be performed by multiplexing 16 barcoded samples in each library.  Pools of 96 DNA samples will be subjected to 1-2 lanes of HiSeq 75bp sequencing. Reads will be mapped to the current build of the human reference genome to facilitate the generation of a comprehensive catalog of somatic mutations associated with 116 known myeloid and cancer driver genes.",EGAD00001000253,AML targeted resequencing study,AML targeted resequencing study, Illumina HiSeq 2000;
EGAS00001000276,Genetic mechanisms of resistance to chemotherapy in breast cancer,"Resistance towards chemotherapy is one of the main causes of treatment failure and death
among breast cancer patients.
The main objective of this project is to identify genetic mechanisms causing some breast
cancer patients not to respond to a particluar type of chemotherapy (epirubicin) while other
patients respond very well to the same treatment.
In the project we will perform genome / exome sequencing of a selection of breast cancer
patients (n=30). These patients are drawn from a cohort where all patients have recieved
treatment with epirubicin monotherapy before surgical removal of a locally advanced breast
tumour, and where all patients have been subjected to objective evaluation of the response to
the therapy.
Subsequent to sequencing, we will analyse the data and compare with the clinical data for
each patient (object response to therapy). The main aim being to identify mutations that are
associated with resistance to epirubicin.
Identification of mutations with strong predictive value, may have a direct impact on cancer
treatment since it opens the possibility for genetic testing of a tumour, and desicion on which
drug is likely to work best, prior to treatment start.",EGAD00001000264,Genetic mechanisms of resistance to chemotherapy in breast cancer,"Resistance towards chemotherapy is one of the main causes of treatment failure and death
among breast cancer patients.The main objective of this project is to
identify genetic mechanisms causing some breast cancer patients not to
respond to a particluar type of chemotherapy (epirubicin) while other
patients respond very well to the same treatment. In the project we
will perform genome / exome sequencing of a selection of breast cancer
patients (n=30). These patients are drawn from a cohort where all
patients have recieved treatment with epirubicin monotherapy before surgical removal of a
locally advanced breast tumour, and where all patients have been
subjected to objective evaluation of the response to the
therapy. Subsequent to sequencing, we will analyse the data and
compare with the clinical data for each patient (object response to
therapy). The main aim being to identify mutations that are associated
with resistance to epirubicin. Identification of mutations with strong
predictive value, may have a direct impact on cancer treatment since
it opens the possibility for genetic testing of a tumour, and desicion
on which drug is likely to work best, prior to treatment start.", Illumina HiSeq 2000;
EGAS00001000277,Chondrosarcoma Targeted Sequencing Study,This Study uses a focused bait pull down library method to target findings of Chondrosarcoma whole genome and whole exome sequencing studies in order to validate findings. This method will also be used on a larger set of tumour only samples in order to find precedence of these finding in a larger set of patients.,EGAD00001000265,Chondrosarcoma Targeted Sequencing Study,This Study uses a focused bespoke bait pull down library method to target findings of Chondrosarcoma whole genome and whole exome sequencing studies in order to validate findings. This method will also be used on a larger set of tumour only samples in order to find precedence of these findings in a larger set of patient samples., Illumina HiSeq 2000;
EGAS00001000278,Osteosarcoma Targeted Sequencing Study,This Study uses a focused bespoke bait pull down library method to target findings of Osteosarcoma whole genome and whole exome sequencing studies in order to validate findings. This method will also be used on a larger set of tumour only samples in order to find precedence of these findings in a larger set of patient samples.,EGAD00001000266,Osteosarcoma Targeted Sequencing Study,This Study uses a focused bespoke bait pull down library method to target findings of Osteosarcoma whole genome and whole exome sequencing studies in order to validate findings. This method will also be used on a larger set of tumour only samples in order to find precedence of these findings in a larger set of patient samples., Illumina HiSeq 2000;
EGAS00001000280,Chordoma Targeted Sequencing Study,This Study uses a focused bespoke bait pull down library method to target findings of Chordoma whole genome and whole exome sequencing studies in order to validate findings. This method will also be used on a larger set of tumour only samples in order to find precedence of these findings in a larger set of patient samples.,EGAD00001000267,Chordoma Targeted Sequencing Study,This Study uses a focused bespoke bait pull down library method to target findings of Chordoma whole genome and whole exome sequencing studies in order to validate findings. This method will also be used on a larger set of tumour only samples in order to find precedence of these findings in a larger set of patient samples., Illumina HiSeq 2000;
EGAS00001000282,Meningioma Targeted Sequencing Study,This Study uses a focused bespoke bait pull down library method to target findings of Meningioma whole genome and whole exome sequencing studies in order to validate findings. This method will also be used on a larger set of tumour only samples in order to find precedence of these findings in a larger set of patient samples.,EGAD00001000273,Meningioma Targeted Sequencing Study,This Study uses a focused bespoke bait pull down library method to target findings of Meningioma whole genome and whole exome sequencing studies in order to validate findings. This method will also be used on a larger set of tumour only samples in order to find precedence of these findings in a larger set of patient samples., Illumina HiSeq 2000;
EGAS00001000285,Validation of a Haloplex platform for targeted re sequencing of the exons of 25 genes,"We recently used the Agilent SureSelect platform to re-sequence a set of genes known to be
mutated in human AML. The results from 10 AML DNA samples were very satisfactory, but
the effort required was significant.
Thus, we decided to re-sequence the same genes using the Haloplax system for target
enrichment in 48 AML samples. We planned to do this using MiSeq and have data from a
pilot of 3 samples. The data is promising but coverage appears pathcy so far.
However, in order to get a better understanding of the data we will need deeper sequencing. We
will need two lanes of HiSeq to get the same degree coverage as Sureselect.

his data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/",EGAD00001000603,Validation of a Haloplex platform for targeted re-sequencing of the exons of 25 genes,"We recently used the Agilent SureSelect platform to re-sequence a set of genes known to be
mutated in human AML. The results from 10 AML DNA samples were very satisfactory, but
the effort required was significant.
Thus, we decided to re-sequence the same genes using the Haloplax system for target
enrichment in 48 AML samples. We planned to do this using MiSeq and have data from a
pilot of 3 samples. The data is promising but coverage appears pathcy so far.
However, in order to get a better understanding of the data we will need deeper sequencing. We
will need two lanes of HiSeq to get the same degree coverage as Sureselect.

his data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/", Illumina HiSeq 2000;
EGAS00001000287,Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability,"Intellectual disability is a common condition that carries lifelong severe medical and developmental consequences. The causes of intellectual disability (ID) remain unknown for the majority of patients due to the extensive clinical and genetic heterogeneity of this disorder. De novo mutations may play an important role in ID as most individuals with ID present as isolated cases without family history and/or clear syndromic indication. In addition, the involvement of such mutations have recently been demonstrated in a small number of individuals with ID. Here we evaluate the diagnostic potential and role of de novo mutations in a cohort of 100 patients with ID of unknown cause using family-based exome sequencing.",EGAD00001000374,ID_trio23_BAM,ID trio23 BAM files, AB SOLiD 4 System;
EGAS00001000287,Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability,"Intellectual disability is a common condition that carries lifelong severe medical and developmental consequences. The causes of intellectual disability (ID) remain unknown for the majority of patients due to the extensive clinical and genetic heterogeneity of this disorder. De novo mutations may play an important role in ID as most individuals with ID present as isolated cases without family history and/or clear syndromic indication. In addition, the involvement of such mutations have recently been demonstrated in a small number of individuals with ID. Here we evaluate the diagnostic potential and role of de novo mutations in a cohort of 100 patients with ID of unknown cause using family-based exome sequencing.",EGAD00001000373,ID_trio21_BAM,ID trio21 BAM files, AB SOLiD 4 System;
EGAS00001000287,Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability,"Intellectual disability is a common condition that carries lifelong severe medical and developmental consequences. The causes of intellectual disability (ID) remain unknown for the majority of patients due to the extensive clinical and genetic heterogeneity of this disorder. De novo mutations may play an important role in ID as most individuals with ID present as isolated cases without family history and/or clear syndromic indication. In addition, the involvement of such mutations have recently been demonstrated in a small number of individuals with ID. Here we evaluate the diagnostic potential and role of de novo mutations in a cohort of 100 patients with ID of unknown cause using family-based exome sequencing.",EGAD00001000379,ID_trio28_BAM,ID trio28 BAM files, AB SOLiD 4 System;
EGAS00001000287,Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability,"Intellectual disability is a common condition that carries lifelong severe medical and developmental consequences. The causes of intellectual disability (ID) remain unknown for the majority of patients due to the extensive clinical and genetic heterogeneity of this disorder. De novo mutations may play an important role in ID as most individuals with ID present as isolated cases without family history and/or clear syndromic indication. In addition, the involvement of such mutations have recently been demonstrated in a small number of individuals with ID. Here we evaluate the diagnostic potential and role of de novo mutations in a cohort of 100 patients with ID of unknown cause using family-based exome sequencing.",EGAD00001000331,ID_trio22_BAM,ID trio22 BAM files, AB SOLiD 4 System;
EGAS00001000287,Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability,"Intellectual disability is a common condition that carries lifelong severe medical and developmental consequences. The causes of intellectual disability (ID) remain unknown for the majority of patients due to the extensive clinical and genetic heterogeneity of this disorder. De novo mutations may play an important role in ID as most individuals with ID present as isolated cases without family history and/or clear syndromic indication. In addition, the involvement of such mutations have recently been demonstrated in a small number of individuals with ID. Here we evaluate the diagnostic potential and role of de novo mutations in a cohort of 100 patients with ID of unknown cause using family-based exome sequencing.",EGAD00001000378,ID_trio27_BAM,ID trio27 BAM files, AB SOLiD 4 System;
EGAS00001000287,Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability,"Intellectual disability is a common condition that carries lifelong severe medical and developmental consequences. The causes of intellectual disability (ID) remain unknown for the majority of patients due to the extensive clinical and genetic heterogeneity of this disorder. De novo mutations may play an important role in ID as most individuals with ID present as isolated cases without family history and/or clear syndromic indication. In addition, the involvement of such mutations have recently been demonstrated in a small number of individuals with ID. Here we evaluate the diagnostic potential and role of de novo mutations in a cohort of 100 patients with ID of unknown cause using family-based exome sequencing.",EGAD00001000330,ID_trio1_BAM,ID trio1 BAM files, AB SOLiD 4 System;
EGAS00001000287,Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability,"Intellectual disability is a common condition that carries lifelong severe medical and developmental consequences. The causes of intellectual disability (ID) remain unknown for the majority of patients due to the extensive clinical and genetic heterogeneity of this disorder. De novo mutations may play an important role in ID as most individuals with ID present as isolated cases without family history and/or clear syndromic indication. In addition, the involvement of such mutations have recently been demonstrated in a small number of individuals with ID. Here we evaluate the diagnostic potential and role of de novo mutations in a cohort of 100 patients with ID of unknown cause using family-based exome sequencing.",EGAD00001000376,ID_trio25_BAM,ID trio25 BAM files, AB SOLiD 4 System;
EGAS00001000287,Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability,"Intellectual disability is a common condition that carries lifelong severe medical and developmental consequences. The causes of intellectual disability (ID) remain unknown for the majority of patients due to the extensive clinical and genetic heterogeneity of this disorder. De novo mutations may play an important role in ID as most individuals with ID present as isolated cases without family history and/or clear syndromic indication. In addition, the involvement of such mutations have recently been demonstrated in a small number of individuals with ID. Here we evaluate the diagnostic potential and role of de novo mutations in a cohort of 100 patients with ID of unknown cause using family-based exome sequencing.",EGAD00001000375,ID_trio24_BAM,ID trio24 BAM files, AB SOLiD 4 System;
EGAS00001000287,Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability,"Intellectual disability is a common condition that carries lifelong severe medical and developmental consequences. The causes of intellectual disability (ID) remain unknown for the majority of patients due to the extensive clinical and genetic heterogeneity of this disorder. De novo mutations may play an important role in ID as most individuals with ID present as isolated cases without family history and/or clear syndromic indication. In addition, the involvement of such mutations have recently been demonstrated in a small number of individuals with ID. Here we evaluate the diagnostic potential and role of de novo mutations in a cohort of 100 patients with ID of unknown cause using family-based exome sequencing.",EGAD00001000377,ID_trio26_BAM,ID trio26 BAM files, AB SOLiD 4 System;
EGAS00001000287,Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability,"Intellectual disability is a common condition that carries lifelong severe medical and developmental consequences. The causes of intellectual disability (ID) remain unknown for the majority of patients due to the extensive clinical and genetic heterogeneity of this disorder. De novo mutations may play an important role in ID as most individuals with ID present as isolated cases without family history and/or clear syndromic indication. In addition, the involvement of such mutations have recently been demonstrated in a small number of individuals with ID. Here we evaluate the diagnostic potential and role of de novo mutations in a cohort of 100 patients with ID of unknown cause using family-based exome sequencing.",EGAD00001000277,Variant_files_100_ID_trios,"High Quality Variant Call files, generated by bioscope, converted to vcf format. 
Complete dataset for all 300 samples.", 
EGAS00001000288,Genentech Colon Cancer Screen,"Identifying and understanding changes in cancer genomes is essential for the development of targeted therapeutics. Here we analyse systematically more than 70 pairs of primary human colon tumours by applying next-generation sequencing to characterize their exomes, transcriptomes and copy-number alterations. We have identified 36,303 protein-altering somatic changes that include several new recurrent mutations in the Wnt pathway gene TCF7L2, chromatin-remodelling genes such as TET2 and TET3 and receptor tyrosine kinases including ERBB3. Our analysis for significantly mutated cancer genes identified 23 candidates, including the cell cycle checkpoint kinase ATM. Copy-number and RNA-seq data analysis identified amplifications and corresponding overexpression of IGF2 in a subset of colon tumours. Furthermore, using RNA-seq data we identified multiple fusion transcripts including recurrent gene fusions involving R-spondin family members RSPO2 and RSPO3 that together occur in 10% of colon tumours. The RSPO fusions were mutually exclusive with APC mutations, indicating that they probably have a role in the activation of Wnt signalling and tumorigenesis. Consistent with this we show that the RSPO fusion proteins were capable of potentiating Wnt signalling. The R-spondin gene fusions and several other gene mutations identified in this study provide new potential opportunities for therapeutic intervention in colon cancer.",EGAD00001000215,RNA sequencing of colon tumor/normal sample pairs,RNA sequencing of colon tumor/normal sample pairs, Illumina HiSeq 2000;
EGAS00001000288,Genentech Colon Cancer Screen,"Identifying and understanding changes in cancer genomes is essential for the development of targeted therapeutics. Here we analyse systematically more than 70 pairs of primary human colon tumours by applying next-generation sequencing to characterize their exomes, transcriptomes and copy-number alterations. We have identified 36,303 protein-altering somatic changes that include several new recurrent mutations in the Wnt pathway gene TCF7L2, chromatin-remodelling genes such as TET2 and TET3 and receptor tyrosine kinases including ERBB3. Our analysis for significantly mutated cancer genes identified 23 candidates, including the cell cycle checkpoint kinase ATM. Copy-number and RNA-seq data analysis identified amplifications and corresponding overexpression of IGF2 in a subset of colon tumours. Furthermore, using RNA-seq data we identified multiple fusion transcripts including recurrent gene fusions involving R-spondin family members RSPO2 and RSPO3 that together occur in 10% of colon tumours. The RSPO fusions were mutually exclusive with APC mutations, indicating that they probably have a role in the activation of Wnt signalling and tumorigenesis. Consistent with this we show that the RSPO fusion proteins were capable of potentiating Wnt signalling. The R-spondin gene fusions and several other gene mutations identified in this study provide new potential opportunities for therapeutic intervention in colon cancer.",EGAD00001000216,Exome capture sequencing of colon tumor/normal pairs,Exome capture sequencing of colon tumor/normal pairs, Illumina HiSeq 2000;
EGAS00001000288,Genentech Colon Cancer Screen,"Identifying and understanding changes in cancer genomes is essential for the development of targeted therapeutics. Here we analyse systematically more than 70 pairs of primary human colon tumours by applying next-generation sequencing to characterize their exomes, transcriptomes and copy-number alterations. We have identified 36,303 protein-altering somatic changes that include several new recurrent mutations in the Wnt pathway gene TCF7L2, chromatin-remodelling genes such as TET2 and TET3 and receptor tyrosine kinases including ERBB3. Our analysis for significantly mutated cancer genes identified 23 candidates, including the cell cycle checkpoint kinase ATM. Copy-number and RNA-seq data analysis identified amplifications and corresponding overexpression of IGF2 in a subset of colon tumours. Furthermore, using RNA-seq data we identified multiple fusion transcripts including recurrent gene fusions involving R-spondin family members RSPO2 and RSPO3 that together occur in 10% of colon tumours. The RSPO fusions were mutually exclusive with APC mutations, indicating that they probably have a role in the activation of Wnt signalling and tumorigenesis. Consistent with this we show that the RSPO fusion proteins were capable of potentiating Wnt signalling. The R-spondin gene fusions and several other gene mutations identified in this study provide new potential opportunities for therapeutic intervention in colon cancer.",EGAD00001000214,Whole genome sequencing of colon samples,Whole genome sequencing of colon samples, Illumina HiSeq 2000;
EGAS00001000288,Genentech Colon Cancer Screen,"Identifying and understanding changes in cancer genomes is essential for the development of targeted therapeutics. Here we analyse systematically more than 70 pairs of primary human colon tumours by applying next-generation sequencing to characterize their exomes, transcriptomes and copy-number alterations. We have identified 36,303 protein-altering somatic changes that include several new recurrent mutations in the Wnt pathway gene TCF7L2, chromatin-remodelling genes such as TET2 and TET3 and receptor tyrosine kinases including ERBB3. Our analysis for significantly mutated cancer genes identified 23 candidates, including the cell cycle checkpoint kinase ATM. Copy-number and RNA-seq data analysis identified amplifications and corresponding overexpression of IGF2 in a subset of colon tumours. Furthermore, using RNA-seq data we identified multiple fusion transcripts including recurrent gene fusions involving R-spondin family members RSPO2 and RSPO3 that together occur in 10% of colon tumours. The RSPO fusions were mutually exclusive with APC mutations, indicating that they probably have a role in the activation of Wnt signalling and tumorigenesis. Consistent with this we show that the RSPO fusion proteins were capable of potentiating Wnt signalling. The R-spondin gene fusions and several other gene mutations identified in this study provide new potential opportunities for therapeutic intervention in colon cancer.",EGAD00010000272,Title not provided,Colon tumour samples, Illumina_2.5M
EGAS00001000288,Genentech Colon Cancer Screen,"Identifying and understanding changes in cancer genomes is essential for the development of targeted therapeutics. Here we analyse systematically more than 70 pairs of primary human colon tumours by applying next-generation sequencing to characterize their exomes, transcriptomes and copy-number alterations. We have identified 36,303 protein-altering somatic changes that include several new recurrent mutations in the Wnt pathway gene TCF7L2, chromatin-remodelling genes such as TET2 and TET3 and receptor tyrosine kinases including ERBB3. Our analysis for significantly mutated cancer genes identified 23 candidates, including the cell cycle checkpoint kinase ATM. Copy-number and RNA-seq data analysis identified amplifications and corresponding overexpression of IGF2 in a subset of colon tumours. Furthermore, using RNA-seq data we identified multiple fusion transcripts including recurrent gene fusions involving R-spondin family members RSPO2 and RSPO3 that together occur in 10% of colon tumours. The RSPO fusions were mutually exclusive with APC mutations, indicating that they probably have a role in the activation of Wnt signalling and tumorigenesis. Consistent with this we show that the RSPO fusion proteins were capable of potentiating Wnt signalling. The R-spondin gene fusions and several other gene mutations identified in this study provide new potential opportunities for therapeutic intervention in colon cancer.",EGAD00010000274,Title not provided,Colon matched tumour samples, Illumina_2.5M
EGAS00001000289,Lung Plasma rearrangement screen,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from lung cancer patients and subjected to short paired end sequencing on the llumina platform. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000367,Lung Plasma rearrangement screen,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from lung cancer patients and subjected to short paired end sequencing on the llumina platform. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.", Illumina HiSeq 2000;
EGAS00001000290,Myeloproliferative Disease Whole Genomes,"Wholegenome libraries will be prepared from at least two serial samples reflecting different stages of disease progression and matched constitutional DNA for 30 Myeloproliferative Disease samples. Five lanes of Illumina HiSeq sequencing will be performed on each of the tumour samples and four lanes for each of the constitutional DNA. Sequencing data will mapped to build 37 of the human reference genome and analysis will be performed to characterize the spectrum of somatic variation present in these samples including single base pair mutations, insertions, deletions as well as larger structural variants and genomic rearrangements.",EGAD00001000385,Myeloproliferative Disease Whole Genomes,"Wholegenome libraries will be prepared from at least two serial samples reflecting different stages of disease progression and matched constitutional DNA for 30 Myeloproliferative Disease samples. Five lanes of Illumina HiSeq sequencing will be performed on each of the tumour samples and four lanes for each of the constitutional DNA. Sequencing data will mapped to build 37 of the human reference genome and analysis will be performed to characterize the spectrum of somatic variation present in these samples including single base pair mutations, insertions, deletions as well as larger structural variants and genomic rearrangements.", Illumina HiSeq 2000;
EGAS00001000291,Myelodysplastic syndrome whole genomes,"Wholegenome libraries will be prepared from at least two serial samples reflecting different stages of disease progression and matched constitutional DNA for 30 Myelodysplastic syndrome patient samples. Five lanes of Illumina HiSeq sequencing will be performed on each of the tumour samples and four lanes for each of the constitutional DNA. Sequencing data will mapped to build 37 of the human reference genome and analysis will be performed to characterize the spectrum of somatic variation present in these samples including single base pair mutations, insertions, deletions as well as larger structural variants and genomic rearrangements.",EGAD00001000386,Myelodysplastic syndrome whole genomes,"Wholegenome libraries will be prepared from at least two serial samples reflecting different stages of disease progression and matched constitutional DNA for 30 Myelodysplastic syndrome patient samples. Five lanes of Illumina HiSeq sequencing will be performed on each of the tumour samples and four lanes for each of the constitutional DNA. Sequencing data will mapped to build 37 of the human reference genome and analysis will be performed to characterize the spectrum of somatic variation present in these samples including single base pair mutations, insertions, deletions as well as larger structural variants and genomic rearrangements.", Illumina HiSeq 2000;
EGAS00001000292,Molecular characterization of invasive lobular carcinoma,"Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer accounting for 10-15% of cases. ILC differs from invasive ductal carcinoma (IDC)with respect to epidemiology, histology, and clinical presentation. Moreover, ILC is less
sensitive to chemotherapy, more frequently bilateral, and more prone to form gastrointestinal, peritoneal, and ovarian metastases than IDCs. In contrast to IDC, the prognostic value of
histological grade (HG) in ILC is controversial. One of the three major components of histological grading (tubule formation) is missing in ILC which hinders the process of grading
in this histological subtype and results in the classification of approximately two thirds of ILC as HG 2.
Over the last decade, a number of gene expression signatures have shed light onto breast cancer classification, allowing breast cancer care to become more personalized. With
respect to the management of estrogen receptor (ER)-positive breast cancer, several gene expression signatures provide prognostic and/or predictive information beyond what is possible with current classical clinico-pathological parameters alone. Nevertheless, most studies using gene expression signature have not considered different histologic subtypes
separately. Recently, a comprehensive research program has elucidated some of the biological underpinnings of invasive lobular carcinoma. Genetic material extracted from 200 ILC tumor samples were studied using gene expression profiling and identified ILC
molecular subtypes. These proliferation-driven gene signatures of ILC appear to have prognostic significance. In particular, the Genomic Grade (GG) gene signature improved upon HG in ILC and added prognostic value to classic clinico-pathologic factors. In addition this study demonstrated that most ILC are molecularly characterized as luminal-A (~75%)followed by luminal-B (~20%) and HER2-positve tumors (~5%). Moreover, we investigated the prognostic value of known gene signatures/ gene modules in the same cohort of ILC. As a second step within the scope of this project, we aim to investigate the interactions
between somatic ILC tumor mutations to observed transcriptome findings. To this end, we aim to perform somatic mutation analysis for the ILC tumors for which Affymetrix gene expression profiling is available. To this end, we will use a gene screen assay, which specifically interrogates the mutational status of a few hundreds of cancer genes. We believe that this pioneering effort will be fundamental for a tailored treatment of ILC with
improvement in patients' outcome.",EGAD00001000288,Molecular characterization of invasive lobular carcinoma,"Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer accounting for 10-15% of cases. ILC differs from invasive ductal carcinoma (IDC)with respect to epidemiology, histology, and clinical presentation. Moreover, ILC is less
sensitive to chemotherapy, more frequently bilateral, and more prone to form gastrointestinal, peritoneal, and ovarian metastases than IDCs. In contrast to IDC, the prognostic value of
histological grade (HG) in ILC is controversial. One of the three major components of histological grading (tubule formation) is missing in ILC which hinders the process of grading
in this histological subtype and results in the classification of approximately two thirds of ILC as HG 2.
Over the last decade, a number of gene expression signatures have shed light onto breast cancer classification, allowing breast cancer care to become more personalized. With
respect to the management of estrogen receptor (ER)-positive breast cancer, several gene expression signatures provide prognostic and/or predictive information beyond what is possible with current classical clinico-pathological parameters alone. Nevertheless, most studies using gene expression signature have not considered different histologic subtypes
separately. Recently, a comprehensive research program has elucidated some of the biological underpinnings of invasive lobular carcinoma. Genetic material extracted from 200 ILC tumor samples were studied using gene expression profiling and identified ILC
molecular subtypes. These proliferation-driven gene signatures of ILC appear to have prognostic significance. In particular, the Genomic Grade (GG) gene signature improved upon HG in ILC and added prognostic value to classic clinico-pathologic factors. In addition this study demonstrated that most ILC are molecularly characterized as luminal-A (~75%)followed by luminal-B (~20%) and HER2-positve tumors (~5%). Moreover, we investigated the prognostic value of known gene signatures/ gene modules in the same cohort of ILC. As a second step within the scope of this project, we aim to investigate the interactions
between somatic ILC tumor mutations to observed transcriptome findings. To this end, we aim to perform somatic mutation analysis for the ILC tumors for which Affymetrix gene expression profiling is available. To this end, we will use a gene screen assay, which specifically interrogates the mutational status of a few hundreds of cancer genes. We believe that this pioneering effort will be fundamental for a tailored treatment of ILC with
improvement in patients' outcome.", Illumina HiSeq 2000;
EGAS00001000293,Evaluation of size selection on cancer specific sequencing libraries,A couple of previously characterized and sequenced libraries will be repeated using a couple of differing size selection criteria and skim sequenced using an Illumina HiSeq. The resulting sequence will be analyzed to determine the optimal DNA library size for our specific downstream analysis.,EGAD00001000301,Evaluation of size selection on cancer specific sequencing libraries,A couple of previously characterized and sequenced libraries will be repeated using a couple of differing size selection criteria and skim sequenced using an Illumina HiSeq. The resulting sequence will be analyzed to determine the optimal DNA library size for our specific downstream analysis., Illumina HiSeq 2000;
EGAS00001000295,Gene Discovery in Age Related Hearing Loss,The aim is to find new candidate genes associated with progressive hearing loss,EGAD00001000198,Gene Discovery in Age-Related Hearing Loss,Gene Discovery in Age-Related Hearing Loss," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000297,Feasibility of targeted capture sequencing in routinely collected FFPE cancer specimens,Testing the feasibility of genome-scale sequencing in routinely collected formalin-fixed paraffin-embedded (FFPE) cancer specimens versus matched fresh-frozen samples using targeted pulldown capture prior to Illumina sequencing.,EGAD00001000354,Feasibility of targeted capture sequencing in routinely collected FFPE cancer specimens,Testing the feasibility of genome-scale sequencing in routinely collected formalin-fixed paraffin-embedded (FFPE) cancer specimens versus matched fresh-frozen samples using targeted pulldown capture prior to Illumina sequencing., Illumina HiSeq 2000;
EGAS00001000300,Breast cancer sequential sampling study,This study aims to whole genome sequence DNA derived from breast cancer patients who received neo-adjuvany chemotherapy. All patients had multiple biopsies performed before chemotherapy. Patients who had residual disease after the course of treatment underwent a further biopsy. We aim to characterise the mutations involved.,EGAD00001000387,Breast cancer sequential sampling study,This study aims to whole genome sequence DNA derived from breast cancer patients who received neo-adjuvany chemotherapy. All patients had multiple biopsies performed before chemotherapy. Patients who had residual disease after the course of treatment underwent a further biopsy. We aim to characterise the mutations involved., Illumina HiSeq 2000;
EGAS00001000301,Cancer Genome Project Exome Sequencing,Agilent whole exome hybridisation capture was performed on genomic DNA derived from cancer and matched normal DNA from the same patients. Next Generation sequencing performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Now we aim to re find and validate the findings of those exome libraries using bespoke pulldown methods and sequencing the products.,EGAD00001000289,Cancer Genome Project Exome Sequencing,Agilent whole exome hybridisation capture was performed on genomic DNA derived from cancer and matched normal DNA from the same patients. Next Generation sequencing performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Now we aim to re find and validate the findings of those exome libraries using bespoke pulldown methods and sequencing the products., Illumina HiSeq 2000;
EGAS00001000305,P647 Targeted resequencing project,"In collaboration with Dr Robert Semple we have identified a family harbouring an autosomal dominant variant, which leads to severe insulin resistance (SIR), short stature and facial dysmorphism. This family is unique within the SIR cohort in having normal lipid profiles, preserved adiponectin and normal INSR expression and phosphorylation. DNA is available for 7 affected and 7 unaffected family members across 3 generations. All 14 samples have been genotyped using microsatellites and the Affymetrix 6.0 SNP chip. 

Linkage analysis identified an 18.8Mb haplotype on chromosome 19 as a possible location of the causative variant. However, Exome sequencing of 3 affected and 1 unaffected family members has not identified the causative variant suggesting the possibility of an intronic or intergenic variant in this region or elsewhere in the genome. We propose to conduct whole genome sequencing of 5 members of the pedigree at a depth of 20X. The chosen samples are two sets of parents plus one member of an unaffected branch of the pedigree who shares the risk haplotype on chromosome 19. Sequencing of the two sets of parents will be used along with the genome-wide SNP data to impute 4 affected children giving an effect sample size of 6 affected individuals.",EGAD00001000383,P647 Targeted resequencing project,"In collaboration with Dr Robert Semple we have identified a family harbouring an autosomal dominant variant, which leads to severe insulin resistance (SIR), short stature and facial dysmorphism. This family is unique within the SIR cohort in having normal lipid profiles, preserved adiponectin and normal INSR expression and phosphorylation. DNA is available for 7 affected and 7 unaffected family members across 3 generations. All 14 samples have been genotyped using microsatellites and the Affymetrix 6.0 SNP chip. 

Linkage analysis identified an 18.8Mb haplotype on chromosome 19 as a possible location of the causative variant. However, Exome sequencing of 3 affected and 1 unaffected family members has not identified the causative variant suggesting the possibility of an intronic or intergenic variant in this region or elsewhere in the genome. We propose to conduct whole genome sequencing of 5 members of the pedigree at a depth of 20X. The chosen samples are two sets of parents plus one member of an unaffected branch of the pedigree who shares the risk haplotype on chromosome 19. Sequencing of the two sets of parents will be used along with the genome-wide SNP data to impute 4 affected children giving an effect sample size of 6 affected individuals.", Illumina HiSeq 2000;
EGAS00001000306,UK10K exome sequence  TWINSUK samples,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. These TwinsUK samples are a subset of the TwinsUK cohort samples with a BMI>=40 that will be exome sequenced by the Obesity group.",EGAD00001000426,UK10K exome sequence: TWINSUK samples,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. These TwinsUK samples are a subset of the TwinsUK cohort samples with a BMI>=40 that will be exome sequenced by the Obesity group.", Illumina HiSeq 2000;
EGAS00001000306,UK10K exome sequence  TWINSUK samples,"In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. These TwinsUK samples are a subset of the TwinsUK cohort samples with a BMI>=40 that will be exome sequenced by the Obesity group.",EGAD00001000429,UK10K_OBESITY_TWINSUK REL-2013-04-20,, Illumina HiSeq 2000;
EGAS00001000318,Whole-exome Sequencing Combined with Functional Genomics Reveals Novel Candidate Driver Cancer Genes in Endometrial Cancer,"Endometrial cancer is the most common gynecological malignancy, with more than 280,000 cases occurring annually worldwide. Although previous studies have identified important common somatic mutations in endometrial cancer, they have primarily focused on a small set of known cancer genes and have thus provided a limited view of the molecular basis underlying this disease. Here we developed an integrated systems biology approach to identifying novel cancer genes contributing to endometrial tumorigenesis. We first performed whole-exome sequencing on 13 endometrial cancers and matched normal samples, systematically identifying somatic alterations with high precision and sensitivity. We then combined bioinformatics prioritization with high-throughput screening (including both shRNA-mediated knockdown and expression of wild type and mutant constructs) in a highly sensitive cell viability assay. Our results revealed 12 potential driver cancer genes including 10 tumor suppressor candidates (ARID1A, INHBA, KMO, TTLL5, GRM8, IGFBP3, AKTIP, PHKA2, TRPS1 and WNT11) and two oncogene candidates (ERBB3 and RPS6KC1). The results in the sensor cell line were recapitulated by siRNA-mediated knockdown in endometrial cancer cell lines. Focusing on ARID1A, we integrated mutation profiles with functional proteomics in 222 endometrial cancer samples, demonstrating that ARID1A mutations frequently co-occur with mutations in the phosphatidylinositol 3-kinase (PI3K) pathway and are associated with PI3K pathway activation. siRNA knockdown in endometrial cancer cell lines increased AKT phosphorylation supporting ARID1A as a novel regulator of PI3K pathway activity. Our study presents the first unbiased view of somatic coding mutations in endometrial cancer and provides functional evidence for diverse driver genes and mutations in this disease.",EGAD00001000201,MDACC-endo,MDACC-endo, AB SOLiD System 3.0;
EGAS00001000322,De novo mutations in cell free foetal DNA  cffDNA ,"This project is to develop and validate a method to detect de novo mutations in a foetal genome through deep sequencing of cell-free DNA from the plasma of pregnant women.

This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/",EGAD00001000596,De novo mutations in cell-free foetal DNA (cffDNA),"This project is to develop and validate a method to detect de novo mutations in a foetal genome through deep sequencing of cell-free DNA from the plasma of pregnant women.

This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/", Illumina HiSeq 2000;
EGAS00001000328,Sequencing and analysis of a South Asian-Indian personal genome,"India with over 1.3 billion people is estimated to carry three times more genetic diversity compared to Europe.  Next-generation sequencing technologies have facilitated the understanding of diversity by enabling whole genome sequencing at greater speed and lower cost.  While multiple genomes from people of European and a few of Asian descent have been sequenced, only recently a single male genome from the Indian subcontinent at sufficient depth and coverage was published.  We have in this study sequenced and analyzed the genome of a South Asian Indian female (SAIF) from the Indian state of Kerala.  We identified over 3.4 million SNPs in this genome including over 89,873 private variations.  Comparison of the SAIF genome with several published personal genomes revealed that this individual shared ~50% of the SNPs with each of these genomes.  Analysis of the SAIF mitochondrial genome showed that it is closely related to the U1a3 haplogroup which has been previously observed in Kerala.  We assessed the SAIF genome for SNPs with health and disease consequences and found that the individual was at a higher risk for multiple sclerosis and a few other diseases.   In assessing SNPs that modulate drug response we found a variation that predicts a favorable response to metformin used for treating diabetes.  SNPs predictive of adverse reaction to warfarin indicated that the SAIF individual is not at risk for bleeding if treated with typical doses of warfarin.  In addition to these, we report the presence of several other SNPs of medical relevance.",EGAD00001000249,SAIF Alignment File,This is the bam file generated after alignment using BWA program for the SAIF genome, Illumina HiSeq 2000;
EGAS00001000328,Sequencing and analysis of a South Asian-Indian personal genome,"India with over 1.3 billion people is estimated to carry three times more genetic diversity compared to Europe.  Next-generation sequencing technologies have facilitated the understanding of diversity by enabling whole genome sequencing at greater speed and lower cost.  While multiple genomes from people of European and a few of Asian descent have been sequenced, only recently a single male genome from the Indian subcontinent at sufficient depth and coverage was published.  We have in this study sequenced and analyzed the genome of a South Asian Indian female (SAIF) from the Indian state of Kerala.  We identified over 3.4 million SNPs in this genome including over 89,873 private variations.  Comparison of the SAIF genome with several published personal genomes revealed that this individual shared ~50% of the SNPs with each of these genomes.  Analysis of the SAIF mitochondrial genome showed that it is closely related to the U1a3 haplogroup which has been previously observed in Kerala.  We assessed the SAIF genome for SNPs with health and disease consequences and found that the individual was at a higher risk for multiple sclerosis and a few other diseases.   In assessing SNPs that modulate drug response we found a variation that predicts a favorable response to metformin used for treating diabetes.  SNPs predictive of adverse reaction to warfarin indicated that the SAIF individual is not at risk for bleeding if treated with typical doses of warfarin.  In addition to these, we report the presence of several other SNPs of medical relevance.",EGAD00001000254,Fastq files for SAIF genome,This dataset contain the raw files generated for SAIF genome project, Illumina HiSeq 2000;
EGAS00001000330,Osteosarcoma whole genome rearrangement screen,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from Osteosarcoma cancer patients and subjected to short paired end sequencing on the llumina platform. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000368,Osteosarcoma whole genome rearrangement screen,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from Osteosarcoma cancer patients and subjected to short paired end sequencing on the llumina platform. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.", Illumina HiSeq 2000;
EGAS00001000332,Helleday HRAS Project,This experiment is looking at the mutational signatures generated by engineered HRAS mutations by using whole genome sequence generated on massively parallel next generation sequencers.,EGAD00001000302,Helleday_HRAS Project,This experiment is looking at the mutational signatures generated by engineered HRAS mutations by using whole genome sequence generated on massively parallel next generation sequencers., Illumina HiSeq 2000;
EGAS00001000334,Genentech Small Cell Lung Cancer (SCLC) Screen,"Exome capture, RNA-Seq, whole genome sequencing of set of Small Cell Lung Cancer samples.",EGAD00001000223,RNA sequencing of SCLC tumor/normal sample pairs and cell lines,RNA sequencing of SCLC tumor/normal sample pairs and cell lines, Illumina HiSeq 2000;
EGAS00001000334,Genentech Small Cell Lung Cancer (SCLC) Screen,"Exome capture, RNA-Seq, whole genome sequencing of set of Small Cell Lung Cancer samples.",EGAD00010000276,Title not provided,SCLC tumor genotypes, Illumina_2.5M
EGAS00001000334,Genentech Small Cell Lung Cancer (SCLC) Screen,"Exome capture, RNA-Seq, whole genome sequencing of set of Small Cell Lung Cancer samples.",EGAD00010000278,Title not provided,SCLC matched normal genotypes, Illumina_2.5M
EGAS00001000334,Genentech Small Cell Lung Cancer (SCLC) Screen,"Exome capture, RNA-Seq, whole genome sequencing of set of Small Cell Lung Cancer samples.",EGAD00001000222,Exome capture sequencing of SCLC tumor/normal pairs and cell lines,Exome capture sequencing of SCLC tumor/normal pairs and cell lines, Illumina HiSeq 2000;
EGAS00001000334,Genentech Small Cell Lung Cancer (SCLC) Screen,"Exome capture, RNA-Seq, whole genome sequencing of set of Small Cell Lung Cancer samples.",EGAD00001000221,Whole genome sequencing of SCLC tumor/normal samples,Whole genome sequencing of SCLC tumor/normal samples, Illumina HiSeq 2000;
EGAS00001000337,Inferring tumor genomes from peripheral blood i.e. CTCs and plasma-DNA using deep sequencing and targeted enrichment,"In this study we tested whether complex tumor genomes can be inferred from the peripheral blood (plasma DNA /CTCs) of 32 patients with stage IV colorectal carcinoma (CRC). To establish the percentage of mutated plasma DNA fragments we used 8 patient samples with different plasma DNA size distributions and KRAS mutations in their corresponding primary tumors and employed ultra-deep pyrosequencing with 3 different sequencing reaction sizes (i.e., 119 bp, 168 bp, and 323 bp). Furthermore, we used massive parallel sequencing of a panel of 68 CRC-associated genes to establish the mutation spectrum of cancer driver genes in the primary tumors, metastases, and CTCs of two colorectal cancer patients. To investigate, whether mutations found in only one CTC (private CTC mutations) are true mutations occurring with allele frequencies below the resolution limits of current detection methods, or whether they are amplification or sequencing artifacts, we performed ultra-deep sequencing of the primary tumors, metastases, plasma DNAs and normal tissues.",EGAD00001000224,Enrichment of CRC,Enrichment of CRC, 454 GS FLX Titanium;
EGAS00001000337,Inferring tumor genomes from peripheral blood i.e. CTCs and plasma-DNA using deep sequencing and targeted enrichment,"In this study we tested whether complex tumor genomes can be inferred from the peripheral blood (plasma DNA /CTCs) of 32 patients with stage IV colorectal carcinoma (CRC). To establish the percentage of mutated plasma DNA fragments we used 8 patient samples with different plasma DNA size distributions and KRAS mutations in their corresponding primary tumors and employed ultra-deep pyrosequencing with 3 different sequencing reaction sizes (i.e., 119 bp, 168 bp, and 323 bp). Furthermore, we used massive parallel sequencing of a panel of 68 CRC-associated genes to establish the mutation spectrum of cancer driver genes in the primary tumors, metastases, and CTCs of two colorectal cancer patients. To investigate, whether mutations found in only one CTC (private CTC mutations) are true mutations occurring with allele frequencies below the resolution limits of current detection methods, or whether they are amplification or sequencing artifacts, we performed ultra-deep sequencing of the primary tumors, metastases, plasma DNAs and normal tissues.",EGAD00001000220,Deep sequencing of CTCs,Deep sequencing of CTCs," 454 GS FLX Titanium;, Illumina MiSeq;"
EGAS00001000337,Inferring tumor genomes from peripheral blood i.e. CTCs and plasma-DNA using deep sequencing and targeted enrichment,"In this study we tested whether complex tumor genomes can be inferred from the peripheral blood (plasma DNA /CTCs) of 32 patients with stage IV colorectal carcinoma (CRC). To establish the percentage of mutated plasma DNA fragments we used 8 patient samples with different plasma DNA size distributions and KRAS mutations in their corresponding primary tumors and employed ultra-deep pyrosequencing with 3 different sequencing reaction sizes (i.e., 119 bp, 168 bp, and 323 bp). Furthermore, we used massive parallel sequencing of a panel of 68 CRC-associated genes to establish the mutation spectrum of cancer driver genes in the primary tumors, metastases, and CTCs of two colorectal cancer patients. To investigate, whether mutations found in only one CTC (private CTC mutations) are true mutations occurring with allele frequencies below the resolution limits of current detection methods, or whether they are amplification or sequencing artifacts, we performed ultra-deep sequencing of the primary tumors, metastases, plasma DNAs and normal tissues.",EGAD00001000225,Deep sequencing of KRAS,Deep sequencing of KRAS, 454 GS FLX Titanium;
EGAS00001000343,Pancreatic Cancer Sequencing Initiative,Pancreatic Cancer Sequencing Initiative for the International Cancer Genome Consortium at the Ontario Institute for Cancer Research.,EGAD00001000262,OICR PANCREATIC CANCER DATASET,OICR PANCREATIC CANCER DATASET, 
EGAS00001000343,Pancreatic Cancer Sequencing Initiative,Pancreatic Cancer Sequencing Initiative for the International Cancer Genome Consortium at the Ontario Institute for Cancer Research.,EGAD00001000276,OICR PANCREATIC CANCER DATASET 2,OICR PANCREATIC CANCER DATASET 2, 
EGAS00001000346,Genetic landscape of pediatric Retinoblastoma,"Retinoblastoma is a pediatric cancer of the developing retina. All retinoblastomas are believed to initiate with biallelic inactivation of the RB1 gene. To identify subsequent genetic lesions in retinoblastoma, we performed whole genome sequencing of tumor and normal DNA of 4 children with retinoblastoma and one matched orthotopic xenograft. Both alleles of RB1 were inactivated in the tumor samples. 3 of the patients had sporadic retinoblastoma and one patient had inherited retinoblastoma. Overall, there were few single nucleotide changes in coding regions of the genome and some of the tumors had few chromosomal lesions. There were very few new genetic lesions in the xenograft compared to the primary tumor. These data suggest that the genome in retinoblastoma is more stable than previously believed and there are relatively few recurrent genetic lesions in known cancer pathways other than the RB1 pathway.",EGAD00001000261,DATA FILES FOR SJRB,DATA FILES FOR SJRB, 
EGAS00001000347,Genetic landscape of pediatric Medulloblastoma,"Medulloblastoma is a heterogenous disease made up of at least four distinct subtypes of disease which appear to exploit and disrupt naturally occurring developmental pathways of cellular growth and hindbrain development. To better understand the driver mutations of this disease, we performed whole genome sequencing of 37 medulloblastomas and the corresponding normal DNA of the 37 affected children treated at St. Jude Children's Research Hospital. We have found several novel mutations which appear subtype specific. These mutations were checked for frequency in a separate tumor cohort of 56 children with medulloblastoma, also treated on the St. Jude Medulloblastoma 2003 trial, and were tested in several animal models of medulloblastoma for proof of oncogenic potential.",EGAD00001000269,DATA FILES FOR SJMB,DATA FILES FOR SJMB, Illumina HiSeq 2000;
EGAS00001000349,Genetic landscape of core-binding factor leukemia,"Pediatric de novo acute myeloid leukemia (AML) is a heterogeneous disease that can be divided into clinically distinct subtypes based on the presence of specific chromosomal abnormalities or gene alterations. One of the best characterized subtypes of AML involves leukemias with alterations of the core-binding factor (CBF)-complex, which comprises the FAB subtypes M2 and M4Eo and associates with a favorable outcome. Patients with the AML M2 subtype harbor a translocation between chromosomes 8 and 21 [t(8;21)] that yields the chimeric fusion gene RUNX1(AML1)-RUNX1T1(ETO), while patients with AML M4Eo express the chimeric fusion gene CBF-SMMHC(MYH11) as a result of an inversion/translocation event of chromosome 16 [inv(16)/t(16;16)]. In an effort to define the total complement of genetic changes in CBF-leukemia, we performed paired-end whole genome sequencing (WGS) on diagnostic leukemia blasts and matched germ line samples from 17 pediatric CBF-leukemia patients using the Illumina platform. Somatic alterations, including single nucleotide variations (SNVs) and structural variations (SVs), including insertions, deletions, inversions, and inter- and intra-chromosomal rearrangements, were detected using complementary analysis pipelines (Bambino, CREST and CONSERTING). Recurrent screening of identified mutations will be performed in a cohort of approximately 94 cases of CBF-leukemias.",EGAD00001000268,DATA FILES FOR SJCBF,DATA FILES FOR SJCBF, Illumina HiSeq 2000;
EGAS00001000353,The genomic architecture of mesothelioma ,"The genome-wide landscape of somatically acquired mutations in mesothelioma has not been deeply characterised to date, but advances in DNA sequencing technology now allow this to be addressed comprehensively. Harnessing massively parallel DNA sequencing platforms, we will identify somatically acquired point mutations in all coding regions of the genome from patients with mesothelioma. In addition, using paired-end sequencing, we will map copy number changes and genomic rearrangements from the same patients.",EGAD00001000360,The genomic architecture of mesothelioma,"The genome-wide landscape of somatically acquired mutations in mesothelioma has not been deeply characterised to date, but advances in DNA sequencing technology now allow this to be addressed comprehensively. Harnessing massively parallel DNA sequencing platforms, we will identify somatically acquired point mutations in all coding regions of the genome from patients with mesothelioma. In addition, using paired-end sequencing, we will map copy number changes and genomic rearrangements from the same patients.", Illumina HiSeq 2000;
EGAS00001000354,Primary Lung Cancer whole genome study,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from lung cancer patients and subjected to short paired end sequencing on the llumina platform. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.",EGAD00001000388,Primary Lung Cancer whole genome study,"Genomic libraries (500 bps) will be generated from total genomic DNA derived from lung cancer patients and subjected to short paired end sequencing on the llumina platform. Paired reads will be mapped to build 37 of the human reference genome to facilitate the generation of genome wide copy number information, and the identification of novel rearranged cancer genes and gene fusions.", Illumina HiSeq 2000;
EGAS00001000356,Exome sequencing of Bilateral Anophthalmia cases  Pilot Study ,This pilot study aims to generate pilot data to inform future study designs by resequencing the whole exomes of 10 unrelated individuals diagnosed with Bilateral Anophthalmia.,EGAD00001000348,Title not provided,Exome sequencing of Bilateral Anophthalmia cases- Pilot Study, Illumina Genome Analyzer II;
EGAS00001000359,Mutation analysis in human iPS cells ,"PCR products were obtained from each target loci using genomic DNA from human iPS cells. Subsequently, PCR products are pooled and subjected to Illumina library preparation.  The library will be sequenced by MiSeq. 

This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/",EGAD00001000357,Mutation analysis in human iPS cells,"PCR products were obtained from each target loci using genomic DNA from human iPS cells. Subsequently, PCR products are pooled and subjected to Illumina library preparation.  The library will be sequenced by MiSeq. 

This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/", Illumina MiSeq;
EGAS00001000360,Balanced Brain Tumour Whole Genome Sequencing,"We propose to definitively characterise the somatic genetics of a number of pediatric malignant tumours including ependymoma, high grade glioma and central nervous system primitive neurectodermal tumours through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing.",EGAD00001000369,Balanced Brain Tumour Whole Genome Sequencing,"We propose to definitively characterise the somatic genetics of a number of pediatric malignant tumours including ependymoma, high grade glioma and central nervous system primitive neurectodermal tumours through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing.", Illumina HiSeq 2000;
EGAS00001000362,Ewings Sarcoma Rearrangement Screen,"Cancer is driven by mutations in the genome. We will uncover the mutations that give rise to Ewings sarcoma, a bone tumour that largely affects children. We will use second generation Illumina massively parallel sequencing, and bespoke software, to characterise the genomes and transcriptomes of Ewings sarcoma tumours.",EGAD00001000389,Ewings Sarcoma Rearrangement Screen,"Cancer is driven by mutations in the genome. We will uncover the mutations that give rise to Ewing's sarcoma, a bone tumour that largely affects children. We will use second generation Illumina massively parallel sequencing, and bespoke software, to characterise the genomes and transcriptomes of Ewing's sarcoma tumours.", Illumina HiSeq 2000;
EGAS00001000367,Assessment of genetic and epigenetic variation in human IPS cells RNA,"n order to progress human induced pluripotent stem cells (hiPSCs) towards the clinic, several outstanding questions must be addressed. It is possible to reprogram different somatic cell types into hiPSCs  and from studies in the mouse, it appears that an epigenetic memory of the starting cell type is carried over to hiPSCs. However a comprehensive comparative study of the characteristics of these hiPSCs has been missing from the literature. Importantly studies which aimed to address these aspects of hiPSCs have used cells from different patients. In order to avoid this important confounding variable and to keep the genetic background constant, tissue samples were procured from the patients and reprogrammed to iPS cells. The transcriptomes of these iPS cells will be compared.
Protocol: primary cultures of cells were reprogrammed to iPS cells. RNA was extracted using a standard column extraction kit.",EGAD00001000604,Assessment of genetic and epigenetic variation in human IPS cells-RNA,"n order to progress human induced pluripotent stem cells (hiPSCs) towards the clinic, several outstanding questions must be addressed. It is possible to reprogram different somatic cell types into hiPSCs  and from studies in the mouse, it appears that an epigenetic memory of the starting cell type is carried over to hiPSCs. However a comprehensive comparative study of the characteristics of these hiPSCs has been missing from the literature. Importantly studies which aimed to address these aspects of hiPSCs have used cells from different patients. In order to avoid this important confounding variable and to keep the genetic background constant, tissue samples were procured from the patients and reprogrammed to iPS cells. The transcriptomes of these iPS cells will be compared.
Protocol: primary cultures of cells were reprogrammed to iPS cells. RNA was extracted using a standard column extraction kit.", Illumina HiSeq 2000;
EGAS00001000369,Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma,"Neuroblastomas are tumors of peripheral sympathetic neurons and are the most common solid tumor in children.   To determine the genetic basis for neuroblastoma we performed whole-genome sequencing (6 cases), exome sequencing (16 cases), genome-wide rearrangement analyses (32 cases), and targeted analyses of specific genomic loci (40 cases) using massively parallel sequencing.    On average each tumor had 19 somatic alterations in coding genes (range, 3-70).  Among genes not previously known to be involved in neuroblastoma, chromosomal deletions and sequence alterations of chromatin remodeling genes, ARID1A and ARID1B, were identified in 8 of 71 tumors (11%) and were associated with early treatment failure and decreased survival.  Using tumor-specific structural alterations, we developed an approach to identify rearranged DNA fragments in sera, providing personalized biomarkers for minimal residual disease detection and monitoring.  These results highlight dysregulation of chromatin remodeling in pediatric tumorigenesis and provide new approaches for the management of neuroblastoma patients.

Data Provider: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC)",EGAD00001000282,Whole genome analyses of the childhood cancer neuroblastoma,"Neuroblastomas are tumors of peripheral sympathetic neurons and are the most common solid tumor in children.   To determine the genetic basis for neuroblastoma we performed whole-genome sequencing (6 cases), exome sequencing (16 cases), genome-wide rearrangement analyses (32 cases), and targeted analyses of specific genomic loci (40 cases) using massively parallel sequencing.    On average each tumor had 19 somatic alterations in coding genes (range, 3-70).  Among genes not previously known to be involved in neuroblastoma, chromosomal deletions and sequence alterations of chromatin remodeling genes, ARID1A and ARID1B, were identified in 8 of 71 tumors (11%) and were associated with early treatment failure and decreased survival.  Using tumor-specific structural alterations, we developed an approach to identify rearranged DNA fragments in sera, providing personalized biomarkers for minimal residual disease detection and monitoring.  These results highlight dysregulation of chromatin remodeling in pediatric tumorigenesis and provide new approaches for the management of neuroblastoma patients."," Illumina HiSeq 2000;, Illumina Genome Analyzer IIx;"
EGAS00001000370,"Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single nucleotide variants and tumoral heterogeneity by massively parallel sequencing","Tumor-derived DNA can be found in the plasma of cancer patients. We explored the use of shotgun massively parallel sequencing of plasma DNA obtained from cancer patients to scan a cancer genome noninvasively. We achieved the profiling of copy number aberrations and point mutations, in a genomewide manner using this approach. By measuring the genomewide aggregated allelic loss and point mutations, we determined the fractional tumor-derived DNA concentrations in plasma and correlated these values with tumor size and surgical treatment. We have also demonstrated the application of this approach to monitoring a complex oncologic scenario, in a patient with two synchronous cancers. In particular, through the use of multi-regional sequencing of tumoral tissues and shotgun sequencing of plasma DNA, we have shown that plasma DNA sequencing is a valuable approach for studying tumoral heterogeneity. Shotgun plasma DNA sequencing is thus a powerful tool for cancer monitoring and research.",EGAD00001000284,"Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing","Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing", Illumina Genome Analyzer IIx;
EGAS00001000370,"Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single nucleotide variants and tumoral heterogeneity by massively parallel sequencing","Tumor-derived DNA can be found in the plasma of cancer patients. We explored the use of shotgun massively parallel sequencing of plasma DNA obtained from cancer patients to scan a cancer genome noninvasively. We achieved the profiling of copy number aberrations and point mutations, in a genomewide manner using this approach. By measuring the genomewide aggregated allelic loss and point mutations, we determined the fractional tumor-derived DNA concentrations in plasma and correlated these values with tumor size and surgical treatment. We have also demonstrated the application of this approach to monitoring a complex oncologic scenario, in a patient with two synchronous cancers. In particular, through the use of multi-regional sequencing of tumoral tissues and shotgun sequencing of plasma DNA, we have shown that plasma DNA sequencing is a valuable approach for studying tumoral heterogeneity. Shotgun plasma DNA sequencing is thus a powerful tool for cancer monitoring and research.",EGAD00001000290,"Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing","Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing", Illumina Genome Analyzer IIx;
EGAS00001000370,"Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single nucleotide variants and tumoral heterogeneity by massively parallel sequencing","Tumor-derived DNA can be found in the plasma of cancer patients. We explored the use of shotgun massively parallel sequencing of plasma DNA obtained from cancer patients to scan a cancer genome noninvasively. We achieved the profiling of copy number aberrations and point mutations, in a genomewide manner using this approach. By measuring the genomewide aggregated allelic loss and point mutations, we determined the fractional tumor-derived DNA concentrations in plasma and correlated these values with tumor size and surgical treatment. We have also demonstrated the application of this approach to monitoring a complex oncologic scenario, in a patient with two synchronous cancers. In particular, through the use of multi-regional sequencing of tumoral tissues and shotgun sequencing of plasma DNA, we have shown that plasma DNA sequencing is a valuable approach for studying tumoral heterogeneity. Shotgun plasma DNA sequencing is thus a powerful tool for cancer monitoring and research.",EGAD00001000308,"Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing","Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing", 
EGAS00001000371,Whole-exome study to identify the causative germline mutations of congenital macrothrombocytopenia,"To identify the causative germline mutations of congenital macrothrombocytopenia, whole-exome study of 6 families (21 individuals) with autosomal dominant mode of transmission.",EGAD00001000286,Whole-exome study of congenital macrothrombocytopenia,Whole-exome study of congenital macrothrombocytopenia, Illumina HiSeq 2000;
EGAS00001000373,Deep sequencing analysis of human iPSC specific SNVs in donor cell population,"CR products were obtained from each target loci using genomic DNA from human iPS cells. Subsequently, PCR products are pooled and subjected to Illumina library preparation.  The library will be sequenced either by HiSeq or MiSeq. 

This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/",EGAD00001000605,Deep sequencing analysis of human iPSC-specific SNVs in donor cell population,"CR products were obtained from each target loci using genomic DNA from human iPS cells. Subsequently, PCR products are pooled and subjected to Illumina library preparation.  The library will be sequenced either by HiSeq or MiSeq. 

This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/"," Illumina MiSeq;, Illumina HiSeq 2000;"
EGAS00001000374,Deep RNA sequencing in CLL,"Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with a heterogeneous clinical and biological behavior.  We have performed deep RNA sequencing in different subpopulations of B-lymphocytes from healthy individuals and CLL cells from a cohort of 98 patients, and characterized the CLL transcriptional landscape with unprecedented resolution. The transcriptomic architecture of CLL uncovered here refines the biological characterization of the disease and opens new perspectives for the clinical management of patients.",EGAD00010000472,Title not provided,CLL Expression Array, Affymetrix U219
EGAS00001000374,Deep RNA sequencing in CLL,"Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with a heterogeneous clinical and biological behavior.  We have performed deep RNA sequencing in different subpopulations of B-lymphocytes from healthy individuals and CLL cells from a cohort of 98 patients, and characterized the CLL transcriptional landscape with unprecedented resolution. The transcriptomic architecture of CLL uncovered here refines the biological characterization of the disease and opens new perspectives for the clinical management of patients.",EGAD00001000083,Recurrent Somatic Mutations in CLL,Recurrent Somatic Mutations in CLL," Illumina Genome Analyzer II;, Illumina Genome Analyzer IIx"
EGAS00001000374,Deep RNA sequencing in CLL,"Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with a heterogeneous clinical and biological behavior.  We have performed deep RNA sequencing in different subpopulations of B-lymphocytes from healthy individuals and CLL cells from a cohort of 98 patients, and characterized the CLL transcriptional landscape with unprecedented resolution. The transcriptomic architecture of CLL uncovered here refines the biological characterization of the disease and opens new perspectives for the clinical management of patients.",EGAD00001000258,Deep RNA sequencing in CLL,Deep RNA sequencing in CLL, Illumina Genome Analyzer II;
EGAS00001000379,Genetic landscape of non-Down syndrome acute megkaryoblastic leukemia,"To define the mutation spectrum in non-Down syndrome acute megkaryoblastic leukemia (non-DS-AMKL), we performed transcriptome sequencing on diagnostic blasts from 14 pediatric patients and validated our findings in a recurrency/validation cohort consisting of 34 pediatric and 28 adult AMKL leukemia samples. Our analysis identified a cryptic chromosome 16 inversion [inv(16)(p13.3q24.3)] in 27% of pediatric cases, which encodes a CBFA2T3-GLIS2 fusion protein. Expression of CBFA2T3-GLIS2 in Drosophila and murine hematopoietic cells induced bone morphogenic protein (BMP) signaling, and resulted in a marked increase in the self-renewal capacity of hematopoietic progenitors. These data suggest that expression of CBFA2T3-GLIS2 directly contributes to leukemogenesis.",EGAD00001000259,DATA FILES FOR SJAMLM7,DATA FILES FOR SJAMLM7, Illumina HiSeq 2000;
EGAS00001000380,GEenetic landscape of hypodiploid acute lymphoblastic leukemia,"Hypodiploid acute lymphoblastic leukemia (ALL) is an aggressive leukemia characterized by aneuploidy and poor outcome. The genetic basis of hypodiploid ALL is unknown. Here, using complementary genome-wide profiling approaches, we show that hypodiploid ALL comprises two subtypes that differ in the severity of aneuploidy, transcriptional profile and submicroscopic genetic alterations. Near haploid cases with 24-31 chromosomes frequently harbor alterations targeting receptor tyrosine kinase- and Ras signaling (71%) and IKZF3 (AIOLOS; 13%). In contrast, low hypodiploid ALL cases with 32-39 chromosomes are characterized by TP53 alterations, almost half of which are present in non-tumor cells, and have alterations of IKZF2 (HELIOS; 53%) and RB1 (41%). Both near haploid and low hypodiploid tumors exhibit activation of Ras and PI3K signaling pathways, and are sensitive to PI3K inhibition, indicating that these drugs should be explored as a new therapeutic strategy for this frequently lethal form of leukemia.",EGAD00001000260,DATA FILES FOR SJHYPO,DATA FILES FOR SJHYPO, 
EGAS00001000381,Whole-genome sequencing analysis of low-grade astrocytomas within the ICGC PedBrain Tumor Project,"In order to investigate the full range of genetic alterations contributing to the tumourigenesis of low-grade astrocytoma, we have conducted a next-generation sequencing-based analysis on a large series of matched tumor-normal pairs. This study, conducted by the International Cancer Genome Consortium PedBrain Tumor Project (ICGC PedBrain, http://www.pedbraintumor.org/), has revealed multiple new insights into the biological basis of this tumor entity.",EGAD00001000271,"Pilot study Pilocytic Astrocytoma ICGC PedBrain, whole genome sequencing of 5 tumors and matched blood","Pilot study Pilocytic Astrocytoma ICGC PedBrain, whole genome sequencing of 5 tumors and matched blood", Illumina HiSeq 2000;
EGAS00001000381,Whole-genome sequencing analysis of low-grade astrocytomas within the ICGC PedBrain Tumor Project,"In order to investigate the full range of genetic alterations contributing to the tumourigenesis of low-grade astrocytoma, we have conducted a next-generation sequencing-based analysis on a large series of matched tumor-normal pairs. This study, conducted by the International Cancer Genome Consortium PedBrain Tumor Project (ICGC PedBrain, http://www.pedbraintumor.org/), has revealed multiple new insights into the biological basis of this tumor entity.",EGAD00001000616,Pilocytic Astrocytoma ICGC PedBrain whole genome sequencing,Pilocytic Astrocytoma ICGC PedBrain whole genome sequencing, Illumina HiSeq 2000;
EGAS00001000381,Whole-genome sequencing analysis of low-grade astrocytomas within the ICGC PedBrain Tumor Project,"In order to investigate the full range of genetic alterations contributing to the tumourigenesis of low-grade astrocytoma, we have conducted a next-generation sequencing-based analysis on a large series of matched tumor-normal pairs. This study, conducted by the International Cancer Genome Consortium PedBrain Tumor Project (ICGC PedBrain, http://www.pedbraintumor.org/), has revealed multiple new insights into the biological basis of this tumor entity.",EGAD00001000617,Pilocytic Astrocytoma ICGC PedBrain RNA sequencing,Pilocytic Astrocytoma ICGC PedBrain RNA sequencing, Illumina HiSeq 2000;
EGAS00001000383,The genomic landscape of large and small tumors in early-onset prostate cancer patients,"This study characterizes the genomic landscape of prostate cancer (PCA) cells in patients below or at the age of 50 years. Tumors of such early onset patients already show a broad spectrum of sizes. To test if the size differences are indicative of special cancer subgroups, we sequenced the genome of the tumor cells and matched control samples from blood.",EGAD00001000306,ICGC prostate cancer whole genome sequencing,ICGC prostate cancer whole genome sequencing, Illumina HiSeq 2000;
EGAS00001000383,The genomic landscape of large and small tumors in early-onset prostate cancer patients,"This study characterizes the genomic landscape of prostate cancer (PCA) cells in patients below or at the age of 50 years. Tumors of such early onset patients already show a broad spectrum of sizes. To test if the size differences are indicative of special cancer subgroups, we sequenced the genome of the tumor cells and matched control samples from blood.",EGAD00001000270,DATA_SET_EOP-PCA-LargeAndSmallTumors1,DATA_SET_EOP-PCA-LargeAndSmallTumors1, Illumina HiSeq 2000;
EGAS00001000390,Targeted gene fusion sequencing  Fus seq  in mesothelioma,This is a small pilot data set to test the feasibility of cDNA exomes across 1200 cancer cell line panel. cDNA exomes or Fus-seq is further explained in this studies Abstract.,EGAD00001000361,Targeted gene fusion sequencing (Fus-seq) in mesothelioma,This is a small pilot data set to test the feasibility of cDNA exomes across 1200 cancer cell line panel. cDNA exomes or Fus-seq is further explained in this studies Abstract., Illumina HiSeq 2000;
EGAS00001000393,Whole-genome-Sequencing of adult medulloblastoma,"Brain tumors constitute the childhood tumors with the highest mortality rates and survival is often associated with severe long-term sequelae due to intensive multimodal treatment regimens. Thus, the PedBrainTumor network aims at the identification of robust biomarkers for clinical management and novel molecular targets for therapeutic interventions. Using massively parallel whole-genome sequencing, and transcriptome and methylome sequencing for subsets of cases, we aim to decipher the molecular causes of medulloblastoma as well as low-grade astrocytoma, and to identify markers to stratify patients for specialized treatment. As the PedBrain network is affiliated with clinical trials in medulloblastoma and pilocytic astrocytoma, validation cohorts for the translation of key findings into clinical settings are readily available.",EGAD00001000275,Data set for Whole-genome-Sequencing of adult medulloblastoma,Data set for Whole-genome-Sequencing of adult medulloblastoma, Illumina HiSeq 2000;
EGAS00001000394,Genome wide mutation analysis of germinal-center B-cell derived lymphomas within the ICGC MMML-Seq Consortium,"Germinal-center B-cell derived lymphomas (GCB-lymphomas) are the most common B-cell lymphomas in children and adults, with Burkitt Lymphomas (BL) predominating in childhood and follicular lymphoma (FL) and diffuse large B-cell lymphomas (DLBCL) predominating in older age groups. The cell-of-origin in all these lymphomas is supposed to be a germinal center B-cell and transformation of FL in DLBCL or intermediate DLBCL/BL (intL) can occur. In the framework of the German ICGC MMML-Seq we are currently exploring sequencing data of GCB-lymphomas and paired normal controls as well as normal B-cell subsets separated by FACS. This includes whole genome, transcriptome, miRNAome and whole methylome datasets.",EGAD00010000377,Title not provided,DNA methylation analysis of 6 primary lymphoma samples, HumanMethylation450k Bead Chip - Genome Studio
EGAS00001000394,Genome wide mutation analysis of germinal-center B-cell derived lymphomas within the ICGC MMML-Seq Consortium,"Germinal-center B-cell derived lymphomas (GCB-lymphomas) are the most common B-cell lymphomas in children and adults, with Burkitt Lymphomas (BL) predominating in childhood and follicular lymphoma (FL) and diffuse large B-cell lymphomas (DLBCL) predominating in older age groups. The cell-of-origin in all these lymphomas is supposed to be a germinal center B-cell and transformation of FL in DLBCL or intermediate DLBCL/BL (intL) can occur. In the framework of the German ICGC MMML-Seq we are currently exploring sequencing data of GCB-lymphomas and paired normal controls as well as normal B-cell subsets separated by FACS. This includes whole genome, transcriptome, miRNAome and whole methylome datasets.",EGAD00010000379,Title not provided,DNA methylation analysis of 2 peripheral blood samples, HumanMethylation450k Bead Chip - Genome Studio
EGAS00001000394,Genome wide mutation analysis of germinal-center B-cell derived lymphomas within the ICGC MMML-Seq Consortium,"Germinal-center B-cell derived lymphomas (GCB-lymphomas) are the most common B-cell lymphomas in children and adults, with Burkitt Lymphomas (BL) predominating in childhood and follicular lymphoma (FL) and diffuse large B-cell lymphomas (DLBCL) predominating in older age groups. The cell-of-origin in all these lymphomas is supposed to be a germinal center B-cell and transformation of FL in DLBCL or intermediate DLBCL/BL (intL) can occur. In the framework of the German ICGC MMML-Seq we are currently exploring sequencing data of GCB-lymphomas and paired normal controls as well as normal B-cell subsets separated by FACS. This includes whole genome, transcriptome, miRNAome and whole methylome datasets.",EGAD00001000278,ICGC MMML-seq Data Freeze November 2012 whole genome sequencing,ICGC MMML-seq Data Freeze November 2012 whole genome sequencing, Illumina HiSeq 2000;
EGAS00001000394,Genome wide mutation analysis of germinal-center B-cell derived lymphomas within the ICGC MMML-Seq Consortium,"Germinal-center B-cell derived lymphomas (GCB-lymphomas) are the most common B-cell lymphomas in children and adults, with Burkitt Lymphomas (BL) predominating in childhood and follicular lymphoma (FL) and diffuse large B-cell lymphomas (DLBCL) predominating in older age groups. The cell-of-origin in all these lymphomas is supposed to be a germinal center B-cell and transformation of FL in DLBCL or intermediate DLBCL/BL (intL) can occur. In the framework of the German ICGC MMML-Seq we are currently exploring sequencing data of GCB-lymphomas and paired normal controls as well as normal B-cell subsets separated by FACS. This includes whole genome, transcriptome, miRNAome and whole methylome datasets.",EGAD00001000281,ICGC MMML-seq Data Freeze November 2012 transcriptome sequencing,ICGC MMML-seq Data Freeze November 2012 transcriptome sequencing, Illumina HiSeq 2000;
EGAS00001000394,Genome wide mutation analysis of germinal-center B-cell derived lymphomas within the ICGC MMML-Seq Consortium,"Germinal-center B-cell derived lymphomas (GCB-lymphomas) are the most common B-cell lymphomas in children and adults, with Burkitt Lymphomas (BL) predominating in childhood and follicular lymphoma (FL) and diffuse large B-cell lymphomas (DLBCL) predominating in older age groups. The cell-of-origin in all these lymphomas is supposed to be a germinal center B-cell and transformation of FL in DLBCL or intermediate DLBCL/BL (intL) can occur. In the framework of the German ICGC MMML-Seq we are currently exploring sequencing data of GCB-lymphomas and paired normal controls as well as normal B-cell subsets separated by FACS. This includes whole genome, transcriptome, miRNAome and whole methylome datasets.",EGAD00001000279,ICGC MMML-seq Data Freeze November 2012 whole exome sequencing,ICGC MMML-seq Data Freeze November 2012 whole exome sequencing, Illumina Genome Analyzer IIx;
EGAS00001000394,Genome wide mutation analysis of germinal-center B-cell derived lymphomas within the ICGC MMML-Seq Consortium,"Germinal-center B-cell derived lymphomas (GCB-lymphomas) are the most common B-cell lymphomas in children and adults, with Burkitt Lymphomas (BL) predominating in childhood and follicular lymphoma (FL) and diffuse large B-cell lymphomas (DLBCL) predominating in older age groups. The cell-of-origin in all these lymphomas is supposed to be a germinal center B-cell and transformation of FL in DLBCL or intermediate DLBCL/BL (intL) can occur. In the framework of the German ICGC MMML-Seq we are currently exploring sequencing data of GCB-lymphomas and paired normal controls as well as normal B-cell subsets separated by FACS. This includes whole genome, transcriptome, miRNAome and whole methylome datasets.",EGAD00001000356,ICGC MMML-seq Data Freeze March 2013 transcriptome sequencing,ICGC MMML-seq Data Freeze March 2013 transcriptome sequencing, Illumina HiSeq 2000;
EGAS00001000394,Genome wide mutation analysis of germinal-center B-cell derived lymphomas within the ICGC MMML-Seq Consortium,"Germinal-center B-cell derived lymphomas (GCB-lymphomas) are the most common B-cell lymphomas in children and adults, with Burkitt Lymphomas (BL) predominating in childhood and follicular lymphoma (FL) and diffuse large B-cell lymphomas (DLBCL) predominating in older age groups. The cell-of-origin in all these lymphomas is supposed to be a germinal center B-cell and transformation of FL in DLBCL or intermediate DLBCL/BL (intL) can occur. In the framework of the German ICGC MMML-Seq we are currently exploring sequencing data of GCB-lymphomas and paired normal controls as well as normal B-cell subsets separated by FACS. This includes whole genome, transcriptome, miRNAome and whole methylome datasets.",EGAD00001000355,ICGC MMML-seq Data Freeze March 2013 whole genome sequencing,ICGC MMML-seq Data Freeze March 2013 whole genome sequencing, Illumina HiSeq 2000;
EGAS00001000394,Genome wide mutation analysis of germinal-center B-cell derived lymphomas within the ICGC MMML-Seq Consortium,"Germinal-center B-cell derived lymphomas (GCB-lymphomas) are the most common B-cell lymphomas in children and adults, with Burkitt Lymphomas (BL) predominating in childhood and follicular lymphoma (FL) and diffuse large B-cell lymphomas (DLBCL) predominating in older age groups. The cell-of-origin in all these lymphomas is supposed to be a germinal center B-cell and transformation of FL in DLBCL or intermediate DLBCL/BL (intL) can occur. In the framework of the German ICGC MMML-Seq we are currently exploring sequencing data of GCB-lymphomas and paired normal controls as well as normal B-cell subsets separated by FACS. This includes whole genome, transcriptome, miRNAome and whole methylome datasets.",EGAD00001000645,ICGC MMML-seq Data Freeze July 2013 whole genome sequencing,ICGC MMML-seq Data Freeze July 2013 whole genome sequencing, 
EGAS00001000394,Genome wide mutation analysis of germinal-center B-cell derived lymphomas within the ICGC MMML-Seq Consortium,"Germinal-center B-cell derived lymphomas (GCB-lymphomas) are the most common B-cell lymphomas in children and adults, with Burkitt Lymphomas (BL) predominating in childhood and follicular lymphoma (FL) and diffuse large B-cell lymphomas (DLBCL) predominating in older age groups. The cell-of-origin in all these lymphomas is supposed to be a germinal center B-cell and transformation of FL in DLBCL or intermediate DLBCL/BL (intL) can occur. In the framework of the German ICGC MMML-Seq we are currently exploring sequencing data of GCB-lymphomas and paired normal controls as well as normal B-cell subsets separated by FACS. This includes whole genome, transcriptome, miRNAome and whole methylome datasets.",EGAD00001000648,ICGC MMML-seq Data Freeze July 2013 transcriptome sequencing,ICGC MMML-seq Data Freeze July 2013 transcriptome sequencing, 
EGAS00001000400,Integrative genomic analyses reveal androgen-driven somatic alteration landscape in early-onset prostate cancer,"Early-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of prostate cancer. To compare the genomic alteration landscapes of EO-PCA with ""classical"" (elderly-onset) PCA, we performed deep sequencing-based genomics analyses in eleven tumors diagnosed at young age, and pursued comparative assessments with seven elderly-onset PCA genomes. Remarkable age-related differences in structural rearrangement (SR) formation became evident, suggesting distinct disease pathomechanisms. Whereas EO-PCAs harbored a prevalence of balanced SRs, with a specific abundance of androgen-regulated ETS gene fusions including TMPRSS2:ERG, elderly-onset PCAs displayed primarily non-androgen-associated SRs. Data from a validation cohort of >10,000 patients showed age-dependent androgen receptor levels and a prevalence of SRs affecting androgen-regulated genes, further substantiating the activity of a characteristic ""androgen-type"" pathomechanism in EO-PCA.",EGAD00001000306,ICGC prostate cancer whole genome sequencing,ICGC prostate cancer whole genome sequencing, Illumina HiSeq 2000;
EGAS00001000400,Integrative genomic analyses reveal androgen-driven somatic alteration landscape in early-onset prostate cancer,"Early-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of prostate cancer. To compare the genomic alteration landscapes of EO-PCA with ""classical"" (elderly-onset) PCA, we performed deep sequencing-based genomics analyses in eleven tumors diagnosed at young age, and pursued comparative assessments with seven elderly-onset PCA genomes. Remarkable age-related differences in structural rearrangement (SR) formation became evident, suggesting distinct disease pathomechanisms. Whereas EO-PCAs harbored a prevalence of balanced SRs, with a specific abundance of androgen-regulated ETS gene fusions including TMPRSS2:ERG, elderly-onset PCAs displayed primarily non-androgen-associated SRs. Data from a validation cohort of >10,000 patients showed age-dependent androgen receptor levels and a prevalence of SRs affecting androgen-regulated genes, further substantiating the activity of a characteristic ""androgen-type"" pathomechanism in EO-PCA.",EGAD00001000303,ICGC prostate cancer whole genome mate-pair sequencing,ICGC prostate cancer whole genome mate-pair sequencing, Illumina Genome Analyzer IIx;
EGAS00001000400,Integrative genomic analyses reveal androgen-driven somatic alteration landscape in early-onset prostate cancer,"Early-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of prostate cancer. To compare the genomic alteration landscapes of EO-PCA with ""classical"" (elderly-onset) PCA, we performed deep sequencing-based genomics analyses in eleven tumors diagnosed at young age, and pursued comparative assessments with seven elderly-onset PCA genomes. Remarkable age-related differences in structural rearrangement (SR) formation became evident, suggesting distinct disease pathomechanisms. Whereas EO-PCAs harbored a prevalence of balanced SRs, with a specific abundance of androgen-regulated ETS gene fusions including TMPRSS2:ERG, elderly-onset PCAs displayed primarily non-androgen-associated SRs. Data from a validation cohort of >10,000 patients showed age-dependent androgen receptor levels and a prevalence of SRs affecting androgen-regulated genes, further substantiating the activity of a characteristic ""androgen-type"" pathomechanism in EO-PCA.",EGAD00001000304,ICGC prostate cancer miRNA sequencing,ICGC prostate cancer miRNA sequencing, Illumina HiSeq 2000;
EGAS00001000400,Integrative genomic analyses reveal androgen-driven somatic alteration landscape in early-onset prostate cancer,"Early-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of prostate cancer. To compare the genomic alteration landscapes of EO-PCA with ""classical"" (elderly-onset) PCA, we performed deep sequencing-based genomics analyses in eleven tumors diagnosed at young age, and pursued comparative assessments with seven elderly-onset PCA genomes. Remarkable age-related differences in structural rearrangement (SR) formation became evident, suggesting distinct disease pathomechanisms. Whereas EO-PCAs harbored a prevalence of balanced SRs, with a specific abundance of androgen-regulated ETS gene fusions including TMPRSS2:ERG, elderly-onset PCAs displayed primarily non-androgen-associated SRs. Data from a validation cohort of >10,000 patients showed age-dependent androgen receptor levels and a prevalence of SRs affecting androgen-regulated genes, further substantiating the activity of a characteristic ""androgen-type"" pathomechanism in EO-PCA.",EGAD00001000305,ICGC prostate cancer RNA sequencing,ICGC prostate cancer RNA sequencing, Illumina HiSeq 2000;
EGAS00001000404,Myeloproliferative Neoplasms  MPN  Exome Validation Study,Experiments using targeted pulldown methods will be sequenced to validate findings in the exomes of patients with Myeloproliferative Neoplasms (MPN).,EGAD00001000619,Myeloproliferative Neoplasms (MPN) Exome Validation Study,Experiments using targeted pulldown methods will be sequenced to validate findings in the exomes of patients with Myeloproliferative Neoplasms (MPN)., Illumina HiSeq 2000;
EGAS00001000405,Angiosarcoma follow up study,A bespoke targeted pulldown experiment will be performed on patients with Angiosarcoma. the resulting products will be sequenced to determine the prevalence of previously found mutations in these patients.,EGAD00001000620,Angiosarcoma follow up study,A bespoke targeted pulldown experiment will be performed on patients with Angiosarcoma. the resulting products will be sequenced to determine the prevalence of previously found mutations in these patients., Illumina HiSeq 2000;
EGAS00001000408,Targeted sequencing of genes recurrently mutated in AML,"Background Massively parallel sequencing technology has transformed cancer genomics. It is now feasible, in a clinically relevant time-frame, for a clinically manageable cost, to screen DNA from patient tumours for mutations essentially genome-wide. The challenge for personalised medicine will be to increase the sample size to thousands or tens of thousands of well-characterised cases in order to attain sufficient statistical power to stratify patients accurately across the complexity and genomic heterogeneity expected for most of the common tumour types. Currently, whole genome sequencing on this scale is not feasible, and targeted sequencing of relevant portions of the genome will be required. Pilot data We have developed protocols for large-scale, multiplexed sequencing of 100-200 genes in thousands of samples. Essentially, using robotic technology, genomic DNA from the cancer specimen is processed into sequencing libraries with unique DNA barcodes, thereby allowing sequencing reads to be attributed to the sample they derive from. Currently, these sequencing libraries can be generated in a 96-well format using fully automated protocols, and we are exploring methods to expand this to a 384-well format. The sequencing libraries are pooled and hybridized to custom sets of RNA baits representing the genomic regions of interest. Sequencing of the pulled-down libraries is done in pools of 48-96 samples per lane of an Illumina Hi-Seq. This protocol is already implemented at the Sanger Institute. We have published proof that somatic mutations in novel cancer genes can be identified from exome-wide sequencing. In unpublished pilot data, we have established the feasibility of robotic library production, custom pull-down, and multiplexed sequencing of barcoded libraries for 100 known myeloid cancer genes across 760 myelodysplasia samples. Highlights of the data thus far analysed reveal that the coverage is remarkably even between samples; when 96 samples are run, average coverage per lane of sequencing is ~250, with 90-95% of targeted exons covered by >25 reads; known mutations can be discovered in the data set; and the protocol is amenable to whole genome amplified DNA. The bioinformatic algorithms for identification of substitutions and indels in pull-down data are well-established; we have pilot data proving that copy number changes, LOH and genomic rearrangements in specific regions of interest can also be identified by tiling of baits across the relevant loci. Proposal We propose to apply this methodology to 10000 samples from patients with AML enrolled in clinical trials over the last 10-20 years. Oncogenic point mutations and potentially genomic rearrangements will be identified, and linked to clinical outcome data, with a view to undertaking the following sorts of analyses:  Identification of co-occurrence, mutual exclusivity and clusters of driver mutations.  Correlation of prognosis with driver mutations and potentially gene-gene interactions  Exploration of genomic markers of drug response Ultimately, we would like to be in a position to release the mutation data together with matched clinical outcome data to genuine medical researchers via a controlled access approach, possibly within the COSMIC framework (www.sanger.ac.uk/genetics/CGP/cosmic/). The vision here is to generate a portal whereby a clinician faced with an AML patient and his / her mutational profile can obtain a personalised prediction of outcome, together with a fair assessment of the uncertainty of the estimate. With a sufficient sample size, there would also be the potential to develop decision support algorithms for therapeutic choices based on such data.",EGAD00001000606,Targeted sequencing of genes recurrently mutated in AML,"Background Massively parallel sequencing technology has transformed cancer genomics. It is now feasible, in a clinically relevant time-frame, for a clinically manageable cost, to screen DNA from patient tumours for mutations essentially genome-wide. The challenge for personalised medicine will be to increase the sample size to thousands or tens of thousands of well-characterised cases in order to attain sufficient statistical power to stratify patients accurately across the complexity and genomic heterogeneity expected for most of the common tumour types. Currently, whole genome sequencing on this scale is not feasible, and targeted sequencing of relevant portions of the genome will be required. Pilot data We have developed protocols for large-scale, multiplexed sequencing of 100-200 genes in thousands of samples. Essentially, using robotic technology, genomic DNA from the cancer specimen is processed into sequencing libraries with unique DNA barcodes, thereby allowing sequencing reads to be attributed to the sample they derive from. Currently, these sequencing libraries can be generated in a 96-well format using fully automated protocols, and we are exploring methods to expand this to a 384-well format. The sequencing libraries are pooled and hybridized to custom sets of RNA baits representing the genomic regions of interest. Sequencing of the pulled-down libraries is done in pools of 48-96 samples per lane of an Illumina Hi-Seq. This protocol is already implemented at the Sanger Institute. We have published proof that somatic mutations in novel cancer genes can be identified from exome-wide sequencing. In unpublished pilot data, we have established the feasibility of robotic library production, custom pull-down, and multiplexed sequencing of barcoded libraries for 100 known myeloid cancer genes across 760 myelodysplasia samples. Highlights of the data thus far analysed reveal that the coverage is remarkably even between samples; when 96 samples are run, average coverage per lane of sequencing is ~250, with 90-95% of targeted exons covered by >25 reads; known mutations can be discovered in the data set; and the protocol is amenable to whole genome amplified DNA. The bioinformatic algorithms for identification of substitutions and indels in pull-down data are well-established; we have pilot data proving that copy number changes, LOH and genomic rearrangements in specific regions of interest can also be identified by tiling of baits across the relevant loci. Proposal We propose to apply this methodology to 10000 samples from patients with AML enrolled in clinical trials over the last 10-20 years. Oncogenic point mutations and potentially genomic rearrangements will be identified, and linked to clinical outcome data, with a view to undertaking the following sorts of analyses: ? Identification of co-occurrence, mutual exclusivity and clusters of driver mutations. ? Correlation of prognosis with driver mutations and potentially gene-gene interactions ? Exploration of genomic markers of drug response Ultimately, we would like to be in a position to release the mutation data together with matched clinical outcome data to genuine medical researchers via a controlled access approach, possibly within the COSMIC framework (www.sanger.ac.uk/genetics/CGP/cosmic/). The vision here is to generate a portal whereby a clinician faced with an AML patient and his / her mutational profile can obtain a ?personalised? prediction of outcome, together with a fair assessment of the uncertainty of the estimate. With a sufficient sample size, there would also be the potential to develop decision support algorithms for therapeutic choices based on such data.", Illumina MiSeq;
EGAS00001000411,The Cardiogenics study,"Cardiogenics is an European collaborative project, it started in January 2007 and was funded by the European Commission through its Sixth Framework Program (reference LSHM -CT-2006-037593) until 2011. It involved several laboratories from France (INSERM UMRS937), Germany (Lbeck University; Regensburg University), United Kingdom (the Welcome Trust Sanger Institute; University of Leicester) and Sweden (Uppsala University Hospital) and was coordinated by a management group composed of scientists from these different institutions. Under the coordination of the management group the laboratories are still developing projects using Cardiogenics data sets.  As part of the Cardiogenics project, RNA from monocytes and macrophages of 363 patients with coronary artery disease and 395 healthy individuals was prepared and genome-wide expression was assessed in both cell types using the Illumina HumanRef 8 v3 Beadchip .  The DNA of all these individuals was genotyped using the Human 610 Quad custom arrays. Both data sets were used to conduct eQTL analyses. A subsample of subjects included in an allelic-imbalance substudy were also genotyped using the Illumina Human Custom 1.2M array. Detailed description of these datasets can be found in Shah S et al. Circ Cardiovs Genet 2011; Rotival M et al. Plos Genet 2011, Almlf et al. Plos One 2012 and Garnier S et al. Plos Genet 2013",EGAD00010000448,Title not provided,Macrophage Gene Expression, Illumina Human-Ref-8 v3 beadchip
EGAS00001000411,The Cardiogenics study,"Cardiogenics is an European collaborative project, it started in January 2007 and was funded by the European Commission through its Sixth Framework Program (reference LSHM -CT-2006-037593) until 2011. It involved several laboratories from France (INSERM UMRS937), Germany (Lbeck University; Regensburg University), United Kingdom (the Welcome Trust Sanger Institute; University of Leicester) and Sweden (Uppsala University Hospital) and was coordinated by a management group composed of scientists from these different institutions. Under the coordination of the management group the laboratories are still developing projects using Cardiogenics data sets.  As part of the Cardiogenics project, RNA from monocytes and macrophages of 363 patients with coronary artery disease and 395 healthy individuals was prepared and genome-wide expression was assessed in both cell types using the Illumina HumanRef 8 v3 Beadchip .  The DNA of all these individuals was genotyped using the Human 610 Quad custom arrays. Both data sets were used to conduct eQTL analyses. A subsample of subjects included in an allelic-imbalance substudy were also genotyped using the Illumina Human Custom 1.2M array. Detailed description of these datasets can be found in Shah S et al. Circ Cardiovs Genet 2011; Rotival M et al. Plos Genet 2011, Almlf et al. Plos One 2012 and Garnier S et al. Plos Genet 2013",EGAD00010000450,Title not provided,Genome Wide Genotype Data," Illumina Human Custom 1,2M and Human 610 Quad Custom arrays"
EGAS00001000411,The Cardiogenics study,"Cardiogenics is an European collaborative project, it started in January 2007 and was funded by the European Commission through its Sixth Framework Program (reference LSHM -CT-2006-037593) until 2011. It involved several laboratories from France (INSERM UMRS937), Germany (Lbeck University; Regensburg University), United Kingdom (the Welcome Trust Sanger Institute; University of Leicester) and Sweden (Uppsala University Hospital) and was coordinated by a management group composed of scientists from these different institutions. Under the coordination of the management group the laboratories are still developing projects using Cardiogenics data sets.  As part of the Cardiogenics project, RNA from monocytes and macrophages of 363 patients with coronary artery disease and 395 healthy individuals was prepared and genome-wide expression was assessed in both cell types using the Illumina HumanRef 8 v3 Beadchip .  The DNA of all these individuals was genotyped using the Human 610 Quad custom arrays. Both data sets were used to conduct eQTL analyses. A subsample of subjects included in an allelic-imbalance substudy were also genotyped using the Illumina Human Custom 1.2M array. Detailed description of these datasets can be found in Shah S et al. Circ Cardiovs Genet 2011; Rotival M et al. Plos Genet 2011, Almlf et al. Plos One 2012 and Garnier S et al. Plos Genet 2013",EGAD00010000446,Title not provided,Monocyte Gene Expression, Illumina Human-Ref-8 v3 beadchip
EGAS00001000413,The Transcriptome of PLX4032 resistance,"We have collected material from a patient who had BrafV600E mutant melanoma that was
treated with PLX4032. We have germline DNA from the patient and DNA and RNA from
distinct lesions before and after treatment with PLX4032. We have transcriptome sequenced these samples to obtain a snap shot of the mechanisms of resistance that are operative.",EGAD00001000599,The Transcriptome of PLX4032 resistance,"We have collected material from a patient who had BrafV600E mutant melanoma that was
treated with PLX4032. We have germline DNA from the patient and DNA and RNA from
distinct lesions before and after treatment with PLX4032. We have transcriptome sequenced these samples to obtain a snap shot of the mechanisms of resistance that are operative.", Illumina HiSeq 2000;
EGAS00001000420,Breast Cancer FRT RNA seq,"We propose to definitively characterise the somatic genetics of ER+ve, HER2-ve breast cancer through generation of comprehensive catalogues of somatic mutations in breast cancer cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.",EGAD00001000338,Breast Cancer FRT RNA seq,"We propose to definitively characterise the somatic genetics of ER+ve, HER2-ve breast cancer through generation of comprehensive catalogues of somatic mutations in breast cancer cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.", Illumina HiSeq 2000;
EGAS00001000425,Congenital Heart Disease   Pilot,This pilot study aims to generate pilot data to inform future study designs by resequencing the whole exomes of 10 unrelated individuals diagnosed with Congenital Heart Disease (CHD).,EGAD00001000351,Congenital Heart Disease - Pilot,This pilot study aims to generate pilot data to inform future study designs by resequencing the whole exomes of 10 unrelated individuals diagnosed with Congenital Heart Disease (CHD)., Illumina Genome Analyzer II;
EGAS00001000427,Prostate Cancer Whole Genome Validations,We propose to definitively characterise the somatic genetics of Prostate cancer through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing. This study will aim to validate the findings of the whole genome study by re-sequencing regions of interest using a bespoke pulldown bait. See ICGC website for more information: http://icgc.org/icgc/cgp/70/508/71331,EGAD00001000621,Prostate Cancer Whole Genome Validations,We propose to definitively characterise the somatic genetics of Prostate cancer through generation of comprehensive catalogues of somatic mutations by high coverage genome sequencing. This study will aim to validate the findings of the whole genome study by re-sequencing regions of interest using a bespoke pulldown bait. See ICGC website for more information: http://icgc.org/icgc/cgp/70/508/71331, Illumina MiSeq;
EGAS00001000437,Deep sequencing of S7EPC genome,"PCR products were obtained from each target loci using genomic DNA from human iPS cells. Subsequently, PCR products are pooled and subjected to Illumina library preparation.  The library will be sequenced either by HiSeq or MiSeq. 

This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/",EGAD00001000607,Deep sequencing of S7EPC genome,"PCR products were obtained from each target loci using genomic DNA from human iPS cells. Subsequently, PCR products are pooled and subjected to Illumina library preparation.  The library will be sequenced either by HiSeq or MiSeq. 

This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/", Illumina MiSeq;
EGAS00001000439,Noninvasive prenatal molecular karyotyping from maternal plasma,"Fetal DNA is present in the plasma of pregnant women. Massively parallel sequencing of  maternal plasma DNA has been used to detect fetal trisomies 21, 18, 13 and selected sex  chromosomal aneuploidies noninvasively. Case reports describing the detection of fetal  microdeletions from maternal plasma using massively parallel sequencing have been reported.  However, these previous reports were either polymorphism-dependent or used statistical  analyses which were confined to one or a small number of selected parts of the genome. In  this report, we reported a procedure for performing noninvasive prenatal karyotyping at 3 Mb  resolution across the whole genome through the massively parallel sequencing of maternal  plasma DNA. This method has been used to analyze the plasma obtained from 6 cases. In 5  cases, fetal microduplications or microdeletions have been detected successfully from maternal  plasma. The two cases with fetal microduplications represented the first noninvasive prenatal  detection of such changes from maternal plasma. In the remaining case, the plasma DNA  sequencing result was consistent with the pregnant mother being a carrier of a microduplication.  Simulation analyses were performed for determining the number of plasma DNA molecules that  would need to be sequenced and aligned for enhancing the diagnostic resolution of noninvasive  prenatal karyotyping to 2 Mb and 1 Mb. In conclusion, noninvasive prenatal molecular  karyotyping from maternal plasma by massively parallel sequencing is feasible and would  enhance the diagnostic spectrum of noninvasive prenatal testing.",EGAD00001000395,Noninvasive Prenatal Molecular Karyotyping from Maternal Plasma,Noninvasive Prenatal Molecular Karyotyping from Maternal Plasma, 
EGAS00001000441,Subclonal analysis in S7RE2 and S7RE14 iPS cells,"PCR products were obtained from each target loci using genomic DNA from human iPS cells. Subsequently, PCR products are pooled and subjected to Illumina library preparation.  The library will be sequenced either by HiSeq or MiSeq. 

This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/",EGAD00001000608,Subclonal analysis in S7RE2 and S7RE14 iPS cells,"PCR products were obtained from each target loci using genomic DNA from human iPS cells. Subsequently, PCR products are pooled and subjected to Illumina library preparation.  The library will be sequenced either by HiSeq or MiSeq. 

This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/", Illumina MiSeq;
EGAS00001000442,"Cell-type, allelic and genetic signatures in the human pancreatic beta cell transcriptome","Pancreatic beta cells within the islets of Langerhans are centrally involved in the pathogenesis of both type 1 and type 2 diabetes. Describing the differentiated state of the human beta cell has been hampered so far by technical (low resolution microarrays) and biological limitations (whole islet preparations rather than isolated beta cells). We circumvent these by deep RNA sequencing of purified beta cells from 11 individuals, presenting here the first characterization of the human beta cell transcriptome. Additionally, we perform the first comparison of gene expression profiles between beta cells, whole islets (N=7) and beta cell depleted islet preparations (N=5), revealing thus beta cell specific expression signatures. Finally, we combine this with whole-genome sequencing data for 7 of our donors, describing here the first set of genetic variants controlling inter-individual variability in beta cell gene expression.",EGAD00001000393,Human pancreatic beta cell RNA-seq,, Illumina HiSeq 2000;
EGAS00001000446,Passive and active DNA methylation and the interplay with genetic variation in gene regulation,"DNA methylation is an essential1 epigenetic mark whose role in gene regulation and its dependency on genomic sequence and environment are not yet fully understood2,3. In this study we provide novel insights into the mechanistic relationships between genetic variation, DNA methylation and transcriptome sequencing data in three different cell-types of the GenCord human population cohort4. We find that the association between DNA methylation and gene expression variation among individuals are likely due to different mechanisms from those establishing methylation-expression patterns during differentiation. Furthermore, cell-type differential DNA methylation may delineate a platform in which more local inter-individual changes may respond to or act in gene regulation. We show that unlike genetic regulatory variation, DNA methylation alone does not significantly drive allele specific expression.. Finally, inferred mechanistic relationships using genetic variation as well as correlations with TF abundance reveal both a passive and active role of DNA methylation to regulatory interactions influencing gene expression.",EGAD00001000425,GENCORD2_RNAseq,GENCORD2 RNA-seq BAM files using BWA," Illumina Genome Analyzer II;, Illumina HiSeq 2000;"
EGAS00001000446,Passive and active DNA methylation and the interplay with genetic variation in gene regulation,"DNA methylation is an essential1 epigenetic mark whose role in gene regulation and its dependency on genomic sequence and environment are not yet fully understood2,3. In this study we provide novel insights into the mechanistic relationships between genetic variation, DNA methylation and transcriptome sequencing data in three different cell-types of the GenCord human population cohort4. We find that the association between DNA methylation and gene expression variation among individuals are likely due to different mechanisms from those establishing methylation-expression patterns during differentiation. Furthermore, cell-type differential DNA methylation may delineate a platform in which more local inter-individual changes may respond to or act in gene regulation. We show that unlike genetic regulatory variation, DNA methylation alone does not significantly drive allele specific expression.. Finally, inferred mechanistic relationships using genetic variation as well as correlations with TF abundance reveal both a passive and active role of DNA methylation to regulatory interactions influencing gene expression.",EGAD00001000428,GENCORD2_GENOTYPES,204 individuals were genotyped with the Illumina 2.5M Omni chip. Filtered genotypes were imputed into the 1000 genomes project European panel SNPs. Beagle R2 is indicated in VCF files for further filtering. See Materials and Methods in publication for details., 
EGAS00001000446,Passive and active DNA methylation and the interplay with genetic variation in gene regulation,"DNA methylation is an essential1 epigenetic mark whose role in gene regulation and its dependency on genomic sequence and environment are not yet fully understood2,3. In this study we provide novel insights into the mechanistic relationships between genetic variation, DNA methylation and transcriptome sequencing data in three different cell-types of the GenCord human population cohort4. We find that the association between DNA methylation and gene expression variation among individuals are likely due to different mechanisms from those establishing methylation-expression patterns during differentiation. Furthermore, cell-type differential DNA methylation may delineate a platform in which more local inter-individual changes may respond to or act in gene regulation. We show that unlike genetic regulatory variation, DNA methylation alone does not significantly drive allele specific expression.. Finally, inferred mechanistic relationships using genetic variation as well as correlations with TF abundance reveal both a passive and active role of DNA methylation to regulatory interactions influencing gene expression.",EGAD00010000460,Title not provided,GENCORD2 DNA methylation , 
EGAS00001000447,Germline Aberrations of PAX5 Cause Susceptibility to pre-B cell Acute Lymphoblastic Leukemia,"A novel heterozygous germline variant, c.547G>A (p.Gly183Ser), in the paired box protein encoding gene, PAX5, was found to segregate with disease in two unrelated kindreds with autosomal dominant pre-B cell acute lymphoblastic leukemia (ALL). Leukemic cells from both families exhibited 9p deletion, with loss-of-heterozygosity and retention of the mutant PAX5 allele at 9p13 . Two additional sporadic ALL cases with 9p loss demonstrated PAX5 Gly183 substitution in the leukemic cells. Functional analysis of the PAX5 germline variants demonstrated reduced transcriptional activity, as well as decreased interaction with Groucho-4. These data extend the role of PAX5 alterations in the pathogenesis of pre-B ALL, and implicate PAX5 in a novel syndrome of germline susceptibility to pre-B cell neoplasia.",EGAD00001000654,DATA FILES FOR BALL-PAX5,, Illumina HiSeq 2000;
EGAS00001000449,The landscape of somatic mutations in epigenetic regulators across 1000 pediatric cancer genomes,"To define the frequency and pattern of somatic mutations in epigenetic regulators in pediatric cancer, we sequenced 633 genes, encoding the majority of proteins involved in patterning the epigenome, in 1000 pediatric tumors spanning 21 different cancer subtypes. This analysis establishes an epigenetic landscape of pediatric cancer, which expands the knowledge for potential therapeutic targets and for developing personalized therapy.",EGAD00001000657,DATA FILES FOR Histone Capture bams,, Illumina HiSeq 2000;
EGAS00001000451,Plasma-Seq of patients with metastatic prostate cancer,"Study 1 In this study we analysed patients with metastatic prostate cancer to scan their tumor genomes noninvasively in plasma DNA. We wanted to make whole-genome analysis from plasma DNA amenable to clinical routine applications and developed an approach based on a benchtop high-throughput platform, i.e. Illuminas MiSeq instrument. We performed whole-genome sequencing from plasma at a shallow sequencing depth to establish a genome-wide copy number profile of the tumor at low costs within 2 days. The genome-wide profiling in the plasma of our patients revealed multiple copy number aberrations including those previously reported in prostate tumors, such as losses in 8p and gains in 8q. High-level copy number gains in the AR locus were observed in patients with CRPC but not with CSPC disease. We identified the TMPRSS2-ERG rearrangement associated 3-Mbp deletion on chromosome 21 and found corresponding fusion plasma fragments in these cases. In an index case multiregional sequencing of the primary tumor identified different copy number changes in each sector, suggesting multifocal disease. Our plasma analyses of this index case, performed 13 years after resection of the primary tumor, revealed novel chromosomal rearrangements, which were stable in serial plasma analyses over a 9 months period, which is consistent with the presence of one metastatic clone.  Our approach provides specific genomic signatures within 2 days which may therefore serve as liquid biopsy.",EGAD00001000364,Dataset Plasma-seq,"We performed low coverage whole genome sequencing of plasma DNA from prostate cancer patients to establish copy number profiles on both a genome-wide and a gene-specific level. The data include plasma samples from prostate cacner patients (n=13), non-malignant controls (males, n=10 and females, n=9), plasma samples from pregnancies with aneuploid and euploid fetuses (n=4). Furthermore, we sequenced different tumor samples (n=6) of one patients and a serial dilution of HT29 in a background of normal DNA (n=9).", Illumina MiSeq;
EGAS00001000451,Plasma-Seq of patients with metastatic prostate cancer,"Study 1 In this study we analysed patients with metastatic prostate cancer to scan their tumor genomes noninvasively in plasma DNA. We wanted to make whole-genome analysis from plasma DNA amenable to clinical routine applications and developed an approach based on a benchtop high-throughput platform, i.e. Illuminas MiSeq instrument. We performed whole-genome sequencing from plasma at a shallow sequencing depth to establish a genome-wide copy number profile of the tumor at low costs within 2 days. The genome-wide profiling in the plasma of our patients revealed multiple copy number aberrations including those previously reported in prostate tumors, such as losses in 8p and gains in 8q. High-level copy number gains in the AR locus were observed in patients with CRPC but not with CSPC disease. We identified the TMPRSS2-ERG rearrangement associated 3-Mbp deletion on chromosome 21 and found corresponding fusion plasma fragments in these cases. In an index case multiregional sequencing of the primary tumor identified different copy number changes in each sector, suggesting multifocal disease. Our plasma analyses of this index case, performed 13 years after resection of the primary tumor, revealed novel chromosomal rearrangements, which were stable in serial plasma analyses over a 9 months period, which is consistent with the presence of one metastatic clone.  Our approach provides specific genomic signatures within 2 days which may therefore serve as liquid biopsy.",EGAD00001000396,Plasma-Seq follow-up CSPC4,We performed serial plasma-Seq analyses on a male who progressed from castration-sensitive to castration-resistant prostate cancer within 10 months following treatment with androgen-deprivation therapy., Illumina MiSeq;
EGAS00001000453,Identification of mutations and structural rearrangements in plasma DNA form metastatic prostate cancer patients,"In this study we analysed patients with metastatic prostate cancer to scan their tumor genomes noninvasively in plasma DNA. We enriched 1.3 Mbp of seven plasma DNAs (4 CRPC cases: CRPC1-3 and CRPC5; 3 CSPC cases: CSPC1-2 and CSPC4) including exonic sequences of 55 cancer genes and 38 introns of 18 genes, where fusion breakpoints have been described using Sure Select Custom DNA Kit.",EGAD00001000365,Dataset Gene-Breakpoint Panel,"In this study we analysed patients with metastatic prostate cancer to scan their tumor genomes noninvasively in plasma DNA. We enriched 1.3 Mbp of seven plasma DNAs (4 CRPC cases: CRPC1-3 and CRPC5; 3 CSPC cases: CSPC1-2 and CSPC4) including exonic sequences of 55 cancer genes and 38 introns of 18 genes, where fusion breakpoints have been described using Sure Select Custom DNA Kit.", Illumina MiSeq;
EGAS00001000476,Negligible impact on missing heritability of autoimmune-locus rare coding-region variants,"Genome wide association studies (GWAS) have identified common variants of modest effect size at hundreds of loci for common autoimmune diseases - however a substantial fraction of heritability remains unexplained, and to which rare variants may contribute.  To discover rare variants and test them for association with a phenotype, the majority of studies re-sequence a small initial sample size and then genotype the discovered variants in a larger sample set. This approach will fail to analyse a large fraction of the rare variants present in the entire sample set. Here we perform simultaneous amplicon sequencing-based variant discovery and genotyping for coding exons of 25 GWAS risk genes in 41,911 white-European origin UK subjects comprising 24,892 subjects with six autoimmune disease phenotypes and 17,019 controls, and show that rare coding-region variants at known loci play a negligible role in common autoimmune disease susceptibility. These results do not support the rare variant - synthetic genome-wide association hypothesis. Many known autoimmune disease risk loci contain multiple independent common and low frequency variant association signals, and so genes in these loci are a priori stronger candidates to harbor rare coding-region variants than other genes. Our data suggest that the missing heritability for common autoimmune diseases may not lie in the rare coding-region variant portion of the allelic spectrum, but perhaps as others have proposed in very many common variant signals of weak effect.",EGAD00001000623,"VCF file, post sample QC","This VCF contains the full sequence data post QC. This consists of 41,911 individuals. All polymorphic sites are present in this VCF.", 
EGAS00001000484,Whole genome and transcriptome analysis of a sporadic and recurring parathyroid carcinoma,"Parathyroid carcinoma is an extremely rare endocrine malignancy with an estimated incidence of less than 1 per million population. Excessive secretion of parathyroid hormone, extremely high serum calcium level and the deleterious effects of hypercalcemia are the clinical manifestations of the disease. Up to 60% of patients develop multiple disease recurrences and although long-term survival is possible with palliative surgery, permanent remission is rarely achieved. Molecular drivers of sporadic parathyroid carcinoma have remained largely unknown. Previous studies, mostly based on familial cases of the disease, suggested a potential role for the tumor suppressor MEN1 and proto-oncogene RET in benign parathyroid tumorigenesis while the tumor suppressor HRPT2 and proto-oncogene CCND1 may also act as drivers in parathyroid cancer. Here, we report the complete genomic analysis of a sporadic and recurring parathyroid carcinoma. Mutational landscapes of the primary and recurrent tumor specimens were analyzed using high throughput sequencing technologies. Such molecular profiling allowed for identification of somatic mutations never previously identified in this malignancy. These included single nucleotide point mutations in well characterized cancer genes such as mTOR, MLL2, CDKN2C and PIK3CA. Comparison of acquired mutations in patient-matched primary and recurrent tumors revealed loss of PIK3CA activating mutation during the evolution of the tumor from the primary to the recurrence. Structural variations leading to gene fusions and regions of copy loss and gain were identified at a single-base resolution. Loss of short arm of chromosome 1 along with somatic mis-sense and truncating mutations in CDKN2C and THRAP3, respectively, provide new evidence for the potential role of these genes as tumor suppressors in parathyroid cancer. The key somatic mutations indentified in this study can serve as novel diagnostic markers as well as therapeutic targets.",EGAD00001000370,Sporadic Parathyroid Carcinoma,"This dataset is compromised of 5 sequencing experiments from a single patient with sporadic and recurring parathyroid carcinoma. The samples include whole genome sequence of the primary tumor, the first recurrent tumor and peripheral blood. Whole transcriptome sequence of the first and second recurrent tumors are also included.", Illumina HiSeq 2000;
EGAS00001000490,Sequencing component for the whole genome methylation analysis in PBMCs and cell subsets  pilot study ,"DNA methylation has been shown to play a major role in determining cellular phenotype by regulating gene expression. Moreover, dysregulation of differentially methylated genes has been implicated in disease pathogenesis of various conditions including cancer development as well as autoimmune diseases such as systemic Lupus erythematosus and rheumatoid arthritis. Evidence is rapidly accumulating for a role of DNA methylation in regulating immune responses in health and disease. However, the exact mechanisms remain unknown. The overall aim of the project is to investigate the role of epigenetic mechanisms in regulating immunity and their impact on autoimmune disease pathogenesis.
The aim of this pilot study is to perform whole genome methylation analysis in peripheral blood mononuclear cells (PBMCs) and cell subsets (CD4, CD8, CD14, CD19, CD16 and whole PBMCs) obtained from 6 healthy volunteers. Whole genome methylation analysis will be performed using two methodological approaches, the Infinium Methylation Bead Array K450 (Illumina) and MeDIP-seq. mRNA expression arrays will also be performed in order to correlate DNA methylation with gene expression as well as genotyping on the Illumina OmniExpress chip",EGAD00001000394,Sequencing component for the whole genome methylation analysis in PBMCs and cell subsets (pilot study),"DNA methylation has been shown to play a major role in determining cellular phenotype by regulating gene expression. Moreover, dysregulation of differentially methylated genes has been implicated in disease pathogenesis of various conditions including cancer development as well as autoimmune diseases such as systemic Lupus erythematosus and rheumatoid arthritis. Evidence is rapidly accumulating for a role of DNA methylation in regulating immune responses in health and disease. However, the exact mechanisms remain unknown. The overall aim of the project is to investigate the role of epigenetic mechanisms in regulating immunity and their impact on autoimmune disease pathogenesis.
The aim of this pilot study is to perform whole genome methylation analysis in peripheral blood mononuclear cells (PBMCs) and cell subsets (CD4, CD8, CD14, CD19, CD16 and whole PBMCs) obtained from 6 healthy volunteers. Whole genome methylation analysis will be performed using two methodological approaches, the Infinium Methylation Bead Array K450 (Illumina) and MeDIP-seq. mRNA expression arrays will also be performed in order to correlate DNA methylation with gene expression as well as genotyping on the Illumina OmniExpress chip", Illumina Genome Analyzer II;
EGAS00001000492,Assessment of genetic and epigenetic variation in human IPS cells,"In order to progress human induced pluripotent stem cells (hiPSCs) towards the clinic, several outstanding questions must be addressed. It is possible to reprogram different somatic cell types into hiPSCs  but it is unlcear whether some cell types carry through fewer mutations through reprogramming (either due to mutations present in the primary cells, or mutations accumulated during reprogramming). Through in depth analysis of hiPSCs generated from different somatic cells, it will be possible to assess the variation in genetic stability of different cell types.",EGAD00001000384,Assessment of genetic and epigenetic variation in human IPS cells,"In order to progress human induced pluripotent stem cells (hiPSCs) towards the clinic, several outstanding questions must be addressed. It is possible to reprogram different somatic cell types into hiPSCs  but it is unlcear whether some cell types carry through fewer mutations through reprogramming (either due to mutations present in the primary cells, or mutations accumulated during reprogramming). Through in depth analysis of hiPSCs generated from different somatic cells, it will be possible to assess the variation in genetic stability of different cell types.", Illumina HiSeq 2000;
EGAS00001000509,an integrated molecular study of clear cell renal cell carcinoma (ccRCC) including whole-genome/exome and RNA sequencing as well as array-based gene expression/copy-number/methylation analyses,an integrated molecular study of clear cell renal cell carcinoma (ccRCC) including whole-genome/exome and RNA sequencing as well as array-based gene expression/copy-number/methylation analyses,EGAD00010000480,Title not provided,ccRCC case samples using 250K Nsp, Affymetrix_250K(Nsp) - gtype
EGAS00001000509,an integrated molecular study of clear cell renal cell carcinoma (ccRCC) including whole-genome/exome and RNA sequencing as well as array-based gene expression/copy-number/methylation analyses,an integrated molecular study of clear cell renal cell carcinoma (ccRCC) including whole-genome/exome and RNA sequencing as well as array-based gene expression/copy-number/methylation analyses,EGAD00010000486,Title not provided,ccRCC case samples using expression array, Agilent Human Whole Genome 4x44k v2 - Feature Extraction
EGAS00001000509,an integrated molecular study of clear cell renal cell carcinoma (ccRCC) including whole-genome/exome and RNA sequencing as well as array-based gene expression/copy-number/methylation analyses,an integrated molecular study of clear cell renal cell carcinoma (ccRCC) including whole-genome/exome and RNA sequencing as well as array-based gene expression/copy-number/methylation analyses,EGAD00001000597,Integrated molecular analysis of clear cell renal cell carcinoma,, Illumina HiSeq 2000;
EGAS00001000521,Whole exome and whole genome sequencing of juvenile myelomonocytic leukemia (JMML),"To obtain a complete registry of gene mutations in JMML, whole-exome sequencing was performed for paired tumor-normal DNA from 13 JMML cases, of which 2 cases were also analyzed by whole genome sequencing.",EGAD00001000427,Whole exome and whole genome sequencing of juvenile myelomonocytic leukemia (JMML),, Illumina HiSeq 2000;
EGAS00001000532,Chromosome Y Philogeny in Sardinia,"Genetic variation within the male specific portion of the Y chromosome (MSY) can clarify the origins of contemporary populations, but previous studies were hampered by partial genetic information. Population sequencing of 1,204 Sardinian males identified 11,763 MSY single nucleotide polymorphisms (SNPs), of which 6,751 have not previously been observed. We constructed a MSY phylogenetic tree containing all main haplogroups found in Europe along with many Sardinian-specific lineage clusters within each haplogroup. The tree was calibrated with archaeological data from the initial expansion of the Sardinian population ~7,700 years ago. The ages of nodes highlight different genetic strata in Sardinia and reveal presumptive timing of  coalescence with other human populations. We calculate a putative age for coalescence of ~180-200,000 years ago, consistent with previous mitochondrial DNA (mtDNA) based estimates.",EGAD00001000618,Sardinian Chromsome Y 2012 Analysis,1204 Sardinian males, 
EGAS00001000546,Landscape of gene mutations in Down syndrome-related myeloid disorders,"To identify the spectrum of gene mutations in Down syndrome-related myeloid disorders, whole genome sequencing of 4 trio samples from TAM/AMKL/complete remission (CR) phases and whole exome sequencing of 15 TAM and 14 DS-AMKL samples were performed.",EGAD00001000628,Landscape of gene mutations in Down syndrome-related myeloid disorders,," Illumina HiSeq 2000;, Illumina Genome Analyzer IIx;"
EGAS00001000552,Reference epigenomes generated as part of the International Human Epigenomics Consortium (IHEC),"The term epigenome refers to chemical modifications of DNA and proteins that control genome (a term referring to all the DNA within our cells) structure and activity. In contrast to the genome, which remains mostly the same throughout an individuals life, the epigenome changes during development and aging, in response to various external stimuli and as diseases emerge. Epigenome changes can result in profound changes in which genes are turned on and hence how cells behave. Thus, an understanding of what epigenome states exist in different cell types and how these states are specified are critically important to many aspects of human health and disease. We propose to build on our internationally leading experience in epigenome mapping to establish a major Canadian centre of epigenome analysis that will demonstrate an ability to deliver complete reference epigenome information on a full spectrum of normal and diseased human cell types; to improve the technology for broader applications in the future; and to make this technology rapidly available to Canadian scientists. To accomplish this goal we have developed an integrated program with internationally recognized biologists and clinicians with specialized access to, and knowledge of, the normal and diseased cell types we will analyze. This collaborative team effort will transform our understanding of the relationship between epigenome modifications and how genes are turned on or turned off, and lay the foundation for larger studies to revolutionize our understanding of how diseases develop and how to anticipate and treat them more effectively.",EGAD00001000629,ChIP-seq assays for CEMT_9 (IX1242),ChIP-seq assays for CEMT_9 (IX1242)., 
EGAS00001000552,Reference epigenomes generated as part of the International Human Epigenomics Consortium (IHEC),"The term epigenome refers to chemical modifications of DNA and proteins that control genome (a term referring to all the DNA within our cells) structure and activity. In contrast to the genome, which remains mostly the same throughout an individuals life, the epigenome changes during development and aging, in response to various external stimuli and as diseases emerge. Epigenome changes can result in profound changes in which genes are turned on and hence how cells behave. Thus, an understanding of what epigenome states exist in different cell types and how these states are specified are critically important to many aspects of human health and disease. We propose to build on our internationally leading experience in epigenome mapping to establish a major Canadian centre of epigenome analysis that will demonstrate an ability to deliver complete reference epigenome information on a full spectrum of normal and diseased human cell types; to improve the technology for broader applications in the future; and to make this technology rapidly available to Canadian scientists. To accomplish this goal we have developed an integrated program with internationally recognized biologists and clinicians with specialized access to, and knowledge of, the normal and diseased cell types we will analyze. This collaborative team effort will transform our understanding of the relationship between epigenome modifications and how genes are turned on or turned off, and lay the foundation for larger studies to revolutionize our understanding of how diseases develop and how to anticipate and treat them more effectively.",EGAD00001000633,ChIP-seq assays for CEMT_8 (IX1241),ChIP-seq assays for CEMT_8 (IX1241)., 
